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Abstract 
 
Inflammasomes are molecular complexes activated by infection and cellular stress, which are 
responsible for activating caspase-1 and subsequently facilitating interleukin (IL)-1β processing and 
macrophage cell death. It has been anticipated that excessive inflammasome activity would 
contribute to autoimmunity. However, we have made the paradoxical observation that the 
autoimmune New Zealand black (NZB) mouse is deficient in AIM2 (absent in melanoma 2) and 
NLRP3 (NACHT domain-, LRR-, and PYD-containing protein 3) inflammasome responses. NZB 
mice develop anti-erythrocyte antibodies and haemolytic anaemia, and also anti-nuclear antibodies 
typical of lupus. This suggests that high inflammasome function is not required for loss of tolerance 
and autoantibody production. Our long-term goal is to investigate the hypothesis that 
inflammasome deficiencies alter the interaction of the host with both microflora and pathogens, 
promoting prolonged production of cytokines such as type I interferon (IFN), which contribute to 
the development of autoimmunity. 
During inflammasome activation the adapter protein ASC (apoptosis-associated speck-like protein 
containing a CARD) undergoes dramatic relocalisation into a single speck. To enhance our ability 
to measure inflammasome formation we have developed a flow cytometric assay that provides a 
direct and quantitative measure of this ASC speck formation. This assay, described in chapter 3, 
allows rapid quantification of individual responding cells within a mixed population. It can also 
provide a rapid and sensitive technique for investigating molecular interactions in inflammasome 
formation. 
The first cross progeny of NZB and NZW mice develop more severe lupus nephritis than the 
NZB strain. Chapter 4 investigated AIM2 and NLRP3 inflammasome function in macrophages 
from NZB, New Zealand white (NZW) and the first cross progeny NZB/W F1 mice. The NZW 
parental strain showed strong inflammasome function, whilst the NZB/W F1 have haploinsufficient 
expression of NLRP3 and show reduced NLRP3 and AIM2 inflammasome responses, particularly 
at low stimulus strength. It remains to be established whether the low inflammasome function could 
contribute to loss of tolerance and the onset of autoimmunity in NZB and NZB/W F1 and this 
would be best achieved by genetic manipulation.  
We previously demonstrated an intronic point mutation in the Nlrp3 gene from NZB mice 
that generates a splice acceptor site, and proposed that this is the cause of NLRP3 inflammasome 
deficiency in this strain. The mutation leads to inclusion of a pseudoexon that introduces an early 
termination codon. In chapter 5, exon skipping antisense oligonucleotides (AON) were used to 
prevent aberrant splicing of Nlrp3 in NZB macrophages and show that this restores both NLRP3 
protein expression and NLRP3 inflammasome activity. Thus the single point mutation leading to 
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aberrant splicing is the sole cause of NLRP3 inflammasome deficiency in NZB macrophages. The 
NZB mouse provides a model for addressing a splicing defect in macrophages and could be used to 
further investigate AON design and delivery of AONs to macrophages in vivo. This work also 
supports our aim to restore NLRP3 inflammasome function in the NZB mouse using CRISPR/Cas9 
technology. Included in chapter 5 are details of the planning and in vitro testing of a CRISPR/Cas9 
approach for correcting the mutation in NZB mice that is in the process of being implemented in 
vivo.  
Ultimately, assessment of inflammasome function in autoimmune patients is necessary to 
determine if the deficiency observed in the NZB mouse bears any relationship to human disease 
etiology. This requires optimisation of the experimental conditions required to measure 
inflammasome activation in human monocytes. Chapter 6 demonstrates techniques for measuring 
NLRP3 inflammasome responses in human monocytes. Analysis of the AIM2 inflammasome in 
human cells remains a challenge, as IL-1β release from human monocytes in response to chemically 
transfected dsDNA and other transfection complexes was inhibited by MCC950, a small molecule 
inhibitor of the NLRP3 inflammasome. This suggests that this response is mediated by the NLRP3 
inflammasome and not the AIM2 inflammasome. This work provides important information for 
measurement of inflammasome responses in human cells particularly those expected to be mediated 
by AIM2.  
 The role of inflammasomes in autoimmune disease is still poorly understood and is likely to 
be complex. This thesis lays the groundwork for genetic manipulation of naturally occurring 
autoimmune mouse models that will allow the relationship between inflammasome activity and 
disease phenotype in these mice to be established. The work presented here also provides valuable 
tools and techniques for measuring inflammasome activation and important insight into 
inflammasome activation in human monocytes. This will enhance future studies of inflammasome 
activity in human cells including comparisons of systemic lupus erythematosus (SLE) patients and 
healthy controls.  
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CHAPTER 1: Introduction 
1.1 Overview   
Inflammasomes are molecular complexes of the innate immune system that are activated by 
infection and cellular stress, resulting in the processing and release of pro-inflammatory cytokines 
and cell death. Inflammasomes play an important role in host defence against invading pathogens. 
Interest in the role of inflammasomes in autoimmunity is growing and it has been anticipated that 
excessive inflammasome activity would contribute to autoimmunity. However, we have made the 
paradoxical observation that the autoimmune New Zealand black (NZB) mouse is deficient in 
absent in melanoma 2 (AIM2) and NACHT domain-, LRR-, and PYD-containing protein 3 
(NLRP3) inflammasome responses. NZB mice develop anti-erythrocyte antibodies and haemolytic 
anaemia, and also anti-nuclear antibodies typical of lupus. This suggests that high inflammasome 
function is not required for loss of tolerance and autoantibody production. Some evidence suggests 
that inflammasome responses play a role in kidney damage at later stages of autoimmune disease 
and, consistent with this, NZB mice have minimal glomerulonephritis. Genes conferring 
susceptibility can contribute to different phases of autoimmune disease; they could promote loss of 
tolerance or be involved in later tissue damage. Individual genes could contribute differently to each 
stage of disease. This project investigates the role of inflammasome function in autoimmune mice 
and develops techniques to assess inflammasome activation in mouse and human myeloid cells. 
This chapter reviews current literature about the role of inflammasomes in autoimmunity and 
proposes ways in which inflammasome deficiency may affect the course of autoimmune disease. 
Further background information specific to each results chapter is provided in the introduction 
sections of the papers presented in chapter 3, 4 and 5 and in the introduction to chapter 6.  
1.2 Inflammasomes 
1.2.1 Inflammasomes are platforms for caspase activation 
Inflammasomes are cytosolic multiprotein signalling complexes formed in response to microbial 
and endogenous danger signals, that recruit and activate inflammatory caspases (Schroder and 
Tschopp, 2010). Caspases are a family of cysteine proteases with established roles in apoptosis and 
inflammation (Fernandez 2014). They have been broadly classified into two groups based on these 
roles. The apoptotic initiator caspases, caspases -2, -8, -9 and -10, are responsible for the cascade of 
proteolytic activity resulting in apoptotic cell death (McIlwain et al., 2013). The inflammatory 
caspases, caspases -1, -11 and -12 in rodents and caspases -1, -4 and -5 in humans control 
inflammatory host defence responses by modulating lytic cell death and the maturation and release 
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of pro-inflammatory cytokines (Jimenez Fernandez and Lamkanfi, 2015). The activation of 
caspase-1 is mediated through recruitment to canonical inflammasomes (Man et al., 2017, Schroder 
and Tschopp, 2010). While they have most commonly been studied in myeloid immune cells, 
important roles for inflammasomes have also been established in other cell types such as epithelial 
cells (Sellin et al., 2017) and T cells (Arbore et al., 2016).  The role of inflammasomes in a wide 
range of inflammatory pathologies has led to an enormous amount of research interest in the last 
decade (Guo et al., 2015, Hoffman and Broderick, 2016). The canonical inflammasome complex 
has three basic components – an initiator protein that senses a stimulus, the adaptor protein 
apoptosis-associated speck-like protein containing a CARD (ASC) and the recruited caspase.  
1.2.2 Inflammasome initiator proteins 
There exist a number of different inflammasomes named after the initiator protein involved. 
Initiator proteins have two key features - inducible oligomerisation, and an effector domain of the 
death fold superfamily, either a pyrin domain (PYD) or a caspase recruitment domain (CARD). 
Three known initiator proteins are members of the Nod-like receptor (NLR) family, NLRP1, 
NLRP3 and NACHT domain-, LRR-, and CARD-containing protein 4 (NLRC4) (Martinon et al., 
2002, Agostini et al., 2004, Mariathasan et al., 2004). All NLR family inflammasome proteins have 
a central nucleotide-binding and oligomerisation NACHT domain that is most often flanked by C-
terminal leucine-rich repeats (LRRs) and an N-terminal PYD or CARD (Schroder and Tschopp, 
2010, Martinon et al., 2001). The LRRs are thought to be involved in stimulus sensing while the 
NACHT domain enables oligomerization and the CARD and PYD domains mediate downstream 
signalling. Subfamilies of NLR exist, distinguished by their N-terminal effector domain 
(MacDonald et al., 2013). The NLRPs have a PYD domain while the NLRCs have a CARD. Other 
initiator proteins include AIM2 a member of the PYD and HIN domain containing protein family 
(PYHIN) (Roberts et al., 2009, Hornung et al., 2009, Burckstummer et al., 2009, Fernandes-
Alnemri et al., 2009) and pyrin (Yu et al., 2006, Xu et al., 2014). Pyrin contains an N-terminal 
PYD, a coiled-coil domain and a C-terminal B30.2/SPRY domain.  
1.2.3 Inflammasome complex formation 
The induced clustering of initiator proteins allows them to recruit the adaptor molecule ASC via 
homotypic PYD-PYD interactions (Figure 1.1), or for NLRC4, via CARD-CARD interactions. This 
initiates the oligomerisation of ASCs through their PYDs into a long triple helical filament (Lu et 
al., 2014, Sborgi et al., 2015). Death-fold domains have six interaction faces that mediate the 
interactions between adjacent molecules within an individual strand as well as interactions between 
the three strands of the triple helix (Vajjhala et al., 2017, Lu et al., 2014). Once the filaments are 
nucleated all of the ASC in a cell can be included within minutes as the filaments extend in a prion-
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(eg.  AIM2,  NLRP3) 
like manner (Cheng et al., 2010, Cai and Chen, 2014). The ASC CARD domains are left exposed 
on the surface of the filament where they can recruit procaspase-1, which consists of an N-terminal 
CARD and a catalytic domain, utilising further death-fold interactions (Vajjhala et al., 2017). In 
vitro structural studies have suggested that procaspase-1 may also form filaments (Lu et al., 2014), 
but the requirement for activation seems to be dimerisation and subsequent intermolecular cleavage 
(Srinivasula et al., 2002). ASC CARD is also proposed to mediate the clustering of ASC filaments 
into a tight cytosolic speck (Broz and Dixit, 2016). Procaspase-8 can also be recruited to the ASC 
filaments and interacts with ASC PYD via its tandem death effector domain (DED) in an unusual 
non-homotypic interaction. This can nucleate procaspase-8 DED filaments in vitro and when 
expressed in HEK293 cells, but like caspase-1, activation is initiated by dimerization, and the role 
of the filament structure in activation is not established  (Sagulenko et al., 2013, Vajjhala et al., 
2015).  
 
Figure 1.1.  A model of domain interactions in inflammasome formation. Agonist-induced 
clustering of the initiator proteins AIM2 or NLRP3 results in the exposure of PYDs and initiates the 
formation of an ASC filament via PYD-PYD interaction. ASC then nucleates procaspase-1 
filaments via CARD-CARD interactions. Procaspase-8 can also be recruited via interactions of its 
tandem DEDs with the ASC PYD. The induced proximity of caspases leads to their dimerisation 
and activation. Adapted from (Vajjhala et al., 2017). 
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1.2.4 Cytokine processing 
Caspase-1 cleaves pro-interleukin (IL)-1β and pro-IL-18 allowing active, pro-inflammatory IL-1β 
and IL-18 to be released from the cell (Schroder and Tschopp, 2010, Thornberry et al., 1992, Gu et 
al., 1997). IL-1β and IL-18 play pivotal roles in local and systemic inflammation (Dinarello, 2009, 
Biet et al., 2002). IL-1β is a potent endogenous pyrogen that induces the expression of many pro-
inflammatory genes including those that encode for IL-6 and inducible nitric oxide synthase 
(Tschopp et al., 2003). T cell responses are amplified by IL-1β and it plays a key role in the 
differentiation of TH17 cells as well as enhancing the expansion and survival of naïve and memory 
T cells (Sims and Smith, 2010, Gabay et al., 2010, Dinarello, 2009). IL-1β also increases B cell 
proliferation and antibody production when acting with antigen and activates neutrophils for 
antimicrobial activity (Jelinek and Lipsky, 1987, Strowig et al., 2012). IL-18 works together with 
IL-12 to enhance proliferation of TH1 cells and interferon (IFN)-γ production by these cells as well 
as from CD8+ T cells, natural killer cells and activated B cells (Lebel-Binay et al., 2000). Both 
cytokines have chemoattractive properties and enhance production of adhesion molecules, 
promoting tissue infiltration of immune cells (Dinarello, 2009, Biet et al., 2002). These pro-
inflammatory cytokines play essential roles in the response to infections and tissue injury but 
persistent and/or elevated production can be destructive and compromise tissue function (Sims and 
Smith, 2010).    
1.2.5 Inflammasome-mediated cell death 
Cell death can be an effective defence against infection by eliminating a replicative niche for 
intracellular pathogens and allowing their release for attack by other arms of the immune system in 
the extracellular environment. Caspase-1 initiates a pro-inflammatory, lytic cell death termed 
pyroptosis (Miao et al., 2011). Pyroptosis is distinguished by the requirement for inflammatory 
caspases and involves the formation of pores in the cell membrane resulting in swelling of the cell 
and osmotic lysis (Bergsbaken et al., 2009). Lysed cells release intracellular content such as DNA, 
ATP, high-mobility group protein B1 and reactive oxygen species (ROS) into the extraceulluar 
milieu triggering adaptive immune responses and inflammation (Kono and Rock, 2008). This 
contrasts with apoptosis, which is non-lytic and usually does not induce inflammation as the cell 
shrinks and fragments into apoptotic bodies that are engulfed by surrounding phagocytes (Fink and 
Cookson, 2005). Pyroptosis occurs rapidly and loss of membrane integrity can be detected within 
15 minutes of triggering the AIM2 inflammasome in mouse bone marrow derived macrophages 
(BMMs) (Vitak et al., 2016). Pyroptosis is mediated by cleavage of Gasdermin D (GSDMD) by 
activated inflammatory caspases (Kayagaki et al., 2015, Shi et al., 2015). The N-terminal cleavage 
product initiates pyroptosis by oligomerising and forming pores in the plasma membrane (Aglietti 
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et al., 2016, Ding et al., 2016, Liu et al., 2016, Sborgi et al., 2016). GSDMD was shown to be 
required for early caspase-1-mediated pyroptosis and release of IL-1β following canonical 
inflammasome activation (Kayagaki et al., 2015, Shi et al., 2015).  
Inflammasome-activated caspase-8 initiates apoptotic cell death (Sagulenko et al., 2013, 
Aachoui et al., 2013), providing a means for inflammasome-mediated death of cells that do not 
express caspase-1 (Chung et al., 2016). Inflammasome-mediated apoptosis could also serve as a 
backup pathway for eliminating cells infected by a pathogen that can inhibit caspase-1, for example 
Yersinia species that secrete YopM which can directly block caspase-1 activity (LaRock and 
Cookson, 2012). Caspase-1 also activates caspase-3 (Sagulenko, unpublished) and could induce 
apoptosis in the event that GSDMD is inhibited. The existence of multiple, redundant pathways of 
cell death following inflammasome activation emphasises the importance of cell death as a defence 
mechanism.  
1.2.6 The NLRP3 inflammasome 
The NLRP3 inflammasome is the most widely studied, however its mechanism of activation is not 
completely understood. Two signals are required for canonical NLRP3 inflammasome activation in 
macrophages (Figure 1.2). The first is a priming step, which is achieved via activation of receptors 
that signal through myeloid differentiation primary response 88 (MyD88) and activate nuclear 
factor-kB (NF-kB). This is achieved by microbial compounds such as the Toll-like receptor 4 
(TLR4) ligand lipopolysaccharide (LPS), or endogenous molecules like tumour necrosis factor 
(TNF)-α. Most studied cells, such as resting BMMs, have insufficient NLRP3 protein levels for 
inflammasome activation (Bauernfeind et al., 2009) and the main role of priming was initially 
thought to be NF-kB-mediated upregulation of NLRP3 and pro-IL-1β expression levels 
(Bauernfeind et al., 2009, Franchi et al., 2009). Upregulation of NLRP3 expression levels does play 
a role and Nlrp3-/- cells reconstituted with high levels of NLRP3 do not require priming (Juliana et 
al., 2012, Schroder et al., 2012). However, it was also shown that LPS can rapidly prime the 
NLRP3 inflammasome by a transcription-independent mechanism whilst NLRP3 expression 
remains unchanged. This involves post-translational modifications including deubiquitination of 
NLRP3 (Juliana et al., 2012). Priming is then followed by a triggering signal that results in NLRP3 
oligomerisation and exposure of clustered PYD to recruit ASC. A wide range of external and host-
derived danger signals have been identified as triggering stimuli for the activation of NLRP3 
(Bauernfeind and Hornung, 2013). This includes whole pathogens such as Candida albicans, 
influenza virus, Sendai virus, adenovirus and bacteria, including Staphylococcus aureus and 
Listeria monocytogenes (Hise et al., 2009, Ichinohe et al., 2009, Park et al., 2013, Barlan et al., 
2011, Craven et al., 2009, Meixenberger et al., 2010).  
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Figure 1.2. Canonical NLRP3 inflammasome activation requires two signals. The first signal 
for NLRP3 inflammasome activation is a priming signal, for example the recognition of 
extracellular LPS by TLR4. This initiates signalling through NF-κB leading to increased pro-IL-1β 
expression and induced expression and post-translational modification of NLRP3. The second, 
activating, signal can be triggered by the detection of a variety of DAMPs and PAMPs. A number 
of mechanisms have been proposed to mediate the activation of the NLRP3 inflammasome by these 
activating stimuli including K+ efflux, phagosomal rupture, Ca2+ influx and mitochondrial ROS 
production. NEK7 acts downstream of K+ efflux and is essential for NLRP3 oligomerisation. 
NLRP3 oligomerization then initiates inflammasome formation. Adapted from (Man and 
Kanneganti, 2015). 
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NLRP3 is also activated by the bacterial ionophore nigericin and host-derived molecules that 
indicate cellular damage including ATP and monosodium urate (MSU) (Mariathasan et al., 2006, 
Martinon et al., 2006). A number of environmental irritants have also been implicated as activators 
of NLRP3, including silica and asbestos (Hornung et al., 2008, Dostert et al., 2008). These diverse 
stimuli generally lead to K+ efflux and this is believed to induce NLRP3 clustering (Munoz-Planillo 
et al., 2013). High concentrations of extracellular K+ have been reported to block NLRP3 but not 
AIM2 or NLRC4 inflammasome activation (Petrilli 2007, Franchi 2007). It has been reported that 
silica crystals and aluminium salts activate the NLRP3 inflammasome via lysosomal damage and 
rupture (Hornung et al., 2008). Other proposed mechanisms include the release of ROS and calcium 
influx (Zhou et al., 2011, Lee et al., 2012). Three groups have independently identified NEK7, from 
the family of NIMA-related kinases (NEKs), as a positive regulator of the NLRP3 inflammasome 
acting downstream of K+ efflux (He 2016, Shi 2016 and Schmid-Burgk 2016). A model is 
suggested in which K+ efflux is induced by NLRP3-activating stimuli, leading to the association of 
NEK7 and NLRP3 which is critical for NLRP3 oligomerisation and activation (He 2016).  
Gain-of-function mutations in Nlrp3 leading to hyper activation of the NLRP3 
inflammasome have been implicated in the pathogenesis of cryopyrin-associated periodic 
syndromes (Agostini et al., 2004, Hoffman et al., 2001, Aksentijevich et al., 2002). In addition, the 
activation of the NLRP3 inflammasome by danger signals has been implicated in a number of 
diseases including type II diabetes, gout, atherosclerosis and Alzheimer’s disease (Leemans et al., 
2011, Peng et al., 2015, Kingsbury et al., 2011, Liu et al., 2014, Mitroulis et al., 2010).  
1.2.7 The AIM2 inflammasome 
AIM2 triggers inflammasome formation in response to cytoplasmic double stranded DNA 
(dsDNA), and leads to similar downstream responses as seen with the NLRP3 inflammasome 
(Roberts et al., 2009, Hornung et al., 2009, Burckstummer et al., 2009, Fernandes-Alnemri et al., 
2009). AIM2 recognises dsDNA in the cytosol and binds to it directly via its HIN domain, and 
recruits ASC via its PYD domain to initiate inflammasome formation (Hornung et al., 2009, 
Roberts et al., 2009).  
Activation of the AIM2 inflammasome is dependent on the length of the dsDNA. 
Approximately 250-300 bp is required for the efficient formation of AIM2:dsDNA complexes 
(Morrone et al., 2015). Shorter DNA is less efficient at activating AIM2 but 44-bp DNA still kills 
cells when transfected at high concentrations (Roberts et al., 2009). The crystal structure of AIM2 
binding dsDNA shows that the AIM2 HIN domain binds to both strands of the DNA via interaction 
with the phosphate backbone (Jin et al., 2012). This is in keeping with the requirement for dsDNA 
and not single stranded DNA (ssDNA) to activate AIM2 inflammasome responses and supports 
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sequence-independent stimulation of AIM2 by the dsDNA. This means that AIM2 has no 
specificity for foreign over self-DNA, and instead recognises DNA as a danger signal because of its 
aberrant location in the cytoplasm. In this regard, AIM2 is similar to a second cytosolic DNA 
receptor, cyclic GMP-AMP synthase (cGAS). cGAS also binds the phosphate backbone of both 
strands of DNA in a sequence-independent manner (Civril et al., 2013), and initiates production of 
IFN-β (Sun et al., 2013, Wu et al., 2013).   
The sequence independent nature of dsDNA recognition by AIM2 allows the AIM2 
inflammasome to mediate responses to diverse microbial threats as well as cellular stress. Cytosolic 
DNA can originate from exogenous sources such as DNA viruses, retroviruses and bacteria that 
lyse in the cytosol (Rathinam and Fitzgerald, 2011, Yan et al., 2010, Jones et al., 2010). 
Endogenous sources of cytosolic DNA include reverse transcription of endogenous retroelements, 
released mitochondrial DNA, genomic DNA damage and DNA that escapes from the phagosome 
following phagocytosis of apoptotic cells (Kassiotis and Stoye, 2016, Okabe et al., 2005, White and 
Kile, 2015, Shen et al., 2015).  
AIM2 plays a role in host protection against infection with DNA viruses. Mouse 
macrophages and human keratinocytes have been shown to initiate inflammasome responses to 
viruses such as mouse cytomegalovirus (MCMV) and vaccinia virus, and human papillomaviruses 
(Rathinam et al., 2010, Hornung et al., 2009, Reinholz et al., 2013). AIM2 has been shown to be 
essential for IL-18 induction in response to MCMV infection in vivo (Rathinam et al., 2010). The 
AIM2 inflammasome contributes to the immune response to bacteria including Listeria 
monocytogenes, Mycobacterium tuberculosis, streptococcus pneumoniae and Francisella 
tularensis subspecies novicida (F. novicida) (Rathinam et al., 2010, Kim et al., 2010, Warren et al., 
2010, Sauer et al., 2010, Saiga and Takeda, 2010, Fang et al., 2011, Fernandes-Alnemri et al., 
2010). AIM2 has also been shown to mediate a response to the fungal pathogen Aspergillus 
fumigatus and in the response to the protozoan Plasmodium berghei acts redundantly with NLRP3 
in vivo (Karki et al., 2015, Kalantari et al., 2014).  
1.2.8 Other canonical inflammasomes 
The NLRC4 inflammasome is activated by cytosolic bacterial flagellin and components of the 
bacterial type III secretion system (Miao et al., 2007). These bacterial products are sensed by 
NAIPs (NLR family, apoptosis inhibitory proteins), which upon detection of their ligand recruit 
NLRC4 (Zhao et al., 2011, Kofoed and Vance, 2011). The cryo-electron microscopy structure of 
activated NAIP2-NLRC4 showed that a single activated NAIP2 initiates NLRC4 polymerisation. 
Encountering the activated NAIP initiates a conformational change of NLC4 into its active state and 
activated NLRC4 can then trigger the activating conformational change in the next NLRC4 
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molecule, generating a 10-12 membered wheel-like structure (Zhang et al., 2015). The NLRC4 
CARD domains cluster in the hub of this structure, and can interact directly with caspase-1 
(Mariathasan et al., 2004). NLRC4-dependent pyroptosis proceeds efficiently in ASC deficient cells 
(Broz et al., 2010). However, ASC is required for optimal cytokine processing and ASC-deficient 
cells are strongly impaired in their ability to secrete IL-1β in response to S.typhimurium, L. 
pneumophila and P. aeruginosa (Broz et al., 2010). It is proposed that ASC recruited to NLRC4 via 
its CARD then initates the typical PYD-based ASC filament and recruitment of caspase-1 as seen 
with PYD-containing initiator proteins (Dick et al., 2016). 
NLRP1 was the first NLR described to form an inflammasome (Martinon et al., 2002). The 
single NLRP1 gene found in humans contains a PYD, nucleotide binding domain, LRR, function-
to-find domain and a CARD (Martinon et al., 2002). There is no known ligand for human NLRP1. 
However, human NLRP1 PYD and LRR domains have autoinhibitory functions and gain-of-
function mutations in these domains predispose individuals to inflammatory skin diseases (Zhong et 
al., 2016). Mice have three paralogs of NLRP1 (NLRP1a, b and c) and none of them contain a PYD 
(Boyden and Dietrich, 2006). Mouse NLRP1b is activated by the anthrax lethal toxin (LeTx) 
(Levinsohn et al., 2012, Hellmich et al., 2012). Similar to NLRC4, NLRP1b can interact with 
caspase-1 directly via CARD-CARD interactions and ASC is not required for NLRP1b mediated 
pyroptosis and secretion of IL-1β in response to LeTx (Van Opdenbosch et al., 2014). Nlrp1a can 
also form an inflammasome independent of ASC and activating mutations in Nlrp1a cause a lethal, 
inflammatory phenotype in homozygous mice that is dependent on IL-1β and caspase-1, but 
independent of ASC (Masters et al., 2012). 
The pyrin inflammasome senses modification of Rho GTPases by bacterial toxins (Xu et al., 
2014). Human pyrin contains an N-terminal PYD, a zinc finger domain, a coiled-coil domain and a 
B30.2/SPRY domain while mouse pyrin lacks the B30.2/SPRY domain (Heilig and Broz, 2018). 
Gain-of-function mutations in the MEFV gene that encodes pyrin have been associated with 
autoinflammatory diseases such as familial mediteranean fever (FMF) (Chae et al., 2011). 
1.2.9 The non-canonical and alternative inflammasomes 
In 2011 Kayagaki et al. discovered that IL-1β release and pyroptosis in response to Gram-negative 
bacteria is blocked in caspase-11 deficient macrophages and identified the caspase-11-dependent 
inflammasome termed the “noncanonical inflammasome” (Figure 1.3) (Kayagaki et al., 2011). 
Intracellular LPS was soon identified as the trigger for noncanonical inflammasome activation and 
the recognition of LPS was shown to be independent of the receptor for extracellular LPS, TLR4 
(Hagar et al., 2013, Kayagaki et al., 2013). The lipid A component of LPS is proposed to bind 
directly to the CARD domain of caspase-11 and to human caspase-4 and -5 (Shi et al., 2014). 
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Caspase-4, -5 and -11 subsequently cleave GSDMD leading to pyroptosis, but these caspases do not 
directly cleave pro-IL-1β (Kayagaki et al., 2015, Shi et al., 2015). However, the canonical NLRP3 
inflammasome does become activated downstream of noncanonical inflammasome responses and 
this is thought to be mediated by K+ efflux (Ruhl and Broz, 2015). GSDMD is required for IL-1β 
release in response to intracellular LPS (Kayagaki et al., 2015, Shi et al., 2015). While a direct link 
between GSDMD activation and NLRP3 activation has not been shown it is proposed that plasma 
membrane disruption by GSDMD may lead to sufficient K+ efflux to activate NLRP3 (Prochnicki 
et al., 2016). 
Human monocytes, but not macrophages, have been shown to release IL-1β in response to 
TLR2 or TLR4 ligands alone (Netea et al., 2009). An alternative NLRP3 inflammasome pathway 
has recently been described in human monocytes in response to LPS (Gaidt et al., 2016). This 
pathway does not require K+ efflux, is induced by TLR4 signalling alone and does not require a 
second stimulus. Following TLR4 recognition of LPS, TRIF-RIPK1-FADD-CASP8 signalling 
activates NLRP3. Alternative inflammasome activity required ASC and Caspase-1 but there was 
apparently no evidence found for ASC speck formation or pyroptosis, although much of this work 
was done by modelling the response in a B cell line transdifferentiated to monocyte-like cells (Gaidt 
et al., 2016). 
Inflammatory responses initiate host defence against pathogens and other external threats 
and the inflammasomes play an important part in this. Much attention has been focussed on the 
effects of over-activation of inflammasomes, and the role of this in diverse pathologies such as 
gout, atherosclerosis and Alzheimer’s disease, as well as a range of “autoinflammatory” conditions 
(Leemans et al., 2011, Peng et al., 2015, Kingsbury et al., 2011, Liu et al., 2014). Autoinflammatory 
diseases arise directly from dysregulation of the innate immune system and a number of activating 
mutations in inflammasome components such as NLRP3 have been associated with these conditions 
(Martinon and Aksentijevich, 2015). Recently there is growing interest in the role of 
inflammasomes in autoimmune disease, which also involves aberrant inflammation, however, here 
the role of inflammasomes is less clear.  
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Figure 1.3. Comparison of canonical and noncanonical inflammasomes. In the canonical 
inflammasome pathway, pathogen-­‐‑associated molecular patterns or danger-­‐‑associated molecular 
patterns activate their respective inflammasome sensors, including NLRP1b, NLRP3, NLRC4, 
AIM2, or Pyrin. Activation of the NLRP3 and NLRC4 inflammasomes requires the kinase NEK7 
and ligand-­‐‑binding NAIP proteins, respectively. Inflammasome formation allows activation of 
caspase-1. Caspase-­‐‑1 directly cleaves gasdermin D and the precursor cytokines pro-­‐‑IL-­‐‑1β and pro-­‐‑
IL-­‐‑18, initiating pyroptosis and maturation of IL-­‐‑1β and IL-­‐‑18, respectively. The cleaved N-­‐‑
terminal portion of gasdermin D initiates pyroptosis by forming pores in the host cell membrane. In 
the noncanonical inflammasome pathway, cytosolic LPS from Gram-­‐‑negative bacteria is recognized 
by either caspase-­‐‑4 or caspase-­‐‑5 in human cells or by caspase-­‐‑11 in mouse cells. These 
inflammatory caspases directly cleave gasdermin D and initiate pyroptosis. The maturation of IL-­‐‑1β 
and IL-­‐‑18 in response to non-canonical inflammasome stimuli requires downstream activation of 
the NLRP3 inflammasome. Adapted from (Man et al., 2017). 
1.3 Autoimmune disease  
The maintenance of a balance between tolerance to self antigen and protective immune responses to 
pathogens is essential for host health. To meet this requirement, the immune system has evolved 
multiple mechanisms for controlling self-reactivity, and defects in this complex network can lead to 
the breakdown of tolerance and enable autoimmunity (Yang et al., 2018, Theofilopoulos et al., 
2017). Autoimmune diseases may arise due to chronic activation of the immune system leading to 
tissue inflammation and damage (Shaw et al., 2011). Unlike autoinflammatory diseases, 
autoimmune diseases involve both the innate and adaptive immune responses (Theofilopoulos et al., 
Canonical Inflammasomes Noncanonical Inflammasomes 
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2017). Dysregulation of innate immune outputs can contribute to aberrant adaptive responses such 
as autoantibody production or autoreactive T lymphocytes that are responsible for tissue destruction 
(Waldner, 2009, Goodnow et al., 2005).  
Most autoimmune diseases are clinically heterogeneous (Cho and Feldman, 2015). They can 
be monogenic but are more commonly complex and polygenic and can also involve environmental 
stimuli (Su and Anderson, 2009, Temajo and Howard, 2014, Cooper et al., 1999). Autoimmune 
diseases are numerous and span a range of pathologies from organ-specific disease such as type I 
diabetes to systemic manifestations such as rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE) (Waldner, 2009). This project focuses on inflammasome function in NZB 
mice, which are a model for two autoimmune diseases, SLE and autoimmune haemolytic anaemia 
(AIHA). 
1.4 Systemic lupus erythematosus   
SLE is a multifactorial autoimmune disease characterised by the presence of circulating 
autoantibodies that recognise nucleic acid-associated proteins or DNA itself (Napirei et al., 2000). 
The specificity of autoantibodies produced is believed to result from antigen-nucleic acid 
complexes that stimulate synergistic signalling between the B cell receptor and TLR7 or TLR9, that 
recognise RNA and unmethylated DNA respectively (Suthers and Sarantopoulos, 2017). 
Autoantibodies form immune complexes with DNA and cell debris and these complexes can then 
accumulate in a range of organs where they can activate the complement cascade and engage 
inflammatory cells, leading to tissue damage (Crampton et al., 2014). Clinical presentations range 
from photosensitivity and arthritis to kidney damage and disease of the central nervous system 
(Azevedo et al., 2014). Shortened lifespan can occur in SLE patients and is usually due to kidney 
damage, cardiovascular disease or infection (Mok et al., 2013, Nossent et al., 2007). SLE affects 
approximately 1 in 1400 people and it has a strong female bias with a female to male ratio of 9 to 1 
in people with onset of disease between 15 and 50 years (Kono et al., 1994, Somers et al., 2014). 
SLE is rarely the result of a single gene mutation; however the phenotype has been 
documented to arise from deficiency in early components of the complement cascade (Sterner et al., 
2014), and mutations in the genes for deoxyribonuclease 1 (DNASE1) and deoxyribonuclease 1-
like 3 (DNASE1L3) (Belot and Cimaz, 2012). More often disease is polygenic and linkage studies 
and candidate gene analysis have revealed a large set of genes and loci that link to SLE (Cui et al., 
2013). Amongst these, genetic variants in MHC Class II and Fcγ receptors, mainly Fcγ R IIA, IIB, 
IIIA, IIIB, are consistently associated with SLE predisposition (Brown et al., 2007, Relle and 
Schwarting, 2012). SLE-associated gene variants can be grouped according to the mechanistic 
pathways that they potentially influence. These pathways include DNA degradation, clearance of 
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immune complexes and cell debris, activation of TLR and IFN pathways, NF-κB signalling, B 
and/or T cell function and signalling and monocyte and neutrophil signalling. In addition, many 
candidate susceptibility genes also exist for which the function in disease is unknown (Cui et al., 
2013). A number of environmental factors have also been implicated in disease progression 
including ultra violet light, vitamin D deficiency and infection with Epstein-Barr virus (Cooper et 
al., 1998, Fox, 1988). Human studies into SLE have been complemented with investigations in 
murine models, which provide a way around the genetic heterogeneity found in human populations 
(Cunninghame Graham and Vyse, 2004).  
1.5 Mouse models of SLE 
A number of mouse models that develop spontaneous SLE-like disease have been established. 
These include both monogenic models, and polygenic models that are generally considered to better 
represent the majority of human SLE cases (Morel, 2010). In animal models with spontaneous SLE 
a few single gene mutations have been identified that alone dramatically increase the risk of 
disease. These genes include Fas and Fas ligand genes. MRL/Faslpr mice have a mutation that 
disrupts the Fas gene, which is essential for maintaining appropriate numbers of lymphocytes 
(Watson et al., 1992). These mice display lymphoproliferative pathology, B-cell hyperactivity, 
circulating immune complexes and glomerulonephritis (GN) (Watson et al., 1992, Perry et al., 
2011). The BXSB model shows SLE symptoms that have higher incidence, earlier onset and 
increased severity in males compared to females, due to duplication of TLR7 on the Y chromosome 
(Pisitkun et al., 2006). In both cases these mutations work together with background genes that 
shape the autoantibody profile and the type and severity of resulting end organ disease 
(Theofilopoulos and Kono, 2002). 
Disease in other models is more complex. The NZB strain is a model of severe autoimmune 
haemolytic anaemia and SLE (Izui et al., 1994, Andrews et al., 1978, Kotzin and Palmer, 1987). 
These mice develop anti-erythrocyte antibodies and antinuclear antibodies as well as exhibiting 
polyclonal B cell activation, elevated serum IgM and mild, late-onset GN (Scatizzi et al., 2012, 
Borchers et al., 2000). The first cross progeny of NZB and New Zealand White (NZW) mice, 
termed here NZB/W F1, are considered a good model for human SLE. They develop anti-nuclear 
antibodies and immune complex mediated GN at around 5-6 months of age, dying around 10-12 
months from kidney failure (Borchers et al., 2000, Perry et al., 2011). Disease in the NZB/W F1 
mice also shows female bias (Perry et al., 2011). Neither of the parental strains develop severe 
kidney disease; NZB mice develop only mild GN and NZW mice have only a low incidence of 
autoimmune disease (Alexander et al., 2002). As such both parents must pass on genetic loci that 
contribute to disease in the offspring. Eight susceptibility loci have been linked to lupus-like disease 
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in NZB/W F1 mice; they are termed Lbw1-8 and correspond to locations on chromosomes 17, 4, 5, 
6, 7, 18, 1 and 11 respectively (Kono et al., 1994). Heterozygosity at Lbw1 conferred the greatest 
susceptibility while Lbw2, 4, 7 and 8 are inherited from the NZB strain and Lbw3, 5 and 6 from 
NZW (Theofilopoulos and Kono, 2001). Another series of loci, some of which overlap with Lbw 
intervals, have been defined as New Zealand black autoimmunity (Nba)1-6 and derive from the 
NZB strain (Drake et al., 1994, Vyse et al., 1997, Xie et al., 2002, Xie et al., 2005, Kikuchi et al., 
2005b).  
 New Zealand Mixed (NZM) 2410 mice were derived from NZB/W F1 mice by 
backcrossing to NZW and then using brother-sister matings. Three prominent lupus susceptibility 
loci were identified in these mice, Sle1-3 (Nguyen et al., 2002). They are found on chromosome 1, 
4 and 7 respectively, and Sle1 and Sle 3 are derived from NZW while Sle2 contains a mixture of 
NZB and NZW genetic material (Morel et al., 2000). The NZW Sle1 locus overlaps NZB Lbw7 and 
is associated with autoantibody production, demonstrating that both parental strains can contribute 
susceptibility in the same region of chromosome 1. Sle1 appears to be an initiating factor and only 
causes GN when in combination with either Sle2 or Sle3, that affect the activation of B and T cells. 
Similarly neither Sle2 nor Sle3 alone leads to GN.  Four suppressive loci, labelled Sles (SLE 
suppressor) were also identified in the NZW genome. Taken together these loci demonstrate the 
complexity of the genetic basis of SLE and the importance of interactions between susceptibility 
genes in the development of autoimmunity.  
1.6 NZB mice are a model for autoimmune haemolytic anaemia 
AIHA is the collective name for several autoimmune diseases characterised by increased 
destruction of red blood cells (RBCs) due to the presence of anti-erythrocyte autoantibodies 
(Liebman and Weitz, 2017). AIHA is a heterogeneous disease varying with respect to the antibodies 
involved as well as whether it is the primary affliction or secondary to another disease. Incidence of 
the disease is approximately 1 in 80,000 people/year in Caucasians, and 7-22% of people with SLE 
have AIHA (Chaudhary and Das, 2014, Scatizzi et al., 2012). Literature on the disease consists 
mostly of clinical case reports and there is very little knowledge of the genetics behind human 
AIHA. One linkage study suggests the presence of a susceptibility locus on chromosome 11q14 in 
African-American SLE patients with a history of haemolytic anaemia (Sawalha et al., 2002). NZB 
mice spontaneously develop AIHA (Konno et al., 2013). The amount of IgG bound to RBCs 
increases from 3 months of age and induces anaemia from around 6 months of age onwards. 
Although the Lbw2 lupus susceptibility locus on chromosome 4 has been found to confer 
susceptibility to AIHA in NZB, the gene responsible is still unknown (Scatizzi et al., 2012). 
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1.7 NZB mice combine inflammasome deficiency and autoimmune disease.  
Studies from our laboratory investigating the mechanism of cytosolic DNA-dependent macrophage 
death identified p202, that is highly expressed in NZB macrophages, as an antagonist of AIM2 
inflammasome responses (Roberts et al., 2009). p202, like AIM2, is a member of the PYHIN 
family, but contains two HIN domains and no PYD. One of these HIN domains binds dsDNA, 
whilst the other mediates p202 tetramer formation (Yin et al., 2013). p202 binds directly to AIM2, 
and presumably prevents the AIM2 PYD clustering required to initiate an inflammasome response. 
As a result of high p202 expression NZB mouse macrophages are deficient in AIM2-mediated 
caspase-1 activation and cell death in response to cytosolic DNA (Yin et al., 2013) and AIM2-
dependent IL-1β production in response to mouse cytomegalovirus (Appendix 2) (Sester et al., 
2015a). Knockdown of p202 restored AIM2 function to a level similar to the C57BL/6 mouse, 
which has little or no p202 expression. Interestingly, not only NZB, but other lupus-prone strains 
BXSB and MRL also express elevated levels of p202 (Chen et al., 2008, Haywood et al., 2006, Ichii 
et al., 2010), although a role in murine autoimmunity remains to be established. While there is no 
human orthologue of p202 (Cridland et al., 2012), AIM2 function in humans could be suppressed 
by other means including the proposed inhibitor pyrin domain only protein 3 (POP3) (Khare et al., 
2014).  
In searching for a control inflammasome response for experiments on p202 function it was 
found that NZB mice are also deficient in NLRP3 inflammasome responses. NZB macrophages 
have no NLRP3 response to ATP, nigericin and Candida albicans (Appendix 2) (Sester et al., 
2015a). This deficient response was quickly attributed to a profound deficiency of NLRP3 protein 
in NZB cells. Further investigation revealed a single G to A point mutation in an intron in NZB 
DNA that introduces a splice acceptor site for a novel exon. This novel exon introduces a premature 
stop codon leading to a truncated product that is evidently unstable. PCR confirmed that Nlrp3 
cDNA from NZB macrophages predominantly includes the extra exon. Thus, by two separate 
mechanisms NZB mice have significantly reduced inflammasome activity; AIM2 is antagonised by 
p202, and NLRP3 is functionally null. These findings pose the question of whether inflammasome 
deficiency contributes to development of autoimmune disease.  
1.8 Studies into the role of inflammasomes in autoimmunity.  
1.8.1 Inflammasome function in mouse models of autoimmune disease 
From the work of our laboratory described above, it is evident that normal AIM2 and NLRP3 
inflammasome function is not required for, and inflammasome deficiency may even contribute to, 
loss of tolerance and autoantibody production in NZB mice. In contrast, a contributing role for 
inflammasome activity in autoimmunity has been proposed and has gained interest in recent years 
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(Shaw et al., 2011). Studies into the function of inflammasomes in other mouse models of 
autoimmunity are limited and have yielded some conflicting results.  
 Experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis 
driven by T cell autoreactivity to antigens in the central nervous system. One study found Nlrp3-/- 
mice to have delayed and reduced EAE symptoms (Gris et al., 2010). In another independent 
investigation Asc-/- mice but not Nlrp3-/- mice were protected from EAE (Shaw et al., 2010). It has 
been proposed by Inoue et al., that these differences are due to how EAE was induced and this 
group reported that Nlrp3-/- and Asc-/- mice were resistant or sensitive to EAE depending on how 
much Mycobacteria was included in the injection given to initiate disease (Inoue et al., 2012). 
These results suggest that the involvement of inflammasome components in EAE could relate to the 
response to the EAE-inducing vaccination rather than being intrinsic to the disease process and 
whether there is a subset of multiple sclerosis patients with aberrant NLRP3 inflammasome 
function requires further investigation. 
The NLRP3 inflammasome has been shown to be active in the kidneys of NZB/W F1 mice 
during disease but not at 8 weeks old, prior to disease symptoms (Tsai et al., 2011). The same study 
found that treating NZB/W F1 mice with epigallocatechin-3-gallate reduced kidney injury by 
decreasing the production of ROS. This was correlated, at least in part, to the decreased levels of 
NLRP3 activity observed in the kidneys of treated mice compared to controls. Further groups have 
also administered treatments to lupus model mice and seen improvement in kidney disease 
symptoms alongside decreased expression and activity of NLRP3 in the kidney (Zhu et al., 2013, 
Zhao et al., 2015). Caspase-1 has been shown to be necessary for immune complex-mediated 
nephritis and maximum autoantibody production in the pristane-induced mouse lupus model 
(Kahlenberg et al., 2014). A second group has shown that Nlrp3R258W mice with hyperactive NLRP3 
develop a more severe lupus-like syndrome upon pristane challenge with higher mortality (Lu et al., 
2016). Pristane injection itself seems to induce sustained IL-1β production (Herman et al., 2012), 
and the relevance of these findings to the normal initiation of disease in patients is not clear. Fu et 
al. observed reduced kidney damage in NZM2328 mice, an NZM strain produced by extended 
backcrosses of NZB/W F1 mice with NZW mice, following NLRP3 inflammasome inhibition (Fu 
et al., 2017). Treatment of NZM2328 mice with the NLRP3 inhibitor MCC950 for six weeks led to 
reduced production of IL-1β in the kidneys and decreased active caspase-1, measured with a FAM-
FLICA caspase-1 probe, in glomerular podocytes. Reduced proteinuria and renal lesions were also 
observed following MCC950 treatment. Together, these studies support a role for inflammasome 
activity in promoting lupus-like autoimmune disease, particularly in contributing to kidney damage.  
Interestingly, against the perception that inflammasomes promote autoimmunity, Lech et al. 
found that knocking out NLRP3 in C57BL/6-lpr/lpr (B6lpr) mice exacerbated disease phenotype 
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(Lech et al., 2014). These mice carry the Faslpr mutation on the C57BL/6 background, and although 
they have lymphoproliferation and autoantibodies, they have only very mild kidney pathology in 
comparison with the MRL background on which this mutation was first described, which has lethal 
GN (Itoh et al., 1993). For this work Nlrp3-deficient, Asc-deficient, IL-1 receptor (Il-1r)-deficient 
and IL-18-deficient B6lpr mice were generated to investigate the role of inflammasomes in 
autoimmunity. It was found that NLRP3 and ASC but not IL-1R and IL-18 actually protect B6lpr 
mice from kidney disease and when NLRP3 or ASC were knocked out they developed lung disease 
and severe lupus nephritis that was not seen in age-matched controls. NLRP3 and ASC-deficient 
mice developed more severe splenomegaly and lymphadenopathy and also appeared to have 
increased activation of antigen-presenting cells and lymphocyte expansion, but the latter appears to 
just be in proportion with increased spleen size. NLRP3 and ASC deficiency had little overall effect 
on autoantibody production in these mice, but Nlrp3-/- B6lpr mice did have significantly increased 
anti-dsDNA IgG levels. Finally, they suggest that a lack of ASC or NLRP3 impairs transforming 
growth factor (TGF)-b1 signalling, showing reduced expression of most TGF-b target genes and 
phosphorylation of the TGF-b downstream target Smad-2 in the spleens of Nlrp3-/- or Asc-/- B6lpr 
mice. The TGF-β pathway is known to impact on immune tolerance and T cell-mediated 
autoimmunity (Sheng et al., 2015). TGF-β production has been shown to be deficient in SLE 
patients and NZB/W F1 mice (McCarron and Marie, 2014). Thus in the B6lpr model NLRP3 was 
protective against lupus nephritis, although the authors suggest this was related to some 
uncharacterised role in TGF-β signalling, rather than canonical inflammasome function (Lech et al., 
2014).  
Recent work has described a role for the NLRP3 inflammasome in the optimal induction of 
T-helper (Th) 1 responses (Arbore et al., 2016). T cell intrinsic NLRP3 activity and subsequent IL-
1β production was required for optimal production of IFN-γ by Th1 cells. Reduced IFN-γ secretion 
by Th1 cells due to NLRP3 deficiency in a mouse model of colitis led to uncontrolled Th17 cell 
infiltration in the intestine, increased epithelial damage and aggravated disease (Arbore et al., 
2016). However, it was not assessed whether this was dependent on inflammasome formation and 
IL-1β, and could represent an uncharacterised signalling role for NLRP3. Such a role for NLRP3, 
independent of inflammasome activation, has been described for promoting Th2 cell polarisation 
and optimal IL-4 production (Bruchard et al., 2015). These results reveal potential T cell-intrinsic 
roles for NLRP3 in protecting against autoimmune disease and suggest that it is overly simplistic to 
view NLRP3 as purely exacerbating inflammation through canonical inflammasome activation and 
IL-1β production.  
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1.8.2 Inflammasome components and mouse susceptibility loci 
AIM2 and p202 both fall within the Nba2 lupus-susceptibility locus of NZB mice on chromosome 1 
(Rozzo et al., 2001). This locus also contains FcγRIIb and genes for signaling lymphocytic 
activation molecule (SLAM) factors, which have been strongly implicated in autoantibody 
production, and a role for p202/AIM2 has not been confirmed (Jorgensen et al., 2010). The NZB 
null allele of Nlrp3 falls within the Lbw8 lupus susceptibility locus on chromosome 11 thought to 
contribute to autoantibody production (Kono et al., 1994). The genetic intervals defined in these 
studies are quite large, and the locus may be complex; although we propose that the NZB null allele 
of Nlrp3 is a candidate susceptibility gene, the IL-4 gene in this region is another suggested 
candidate (Morel et al., 1999). Despite extensive experimentation, causative genes in mouse lupus 
susceptibility loci remain largely uncharacterised, and interest has waned with the onset of genome-
wide association studies (GWAS) and next generation sequencing allowing more detailed 
investigation of human SLE genetics.  
1.8.3 Human inflammasome gene polymorphisms and autoimmune disease.  
GWAS has not revealed association of SLE with NLRP3 or AIM2, although the human NLRP3 
gene on chromosome 1q44 is within a region found to be associated with SLE in a Mexican family 
study (Shai et al., 1999). A number of inflammasome gene variants have been associated with 
autoimmune conditions (Table 1.1). Polymorphisms in the gene encoding NLRP1 have been 
associated with diverse autoimmune diseases including SLE, but their effect on inflammasome 
function is unknown (Masters, 2013). A polymorphism in the gene encoding IL-1b has been 
associated with juvenile SLE, and again it is not known whether this would increase or decrease IL-
1β function (Pontillo et al., 2015). The G allele of NLRP3 SNP rs10754558, that produces higher 
NLRP3 mRNA expression and increased IL-1b expression (Hitomi et al., 2009, Zhou et al., 2016), 
is suggested to be protective against type I diabetes (T1D), as it was less frequent in T1D patients 
from Northern Brazil (Pontillo et al., 2010). Interestingly, the same polymorphism has also been 
associate with type 2 diabetes, however, in this case the G allele was associated with increased risk 
of developing the disease (Wang et al., 2015). Two different polymorphisms, NLRP3 rs4353135 
and rs6672995, found in a predicted regulatory region downstream of NLRP3 have been associated 
with Crohn’s disease. Homozygosity for the risk alleles was associated with the decreased NLRP3 
and IL-1b expression (Villani et al., 2009). However, a large UK study could not replicate these 
results (Lewis et al., 2011). The combined results of these studies are not conclusive, but there are 
some reports suggesting that higher NLRP3 activity could protect against certain autoimmune 
conditions. 
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 Table 1.1. Genetic polymorphisms in inflammasome-related genes and associated autoimmune 
diseases. Adapted from (Yang and Chiang, 2015). 
SNPs Autoimmune 
disease (ethnicity) 
Influence  Ref 
NLRP1 
rs6502867/rs4790797 
Vitiligo-associated 
autoimmune disease 
(USA/UK 
Caucasian 
Susceptibility (Jin et al., 2007) 
NLRP1 
rs12150220/rs2670660 
SLE (Brazilian) Susceptibility (Pontillo et al., 
2012) 
NLRP1 rs878329 RA (Chinese) Susceptibility (Sui et al., 
2012) 
NLRP1 rs12150220 Autoimmune 
Addison’s disease 
(Polish) 
Susceptibility (Zurawek et 
al., 2010) 
NLRP3 rs10159239 RA (UK Caucasian) Susceptibility (Mathews et 
al., 2014) 
NLRP3 
rs4925648/rs4925659 
RA (UK Caucasian) Treatment response (Mathews et 
al., 2014) 
NLRP3 rs35829419 
(Q705K) 
RA (Swedish) Susceptibility/severity (Kastbom et 
al., 2008) 
NLRP3 rs10733113 Psoriasis (Swedish) Severity (Carlstrom et 
al., 2012) 
NLRP3 rs4353135 
 
Juvenile idiopathic 
arthritis 
(Taiwanese) 
Susceptibility/ 
inflammatory activity 
(Yang et al., 
2014a) 
NLRP3 rs4353135, 
Rs6672995  
Crohn’s disease 
(European) 
Susceptibility (Villani et al., 
2009) 
NLRP3 rs10754558 Type 1 diabetes 
(Brazilian) 
Susceptibility  (Pontillo et al., 
2010) 
NLRP3 rs10754558 Type 2 diabetes 
(Chinese) 
Susceptibility (Wang et al., 
2015) 
IL-1β rs1143634 
(−511A > G) 
RA (UK Caucasian) Susceptibility (Harrison et 
al., 2008) 
IL-1β rs1143634 
(+3953 C > T) 
SLE (Colombian) Susceptibility (Camargo et 
al., 2004) 
IL-1β rs1143629 Juvenile SLE 
(European 
Caucasian) 
Susceptibility (Pontillo et al., 
2015) 
IL-18 rs187238 
(−137G > C) 
RA (Europeans) 
SLE (Asians) 
Susceptibility (Wen et al., 
2014) 
IL-18 
rs187238/rs1946518 
Multiple sclerosis 
(Turkish) 
Susceptibility (Karakas Celik 
et al., 2014) 
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1.8.4 Expression of inflammasome components in autoimmune disease 
Human studies have delivered mixed reports of expression levels of inflammasome components in 
autoimmune disease. AIM2 mRNA levels have been observed to be elevated in SLE patient 
peripheral blood mononuclear cells (PMBCs) (Zhang et al., 2013, Kimkong et al., 2009) and 
isolated monocytes (Liu et al., 2017). This isn’t unexpected as AIM2 is induced by IFN (DeYoung 
et al., 1997) and many SLE patients have elevated levels of IFN-induced genes (Baechler et al., 
2003). Expression of NLRP3 and NLRP1 were found to be down regulated in PBMCs of SLE 
patients (Yang et al., 2014b). However, in another study, expression levels of NLRP3 and caspase-1 
but not NLRP1 were found to be elevated in SLE patient monocytes (Liu et al., 2017). Expression 
levels of NLRP3, ASC and caspase-1 were elevated in immune thromboycytopenia and bullous 
pemphigoid patients with active disease (Qiao et al., 2016, Fang et al., 2016). NLRP3 and IL-1b 
mRNA expression has also been shown to be higher in patients with Mooren’s ulcer compared to 
healthy controls (Li et al., 2016). Liu et al. found no difference in IL-1b mRNA levels in the 
monocytes of SLE patients compared to controls, however they did observe increased IL-18 
expression (Liu et al., 2017). Increased expression of inflammasome components and mRNA levels 
of IL-1b and IL-18 does not infer increased function so demonstration of elevated inflammasome 
function and evidence of inflammasome-dependent activation and secretion of IL-1b and IL-18 in 
autoimmune patients is required.  
1.8.5 Inflammasome function in autoimmune patients 
Plasma IL-1b levels are reported to be elevated in Sjorgen’s syndrome patients and females with 
neuropsychiatric lupus (Szodoray et al., 2004, Dellalibera-Joviliano et al., 2003). Xu et al. showed 
no difference in plasma IL-1β levels between AIHA patients and controls (Xu et al., 2012). 
Accounts of the level of IL-1b in the serum of SLE patients vary widely. Two studies did not detect 
IL-1b in patients (Willis et al., 2012, Suzuki et al., 1995). One study found increased expression in 
a small percentage of patients during high disease activity compared to remission (Sturfelt et al., 
1997) while others observed decreased expression in SLE relative to controls (Yang et al., 2014b, 
Becker-Merok et al., 2010). Elevated levels of serum IL-18 in SLE patients have been documented 
in multiple studies (Calvani et al., 2004, Tucci et al., 2008, Hu et al., 2010). Active IL-1b and IL-18 
in the blood of patients does not necessarily indicate inflammasome involvement as both can be 
cleaved and activated independently of inflammasomes (Robertson et al., 2006, Black et al., 1988, 
Hazuda et al., 1990, Coeshott et al., 1999, Mizutani et al., 1991).   
Analysis of inflammasome function in cells taken from human patients is limited.  Two 
studies have been performed by the same group, investigating the role of the pro-inflammatory 
P2X7 purinergic receptor in SLE and RA (Portales-Cervantes et al., 2010, Portales-Cervantes et al., 
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2012). The inflammasome response to extracellular ATP is determined both by NLRP3 function, 
and by P2X7 receptor (P2X7R) that detects the ATP, as there are established polymorphisms that 
affect P2X7 function (Gong and Chen, 2015, Stokes et al., 2010). Monocytes from a subset of SLE 
and RA patients had significantly deficient NLRP3 inflammasome responses, measured by IL-1β 
release in response to LPS and ATP, which could not be explained solely by P2X7 genotype 
(Portales-Cervantes et al., 2010, Portales-Cervantes et al., 2012). In contrast, two studies have 
shown a modest increase in IL-1b release by monocytes from SLE patients compared to control, 
following LPS priming and ATP treatment (Liu et al., 2017, Yang et al., 2015). Liu et al. found that 
IL-1b release was enhanced by overnight pre-treatment with IFN-α to a greater extent in monocytes 
from SLE patients (Liu et al., 2017). While a representative western blot showed higher levels of 
procaspase-1 in SLE monocytes compared to controls, there was no observable difference in 
caspase-1 cleavage in response to LPS priming and ATP treatment, with or without IFN-α pre-
treatment, between patient and control cells, suggesting no intrinsic difference in NLRP3 function. 
P2X7 receptor genotype, an important determinant of this response, was not assessed in either 
study. SLE patient macrophages have shown increased caspase-1 activation in response to 
neutrophil extracellular traps (NETs) and antimicrobial peptide LL37 (Kahlenberg et al., 2013). 
Patient macrophages also released elevated amounts of IL-1b and IL-18 in response to these 
stimuli.  
Taken together, the current literature on the role of inflammasomes in autoimmune disease 
is far from conclusive. There is some evidence consistent with a hypothesis that decreased 
inflammasome function can contribute to loss of tolerance and autoantibody production, but other 
results suggest some elevation of inflammasome responses in SLE patients, so further investigation 
is warranted. 
1.9 How inflammasome deficiency might contribute to autoimmunity.  
Deficiencies in inflammasome function could alter responses to both pathogens and commensal 
organisms. Inflammasomes are necessary for the clearance of a number of bacterial, fungal and 
viral pathogens. Inflammasome deficiency could lead to the increased viability of cells harbouring 
intracellular infections, and prolonged production of pro-inflammatory cytokines and type I IFN 
(Figure 1.4).  
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Figure 1.4. Model for inflammasome deficiency contributing to autoimmunity. Infected 
macrophages with normal inflammasome function release IL-1b and IL-18, undergo pyroptosis and 
released organisms may be phagocytosed and killed by neutrophils. Inflammasome deficiency 
prevents pathogen clearance and enables ongoing inflammation. This could lead to loss of tolerance 
and autoantibody production via chronic type I interferon and IL-6 production. 
1.9.1 Type I Interferon and autoimmune disease 
There are three types of IFNs: type I, type II and type III (Pestka et al., 2004). IFN-α and IFN-β are 
the major studied type I IFNs. The IFN-α family is encoded by more than 13 genes, the gene family 
having expanded independently in mouse and human, while IFN-β exists as a single gene in most 
species (Hervas-Stubbs et al., 2011). IFN-β is produced by most cell types, whereas IFN-α is 
predominantly produced by plasmacytoid dendritic cells (pDCs) (Hagberg et al., 2011).  All type I 
IFNs signal through the type I IFN receptor (IFNAR), composed of two subunits IFNAR1 and 
IFNAR2, which are expressed in most tissues (de Weerd et al., 2007). Downstream signalling leads 
to the induction of hundreds of IFN-stimulated genes (de Weerd et al., 2007). The IFN-stimulated 
genes encode for proteins that have a wide spectrum of effects on many different cell types, best 
known for their potent anti-viral effects (Hervas-Stubbs et al., 2011). It is not clear why so there are 
so many IFN-α genes when all of the proteins encoded signal through the same receptor; it is 
possibly to allow diversity of regulation and different sites of expression. As IFN-α and IFN-β use 
the same receptor they have very similar functions and effects on immune responses, but it has been 
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suggested that there are subtle differences in the binding properties of the two that modify 
downstream signalling (Piehler et al., 2012). 
Type I IFN is a major driver of SLE and microarray studies have shown dysregulation of the 
IFN pathway in peripheral blood cells of approximately 50% of SLE patients (Baechler et al., 
2003). IFN-α is the predominant circulating type I IFN in the blood of SLE patients, but IFN-β is 
also present (Crow, 2016). This IFN gene expression serves as a marker for more severe disease 
outcomes (Baechler et al., 2003) and IFN-α treatment has also been linked to the onset and 
exacerbation of a number of autoimmune diseases (Gota and Calabrese, 2003). Monocytes have 
been reported to adopt characteristics of myeloid dendritic cells (DCs) in a subset of SLE patients, 
and serum from these patients can cause normal monocytes to differentiate into DCs (Rodriguez-Pla 
et al., 2014). IFN-α was shown to be necessary but not sufficient for this transformation. DCs 
control T cell proliferation and differentiation as well as inducing the differentiation of naïve B cells 
into plasma cells that secrete immunoglobulins (Banchereau et al., 2004). Unregulated DC 
maturation could thus lead to loss of tolerance and autoantibody production. Studies in mouse 
models of autoimmune disease further support a role for elevated levels of type I IFN in 
autoimmune disease progression. Elevated levels of  type I IFN responsive genes have been 
documented in pre-autoimmune NZB/W F1 mice (Lu et al., 2007) and IFN treatment accelerates 
disease (Adam et al., 1980).  
Disrupting the function of IFNAR1 in NZB mice greatly reduced disease characteristics 
including significant reductions in auto-antibody production and haemolytic anaemia (Santiago-
Raber et al., 2003). IFNAR deficiency similarly reduced SLE disease on the C57BL/6-lpr/lpr 
background (Braun et al., 2003). However, absence of functional IFNAR in lupus-prone MRL/lpr 
mice enhanced autoantibody production and renal disease (Hron and Peng, 2004). It is unclear why 
the effect of IFNAR disruption varies between lupus model mice, but it may be due to the genetic 
background of each model. IFNAR1 deficiency has also been shown to prevent disease in a mouse 
model of Sjorgen’s syndrome as well as delaying onset of disease and reducing symptoms in a 
mouse model of type I diabetes (Qaisar et al., 2017). A recent phase IIb clinical trial to assess the 
efficacy and safety of anifrolumab, an IFNAR inhibitor, reported substantially reduced disease 
activity in adults with moderate-to-severe SLE (Furie et al., 2017). These results support a role for 
type I IFN in SLE and a number of other autoimmune diseases and promote IFNAR as a potential 
therapeutic target. The role of type I IFN in autoimmune disease is further highlighted by studies 
into aberrant responses to cytosolic DNA. 
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1.9.2 Cytosolic DNA responses and autoimmune disease 
Mutations in genes involved in the clearance of DNA have been associated with autoimmune 
disease (Shrivastav and Niewold, 2013). Three prime repair exonuclease 1 (TREX1) is a 
cytoplasmic 3’-5’ DNA exonuclease that metabolises cytosolic DNA (Stetson et al., 2008, Mazur 
and Perrino, 1999). Mutations in TREX1 have been associated with autoimmune and inflammatory 
diseases that are characterised by an increase in type I IFN and other cytokine production, such as 
Aicardi-Goutieres syndrome (AGS), familial chilblain lupus and SLE (Namjou et al., 2011, Stetson 
et al., 2008, Morita et al., 2004, Peschke et al., 2016, Lee-Kirsch et al., 2007, Crow et al., 2006). 
AGS is an inherited encephalopathy accompanied by elevated levels of type 1 IFN and 
autoantibody production (Aicardi and Goutieres, 1984, Lebon et al., 1988, Cuadrado et al., 2015). 
TREX1 mutations that are associated with AGS are loss-of-function mutations that severely 
compromise exonuclease activity leading to abnormal cytosolic DNA accumulation (Lehtinen et al., 
2008). Trex1-/- mice have an elevated IFN signature, produce autoantibodies and develop profound 
tissue inflammation and significant mortality (Stetson et al., 2008, Morita et al., 2004).  
Cytosolic DNA not degraded by TREX-1 can be recognized by cGAS. Upon binding to 
dsDNA, cGAS catalyses production of cyclic GMP-AMP (cGAMP) that acts as a second 
messenger, binding to and activating stimulator of interferon genes (STING) (Sun et al., 2013, Wu 
et al., 2013, Cai et al., 2014). Activated STING then recruits TANK-binding kinase 1 (TBK1), 
which phosphorylates and activates interferon regulatory factor 3 (IRF3) (Tanaka and Chen, 2012), 
which induces type I IFN expression (Honda et al., 2006). Investigations in mice lacking cGAS 
show an essential role in the type I IFN response to a variety of pathogens including DNA viruses, 
retroviruses and intracellular bacteria (Collins et al., 2015, Gao et al., 2013, Li et al., 2013, Stavrou 
et al., 2015, Storek et al., 2015, Watson et al., 2015). Disease in Trex1-/- mice is entirely cGAS-
dependent and knockout of cGAS in these mice ameliorates the autoimmune phenotype (Gao et al., 
2015, Gray et al., 2015). Myocarditis and mortality in Trex1-/- mice can be substantially reduced by 
treatment with a cocktail of reverse transcription inhibitors (Beck-Engeser et al., 2011) suggesting 
that reverse transcription of retroelements is one possible source of the accumulating DNA. Further 
supporting the relevance of this pathway in autoimmune disease, mutations that cause spontaneous 
activation of STING have been shown to result in a familial-lupus-like disease (Jeremiah et al., 
2014). These results support a role for type I IFN production in response to the accumulation of 
cytosolic DNA in promoting autoimmune disease. The interactions between inflammasomes and 
the type I IFN pathway is an area of current interest that could link inflammasome deficiency with 
autoimmune disease.  
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1.9.3 Inflammasomes and interferon 
The balance between type I IFN production and inflammasome activation is proposed to be 
essential for immune homeostasis (Wang et al., 2017). Type I IFN production has been shown to 
reduce inflammasome function (Guarda et al., 2011). Firstly, IFN-β suppressed NLRP3 and 
NLRP1b but not AIM2 inflammasome-dependent caspase-1 activation in mouse macrophages by an 
undefined mechanism that involves signal transducer and activator of transcription 1 (STAT1) 
(Guarda et al., 2011). As well as suppressing caspase-1 activation IFN-β or IFN-α treatment 
reduced the levels of available pro-IL-1β through induction of IL-10 secretion. IFN-β also 
suppressed IL-1β production in human primary monocytes (Guarda et al., 2011). Evidence is also 
accumulating to support inflammasome-mediated restriction of type I IFN production, as discussed 
below.  
Our previous work has shown that NZB macrophages make significantly more IFN-β in 
response to transfected DNA than C57BL/6 macrophages, and this is likely due to their lower 
AIM2-mediated cell death permitting ongoing cytokine release (Yin et al., 2013).  Similarly, when 
AIM2, ASC or caspase-1 is knocked out of DCs and macrophages, they have a markedly increased 
IFN-β production in response to DNA, largely due to decreased cell death (Corrales et al., 2016). 
Two further studies have also shown enhanced interferon production in response to transfected 
dsDNA in Aim2-deficient macrophages (Gray et al., 2015, Rathinam et al., 2010). Dual knockdown 
of Trex1 and Aim2 results in much higher IFN-β transcript levels than Trex1 or Aim2 alone (Nakaya 
et al., 2017). This demonstrates the combined effect of the accumulation of DNA due to the absence 
of TREX1 and prolonged cytosolic sensing because the cells are not undergoing AIM2 
inflammasome-dependent pyroptosis. Inflammasomes may also inhibit type I IFN production by 
mechanisms independent of cell death. Recently, Wang et al., showed that cGAS is a direct 
cleavage target of caspase-1 and hence inflammasome activation reduced the production of type I 
IFN and other cytokines (Wang et al., 2017). Presumably this mechanism would only be important 
in cells that do not undergo pyroptosis, as the rapid cell death naturally terminates cytokine 
production. cGAS was also cleaved by caspase-4, -5 and -11 following non-canonical 
inflammasome activation (Wang et al., 2017).  
There is a further level of antagonism between the inflammasome and type I IFN 
production, involving IL-1β. IL-1β has been shown to attenuate type I IFN production and antiviral 
activity in hepatocytes and a human fibroblast cell line (Kohase et al., 1988, Tian et al., 2000), and 
also in the context of Mycobacterium tuberculosis infection (Mayer-Barber et al., 2014). Levels of 
IFN-β and bacterial replication were significantly elevated in IL-1r type 1 (Il1r1) knockout mice in 
response to M. tuberculosis compared to wild-type mice. Mice deficient for both IL1R1 and 
IFNAR1 were less susceptible to infection than Il1r1-/- mice. These results suggest that suppression 
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of type 1 IFN is a major mechanism of IL-1 in host resistance to M. tuberculosis. Overall it seems 
that type I IFN and inflammasome responses are mutually antagonistic. Inflammasome deficiencies 
could thus presumably predispose an individual to excessive type I IFN production.  
1.9.4 Inflammasomes and IL-6  
IL-6 is an important cytokine in B cell maturation and antibody production and serum concentration 
of IL-6 is elevated in several autoimmune diseases including SLE and RA (Solus et al., 2015). It 
has recently been reported that knocking out Aim2 in a mouse model of Alzheimer’s disease led to 
increased expression of IL-6 (Wu et al., 2017). While studying responses to host-derived DNA in 
influenza damaged lung tissue, Schattgen et al. observed that levels of IL-6 were significantly 
elevated in Aim2-/- mice five days post infection with influenza A virus compared to control mice 
(Schattgen et al., 2016). It is likely that the IL-6 is produced as a result of cGAS activation as the 
induction of IL-6 in mouse macrophages in response to transfection with 45 bp dsDNA, is 
dependent on cGAS and STING (Li et al., 2013).  This suggests that IL-6 is another potentially 
pathogenic cytokine that could be upregulated due to inflammasome deficiency.  
1.9.5 Inflammasomes and the microbiome 
Alterations to the intestinal microbiome have been observed in Nlrp3-/- mice (Hirota et al., 2011). 
Man et al., also reported differences in the microbiota between Aim2-/- and wild type mice that 
could be corrected by co-housing (Man et al., 2015). There are conflicting reports for a role of ASC 
in the regulation of the microbiome (Elinav et al., 2011, Mamantopoulos et al., 2017). Recent work 
using Asc-/- and wildtype littermate controls showed that differences in microbiota between colonies 
were dependent on maternal inheritance rather than Asc genotype, which had no reliable effect on 
microbiota when mice were separated from their wildtype littermates (Mamantopoulos et al., 2017) 
Consequently further analysis is required to confirm that microbiome alterations in Nlrp3-/- and 
Aim2-/- mice are truly genotype dependent. Whether these two genes, and the many other genetic 
differences in NZB mice generates an altered microbiome remains to be established. Nevertheless, 
there is some evidence for an impact of the microbiota on development of NZB autoimmunity. 
Germ-free NZB mice have been shown to have delayed and reduced splenomegaly (East and 
Branca, 1969). Altered mucosal microbiota could contribute to autoimmunity in a number of ways 
including molecular mimicry, microbial alteration of host antigens or induced exposure of self-
antigen and altering the production of pro- or anti-inflammatory cytokines and thus modulating 
intestinal mucosal barrier integrity (Kuhn et al., 2014, Luckey et al., 2013). 
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1.10 Hypothesis and Research Aims  
The profound inflammasome deficiencies in autoimmune model NZB mice (Appendix 2) (Sester et 
al., 2015a) provided the starting point for this project. We propose two possible consequences for 
inflammasome deficiency in these mice. Firstly that low inflammasome function could lead to 
increased production of cytokines such as IL-6 and type I IFN that promote loss of tolerance. 
Second, we propose that inflammasome deficiency could play a protective role against later stage 
organ damage. The inflammasome function of NZW was not known, and we hypothesised that 
NZB/W F1 mice would have some degree of deficient inflammasome response. A partial deficiency 
could predispose the mice to loss of tolerance but that at the same time, whatever remaining 
inflammasome function they have could contribute to kidney damage later in the disease. The 
NLRP3 deficiency in NZB mice is due to an aberrantly spliced exon, introduced due to a single 
point mutation. We hypothesise that it will be possible to restore NLRP3 function in these mice by 
correcting the splicing defect and that this may reduce autoantibody and anti-erythrocyte antibody 
production. Restoring NLRP3 function in these mice could however increase kidney damage. There 
are few, conflicting reports of inflammasome function in humans with SLE and they look only at 
down-stream inflammasome outputs that are not always indicative of inflammasome activity. We 
predict that there exists at least a subpopulation of SLE patients with decreased inflammasome 
activity. However, to study this properly we wanted a quantitative assay for early stage 
inflammasome activity.  We proposed that cells with ASC specks, indicative of inflammasome 
activation, could be distinguished by flow cytometry from those in which the inflammasome was 
not activated and the ASC remained diffuse. To test these hypotheses we developed four aims for 
this project.   
 
Aims: 
1.   To develop a direct and quantitative flow cytometry assay for inflammasome formation.  
2.   To determine whether NZB/W F1 mice, which have lupus-like autoimmunity have any 
deficiency in AIM2 and NLRP3 inflammasomes.  
3.   To determine whether the NZB Nlrp3 allele promotes autoimmunity.  
4.   To optimise techniques for assessing inflammasome activity in human monocytes.  
  
 
 
28 
CHAPTER 2: Materials and Methods 
  
These materials and methods are for the extended results sections of Chapters 4 and 5 and for 
Chapter 6. Materials and methods that pertain to the published and submitted papers remain as 
formatted with those papers and are included in Chapters 3-5.  
2.1 Materials  
Nigericin (N7143, Sigma-Aldrich) was dissolved in ethanol at 5 mM or dimethyl sulfoxide 
(DMSO) (Life Technologies) at 10 mM. ATP (adenosine 5'-triphosphate disodium salt hydrate, 
A2383-1G, Sigma-Aldrich) was dissolved in sterile water at 150 mM as required. Calf thymus (CT) 
DNA (Sigma-Aldrich) was further purified by phenol-chloroform and Triton-X114 extraction 
(Stacey et al., 2003). Unless otherwise noted, LPS used was ultra-pure LPS from E. coli 0111:B4 
(InvivoGen). Recombinant human colony stimulating factor (CSF-1) was a gift from Chiron, 
Emeryville, CA. Complete RPMI is RPMI 1640 with 10% heat inactivated foetal calf serum (FCS), 
1x GlutaMAX, 50 U/ml penicillin, 50 µg/ml streptomycin (all Life Technologies). Complete 
DMEM is Dulbecco’s Modified Eagle Medium (DMEM) with 10% heat inactivated FCS, 50 U/ml 
penicillin and 50 µg/ml streptomycin (all Life Technologies). FCS for all applications was heat 
inactivated at 56°C for 30 min to destroy complement factors. Propidium iodide (PI) (Life 
Technologies) was diluted in 1x Phosphate buffered saline (PBS) to a stock concentration of 10 
µg/ml. PBS was Dulbecco’s modified PBS, without calcium or magnesium (Lonza). Proteinase K is 
≥ 600 U/ml, (Thermo Fisher Scientific). 
2.2 Mouse experimentation 
C57BL/6, NZB, NZW, NZB/W F1 and Nlrp3-/- (Martinon et al., 2006) mice were housed under 
specific pathogen-free conditions at the University of Queensland and were used under approval 
353/14 from the University of Queensland Animal Ethics Committee. All C57BL/6 mice used for 
the work described in this thesis were C57BL/6J.  
2.2.1 Intraperitoneal injections and peritoneal lavage 
Intraperitoneal (i.p.) injections were given at a final volume of 100 µl for C. albicans and 400 µl for 
LPS, LPS plus nigericin and associated controls. C. albicans was prepared as previously published 
(Appendix 2) (Sester et al., 2015a). Mice were sacrificed by CO2 asphyxiation and the peritoneal 
cavity was flushed with 5 or 10 ml of sterile ice-cold PBS using a transfer pipette. Peritoneal lavage 
fluid was kept on ice until processed.   
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2.2.2 Assessment of neutrophil and macrophage populations in peritoneal lavage fluid 
Peritoneal lavage fluid was centrifuged at 500g for 5 min. Supernatants were removed and stored 
until assayed for IL-1β. The cells were resuspended in PBS and fixed with paraformaldehyde (PFA) 
(2% final concentration in PBS) on ice for 30 min. Cells were washed with PBS and centrifuged at 
500g for 5 min. Supernatants were removed, cells were resuspended in 1 ml of PBS/0.1% sodium 
azide/0.1% BSA/0.1% FCS and stored overnight at 4°C. Prior to staining cells were blocked in 
PBS/0.1% sodium azide/0.1% BSA/3% FCS with 10% 2.4G2 hybridoma supernatant (anti-mouse 
FcRgII/III) at room temperature for 20 min. One million cells were stained in 100 µl PBS/0.1% 
sodium azide/0.1% BSA/3% FCS plus antibody at room temperature for 45 min. Anti-mouse Ly6G 
(Gr-1) FITC clone 1A8-Ly6g (eBioscience ref 11966880) was used at 1/200 final dilution and rat 
anti mouse F4/80:RPE (Serotec, MCA497PEB batch no. 0205a) was used at 1/10 dilution in 100 µl. 
Stained cells were analysed on a BD Accuri C6 flow cytometer (BD Biosciences). Where the 
absolute number of positive cells is given, Flow-Count Fluorospheres (7547053, Beckman Coulter) 
were used to determine cell numbers. Briefly, a known number of Flow-Count Fluorospheres were 
added to each sample immediately prior to analysis and the sample was mixed thoroughly. The 
number of a given cell type in the original sample was calculated following the formula: number of 
cells in sample = number of cells collected / (number of fluorospheres collected/ number of 
fluorospheres added to sample). 
2.2.3 Measuring anti-erythrocyte antibodies  
Mice were sacrificed and blood was taken by heart puncture and collected in 1.5 ml tubes with an 
added 50mM EDTA as an anticoagulant. Red blood cells were pelleted and resuspended in 1 ml of 
RPMI + 2% FCS. Cells were further diluted 1:10 in RPMI + 2% FCS, 100 µl volume, before 
staining with 1/500 dilution of Alexa Fluor 488 goat anti-mouse IgG (A11001, Invitrogen). After 
incubation for 30 min, 1 ml of PBS/0.1% sodium azide/0.1% BSA/0.1% HI-FCS was added and 
cells were pelleted. The cells were resuspended in 200 µl PBS/0.1% sodium azide/0.1% BSA/0.1% 
HI-FCS and analysed by flow cytometry.  
2.3 CRISPR/Cas9 optimisation for repair of NZB Nlrp3 
2.3.1 Preparation of gRNAs and Cas9 mRNAs  
Guide RNAs (gRNAs) and Cas9 mRNA were prepared using a plasmid-based procedure described 
previously (Ran et al., 2013b) with some modifications. For each gRNA the complementary pair of 
oligos (Table 2.1) was annealed and cloned into pX330 (Addgene #42230). Cloning into pX330 
was performed as described by Ran et al. but the BbsI digest and ligation were combined into one 
step. pX330 was digested with BbsI and ligation components were added directly to the digest. The 
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insertion was sequence verified using the primers U6 seq F and gRNA UniR (Table 2.1). For each 
gRNA a T7-gRNA PCR product was amplified with a T7 promoter sequence introduced on the 
forward primer together with a universal reverse primer (Table 2.1). This product was used as the 
template for in vitro transcription (IVT) using the MEGAshortscript T7 IVT kit (Life Technologies) 
as per the manufacturer’s protocol.  
Cas9 coding region was amplified from pX330 with the addition of a T7 promoter using 
primers Cas9 T7 F and Cas9 R (Table 2.1). The resulting T7-Cas9 PCR product was gel purified 
and used as the template for IVT using mMessage mMachine T7 ULTRA kit (Life Technologies) as 
per the manufacturer’s protocol.  
2.3.2 Transfection of HEK293 cells with Cas9 mRNA or Cas9 expression plasmid (pX330)  
HEK293 cells were plated in 12-well plates at 1.5 x 105 cells per well in complete DMEM and 
incubated overnight. Lipofectamine 2000 and mRNA or plasmid were combined, according to the 
manufacturer’s protocol, in 500 µl of Opti-MEM I (Life Technologies) and incubated at room 
temperature for 10 min. Medium was removed from the wells and replaced with the transfection 
mixture and the plates were incubated for 4 h at 37°C. Transfection mixture was then replaced 
with complete DMEM and cells were incubated for a further 20 h before protein extracts were 
prepared for western blot analysis.  
2.3.3 Transfection and sorting of B16 cells to test CRISPR gRNAs 
B16 cells were plated at 1.5 x 106 cells per well in a 6-well plate in complete RPMI without 
antibiotics. After overnight incubation the cells were transfected with 12 µl of Lipofectamine 
2000, 0.5 µg of pEF6 plasmid expressing GFP and 2 µg of pX330 expressing gRNA per well as 
per the manufacturer’s protocol. Cells were collected 24 h later and cells with high GFP 
expression were separated via fluorescence-activated cell sorting (FACS) using a BD FACSAria 
Cell Sorter at the Queensland Brain Institute. GFP-high cells were cultured for a further four days 
before their genomic DNA was isolated. To isolate genomic DNA cells were resuspended in 200 
µl of lysis buffer (0.1 M NaCl, 2.5 mM EDTA, 10 mM Tris pH 7.5, 0.5% SDS) with 2 µl 
proteinase K (≥ 600 U/ml) and incubated overnight at 55°C. After the incubation 800 µl of 100% 
ethanol was added and the sample was stored overnight at -20 °C.  The sample was centrifuged (5 
min, 14,000 rpm), washed with 70% ethanol and centrifuged again (5 min, 14,000 rpm). The 
pellet was then air dried and resuspended in Tris-EDTA buffer solution.  
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Table 2.1. Oligos and primers for CRISPR 
Oligo/ Primer  Sequence 5 prime to 3 prime 
gRNA A For. Oligo CACCGATGCTGGTGGTGGGTACTAT 
gRNA A Rev. Oligo AAACATAGTACCCACCACCAGCATC 
gRNA A T7 For.  TAATACGACTCACTATAGGGGATGCTGGTGGTGGGTACTAT 
gRNA B For. Oligo CACCGTCATTAAGTCAAGAACTTTT 
gRNA B Rev. Oligo AAACAAAAGTTCTTGACTTAATGAC 
gRNA B T7 For.  TAATACGACTCACTATAGGGGTCATTAAGTCAAGAACTTTT 
gRNA C For. Oligo CACCGGCTCCAAACTAGAAGTCATA 
gRNA C Rev. Oligo AAACTATGACTTCTAGTTTGGAGCC 
gRNA C T7 For.  TAATACGACTCACTATAGGGGGCTCCAAACTAGAAGTCATA 
gRNA E For. Oligo CACCGGAATAGCTAACTACAGTGTT 
gRNA E Rev. Oligo AAACAACACTGTAGTTAGCTATTCC 
gRNA E T7 For.  TAATACGACTCACTATAGGGGGAATAGCTAACTACAGTGTT 
gRNA F For. Oligo CACCGTGAATAGCTAACTACAGTGT 
gRNA F Rev. Oligo AAACACACTGTAGTTAGCTATTCAC 
gRNA F T7 For.  TAATACGACTCACTATAGGGGTGAATAGCTAACTACAGTGT 
gRNA UniR AAAAGCACCGACTCGGTGCC 
Cas9 T7 F TAATACGACTCACTATAGGGAGAATGGACTATAAGGACCAC
GAC 
Cas9 R GCGAGCTCTAGGAATTCTTAC 
U6 Seq F ACTATCATATGCTTACCGTAAC 
Repair Oligo 1 ACACTATAGAAGTATTTTTCTTTGACTTGTTTTTCATTTATCT
GGATACATTTCCATATGACTTCTAGTTTGGAGCACAAAAAT
GCATAGTACCCACCACCAGCATTTATTCAGCTACTCATTAA
GTCAAGAACTTTTTGTGTAAGTTTCTACATTTTTACTGTTAC
AAATCACTCTGTA 
Repair Oligo 2 ACAAACACTATAGAAGTATTTTTCTTTGACTTGTTTTTCATT
TATCTGGATACATTTGCATATGACTTCTAGTTTGGAGCACAA
AAACCCATAGTACCCACCACCAGCATTTATTCAGCT 
NLRP3 Splice For1 ATGCTGGGTACCAAACTCGG 
NLRP3 Splice Rev1  TCATGCTACACATTAGGGAACCT 
2.3.4 PCR and T7 endonuclease I assays for CRISPR/Cas9 efficiency 
The target genomic region was amplified by PCR using Phusion High-Fidelity DNA polymerase 
(New England Biolabs) and primers NLRP3 splice For1 and NLRP3 splice Rev1 (Table 2.1) as 
per manufacturer’s protocol. PCR Products were purified using the UltraClean 15 DNA 
Purification Kit (Mo Bio Laboratories) and recovered in DNase/RNase free water. T7 
endonuclease I (T7E1) (M0302, New England Biolabs) was used to cleave purified PCR products 
with CRISPR/Cas9-mediated modifications as per the manufacturer’s protocol based on a 
previously published method using the Surveyor nuclease (Guschin et al., 2010). Briefly, 200 ng 
of PCR product in 19 µl 1 x NEBuffer 2 was denatured (95°C, 5 min) and re-annealed (95-85°C, -
2°C/second then 85-25°C, -0.1°C/second) before being incubated with 1 µl T7EI for 15 min at 
37°C. The reaction was stopped by adding 1.5 µl of 0.25 M EDTA, and products analysed on a 
2% agarose gel.  
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2.3.5 Cas9 cell free assay 
The ability of IVT gRNAs in combination with Cas9 nuclease protein (S. pyogenes, M0386, New 
England Biolabs) to cleave target DNA was tested following the nuclease manufacturer’s protocol. 
Briefly, 30 nM Cas9 nuclease and 30 nM gRNA were pre-incubated in Cas9 Nuclease Reaction 
Buffer (New England Biolabs) in a total volume of 27 µl at 25°C for 10 min. Substrate DNA (3 µl 
of 30 nM) was then added and the reaction was incubated at 37°C for 15 min. 1 µl of Proteinase K 
was added followed by a further 10 min incubation at room temperature. Fragments were then 
separated by electrophoresis on a 2% agarose gel.  
2.4 Analysis of human inflammasome function 
2.4.1 Preparation of PBMCs, primary human monocytes and HMDM 
Blood was obtained with informed consent from healthy volunteers under approval of the 
University of Queensland Human Research Ethics Committee. PBMCs were isolated from fresh 
blood as described in chapter 3 (section 3.2.3.7) and previously published (Sester et al., 2015b). 
Isolated PBMCs were stored in liquid nitrogen in FCS with 10% DMSO. Primary human 
monocytes were isolated from thawed PBMCs either by depletion of non-monocytes (negative 
selection) using the MACS monocyte isolation kit II (human) (Miltenyi Biotec) or magnetically 
labelling CD14+ cells with microbeads (positive selection) using MACS CD14 MicroBeads 
(human) (Miltenyi Biotec) according to manufacturer’s instructions. Negative selection was used 
unless otherwise stated. The purity of the acquired monocyte population was routinely tested by 
staining a sample for CD14 with an APC-conjugated CD14 antibody (clone M5E2, BD 
Biosciences) and analysing by flow cytometry. After negative selection, the enriched samples were 
>88% CD14+. Monocytes were differentiated to human monocyte derived macrophages (HMDM) 
by differentiating for 7 days in complete RPMI supplemented with 104 U/ml CSF1 with medium 
refreshed on day 5.  
2.4.2 Plating monocytes for treatment with nigericin and ATP  
For analysis of released IL-1β, monocytes were plated at 7.5 x 104 cells/well (96-well plate) in 
complete RPMI with a final volume of 200 µl/well after treatments. For cell death and ASC speck 
analysis monocytes were plated at 1 x 105 cells/well in a 24-well plate that was coated with poly-
HEMA to prevent adherence in a final volume of 500 µl/well after treatments. Details for poly-
HEMA coating can be found in appendix 1 (Sester et al., 2016). Nigericin and ATP treatments were 
conducted as described in figure legends.  
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2.4.3 Chemical transfection for AIM2 activation 
Priming and pre-treatment of monocytes and PBMCs was conducted in 24-well plates with poly-
HEMA coating. Cells were then collected with PBS + 1% FCS and centrifuged at 300g for 5 min 
followed by two washes with PBS + 1% FCS. After the washing steps monocytes and PBMCs were 
plated at 7.5 x 104 cells/well and 2 x 105 cells/well (96-well plate) respectively in antibiotic-free 
medium (RPMI-1640, 10% FCS, 25 mM HEPES (Life Technologies), 1x GlutaMAX). HMDM 
were differentiated from monocytes seeded at 8 x 104 cells/well (96-well plate) as described above 
and medium was changed to antibiotic-free medium on the day of the transfection. Transfection 
complexes of nucleic acid (CT DNA, poly(dT) (Amersham) or B16-F0 mRNA) with 
Lipofectamine2000 (Thermo Fisher Scientific) or X-tremeGENE HP DNA transfection reagent 
(Sigma-Aldrich) were prepared in RPMI-1640 with 1x GlutaMAX as per the manufacturer’s 
instructions. After transfection complexes were added the plate was centrifuged at 700g for 10 min. 
When used as a positive control, nigericin was added to the appropriate wells after the 
centrifugation step.  
2.4.4 Electroporation of monocytes for AIM2 activation 
Pre-treatment and priming was conducted in 24-well plates coated with poly-HEMA. Cells were 
then collected with PBS + 1% FCS and centrifuged at 300g for 5 min followed by two washes with 
PBS + 1% FCS. Cells were then resuspended in complete RPMI with 25 mM HEPES. Monocytes 
(5.5 x 105) were incubated in the cuvettes at room temperature in 400 µl of complete RPMI with 20 
µg CT DNA and then electroporated at 320 V, 1000 µF using a Bio-Rad Gene Pulser MXcell. 
Monocytes were immediately transferred to 1.5 ml tubes with 600 µl complete RPMI and plated out 
in a 96-well plate for assessing IL-1β release (5 x 104 cells/well in 200 µl) or in poly-HEMA coated 
24-well plates for assessing cell viability or ASC-speck formation (1 x 105 cells/well or 3.5 x 105 
cells/well respectively).  
2.4.5 ELISA analysis of human IL-1β 
170 µl from a total 200 µl cell culture supernatant was collected per well and transferred to a new 
plate. The plate was centrifuged at 500g for 5 min and 130 µl of supernatant was retained for 
ELISA analysis. IL-1β levels in the cell culture supernatants were determined using the Human IL-
1β/IL1F2 DuoSet ELISA kit (R&D Systems DY201) 
2.4.6 Measuring cell viability 
2.4.6.1 Propidium iodide staining of monocytes  
For assessment of cell viability by PI staining, the medium which contained some cells was 
collected and the well was washed with PBS to detach the remaining cells and that was added to the 
 
 
34 
same tube, and samples were kept on ice. PI was then added to the samples at a final concentration 
of 1 µg/ml (nigericin and ATP treatment) or 5 µg/ml (electroporation) and staining was analysed 
using a BD Accuri C6 flow cytometer (BD Biosciences) as outlined in chapter 5.  
2.4.6.2 LDH assay 
Release of lactate dehydrogenase (LDH) into the cell culture medium was assessed as a measure of 
cell viability using the TOX7 In Vitro Toxicology Assay Kit (Sigma-Aldrich) according to the 
manufacturer’s protocol. Percentage of cell death was calculated relative to the total LDH released 
from untreated cells by detergent lysis. LDH Assay Lysis Solution (L2152, Sigma-Aldrich) was 
added at 10% of the volume in the well.  
2.4.6.3 MTT assay  
The MTT assay measures the cleavage of MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide] to an insoluble blue formazan product by cellular reductases 
(Berridge and Tan, 1993) and results are dependent on cell number and metabolic function. The 
assay was performed as previously described (Stacey et al., 1993). 
2.4.7 Monocyte fixation and ASC staining for assessment of ASC speck formation  
Monocytes were fixed with ethanol and immunostained to detect ASC as described in chapter 3 and 
appendix 1 (Sester et al., 2015b, Sester et al., 2016). The blocking step was carried out overnight at 
4°C.  
2.5 Immunoblot analysis 
For analysis of protein expression in adherent HEK293 cells, primary human monocytes and 
HMDM, medium was removed and cell monolayers were directly lysed in 66 mM Tris pH 7.4, 2% 
SDS. Western blotting was conducted as previously described (Sester et al., 2015a). The primary 
antibodies used, for experiments not described in published or submitted papers, were: chapter 5 – 
monoclonal anti-FLAG M2 (F1804-200UG, Sigma-Aldrich), chapter 6 - anti-AIM2 MAb 3B10 
(AG-20B-0040-C100, Adipogen) and anti-GAPDH (2275-PC-100, Trevigen). The HRP-linked 
secondary antibodies used were anti-mouse IgG (7076S, Cell Signalling) and anti-rabbit IgG 
(7074S, Cell Signalling). Different proteins were used as loading controls at different times 
throughout this thesis. When performing western blots, we inactivate HRP using 0.1% sodium 
azide, and re-probe the blot when possible. This requires the use of antibodies from different 
species. Thus, a loading control would be chosen that could be used without the need to strip the 
blot. During the course of this study the S6 antibody ran out and was replaced with GAPDH as this 
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was deemed more useful to the laboratory as a whole. Blots were analysed using an Amersham 
Imager 600RGB (GE Healthcare Life Sciences).  
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Chapter 3: A novel flow cytometric method to assess inflammasome formation 
3.1 Introduction 
This chapter describes a time of flight inflammasome evaluation (TOFIE) assay that provides a 
direct and quantitative measure of ASC speck formation that accompanies inflammasome activation 
(Sester et al., 2015b). Analysis of inflammasome activation can be performed by measurement of 
downstream processes, such as processing of caspase-1 and IL-β, but analysis at the single cell level 
has previously required microscopy and laborious counting of ASC specks. The flow cytometric 
assay developed here allows rapid quantification of individual responding cells within a mixed 
population.  
Presented in this chapter is a published paper (Sester, Thygesen et al. Journal of 
Immunology 2015 194:455-62), as well as the results of additional optimisation experiments 
performed.  Methods for the additional experiments are as per the published paper unless stated 
otherwise. The TOFIE assay has also been published as a protocol in Current Protocols in 
Immunology (Sester et al., 2016) and this is included as Appendix 1.  
3.2 Published Paper 1  
 
Sester DP, Thygesen SJ, Sagulenko V, Vajjhala PR, Cridland JA, Vitak N, Chen KW, Osborne 
GW, Schroder K and Stacey KJ. A novel flow cytometric method to assess inflammasome 
formation. J Immunol. 2015;194(1):455-62.  
 
Contributions to the publication:  
I was joint first author of this publication. Overall I performed ~50% of the experimental work 
presented in the paper + supplementary figures, and my specific contributions to each figure are 
presented in Table 3.1. I also performed a number of experiments in the primary set up and 
optimisation of the technique that did not form part of the publication, and some of these are 
presented in section 3.4. Contributions of all authors were: 
David Sester: Presented experimental work 47%, writing 40%, project design, supervision 
Sara Thygesen: Presented experimental work 50%, writing 20%, project design 
Vitaliya Sagulenko: Presented experimental work 3% 
Parimala Vajjhala, Jasmyn Cridland, Nazarii Vitak, Kaiwen Chen: Supporting experimental work 
Geoffrey Osborne, Kate Schroder: Discussion, reagents, intellectual input 
Katryn Stacey: Writing 40%, project concept, project design, supervision  
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Table 1 I performed the whole experiment apart from running the samples on the CantoII and LSRII and 
taking microscopy images. 
Figure 1 C. I performed the whole experiment up until flow cytometry analysis. 
D. I performed the whole experiment.  
Figure 2 I did all experimental work for this figure. 
Figure 3 I did all of part A and half of part C.  
Figure 4 I performed treatments and staining of the cells. 
Figure 5 I performed all experimental work apart from running samples on the Canto flow cytometer.  
Figures 6&7 I did not contribute to these experiments 
Sup 1-3 I did all sample preparation 
Sup 4 I did not contribute to this experiment 
 
3.2.1 Abstract 
Inflammasomes are large protein complexes induced by a wide range of microbial, stress and 
environmental stimuli, that function to induce cell death and inflammatory cytokine processing. 
Formation of an inflammasome involves dramatic relocalisation of the inflammasome adapter 
protein ASC into a single speck. We have developed a flow cytometric assay for inflammasome 
formation - “time of flight inflammasome evaluation” (TOFIE), which detects the change in ASC 
distribution within the cell. The transit of ASC into the speck is detected by a decreased width or 
increased height of the pulse of emitted fluorescence. This assay can be used to quantify native 
inflammasome formation in subsets of mixed cell populations ex vivo. It can also provide a rapid 
and sensitive technique for investigating molecular interactions in inflammasome formation, by 
comparison of wild-type and mutant proteins in inflammasome reconstitution experiments. 
3.2.2 Introduction 
Inflammasome complexes recruit and activate procaspase-1, which subsequently processes the 
proinflammatory cytokines IL-1β and IL-18 prior to their release from cells, and also initiates a 
rapid lytic form of cell death termed pyroptosis (Schroder and Tschopp, 2010, Aachoui et al., 2013, 
Miao et al., 2011). Recent work has shown that inflammasome formation can also lead to the 
recruitment and activation of procaspase-8, leading to initiation of apoptotic cell death (Pierini et 
al., 2012, Sagulenko et al., 2013). There is great interest in inflammasome processes, due to their 
relevance to a wide range of diseases, including gout, atherosclerosis, Alzheimer’s disease, and type 
II diabetes (Martinon et al., 2006, Duewell et al., 2010, Heneka et al., 2013, McGettrick and 
O'Neill, 2013).  
Table 3.1. Breakdown of my contribution to the figures in the Sester, 2015 publication 
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Formation of inflammasomes is initiated by the induced oligomerisation of one of a number 
of Nod-like receptor proteins such as NLRP3 or NLRC4, or by absent in melanoma 2 (AIM2). 
NLRC4 is activated by cytosolic flagellin, AIM2 by cytosolic DNA, and NLRP3 by diverse stimuli 
including extracellular ATP, the K+ ionophore nigericin, and a range of particulate substances such 
as monosodium urate crystals, cholesterol crystals, β-amyloid, and alum (Schroder and Tschopp, 
2010). A central factor in inflammasome structures is the adapter molecule, ASC (apoptosis-
associated speck like protein containing a CARD). ASC consists of two domains of the death-fold 
superfamily, a pyrin domain (PYD) and a caspase recruitment domain (CARD), which are both 
involved in self-association of ASC within the inflammasome (Masumoto et al., 2001). The 
oligomerisation of ASC provides a platform for recruitment of caspases; procaspase-1 is recruited 
via homotypic CARD-CARD interactions, and procaspase-8 via the PYD of ASC (Sagulenko et al., 
2013).  
ASC was first observed as a protein forming a prominent speck in tumour cells undergoing 
chemotherapy-induced apoptosis (Masumoto et al., 1999). This ASC “speck” is a distinguishing 
feature of inflammasome activation. ASC is diffuse throughout the cytoplasm and nucleus of 
resting macrophages. Upon treatment with inflammasome stimuli such as the NLRP3 agonist 
nigericin, a potassium ionophore, ASC rapidly relocates to form the inflammasome speck. This 
appears to be an “all or nothing” response, with most of the ASC in the cell accumulating in the 
speck within minutes of initiation (Cheng et al., 2010). We have taken advantage of this rapid and 
striking re-localization of ASC to develop a flow cytometric assay for inflammasome activity. This 
technique provides a direct and quantitative measure of early events in inflammasome formation. 
3.2.3 Materials and Methods 
3.2.3.1 Materials 
ATP, nigericin and LPS (L9764, Salmonella minnesota) were purchased from Sigma-Aldrich. ATP 
was reconstituted in water at 150 mM and used fresh or after no more than one freeze-thaw cycle. 
Nigericin was reconstituted in ethanol at 5 mM and stored at 4oC. LPS was prepared as a 10 mg/ml 
stock in PBS/0.1% triethylamine and sonicated before freezing of stocks. Alum was purchased from 
Pierce Biotechnology. Antibodies used were: Rabbit polyclonal anti-ASC (N-15)-R (Santa Cruz 
Biotechnology), Alexa Fluor 488 goat anti-rabbit IgG (H+L) (Life Technologies), PerCP mouse 
anti-human CD14 (MΦP9) (BD Pharmingen), Rat PE-conjugated anti-mouse CD19 (1D3) (BD 
Pharmingen) and APC-conjugated F4/80 (BM8) (eBiosciences). RPMI-1640, DMEM, foetal calf 
serum, Penicillin/Streptomycin, GlutaMAX, HEPES and propidium iodide were purchased from 
Life Technologies. 
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3.2.3.2 Culture, inflammasome activation and fixation of mouse macrophages 
Mice were used under approval from a University of Queensland Animal Ethics Committee. Bone 
marrow-derived macrophages (BMMs) were obtained from wild-type C57BL/6, Casp1-/- (Kuida et 
al., 1995), Asc-/- (Mariathasan et al., 2004) and Nlrp3-/- (Martinon et al., 2006) mice. BMMs were 
differentiated in CSF-1 for 7 days as described previously (Sester et al., 2005). BMMs, in RPMI-
1640 with 10% heat inactivated foetal calf serum (HI-FCS), 50 U/ml penicillin and 50 µg/ml 
streptomycin, 1 x GlutaMAX and 25 mM HEPES (referred to as complete RMPI-1640) were 
treated with 10 ng/ml LPS for 4 h at 37oC (unless otherwise stated in figure legends), then harvested 
from 100 mm x 100 mm, square bacteriological plates (Sterilin Limited) using PBS, and 
resuspended in complete RPMI-1640 lacking HI-FCS (2 x 106 cells/ml). 1 x 106 cells in 
polypropylene tubes were treated with either media alone, 5 mM ATP or 10 µM nigericin and 
incubated at 37˚C for 15 min prior to fixation. Although activation was done under serum-free 
conditions, inclusion of 10% HI-FCS did not affect the efficiency of staining. However, serum 
caused a delay in the response to nigericin but not ATP, both for ASC speck formation and cell 
death, and longer incubations were necessary in the presence of serum. Cells were fixed by addition 
of 4 volumes of ice cold 100% ethanol followed by incubation at room temperature for 15 min. 
Fixed cells were pelleted at 600g for 10 min, and resuspended as outlined below in 
“Immunostaining Cells for ASC for Flow Cytometric Analysis”. Procedures were designed to avoid 
cell harvesting and repeated centrifugation after inflammasome triggering, due to the fragility of 
pyroptotic cells. However, extended incubation in polypropylene tubes can lead to loss of cells by 
adherence. 
3.2.3.3 Production of Casp1-/- iBMM-mASC-EGFP 
Casp1-/- immortalized BMMs (iBMMs) (Sagulenko et al., 2013) were stably transfected with pEF6-
mASC-EGFP (mouse ASC with a C-terminal EGFP fusion) and clones were established by single 
cell deposition using a FACS Aria II. 
3.2.3.4 Activation of BMMs with alum and DNA  
For activation with alum, BMMs were primed with 10 ng/ml LPS for 3 h in complete RPMI-1640 
and then treated for a further 3.5 h with either media alone or 200 µg/ml alum. Unprimed BMMs 
were electroporated in complete RPMI-1640 as outlined previously (Sagulenko et al., 2013) with or 
without 10 µg of calf thymus DNA, washed immediately following electroporation, and incubated 
for a further 45 min. Cells were then fixed and pelleted as above. 
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3.2.3.5 Infection of BMMs with Salmonella 
BMMs were primed with 10 ng/ml LPS for 4 h in complete RPMI-1640 lacking penicillin and 
streptomycin, harvested and 4 x 106 cells were exposed to Salmonella enterica (SL1344) at a MOI 
of 10 in a volume of 50 µl, centrifuged at 700g for 10 min, and then incubated at 37oC for a further 
5 min. Following this, cells and bacteria were re-suspendend and incubated for a further 20 min at 
37oC, after which cells were resuspended in 2 ml of complete RPMI-1640 lacking HI-FCS, 
penicillin or streptomycin but supplemented with 50 µg/ml gentamycin and incubated at 37oC for a 
further 90 min. BMMs were fixed and pelleted as above. 
3.2.3.6 Activation of resident peritoneal cells ex vivo 
Resident peritoneal cells were obtained by lavage with ice cold Ca2+/Mg2+-free PBS and primed 
with 10 ng/ml LPS for 4 h in complete RPMI-1640 at 37oC. Cells were then harvested and treated 
in complete RPMI-1640 lacking HI-FCS with either media alone or 10 µM nigericin for 30 min 
after which cells were fixed and pelleted as above.    
3.2.3.7 Preparation of PBMCs 
Blood was obtained with informed consent from healthy volunteers under approval of the 
University of Queensland Human Research Ethics Committee. 90 ml of fresh blood was diluted 
with 210 ml of sterile PBS. 12.5 ml of Ficoll-Paque PLUS (GE Healthcare) was added to 8 x 50 ml 
tubes and then 37.5 ml of diluted blood was carefully layered on top. Tubes were centrifuged for 45 
min at 400g, room temperature, no brake and minimum acceleration. The interface containing the 
peripheral blood mononuclear cells (PBMCs) was removed and transferred into 8 new tubes.  PBS 
was added to the tubes to 50 ml and centrifuged for 10 min, 400g, 10˚C with the brake on. The 
pellet was resuspended in PBS and respun in 4 tubes of 50 ml, and repeated after pooling cells into 
1 tube. Cells were pelleted and resuspended in complete RPMI-1640.  
3.2.3.8 Treatment of PBMCs  
7.5 x 105 un-primed and primed PBMCs (100 ng/ml LPS for 4 h at 37oC) were treated with either 
media alone for a further 20 min or 5 mM ATP at 37oC. Cells were fixed with paraformaldehyde 
(PFA) (Sigma-Aldrich) at 1% final concentration rather than ethanol to facilitate surface staining of 
the myeloid marker CD14. Whilst both ethanol and PFA fixation permit analysis of ASC specks in 
human PBMCs, ethanol generally gave superior results. Cells with PFA were incubated for 5 min 
on ice and then 1 ml of PBS/0.1% sodium azide/0.1% BSA/1% HI-FCS was added and cells 
pelleted at 500g for 5 min, and resuspended as outlined below in “Immunostaining Cells for ASC 
for Flow Cytometric Analysis”. 
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3.2.3.9 Immunostaining Cells for ASC for Flow Cytometric Analysis 
Supernatant was gently removed from pelleted fixed cells, and cell pellets resuspended in 250 µl of 
PBS/0.1% sodium azide/0.1% BSA/3% HI-FCS (supplemented with 0.1% saponin for samples 
fixed with paraformaldehyde). For mouse cells 10% (v/v) of 2.4G2 hybridoma supernatant (anti-
mouse FcRγII/III) was included and samples were incubated for 20 min. Rabbit anti-ASC (N15)-R 
was added to samples in an additional 250 µl to achieve a final dilution of 1:1500 and incubated for 
90 min, followed by addition of 1 ml of PBS/0.1% sodium azide/0.1% BSA/2% HI-FCS and cells 
pelleted at 600g for 10 min. Supernatant was removed and cells were resuspended in 100 µl of 
1:1500 Alexa Fluor 488 goat anti-rabbit IgG in PBS/0.1% sodium azide/0.1% BSA/3% HI-FCS 
(supplemented with 0.1% saponin for samples fixed with paraformaldehyde) and incubated for 45 
min. Where lineage-specific antibodies were used, they were included at this stage with the 
secondary antibody. CD14 was used at manufacturer’s recommendations whilst F4/80 and CD19 
antibodies were used at 1/800 and 1/300 respectively. Following incubation, 1 ml of PBS/0.1% 
sodium azide/0.1% BSA/1% HI-FCS was added, cells pelleted at 600g for 10 min and resuspended 
in 100-200 µl PBS/0.1% sodium azide/0.1% BSA/0.2% HI-FCS. 
3.2.3.10 Plasmids used for transfections 
Plasmids used included pEF6 mammalian expression vector (Life Technologies), pEF6-mASC-
EGFP (mouse ASC with a C-terminal EGFP fusion), pEF6-hASC-EGFP (human ASC with a C-
terminal EGFP fusion), pEF6-mAIM2 (mouse AIM2), pCDNA3.1 expression vector, pCDNA3.1-
hAIM2 (human AIM2, provided by Ricky Johnstone, Peter MacCallum Cancer Centre, Melbourne), 
and pCDNA3.1-hAIM2-PYD (F27A,F28A) (human AIM2 with F27A and F28A point mutations). 
3.2.3.11 HEK293 Cell Transfection 
HEK293 cells (3.5 x 105) were seeded into 24-well plates (Corning) in 1 ml DMEM with 4.5 g/l 
Glucose, 110 mg/l sodium pyruvate, Glutamax-1 and 10% HI-FCS, and cultured overnight until 
approximately 90% confluency. Transfections for each well were conducted using 2 µl of 
Lipofectamine2000 (Life Technologies) in 50 µl of additive-free DMEM, and a total of 1600 ng 
Qiagen Endo-free Maxi-Prep DNA in 50 µl additive-free DMEM prepared as per manufacturer’s 
instruction. When pEF6- and pCMV-expression vectors (pCDNA3.1) did not fully account for 1600 
ng of DNA, empty pEF6 expression vector was added to make the final amount of DNA 1600 ng. 
All assays used 100 ng of ASC-EGFP expression vector unless otherwise indicated. Prior to 
transfection, culture volume was reduced to 100-150 µl and 100 µl of transfection mix was added 
immediately followed by plate-centrifugation at 1000g for 10 min to enhance transfection. 
Transfections were then routinely allowed to proceed for a further 16-24 h before cells were 
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harvested with PBS, counterstained with 1 µg/ml propidium iodide (PI) to discriminate dead cells 
and analysed by flow cytometry. 
3.2.3.12 Protein extracts and immunoblot analysis 
Protein extracts and immunoblot analysis was conducted as previously described (Yin et al., 2013). 
AIM2 was detected using the anti-AIM2 MAb 3B10 (Cresswell et al., 2005) and loading assessed 
with immunoblotting for tubulin using anti-α-tubulin, clone B-5-1-2 (Sigma-Aldrich).      
3.2.3.13 Flow Cytometry 
Flow cytometers used were a BD Accuri C6 equipped with a 488 nm laser and 530/30 nm, 585/40 
nm and 670 nm LongPass filters, a BD FACSCantoII equipped with a 488 nm laser and 530/30 nm, 
585/42 nm and 670 nm LongPass filters  and a 633 nm laser and 660/20 nm filter, a BD LSRII 
using the 488 nm laser and 530/30 nm laser, and a Beckman-Coulter Gallios equipped with a 488 
nm laser and 488/15 nm filter. Analysis was conducted with either Kaluza ver 1.2 (Beckman 
Coulter), FlowJo 10.X.7 (Tree Star) or FACSDiva 6.1.3 (Becton Dickinson). Samples were gated to 
exclude debris (FSC-Area vs SSC-Area) and then any cell doublets were excluded using FSC-Area 
vs FSC-Width analysis. For HEK293 cells, only ASC-EGFP+ PI- (or free EGFP+ PI-) cells were 
gated and used for further analysis of inflammasome activation state by either W:A or H:A analysis. 
Sorting was conducted on a BD AriaII using the 488 nm laser and 530/30 nm filter running a 20 psi 
and utilizing a 100 µm nozzle with a detailed overview presented in Supp. Fig. 3.2.   
3.2.3.14 Immunofluorescence microscopy for detection of ASC 
For Figure 3.1A, Casp1-/- BMMs grown on glass coverslips were treated for 4 h with 10 ng/ml LPS 
prior to inflammasome induction using 5 µM nigericin for 45 min. The cells were fixed with 1% 
PFA, permeabilised and stained for ASC using rabbit polyclonal anti-ASC (N-15) (Santa Cruz 
Biotechnology) and nuclei stained with DAPI, all as described previously (Sagulenko et al., 2013). 
To assess the number of cells with ASC specks in samples used in flow cytometric analysis in Table 
3.2, a sample was taken and counterstained with propidium iodide, to identify all cells, and 
fluorescence microscopy images were captured for EGFP and propidium iodide. Images of each 
field of cells were taken in several focal planes to ensure that specks were found in focus. Specks 
were manually counted as a percentage of cell nuclei from the images. 250 cells were included in 
each analysis and were counted in a blinded manner. 
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3.2.4 Results 
3.2.4.1 Principle and validation of TOFIE for inflammasome detection 
The flow cytometric assay described here is dependent upon the rapid re-localisation of ASC within 
the cell upon inflammasome activation (Fig. 3.1A). We expected a reduction in the fluorescent 
pulse width, with a concomitant increase in the pulse height (Fig. 3.1B). To investigate this, LPS-
primed BMMs were treated with or without nigericin for 15 min then fixed with ethanol and stained 
for ASC under conditions demonstrated to be specific for ASC (Supp. Fig. 3.1A). On cytometers 
capable of evaluating pulse width in fluorescence channels (BD FACSCantoII, BD LSRII, and BC 
Gallios) a distinct population exhibited a substantially decreased pulse width to pulse area profile 
(W:A) (Fig. 3.1C and Supp. Fig. 3.1B-C), and pulse width to pulse height profile (W:H) (not 
shown), in nigericin-stimulated samples. Analysis on a machine lacking detection of pulse width in 
fluorescence channels (BD Accuri C6) effectively discriminated activated cells with a high pulse 
height to area (H:A) profile (Fig. 3.1D). The total amount of ASC stained per cell (pulse area) was 
higher in cells with specks (Fig. 3.1C and D), which appears to be due to more efficient ethanol 
fixation and retention of ASC when in a compact speck, than in the diffuse state in the untreated 
cells. Paraformaldehyde fixation gave greater retention of diffuse ASC in the cell, but ethanol 
fixation provided the best resolution of the two populations (Figure 3.8). To highlight the time-of-
flight principle underlying this assay, we engineered immortalized BMMs (iBMMs) to express a 
fusion protein of mouse ASC-EGFP (Fig. 3.1E) that allows direct analysis and avoids the issue of 
differential retention of ASC following fixation and intracellular immunostaining. Exposure of 
these cells to LPS followed by nigericin resulted in a defined population with similar levels of 
ASC-EGFP but with clearly increased H:A ratio (Fig. 3.1F). 
Validating the assay for staining native inflammasomes, the quantitative results obtained 
using various cytometers were very similar to results from microscopy with manual counting of 
inflammasomes (Table 3.2).  We also flow-sorted the speck-containing (low-width) and speck-
negative (high-width) populations and subsequently reanalyzed them on different flow-cytometers 
to confirm that the low width population and high H:A populations are equivalent (Supp. Fig. 3.2). 
As a final validation we examined responses in LPS-primed BMMs from mice deficient in 
inflammasome pathway components. The high H:A population indicative of cells with an 
inflammasome was noted in nigericin-stimulated wild-type and caspase-1-deficient BMMs but not 
in ASC- and NLRP3-deficient cells (Fig. 3.2A). Efficient induction of ASC specks required LPS 
priming as expected (Schroder et al., 2012) (also see section 1.2.6 The NLRP3 inflammsome) (Fig. 
3.2B). The formation of functional inflammasomes under these conditions was confirmed in wild-
type cells by rapid pyroptotic death, whilst BMMs deficient in either ASC, caspase 1 or NLRP3 
remained viable (Supp. Fig. 3.3). The reproducibility of the assay within an experiment was 
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confirmed by independent treatment, staining and analysis of quadruplicate samples (Fig. 3.2C). 
Thus although the level of specks sometimes differs between experiments (comparing Fig 3.2A and 
3.2C), this just reflects the biological response, affected by factors such as cell condition.  
 
Figure 3.1. Principle and use of TOFIE for detection of native ASC speck formation in 
primary mouse BMMs. (A) Fluorescence microscopy of ASC specks in LPS-primed Casp1-/- 
BMMs, either resting or activated with nigericin. Cells were stained for ASC (green), and nuclei 
with DAPI (blue). Scale bar = 20 µM. (B) The shape of the fluorescence pulse detected by a flow 
cytometer as a cell moves through the laser beam depends on fluorophore distribution within the 
cell. Diagram of theoretical fluorescent emission profiles for uniform ASC staining and speck 
formation. (C) Analysis of LPS-primed Casp1-/- BMMs either untreated or treated with 10 µM 
nigericin for 15 min and immunostained for ASC, on a BD FACSCantoII cytometer showing a 
population with a low W:A profile for staining of ASC in activated cells, and (D) analysis on an 
Accuri C6 displaying a population with a high H:A ratio for fluorescent staining of ASC in 
activated cells. (E) Stable expression of mASC-EGFP in a Casp1-/- iBMMs clone, showing ASC-
EGFP expression in live PI-negative cells, and (F) TOFIE analysis of LPS-primed (100 ng/ml LPS 
3 h) mASC-EGFP+ cells that had been treated with either media alone or 10 µM nigericin for a 
further 90 min. Vitaliya Sagulenko performed the microscopy in part A, David Sester performed the 
experiments in part E and F and the flow cytometry in part C. 
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Table 3.2. Comparison of percentage of Casp1-/- BMMs with ASC-specks as 
determined by flow cytometry and microscopy. 
Method of analysis Nigericin Dose (µM) 50%:50% Mix of 
0 µM and 10 µM 0 2.5 5 10 
 
Microscopy and 
Counting 
 
5.5 
 
11.3 
 
 
39.4 
 
 
70.7 
 
 
48.9 
 
BD FACS CantoII 
 
 
3.0 
 
9.6 
 
40.6 
 
68.7 
 
44.6 
 
BD LSR II 
 
 
4.8 
 
10.1 
 
34.0 
 
63.4 
 
42.1 
 
Accuri C6 
 
 
3.3 
 
9.9 
 
41.2 
 
70.2 
 
45.7 
LPS-primed cells were treated with the indicated dose of nigericin for 30 min. Samples were 
analysed by the cytometers listed and by fluorescence microscopy. Vitaliya Sagulenko acquired the 
microscopy images and David Sester ran the samples on the BD FACS CantoII and BD LSR II.	  
 
3.2.4.2 Detection of inflammasome formation in response to particulate NLRP3 agonists, AIM2- 
and NLRC4-activators 
To confirm the utility of this assay to detect activation with particulate NLRP3 agonists, we 
exposed mouse BMMs to alum, which resulted in a population of cells with a high H:A profile, 
indicative of ASC specks (Fig. 3.3A). The assay was also applied to treatments that activate either 
AIM2 or NLRC4. TOFIE analysis of BMMs that had either been electroporated with DNA or 
infected with Salmonella enterica Typhimurium revealed cells containing ASC specks (Fig. 3.3B-
C). Alum and Salmonella treatments were performed following LPS priming and the formation of 
specks in response to these stimuli in the absence of LPS priming was not assessed.  
3.2.4.3 Detection of inflammasome formation in lineage-stained cell subpopulations 
One application of TOFIE is the definition of inflammasome-competent cells in populations of 
mixed cell types. Using ex vivo inflammasome activation, resident peritoneal cells were collected, 
LPS-primed and either left untreated or exposed to nigericin. Cells were immunostained for ASC in 
combination with the macrophage marker F4/80 and B cell marker CD19 (Fig. 3.4A). CD19+ cells 
stained moderately for ASC, but did not form ASC specks after treatment with nigericin. However, 
the vast majority of F4/80hi cells displayed a striking transition to the high H:A profile. F4/80int 
cells displayed some propensity to form ASC specks, and a small, yet to be defined, population of 
cells within the F4/80neg/CD19neg population were capable of inflammasome formation. This data 
demonstrates the power of TOFIE in identifying inflammasome-competent cells from within mixed 
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populations, and may allow the rapid identification of cell types not formerly recognized to be 
capable of forming inflammasomes. 
  
 
Figure 3.2. ASC specks are only detected in LPS-primed inflammasome-competent cells. (A) 
TOFIE analysis of BMMs from 4 genotypes (wild-type C57BL/6, Casp1-/-, Asc-/-, Nlrp3-/-) primed 
with LPS and activated with 10 µM nigericin or 5 mM ATP for 15 min. (B) Requirement of LPS-
priming for effective induction of ASC specks in BMMs. Un-primed wild-type BMMs were treated 
with either media alone, 5 mM ATP or 10 µM nigericin and immunostained for ASC in parallel to 
cells shown in Fig. 2A. (C) Reproducibility of TOFIE analysis on Casp1-/- BMMs primed with LPS 
(100 ng/ml, 4 h) then left untreated or activated with 10 µM nigericin or 5 mM ATP for 15 min in 
quadruplicate.  
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Figure 3.3. Detection of ASC specks in wild-type BMMs using TOFIE after AIM2, NLRC4 
and particulate NLRP3 activators. (A) Analysis of LPS-primed BMMs treated with or without 
200 µg/ml alum for 3.5 h. (B) Assessment of ASC speck formation 45 min following 
electroporation of BMMs with either media alone or 10 µg of calf thymus DNA (C) Detection of 
ASC specks in LPS-primed BMMs following infection with Salmonella enterica (Typhimurium) at 
a MOI of 10. Vitaliya Sagulenko performed the experiments for part B.  
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3.2.4.4 Analysis of ASC speck formation in subsets of human PBMCs  
Immunostaining of native ASC in human peripheral blood mononuclear cells (PBMC) revealed 
intermediate and high ASC-expressing cells, with the vast majority of the latter expressing the 
monocyte marker CD14 (Fig. 3.5A-E). We examined speck formation in these populations of ASC-
expressing cells, stimulated ex vivo with and without LPS and ATP (Fig. 3.5F). CD14 could not be 
used as a marker to define speck-containing monocytes, as it was lost from the stimulated cells (not 
shown). Analysis revealed that only the predominantly monocytic “ASC-high” cells formed an 
ASC speck. The vast majority of CD14-negative PBMCs expressed moderate levels of ASC (Fig. 
3.5E) but did not form inflammasome specks with a NLRP3 stimulus (Fig. 3.5F). The moderate 
staining of ASC in CD14-negative cells, which within PBMCs are predominantly T lymphocytes, is 
likely to be bona fide given that a comparison of staining of mouse wild-type and ASC knockout 
cells confirms that lymphocytes express intermediate levels of ASC (not shown) and a functional 
role for ASC has recently been revealed in human T-lymphocytes (Doitsh et al., 2014).  
3.2.4.5 Analysis of inflammasome reconstitution in HEK293 cells 
In addition to staining native ASC, this system can be exploited for convenient and quantitative 
analysis of reconstituted inflammasomes in HEK293 cells. In cells transfected with an ASC-EGFP 
expression plasmid, spontaneous ASC speck formation was highly probable once cells reached a 
critical threshold of expression (grey line in Fig. 3.6A). A similar observation was made when 
expression of either mouse or human ASC-EGFP was analysed by W:A, whilst EGFP alone did not 
show this transition to a low W:A profile with high levels of expression (Fig. 3.6B). The 
spontaneous ASC speck formation is truly dependent on the level of ASC, as these cells are not 
fixed and permeabilised. This effect should not be confused with the apparent higher level of ASC 
in native speck-containing cells (Fig. 3.1C and D), which as noted earlier is largely an effect of 
ethanol fixation. Transient co-expression of the inflammasome initiator AIM2, and its presumed 
recognition of the encoding plasmid DNA, has been shown by microscopy to initiate ASC speck 
formation in HEK293 cells (Fernandes-Alnemri et al., 2009). Analysis by TOFIE revealed that 
AIM2 co-expression increases the fraction of cells containing specks by decreasing the threshold of 
ASC concentration at which speck formation occurs (grey to dashed grey line Fig. 3.6C).  
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Figure 3.4. Identification of inflammasome-competent cell types using TOFIE in combination 
with cell lineage marker analysis. (A) Representative lineage marker analysis with CD19 and 
F4/80 of ex vivo LPS-primed resident peritoneal cells. (B) TOFIE analysis of LPS-primed resident 
peritoneal cells treated with either media alone or 10 µM nigericin for 30 min, gated for F4/80hi, 
F4/80int, CD19+ and F4/80negCD19neg subsets. David Sester performed the flow cytometric analysis.  
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When using transient expression to reconstitute the inflammasome response, the level of 
ASC expression, and hence the percentage of cells forming specks spontaneously, may vary 
between samples. Using microscopy there is no means to eliminate variable spontaneous speck 
formation from the analysis. Using flow cytometry we can analyse data in a window below the 
threshold of ASC expression at which specks tend to form spontaneously, and also exclude poorly 
transfected cells where ASC levels are not sufficient to permit speck formation. This minimizes 
effects of variable transfection efficiency and the effects of any subsequent cell treatments that alter 
the expression of the ASC plasmid, as well as reducing background speck numbers. Using this 
approach of selecting a window of moderate ASC expression, we analysed interactions between 
AIM2 and ASC involved in ASC-speck formation. Increasing amounts of human AIM2 co-
transfected with hASC-EGFP revealed dose-dependent induction of ASC-specks (Fig. 3.7A-B and 
Supp. Fig. 3.4). Previous work showed by in vitro binding studies and yeast two-hybrid analysis 
that two phenylalanines of the human AIM2 pyrin domain are important for the interaction with the 
pyrin domain of ASC (Jin et al., 2013). Here we showed that AIM2 with F27A and F28A mutations 
could not initiate ASC clustering (Fig. 3.7A-B), although it was expressed at similar level to wild-
type (Fig. 3.7C). The advantage of selecting a window of moderate ASC expression in order to 
increase sensitivity of the assay is shown in Supp. Fig. 3.4. This demonstrates the utility of this 
assay for molecular analysis of protein-protein interactions in inflammasome formation that is 
reproducible between independent experiments (Fig. 3.7D). 
3.2.5 Discussion  
Here we have described, validated and demonstrated utility of a convenient flow-cytometric 
assay for directly assessing formation of both native and reconstituted inflammasomes. The analysis 
of inflammasome formation is generally conducted by monitoring downstream processes and 
outcomes, including the assessment of caspase activity, cell death, or release of IL-1β. These 
methods are not direct assessments of the formation of an inflammasome structure, and in some 
cases can be outcomes of non-inflammasome processes. Quantification of released IL-1β by ELISA 
is commonly used as an assay of inflammasome activity. This is confounded by the detection of 
unprocessed pro-IL-1β and can be misleading if cells have lysed without inflammasome activation. 
Immunoblot analysis is required to confirm cleavage to its bioactive form. In addition, IL-1β 
cleavage can occur by inflammasome-independent processes (Netea et al., 2010). Caspase-1 
cleavage measured by western blot provides good evidence for inflammasome activation, but is 
generally only semi-quantitative. 
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Figure 3.5. Detection of ASC specks by TOFIE as a tool for studying inflammasome activation 
in minor cell populations. Paraformaldehyde–fixed and stained human PBMC samples were 
analysed on a BD CantoII. (A) Cells were first gated using FSC-Area vs SSC-Area to exclude 
debris (BLACK EVENTS). (B) Doublets were then excluded (RED EVENTS) using FSC-Area vs 
FSC-Width profile characteristics. (C) PBMC samples gated as per panels A and B, stained with 
secondary antibody alone acting as a negative control to define ASC expression indicated by the 
marker boundary. (D) PBMC samples gated as per panels A and B, stained for ASC, which 
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demonstrated intermediate (GREEN) and high (BLUE) ASC-expressing cells. The percentage 
shown is the % high ASC-expressing cells (BLUE), within the total cells (BLUE and GREEN) (E) 
Co-staining with anti-CD14 revealed the majority of high ASC-expressing cells (BLUE) co-
expressed high levels of the monocyte marker CD14. (F) Detection of ASC specks in human 
PBMCs from two donors either left untreated (control), or treated ex vivo with LPS for 4 h followed 
by ATP for 15 min. Colours define intermediate ASC-expressing (GREEN), high ASC-expressing 
(BLUE), and high ASC-expressing cells with an ASC speck (low W:A profile- PURPLE). The 
percentage of ASChi cells forming specks is indicated. David Sester performed flow cytometric 
analysis.  
 
Analysis of caspase activity by means of fluorogenic inhibitor-based substrates is handicapped by 
the limited specificity of the substrates for caspase-1 (Rozman-Pungercar et al., 2003) and the 
possibility of measuring other non-inflammasome-related caspase or protease activities. 
Inflammasome activation leads to pyroptotic and apoptotic cell death, but only pyroptosis is unique 
to the inflammasome. Pyroptotic death can be used to measure inflammasome responses, but its 
differentiation from other cell-death modalities can be problematic. Determination of 
inflammasome activity is best done by a combination of techniques, and cells with gene knockouts 
are useful for confirming that observations require inflammasome function. The assessment of 
ASC-specks in cells has the obvious advantage of being a direct measure of inflammasome 
formation, and measuring an early step in inflammasome formation, at a single cell level. 
Direct assessment of ASC-speck formation in the past has been conducted by microscopy 
and counting of speck-containing cells. The flow cytometric assay TOFIE has a number of 
advantages over microscopic examination of cells for inflammasome specks, including (i) provision 
of more accurate data by objective analysis of large populations, (ii) ready assessment of 
inflammasome formation by a minority population of cells defined by lineage markers, (iii) lack of 
laborious manual counting of samples, (iv) no potential loss of populations of cells which may be 
less adherent to slides, and (v) ability to control for the effect of variable transfected ASC 
expression level on spontaneous speck formation in inflammasome reconstitution assays. The 
quantitiative nature of this assay may be useful in other situations where proteins undergo dramatic 
relocalisation. Indeed, analysis of fluorescence pulse shape has also been used to determine 
aggregation of Huntingtin protein in cells (Ramdzan et al., 2012).  
The assay described allows rapid and direct quantification of native inflammasomes in cells 
stimulated in vitro or ex vivo, and convenient quantitative assessment of inducers and regulators of 
inflammasome formation. In combination with lineage markers it facilitates detection of 
inflammasome formation in minor populations of mixed cell types. In addition, TOFIE provides a 
rapid quantitative technique for assessing molecular interactions governing inflammasome 
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initiation, when using reconstitution of cells with wild-type and mutated proteins. TOFIE will be a 
sensitive and powerful assay for assessment of inflammasome function in health and disease.  
 
Figure 3.6. Analysis of spontaneous and AIM2-induced ASC-Speck formation in HEK293 
cells using TOFIE. (A) Spontaneous ASC speck formation occurs at a defined threshold of 
expression in the HEK293 reconstitution model. Analysis of mASC-EGFP+ propidium iodide (PI)- 
cells after transfection with 25-400 ng of expression vector revealed a threshold of expression for 
speck formation (high H:A profile) shown by the grey vertical line. (B) HEK293 cells transfected 
with 200-400ng of plasmid encoding EGFP (pEF-d2EGFP or pEGFPN-1) or mouse and human 
ASC- EGFP-fusion proteins (pEF6-mASC-EGFP and pEF6-hASC-EGFP) to achieve similar levels 
of expression. Cells were subsequently gated for EGFP+ PI- HEK293 cells and analysed for low 
W:A profiles (boxed) indicative of ASC specks. (C) Co-expression of mAIM2 with mASC-EGFP 
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(100 ng of both plasmids) decreases the ASC expression level at which specks form (grey dashed 
line). This work was performed by David Sester. 
 
Figure 3.7. Analyzing the role of wild-type and mutant inflammasome proteins in ASC-speck 
formation by TOFIE. (A) Analysis of intermediate hASC-EGFP+ PI- cells co-transfected with 100 
ng of either pCMV-Empty, pCMV-hAIM2 or pCMV hAIM2 F27A,F28A pyrin domain mutant, 
with (B) quantification of dose-response analysis displaying the mean and range of duplicate 
transfections (where error bars are not evident, they fall within the symbol) and (C) confirmation of 
expression of hAIM2 constructs by western blot. (D) Data and mean from three independent 
experiments as outlined in panel A with co-transfection with 100 ng of either pCMV-Empty or 
pCMV-hAIM2. Two experiments included co-transfection with 100 ng of pCMV hAIM2 
F27A,F28A. This work was performed by David Sester. 
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3.3 Supplementary Figures 
 
 
Supplementary Figure 3.1. Specificity of ASC immunostaining in mouse BMM, and ASC 
pulse width:pulse area analysis on additional flow cytometers. (A) Wild-type (WT) or Asc-/- 
BMMs were immunostained for ASC with anti-ASC and secondary antibody, or with secondary 
antibody alone, demonstrating specificity of ASC detection. (B-C) Analysis of untreated (left 
panels) and 10 µM nigericin activated (right panels) LPS-primed Casp1-/- BMMs analysed on (B) 
BD LSRII or (C) Beckman-Coulter Gallios flow cytometers. David Sester performed the flow 
cytometric analysis.  
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Supplementary Figure 3.2.  Sorting regime for low pulse width:height profile cells on a BD 
FACS Aria II, and confirmation of identity of low pulse width and high pulse height 
populations.  (A) Gating within SSC-Height vs SSC-Width and FSC-Height vs FSC-Width plots 
was used to exclude doublets and debris. (B) LPS-primed Casp1-/- BMMs were left untreated or 
treated with 10 µM nigericin for 15 min, before fixation. A portion of the untreated and nigericin 
treated samples were mixed in a 1:1 ratio prior to immunostaining for ASC and sorting. Presumably 
due to higher operating pressure of the BD FACS AriaII, discrimination of low and high W:H (and 
W:A) profiles was not as effective as that observed on other cytometers. Nonetheless, gates were 
employed to sort high W:H cells (P4 Purple events) and low W:H (P3 Blue events). (C) After two 
rounds of purification, samples were used to confirm that the low W:H profile cells were equivalent 
of the high H:A cells observed on the Accuri C6 cytometer. Two rounds of sorting were performed 
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to ensure the purity of the speck positive population because the separation of positive and negative 
populations was not as clear using width vs height profile. David Sester performed flow cytometric 
analysis. 
Supplementary Figure 3.3. Formation of functional inflammasomes as measured by 
downstream pyroptosis. Unprimed and LPS-primed wild-type (WT), Casp1-/-, Asc-/- and Nlrp3-/- 
BMMs were treated as in Figure 2 with either media alone (control), 5 mM ATP or 10 µM nigericin 
for 30 min and then analysed for cell death after addition of 1 µg/ml propidium iodide (PI), on a BD 
Accuri C6 flow cytometer. Wildtype, but not other cells formed a functional inflammasome leading 
to cell death measured by staining with PI. 
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Supplementary Figure 3.4. Increased sensitivity and decreased background, by elimination of 
spontaneous speck formation, is an advantage of TOFIE-based analysis of reconstituted 
inflammasomes in HEK293 cells.  (A) HEK293 cells were transfected as per Figure 5. 
Examination of cells transfected with hASC-EGFP alone (“Empty Vector” sample) allows a region 
(hASC-EGFP WINDOW) to be defined which excludes high hASC-EGFP expressing cells with 
spontaneous speck formation, and also cells with lower levels of hASC-EGFP never capable of 
forming an ASC speck. (B) Analysis of the proportion of cells in high H:A form (ASC-EGFP 
speck) using only cells with intermediate expression of hASC-EGFP (defined by the hASC-
EGFPWINDOW region in panel A. This demonstrates the processing of data for Figure 5A-B. (C) 
Quantification of the proportion of cells with a high H:A profile (ASC-EGFP Speck) in either all 
hASC-EGFP+ cells, or cells with intermediate hASC-EGFP expression levels (hASC-EGFP 
WINDOW) as done in Figure 5B, demonstrates that analysis of the latter reduces the background 
level of specks, and increases sensitivity for detection of inflammasome responses. Data represent 
the mean and range of duplicate transfections within the same biological experiment; where error 
bars are not shown data falls within the symbol. In other experiments we have found that some 
conditions can change the level of ASC-EGFP expression, giving variation in the number of cells 
with spontaneous speck formation. Imposition of a window as described above eliminates this as a 
confounding variable. David Sester performed these experiments.  
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3.4. Extended Results - Optimisation of the TOFIE assay 
Results presented in this section are from additional optimisation experiments that were not 
presented in the publication. 
3.4.1 Paraformaldehyde versus ethanol fixation.  
During the original optimisation experiments PFA fixation was compared to ethanol fixation prior 
to staining for ASC. When Casp1-/- BMMs primed with LPS and stimulated with nigericin were 
fixed with either ethanol as per section 3.2.3.2 or PFA as per section 3.2.3.8, it was found that PFA 
gave greater retention of diffuse ASC in the cell, but ethanol fixation provided the best resolution of 
the two populations (Figure 3.8). Where possible we proceeded to use ethanol fixation, but these 
results show that PFA fixation also works for ASC speck staining, and this may facilitate co-
staining with other antibodies.  
 
Figure 3.8. Comparison of PFA and ethanol fixation. Analysis of ASC specks in BMMs from 
Casp1-/- mice fixed with PFA or ethanol following priming with 10 ng/ml LPS for 4 h and treatment 
with 10 µM nigericin for 15 min at 37°C. PFA and ethanol fixation was conducted as per Sester et 
al., 2015 sections 3.2.3.8 and 3.2.3.2 respectively. The remainder of the staining protocol was also 
conducted as per Sester et al., 2015. 
 
3.4.2 Flexibility of the staining procedure for native ASC.  
For all experiments in the publication, staining with primary antibody was for 90 min at room 
temperature immediately after treatment and fixation of the cells. More flexibility in the staining 
procedure was desired as it is often used following a lengthy cell isolation and treatment protocol. It 
was found that incubation with the primary antibody for 30 or 60 min, or incubation with a lower 
concentration of primary antibody overnight at 4°C all gave similar results to the published protocol 
(Figure 3.9). In addition, cells that were fixed or blocked overnight at 4°C prior to staining gave 
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similar results. These results were acknowledged in a later published protocol (Appendix 1) (Sester 
et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Staining of ASC specks is a flexible procedure. Analysis of BMMs from C57BL/6 
mice primed with 10 ng/ml LPS for 4 h and treated with 10 µM nigericin for 15 min at 37°C. 
Samples were fixed and blocked as per Sester et al., 2015 and then incubated with primary antibody 
for 30, 60, 90 min (1:1500 primary antibody) or overnight (1:6000 primary antibody). Fixed 
Overnight and Blocked Overnight samples were handled as per Sester, 2015 except that the fixing 
or blocking steps respectively were conducted overnight at 4°C, followed by primary antibody 
(1:1500) for 90 min.  
 
3.4.3 Length of BMM treatment with nigericin.  
In Sester et al., 2015, BMMs were only treated with nigericin or ATP for 15 min due to concern 
that once wild type cells initiate pyroptosis they would be fragile, and lose their ASC specks with 
handling. A time course of nigericin treatment on wild type and Casp1-/- BMMs was conducted to 
see if longer incubation times were possible. It was found that in both types of cells the percentage 
of speck-positive BMMs continued to increase up to 1 h (Figure 3.10). Casp1-/- cells do not undergo 
pyroptosis and should not lose specks.  At 1 h there were a similar number of speck-positive cells 
present in wild type cells compared to Casp1-/- cells suggesting that the cells were not losing their 
specks at this time point. This demonstrates that the protocol involving fixation of suspension 
cultures with ethanol is successful at preserving the fragile pyroptotic cells. 
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Figure 3.10. BMMs maintain specks for at least 60 min. TOFIE analysis of BMMs from 
C57BL/6 (Wild Type) and Casp1-/- mice. BMMs were primed with 10 ng/ml LPS for 4 h and then 
treated with media alone (Untreated) or 10 µM nigericin for 15, 30 or 60 min at 37°C. 
 
Notably, Figure 3.10 was performed in the presence of 10% FCS and it was observed that a 
very low percentage of cells had ASC specks at 15 min compared to other experiments performed 
the same way but under serum-free conditions. To confirm that this was due to the presence of 
serum, a comparison of speck formation in the presence and absence of serum was conducted. 
3.4.4 Foetal calf serum delays speck formation in response to nigericin.  
LPS-primed Casp1-/- BMMs were treated with nigericin for 15 min in the presence or absence of 
10% FCS. The presence of FCS greatly reduced the number of cells producing specks at 15 min 
(Figure 3.11).  Some early work suggests that nigericin binds to bovine serum albumin, and this is 
used to experimentally "quench" the effect of nigericin on membrane permeability (Ladoux et al., 
1988). Thus the presence of serum presumably slows the response to nigericin by binding it and 
retarding its interaction with the cell membrane. This effect on the time course should be taken into 
consideration when performing experiments that require nigericin treatment in the presence of 
serum, and this was acknowledged in the published protocol papter (Appendix 1) (Sester et al., 
2016). 
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Figure 3.11. FCS delays ASC speck formation in response to Nigericin. BMMs from Casp1-/- 
mice were primed with 10 ng/ml LPS and treated with nigericin in the presence (+FCS) or absence 
(-FCS) of 10% FCS for 15 min. Percentage of cells with ASC specks (% Speck +) was analysed by 
TOFIE. Data represent the mean and range of two independent experiments.  
 
3.5 Conclusion  
We have developed and published a flow cytometric assay that allows the quantitative measurement 
of cells that have formed ASC specks. Experiments further to the published work have shown that 
the ASC staining procedure can be more flexible than originally described and that cells can be 
treated with nigericin in the presence of serum for at least 1 h and still maintain detectable ASC 
specks. It was also discovered that the presence of FCS during nigericin treatment delays speck 
formation, presumably due to sequestration of nigericin away from the cell membrane. This assay 
could be used for future investigations into the role of inflammasomes in autoimmune disease.  As 
seen in figure 3.5, we were able to assess ASC speck formation in a sub-population of PBMCs from 
human donors. This could be applied to the analysis of inflammasome activity in cells from 
autoimmune patients and comparisons with healthy controls. We were also able to measure 
inflammasome formation in peritoneal cells from mice activated ex vivo (Figure 3.4). Similar 
experiments could be used to compare inflammasome function in autoimmune mouse models. This 
could also be extended to testing the ability of autoantibodies, produced in the mice during disease 
progression, to activate the inflammasome. For example, this could be achieved by stimulating cells 
ex vivo with sera from diseased mice and assessing ASC speck formation similar to experiments 
recently performed using NZM mice (Fu et al., 2017). Overall, this assay is a valuable tool for 
measuring inflammasome activation and was applied within this thesis. 
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Chapter 4: NLRP3 and AIM2 inflammasome function in autoimmune NZB/W 
F1 mice. 
4.1 Introduction 
Our previous work has shown that NZB BMMs are deficient in AIM2 and NLRP3 inflammasome 
responses (Yin et al., 2013, Sester et al., 2015a, Roberts et al., 2009). The AIM2 inflammasome 
deficiency in NZB was due to high expression of the AIM2 antagonist p202 (Yin et al., 2013, 
Roberts et al., 2009, Sester et al., 2015a). In Sester et al., 2015a, which is included as Appendix 2, 
we reported that NZB mice also have a profound deficiency in NLRP3 expression due to a point 
mutation causing aberrant splicing of the NLRP3 gene (Sester et al., 2015a). Since it is possible that 
these deficiencies contribute to the development of autoimmunity in NZB mice, it is of interest to 
ask what the status of AIM2 and NLRP3 inflammasome function is in cells from NZB/W F1 mice, 
which have a more severe lupus-like phenotype. 
Presented in this chapter is a paper that is submitted to Immunology & Cell Biology as well 
as an extended results section. The extended results section outlines attempts made to measure the 
NLRP3 inflammasome response of NZB, NZB/W F1 and NZW mice in vivo.  
4.2 Submitted Paper 
 
NLRP3 and AIM2 inflammasome function in autoimmune NZB/W F1 mouse macrophages 
 
Sara J. Thygesen, David P. Sester, Katryn J. Stacey 
School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Qld 
4072, Australia. 
 
Contributions to the submitted publication: 
I performed all experimental work presented in this paper apart from the work that generated Figure 
4.2, this was performed by David Sester. I prepared all of the figures and the first draft of the 
manuscript. Contributions of all authors were: 
Sara Thygesen: Experimental work: 90%, writing 70%, project design 
David Sester: Experimental work: 10%, project design  
Katryn Stacey: Writing 30%, project design, supervision 
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4.2.1 Abstract 
Inflammasomes are protein complexes activated by infection and cellular stress that promote 
caspase-1 activation and subsequent inflammatory cytokine processing and cell death. It has been 
anticipated that inflammasome activity contributes to autoimmunity. However, we previously 
showed that macrophages from autoimmune New Zealand Black (NZB) mice lack NLRP3 
inflammasome function, and their AIM2 inflammasome responses are compromised by high 
expression of the AIM2 antagonist protein p202. Here we found that the point mutation leading to 
lack of NLRP3 expression occurred early in the NZB strain establishment, as it is shared with the 
related obese strain NZO, but not with the unrelated New Zealand White (NZW) strain. The first 
cross progeny of NZB and NZW mice (NZB/W F1) develop more severe lupus nephritis than the 
NZB strain. Here we have investigated AIM2 and NLRP3 inflammasome function in macrophages 
from NZB, NZW and NZB/W F1 mice. The NZW parental strain showed strong inflammasome 
function, whilst the NZB/W F1 have haploinsufficient expression of NLRP3 and show reduced 
NLRP3 and AIM2 inflammasome responses, particularly at low stimulus strength. It remains to be 
established whether the low inflammasome function could contribute to loss of tolerance and the 
onset of autoimmunity in NZB and NZB/W F1. However, with amplifying inflammatory stimuli 
through the course of disease, the NLRP3 response in the NZB/W F1 is likely sufficient to 
contribute to kidney damage at later stages of disease. 
4.2.2 Introduction 
Inflammasomes are multiprotein signalling complexes that form in cells in response to microbial 
and endogenous danger signals. Inflammasome formation leads to the activation of caspase-1 and 
caspase-8 (Schroder and Tschopp, 2010, Sagulenko et al., 2013). Caspase-1 cleaves pro-interleukin 
(IL)-1β and pro-IL-18 allowing active, pro-inflammatory IL-1β and IL-18 to be released from the 
cell (Schroder and Tschopp, 2010).  Inflammasome activation can also lead to inflammatory lytic 
cell death termed pyroptosis via caspase-1, and in the absence of caspase-1, caspase-8 initiates 
apoptotic cell death (Schroder and Tschopp, 2010, Sagulenko et al., 2013). Inflammasome 
activation requires the oligomerisation of an initiator protein. Well characterised initiator proteins 
include Nod-like receptor (NLR) family member NLRP3, as well as the PYHIN/HIN-200 family 
member absent in melanoma 2 (AIM2) (Schroder and Tschopp, 2010). The induced clustering of 
AIM2 or NLRP3 recruits the adaptor molecule apoptosis-associated speck-like protein containing a 
CARD (ASC) via homotypic pyrin domain interactions and ASC subsequently recruits pro-
caspases, facilitating their activation via dimerisation and proteolytic processing (Schroder and 
Tschopp, 2010).  
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A wide range of external and host-derived danger signals have been identified as stimuli for 
NLRP3. This includes pathogens such as Candida albicans, influenza A virus and Staphylococcus 
aureus (Bauernfeind and Hornung, 2013). NLRP3 is also activated by the bacterial ionophore 
nigericin and host-derived molecules that indicate cellular damage including ATP and gout-
associated uric acid crystals as well as environmental irritants such as silica and asbestos 
(Bauernfeind and Hornung, 2013). These diverse stimuli generally lead to K+ efflux and this is 
believed to induce NLRP3 clustering (Munoz-Planillo et al., 2013). In contrast, AIM2 binds directly 
to double stranded DNA in the cytosol to initiate inflammasome formation (Roberts et al., 2009, 
Hornung et al., 2009). AIM2 activates inflammasome responses to viruses including mouse 
cytomegalovirus (MCMV) and vaccinia, as well as the cytosolic bacterium Francisella tularensis 
(Rathinam et al., 2010). 
The NLRP3 inflammasome has been implicated in a number of diseases including 
hereditary periodic fevers, type II diabetes, atherosclerosis, Alzheimer’s disease and gout (Shao et 
al., 2015). There is also evidence to suggest a role for NLRP3 in the regulation of intestinal 
homeostasis (Hirota et al., 2011, Macia et al., 2015). A role for inflammasomes in autoimmunity 
has been proposed and has gained interest in recent years (Shaw et al., 2011). Various levels of IL-
1b in systemic lupus erythematosus (SLE) patients have been reported, from undetectable to 
increased in a subset of patients (Willis et al., 2012, Sturfelt et al., 1997). Elevation of IL-18 in SLE 
is more clearly established (Wen et al., 2014) but can be produced by inflammasome-independent 
means (Sugawara et al., 2001). Analysis of inflammasome function in cells from human patients is 
limited. Liu et al. have reported that SLE patients had higher caspase-1 activation in response to 
neutrophil extracellular traps (NETs) and antimicrobial peptide LL37 than controls, as well as 
elevated IL-1b release from patient monocytes in response to ATP treatment (Liu et al., 2017). 
However, other studies showed a subset of patients with a decreased NLRP3 inflammasome 
response (Portales-Cervantes et al., 2012). A recent study in a mouse model of mild lupus-like 
autoimmunity suggests that NLRP3 and ASC expression actually protects against kidney disease 
(Lech et al., 2014). Thus there is not a clear consensus on the role of inflammasomes in SLE. 
A number of mouse models of human SLE are available, both genetic and induced. The first 
cross progeny of New Zealand Black (NZB) and New Zealand White (NZW) mice, termed here 
NZB/W F1, are considered one of the best models (Perry et al., 2011). Disease in the NZB/W F1 
mice shows a strong female bias and they develop anti-nuclear antibodies and immune complex-
mediated glomerulonephritis (GN) at around 5-6 months of age, dying at around 10-12 months from 
kidney failure (Perry et al., 2011). Neither of the parental strains develop severe kidney disease. 
NZB mice develop anti-erythrocyte antibodies and are a model of autoimmune haemolytic anaemia 
(Izui et al., 1994). They also have antinuclear antibodies typical of SLE but develop only mild, late-
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onset GN (Andrews et al., 1978, Kotzin and Palmer, 1987). NZW mice have only a low incidence 
of autoimmune disease (Perry et al., 2011). As such, both parents must pass on genetic loci that 
contribute to disease in the offspring.  
 We have recently published that NZB mice are deficient in AIM2 and NLRP3 
inflammasome function (Yin et al., 2013, Sester et al., 2015a). NZB Nlrp3 has a point mutation that 
leads to lack of expression and a complete loss of NLRP3 inflammasome function. In addition, 
reduced AIM2 inflammasome activity exists due to high expression of p202, a PYHIN family 
member that antagonises AIM2 (Roberts et al., 2009, Yin et al., 2013, Cridland et al., 2012). This 
demonstrates that normal NLRP3 and AIM2 inflammasome function is not required for loss of 
tolerance and autoantibody production in these mice. Whether the low inflammasome function 
actually contributes to loss of tolerance remains to be established. With respect to the tissue damage 
stage of disease, NLRP3 is thought to play a role in kidney damage in various models of SLE (Tsai 
et al., 2011, Zhu et al., 2013, Zhao et al., 2015). It is possible that the lack of NLRP3 in NZB mice 
may protect them from severe GN. Given the profound inflammasome deficiency in NZB and the 
interest in the role of inflammasomes in autoimmunity, here we have investigated AIM2 and 
NLRP3 function in cells from NZB, NZW and NZB/W F1 mice in order to ascertain whether cells 
from the NZB/W F1 mice that develop severe kidney damage have intact inflammasome function. 
  
4.2.3 Results 
4.2.3.1 Intermediate expression of p202 in NZB/W F1 macrophages.  
We have previously published that NZB macrophages are deficient in AIM2-mediated responses to 
cytosolic DNA due to high expression of the AIM2 antagonist p202 (Yin et al., 2013, Sester et al., 
2015a). The level of AIM2 activity in NZW and NZB/W F1 macrophages is unknown. We first 
investigated expression of all the protein components of the AIM2 inflammasome. AIM2 
expression was similar in C57BL/6, NZB, NZB/W F1 and NZW bone marrow derived 
macrophages (BMMs) and was not substantially influenced by 3 h lipopolysaccharide (LPS) 
priming (Fig. 4.1A). p202 expression was readily detected in NZB macrophages but was 
undetectable in C57BL/6 and NZW macrophages. The expression of p202 in NZB/W F1 
macrophages was less than NZB but readily observable. Cells from the four genotypes displayed 
similar expression levels of the inflammasome adaptor molecule ASC as well as pro-caspase-1 and 
pro-IL-1b (Fig. 4.1B&C).  From this data, NZW cells appear competent for AIM2-mediated 
inflammasome responses, whilst the response of NZB/W F1 cells may be somewhat compromised 
by p202 expression.  
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Figure 4.1. Intermediate expression of AIM2 antagonist p202 in NZB/W F1 macrophages. (A) 
Protein expression levels of p202 and AIM2 in unprimed and LPS-primed (10 ng/ml, 3h) C57BL/6, 
NZB, NZB/W F1 and NZW BMMs as assessed by western blot. Tubulin expression was assessed 
as a loading control. Results are representative of three independent protein preparations. (B) 
Protein expression levels of pro-caspase-1 and ASC in unprimed and LPS-primed (1 or 10 ng/ml, 
3h) C57BL/6, NZB, NZB/W F1 and NZW BMMs as assessed by western blot. GAPDH levels were 
assessed as a loading control. Results are representative of three independent protein preparations. 
(C) Representative immunoblot and quantification of pro-IL-1β protein expression normalised to 
GAPDH in unprimed and LPS-primed (10 ng/ml, 3 h) C57BL/6, NZB, NZB/W F1 and NZW 
BMMs. Data are from three independent protein preparations and blots. Bars are drawn to the mean 
of the three experiments and symbols show the result of each experiment.  
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4.2.3.2 Reduced AIM2 response to cytosolic DNA and MCMV in NZB/W F1 macrophages 
Rapid loss of membrane integrity, measured by propidium iodide uptake is a convenient measure of 
AIM2 inflammasome-mediated pyroptosis (Sagulenko et al., 2013). As predicted from expression 
analysis, NZW BMMs showed a robust pyroptotic cell death response to electroporated CT DNA 
(Fig. 4.2A&B). NZB BMMs had lower DNA-dependent cell death, previously established as being 
due to high p202 expression (Yin et al., 2013, Sester et al., 2015a). The cell death observed in 
NZB/W F1 macrophages was significantly lower than that of NZW cells, and similar to NZB cells, 
in response to the lower amount of CT DNA. This deficiency was overcome when the cells were 
electroporated with a high dose of CT DNA.  
Further evidence for suboptimal AIM2 function in NZB/W F1 macrophages was provided 
by analysis of IL-1b release in response to MCMV infection (Fig. 4.2C). The NZB/W F1 
macrophages released an amount of IL-1β intermediate between NZW and NZB, which had a low 
inflammasome response to MCMV, as previously published (Sester et al., 2015a). Together, these 
results suggest that the expression of p202 within the NZB/W F1 BMMs is sufficient to handicap 
but not eliminate AIM2 inflammasome responses. BALB/c macrophages similarly express a low 
but functional level of p202 that limits AIM2 responses (Roberts et al., 2009). 
4.2.3.3 NZB/W F1 cells have reduced NLRP3 protein expression.  
In addition to being deficient in AIM2-mediated inflammasome responses, our previous work has 
shown that NZB BMMs are deficient in NLRP3 inflammasome response due to a point mutation 
causing aberrant splicing of NLRP3 transcripts (Sester et al., 2015a, Thygesen et al., 2016). The 
NZB mice were obtained from the Kew animal house (WEHI, Melbourne, Australia) where they 
had been breeding in isolation from stocks held at The Jackson Laboratory (ME, USA), since 1976. 
To ensure the mutation was not newly acquired, this region was sequenced in genomic DNA from 
NZB, NZW and New Zealand obese (NZO) mice from WEHI and Jackson Laboratories. The G to 
A mutation previously defined (Appendix 2) (Sester et al., 2015a) was present in NZB mice from 
both WEHI and Jackson Laboratories (Table 4.1 and Supplementary Information Fig. 4.1). The 
mutation was also present in the genome of NZO mice. NZB and NZO are related strains that 
diverged early in the inbreeding process (Bielschowsky and Goodall, 1970). This indicates that the 
mutation has been present in NZB since the strain was founded. The NZW genome contains the 
wild type G in this location like C57BL/6. The NZB/W F1 mice would thus have one wild type and 
one mutated copy of the Nlrp3 gene, and are anticipated to be haploinsufficient for this gene.  
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Figure 4.2. Deficient AIM2 inflammasome responses in NZB/W F1 macrophages. (A) 
Representative flow cytometric plots of PI staining of C57BL/6 BMMs following electroporation 
with or without 4 µg CT DNA. Samples are first gated to exclude debris on a SSC-area versus FSC-
area plot (scatter gate). Events within the scatter gate are then viewed on a FSC-width vs FSC-area 
plot and gated to exclude doublets (singlet gate). Events within the singlet gate are then analysed for 
PI staining. (B) NZB/W F1 BMMs have a deficient cell death response to low but not high amounts 
of electroporated calf thymus DNA (CT DNA). BMMs from NZB, NZB/W F1 and NZW mice 
were untreated or electroporated with 0, 4 or 20 µg of CT DNA and incubated for 30 min prior to PI 
staining and flow cytometric analysis. Bars are drawn to the mean of three individual experiments. 
Each symbol represents the mean of duplicate treatments within a single experiment **p < 0.01, 
one-tailed paired t test. (C) Deficient IL-1β release by NZB/W F1 BMMs in response to MCMV 
infection. Quantification of IL-1β release by ELISA from LPS-primed C57BL/6, NZB, NZB/W F1 
and NZW BMMs either mock treated or infected with MCMV (MOI 8, 6 h). LPS was from S. 
Minnesota Re595. Bars are drawn to the mean of five (C57BL/6) or six (NZB, NZB/W F1, NZW) 
independent experiments. Each symbol represents the result of a single experiment. **p < 0.01, 
one-tailed paired t test. The experiments presented in this figure were performed by David Sester.  
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Table 4.1. Genomic DNA sequencing revealed the Nlrp3 G to A point mutation is present in NZB 
and NZO, but not NZW, mice from Jackson Laboratories (JAX) and The Walter and Eliza Hall 
Institute (WEHI). 
 
Strain   Location   Sequence  
NZB   WEHI   TTTATCTAGATACATTT  
NZB   JAX   TTTATCTAGATACATTT  
NZO   WEHI   TTTATCTAGATACATTT  
NZO   JAX   TTTATCTAGATACATTT  
NZW   WEHI   TTTATCTGGATACATTT  
NZW   JAX   TTTATCTGGATACATTT  
 
 
NLRP3 responses in BMM in vitro require two signals; an initial priming signal is provided 
by Toll-like receptor stimuli such as LPS, followed by a triggering stimulus such as nigericin or 
ATP. The priming signal increases NLRP3 expression (Bauernfeind et al., 2009), and licences the 
inflammasome to respond to the trigger by deubiquitination of NLRP3 (Juliana et al., 2012). 
NLRP3 levels, under a range of LPS priming conditions, were compared in BMMs from the various 
mouse strains by quantitative western blot (Fig. 4.3). Little or no protein was detected in the NZB 
samples, as expected (Sester et al., 2015a). Expression and induction of NLRP3 was similar in 
NZW and C57BL/6 cells. The NZB/W F1 cells showed an intermediate amount of NLRP3 at 
baseline and with the higher dose of LPS only reached the level of NLRP3 seen in NZW and 
C57BL/6 cells with low priming. The level of NLRP3 is important, since induction of NLRP3 to a 
critical threshold by a TLR stimulus is necessary for NLRP3 function (Bauernfeind et al., 2011).  
4.2.3.4 NZB/W F1 cells have a deficient NLRP3 inflammasome response to nigericin and ATP 
treatment under low priming conditions.  
In vitro experiments for NLRP3 inflammasome responses generally use priming with high doses of 
LPS to provide maximal sensitivity to NLRP3 triggers. However, the degree of priming relevant to 
conditions in vivo is difficult to predict. Consequently we investigated NLRP3 function using two 
doses of LPS priming signal. In response to 10 ng/ml LPS priming followed by nigericin or ATP 
treatment, no significant deficiency in the pyroptotic death of NZB/W F1 cells was seen (Fig. 
4.4A). It was hypothesised that under these conditions the NZB/W F1 cells were expressing enough 
NLRP3 to mount a normal pyroptotic response to nigericin treatment. A lower priming 
concentration (1 ng/ml) yielded less death in the NZB/W F1 cells than C57BL/6 and NZW (Fig. 
4.4B).  
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Figure 4.3. NZB/W F1 cells have intermediate NLRP3 protein expression. Quantitative western 
blot analysis of NLRP3 expression in C57BL/6, NZB, NZB/W F1 and NZW BMMs after 3 h with 
0, 1 or 10 ng/ml ultra-pure LPS. NLRP3 expression was normalized to ribosomal protein S6. Data 
are from three independent protein preparations and blots (except n=2 for C57BL/6 with 0 and 1 
ng/ml LPS). Bars are drawn to the mean of three experiments and symbols show results of each 
experiment. *p < 0.05, one-tailed t test. 
 
 
We also compared ASC speck formation in BMMs from the four mouse strains in response 
to both nigericin and ATP treatments following low dose priming. The percentage of NZB/W F1 
cells with ASC specks after a 30 min nigericin treatment was much lower than that of C57BL/6 and 
NZW and was still lower but increasing after 1 h (Fig. 4.4C&D). Initial experiments failed to detect 
ASC specks in ATP-treated NZW cells although they were readily detectable in C57BL/6 in these 
experiments (data not shown) and previous work (Sester et al., 2015b). The P2X7 receptor that 
mediates responses to ATP has several characterised alleles, and NZW, but not C57BL/6 and NZB, 
carry P451 conferring high sensitivity to ATP stimulation (Adriouch et al., 2002, Elliott et al., 
2005). We reasoned that the failure to observe ASC specks in NZW could relate to a strong P2X7 
response and increased cell fragility. Pre-treatment with caspase-1 inhibitor VX-765 to reduce 
pyroptotic lysis enabled detection of some specks within the NZW strain, although numbers were 
still lower than C57BL/6 (Fig. 4.4E). Under these conditions fewer ASC specks were observed in 
NZB/W F1 cells than NZW cells (Fig. 4.4E).  
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IL-1b release from cells primed with 1 ng/ml LPS was not detectable by ELISA, 
presumably due to insufficient induction of pro-IL-1b. With 10 ng/ml LPS priming, where released 
IL-1b could be detected, NZB/W F1 cells had an intermediate response compared to the parental 
strains after triggering with either nigericin or ATP (Fig. 4.4F). Unexpectedly the levels of IL-1b 
released by C57BL/6 cells in response to nigericin treatment were reproducibly lower than that of 
the NZW and NZB/W F1 cells. To the best of our knowledge no one else has reported decreased 
IL-1b production by C57BL/6 BMMs compared to BMMs derived from other mouse strains. Why 
it has occurred in this study is not apparent, given that the NLRP3 response of C57BL/6 BMMs is 
similar to NZW by other measures, and there is no difference between the BMMs from each strain 
in their induction of pro-IL-1b (Fig. 4.1C). 
4.2.3.5 Deficient IL-1b release in response to alum and Candida albicans in NZB/W F1 cells.  
The inflammasome response in NZB/W F1 mouse cells was checked with two further NLRP3 
stimuli. Alum (aluminium hydroxide) is a commonly used vaccine adjuvant that activates the 
NLRP3 inflammasome (Franchi and Nunez, 2008, Li et al., 2008). Similar to the pattern seen with 
nigericin treatment, NZW macrophages produced much higher levels of IL-1b in response to 
stimulation with alum than C57BL/6 cells (Fig. 4.5A). No IL-1b was released from the NZB cells 
and the response from NZB/W F1 cells was much lower than NZW, but was similar to C57BL/6. In 
response to Candida albicans infection, NZB/W F1 macrophages were deficient in IL-1b release 
when compared to NZW as well as C57BL/6 (Fig. 4.5B). NZB BMMs released little or no IL-1b, 
consistent with the in vitro response to C. albicans being NLRP3-dependent (Hise et al., 2009). C. 
albicans efficiently induced death of infected BMMs; the modest death of NZB BMMs at low 
multiplicity of infection (MOI) suggests partial inflammasome dependence at this dose, but other 
death pathways dominated at the higher MOI, as NZB cells died efficiently (Fig. 4.5C). NZB/W F1 
cells showed a trend for reduced death at the lower MOI.  
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Figure 4.4. NZB/W F1 cells have reduced NLRP3 inflammasome formation and responses to 
nigericin and ATP. (A & B) Flow cytometric analysis of percentage of PI-positive BMMs after 3 h 
LPS priming with (A) 1 or (B) 10 ng/ml ultra-pure LPS and then either no further treatment, 10 µM 
nigericin or 5 mM ATP for 1 h. Gating was performed as per Figure 2A. Bars are drawn to the 
mean of three independent experiments and each symbol represents the mean of duplicate treatment 
wells within one experiment. *p < 0.05, one-tailed, paired ratio t test. (C) Representative flow 
cytometric plots of ASC speck staining of LPS-primed C57BL/6 BMMs with and without nigericin 
treatment. Ethanol fixed samples are first gated to exclude debris on a SSC-area versus FSC-area 
plot (scatter gate). Events within the scatter gate are then viewed on a FSC-width vs FSC-area plot 
and gated to exclude doublets (singlet gate). These single cell events are then plotted on an ASC-
height versus ASC-area plot and the population of cells with a high ASC-height:ASC-area profile, 
representing ASC speck positive cells, are gated (speck +ve cells). (D) Flow cytometric analysis of 
the percentage of BMMs with an ASC speck following 3h of priming with 1 ng/ml ultra-pure LPS 
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and then 30 min or 1 h incubation with or without 10 µM nigericin. Bars show the mean of three 
independent experiments and each symbol represents the mean of two treatments within a single 
experiment. **p < 0.01, one-tailed paired t test. (E) Flow cytometric analysis of the percentage of 
BMMs with an ASC speck following LPS and ATP treatment. BMMs were primed with 1 ng/ml 
ultra-pure LPS for 3 h, with 50 µM VX-765 added for the final 30 min and then treated for 1 h with 
or without 5 mM ATP. Bars show the mean of three independent experiments and each symbol 
represents the mean of two treatments within a single experiment. (F) Quantification of IL-1b levels 
by ELISA from BMMs primed for 3 h with 10 ng/ml ultra-pure LPS and then either no further 
treatment, 5 µM nigericin or 2.5 mM ATP for 1 h. Bars show the mean of four (nigericin) or three 
(ATP) independent experiments and each symbol represents the mean of two treatments within a 
single experiment. *p < 0.05, **p < 0.01, one-tailed paired t test.   
 
4.2.4 Discussion 
The development of SLE can be broadly considered as the result of two processes; (i) loss of B cell 
tolerance leading to autoantibody production, and (ii) tissue damage following autoantibody 
deposition. NZB mice clearly have a strong genetic contribution to loss of B cell tolerance, but have 
limited tissue damage. Our previous work demonstrated that the NZB strain has a complete lack of 
NLRP3 inflammasome function and low AIM2 inflammasome function due to a point mutation in 
the Nlrp3 gene and high p202 expression respectively (Sester et al., 2015a, Yin et al., 2013, 
Thygesen et al., 2016). AIM2 and NLRP3 inflammasome activities are therefore clearly not 
necessary for the development of anti-nuclear and anti-erythrocyte antibodies observed in the NZB 
mice. This result may seem counterintuitive, given the publications suggesting or anticipating a role 
for inflammasomes in autoimmunity (Shaw et al., 2011, Kahlenberg and Kaplan, 2014). However, 
inflammasomes may play a role in the later stage of immune-complex-dependent tissue damage that 
remains mild in the NZB mice. For this reason, we have investigated the inflammasome 
competence of macrophages from NZB/W F1 mice that develop profound kidney damage. The 
NZW parental strain showed strong AIM2 and NLRP3 inflammasome function. However, the 
NZB/W F1 mice still expressed enough p202 to have a reduced AIM2 inflammasome response to 
low amounts of electroporated CT DNA and MCMV infection. In parallel with AIM2 function, the 
inheritance of a mutated Nlrp3 allele from NZB mice led to haploinsufficient expression of NLRP3 
in cells from the F1 mice, and consequently function that was intermediate between NZB and 
NZW.  
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Figure 4.5. Deficient IL-1β production by NZB/W F1 cells in response to particulate and 
infectious stimuli. (A) ELISA quantification of IL-1b released by LPS-primed (10 ng/ml, 3 h) 
C57BL/6, NZB, NZB/W F1 and NZW BMMs treated with or without 200 µg/ml Alum for a further 
3.5 h. Bars are drawn to the mean of two independent experiments and each symbol represents the 
mean of duplicate treatments from an individual experiment. (B) Quantification of IL-1b release by 
ELISA and (C) cell death by LDH assay of LPS-primed (1 ng/ml, 4 h) BMMs that were uninfected 
or infected with C. albicans at the indicated MOI for 6 h. Percentage cell death is calculated relative 
to the total LDH released from untreated cells by detergent lysis. Bars are drawn to the mean of 
three (B) or two (C) independent experiments and each symbol represents the mean of duplicate 
treatments within a single experiment. *p < 0.05, one-tailed paired t test.  
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Despite moderate deficiency in the F1 mice, both inflammasome systems were capable of 
giving substantial responses under conditions of high stimulus. It is possible that in the NZB/W F1 
mice, amplifying loops of tissue damage and inflammation during disease progression provide 
enough stimulus such that even suboptimal inflammasome systems become part of the pathological 
process. The NLRP3 inflammasome has been shown to be active in the kidneys of NZB/W F1 mice 
during disease but not at 8 weeks old, prior to disease symptoms (Tsai et al., 2011). In a number of 
studies treatments have been administered to NZB/W F1 mice and improvement of kidney disease 
symptoms has been observed alongside decreased expression and activity of NLRP3 in the kidney 
(Tsai et al., 2011, Zhu et al., 2013, Zhao et al., 2015). Evidence for the ability of NLRP3 to 
contribute to kidney damage is provided by the pristane-induced experimental model of SLE, where 
mice carrying the gain of function mutation, Nlrp3-R258W developed more severe renal damage upon 
pristane challenge than wild type mice (Lu et al., 2016). 
Normal inflammasome function in the NZB strain is evidently not necessary for 
autoantibody production, but establishing whether or not the inflammasome deficiencies contribute 
to the loss of tolerance will require genetic manipulation of the mouse strains. AIM2 and p202 both 
fall within the Nba2 lupus-susceptibility locus of NZB mice on chromosome 1 (Jorgensen et al., 
2010). This locus also contains FcγRIIb and genes for signaling lymphocytic activation molecule 
(SLAM) factors, which have been strongly implicated in autoantibody production, and a role for 
p202 has not been confirmed (Jorgensen et al., 2010). The NZB null allele of Nlrp3 falls within 
the lbw8 lupus susceptibility locus on chromosome 11 thought to contribute to autoantibody 
production (Kono et al., 1994) and is therefore a candidate gene for this effect.  
Deficient inflammasome activity could alter responses to both pathogens and commensal 
organisms, particularly given the potential role of NLRP3 in intestinal barrier function (Macia et al., 
2015, Hirota et al., 2011). Loss of inflammasome-dependent cell death could lead to increased 
viability of cells harbouring intracellular infections, and consequently prolonged production of 
cytokines predisposing to loss of tolerance. Type I interferon (IFN) plays a central role in SLE, and 
elevated levels of IFN-responsive genes have been documented in pre-autoimmune NZB/W F1 
mice (Lu et al., 2007). Our previous work has shown that NZB macrophages make significantly 
more IFN-β in response to transfected DNA than C57BL/6 macrophages, and this is likely due to 
their lower AIM2-mediated cell death permitting ongoing cytokine release (Yin et al., 2013). 
Similarly when AIM2, ASC or caspase-1 is knocked out of dendritic cells and macrophages, they 
have a markedly increased IFN-β response to DNA, largely due to decreased cell death (Corrales et 
al., 2016). Recent work has also shown that the cytosolic DNA receptor leading to IFN-β 
production, cGMP-AMP synthase (cGAS), is a direct cleavage target of caspase-1 (Wang et al., 
2017) and furthermore IL-1β has been reported to attenuate type I IFN production and responses 
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(Kohase et al., 1988, Tian et al., 2000, Mayer-Barber et al., 2014). Overall it seems that type I IFN 
and inflammasome responses are mutually antagonistic, and so IL-1b may not be a major player in 
the etiology of SLE that is IFN-driven. 
Unconventional roles for inflammasome components may also be relevant to autoimmunity. 
Recent work has shown a requirement for NLRP3 in optimal activation of the T-cell receptor in 
Th1, Th2 and Th17 cells (Bruchard et al., 2015, Arbore et al., 2016, Meng et al., 2009) and its 
deficiency may have unexpected effects on T cell differentiation in NZB mice. Interestingly, against 
the perception that inflammasomes promote autoimmunity, Lech et al. found that knocking out 
NLRP3 in C57BL/6-lpr/lpr mice exacerbated disease phenotype (Lech et al., 2014). Female 
C57BL/6-lpr/lpr mice develop mild, spontaneous lupus-like autoimmunity and when NLRP3 or 
ASC were knocked out they developed lung disease and severe lupus nephritis. Thus in the 
C57BL/6-lpr/lpr model NLRP3 was protective against lupus nephritis, although the authors suggest 
this was related to an uncharacterised role in TGF-β signalling, rather than canonical inflammasome 
function (Lech et al., 2014). 
In summary, this study has found that the profound deficiency of AIM2 and NLRP3 
inflammasomes in the parental NZB mouse strain (Sester et al., 2015a, Yin et al., 2013, Thygesen et 
al., 2016) does affect inflammasome responses in macrophages of the NZB/W F1 lupus model 
mouse. It is possible that the moderate NLRP3 deficiency in NZB/W F1 mice contributes to the loss 
of tolerance while the presence of even a limited amount of NLRP3 may be acting at later stages of 
disease to enhance kidney damage. Being entirely deficient in NLRP3 inflammasome function may 
protect the NZB mice from kidney damage. This work highlights the complex role that 
inflammasomes could play in autoimmune disease.   
4.2.5 Methods 
4.2.5.1 Materials 
Nigericin (N7143, Sigma-Aldrich, St Louis, USA) was dissolved in ethanol at 5 mM. ATP 
(adenosine 5'-triphosphate disodium salt hydrate, A2383-1G, Sigma-Aldrich) was dissolved in 
sterile water at 150 mM as required. CT DNA (Sigma-Aldrich) was further purified by phenol-
chloroform and Triton-X114 extraction (Stacey et al., 2003). Unless otherwise noted, LPS used was 
ultra-pure LPS from E. coli 0111:B4 (InvivoGen, San Diego, USA). Salmonella minnesota Re595 
LPS (Sigma-Aldrich) was used only in Figure 4.2. Alum was Imject Alum adjuvant (cat# 77161, 
Thermo Fisher Scientific, Waltham, Massachusetts, USA). Recombinant human colony stimulating 
factor (CSF-1) was a gift from Chiron, Emeryville, CA. Complete RPMI 1640 is RPMI 1640 with 
10% heat inactivated foetal calf serum (FCS), 1x GlutaMAX, 50 U/ml penicillin, 50 µg/ml 
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streptomycin and 25 mM HEPES (all Life Technologies, Grand Island, USA). Propidium iodide 
(PI) (Life Technologies) was diluted in 1x PBS to a stock concentration of 10 µg/ml.  
4.2.5.2 Mice and cell culture 
C57BL/6, NZB, NZW and NZB/W F1 mice were housed under specific pathogen-free conditions at 
the University of Queensland and were used under approval 353/14 from the University of 
Queensland Animal Ethics Committee. Female mouse bone marrow derived macrophages (BMMs) 
were differentiated in CSF-1 for 7-10 days as previously described (Sester et al., 2015a). 
4.2.5.3 Sequencing of Nlrp3 point mutation  
NZB, NZO and NZW genomic DNAs were kindly supplied by Tom Brodnicki (Immunogenetics 
Laboratory, St Vincent’s Institute of Medical Research, Melbourne, Australia). The region of 
interest was amplified by PCR using forward primer Nlrp3Intron For1 (5'-
TCTTTCGTCTCCCTTCCT-3') and reverse primer mNlrp3SpliceSite R (5'-
TGAATAAATGCTGGTGGTG-3'). The following cycling conditions were used: initial 
denaturation of 95°C for 3 min followed by 35 cycles of 94°C for 30 sec, 58°C for 30 sec, 72°C for 
1 min and a final extension at 72°C for 10 min. Products were run on a 2% agarose gel and DNA 
was extracted using the UltraClean 15 DNA purification kit (MoBio Laboratories, Carlsbad, USA). 
Products were sequenced by the Australian Genome Research Facility (North Melbourne, 
Australia) using mNLRP3SliceSite R primer.  
4.2.5.4 Immunoblot analysis 
Quantitative western blotting was performed as previously described (chapter 5, section 5.2.5.6) 
(Thygesen et al., 2016). Primary antibodies used were anti-NLRP3/NALP3 mAb Cryo-2 (#AG-
20B-0014 Adipogen, San Diego, USA), anti-a-Tubulin (B-5-12, Sigma Aldrich), S6 Ribosomal 
Protein (5G10) rabbit mAb (Cell Signaling Technology, Danvers, USA) and anti-mouse IL-1β (AF-
401-NA; R&D Systems Inc., Minneapolis, USA). Secondary antibodies used were anti-rabbit 
(Dylight) 800 conjugate, anti-rabbit (Dylight) 680 conjugate, anti-Mouse (Dylight) 800 conjugate, 
anti-mouse (Dylight) 680 conjugate (#5151P, #5366P, #5257 and #5470P respectively, Cell 
Signaling Technology), and IRDye® 800CW Donkey anti-Goat IgG (H + L) (LI-COR Biosciences, 
Lincoln, USA).  
Non-quantitative western blotting was conducted as previously described.(Sester et al., 
2015a) The primary antibodies used were polyclonal rabbit anti-AIM2 (made to full-length 
recombinant mouse AIM2 and tested on Aim2-/- BMM extracts), anti-p202 (goat, S-19; Santa Cruz 
Biotechnology, Dallas, Texas, USA), Caspase-1 p20 (mouse) mAb (Adipogen), ASC (N15)-R 
rabbit polyclonal IgG (Santa Cruz Biotechnology) and anti-GAPDH (Trevigen, Gaithersburg, 
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USA). The HRP-linked secondary antibodies used were anti-mouse IgG, anti-rabbit IgG (both Cell 
Signalling) and anti-goat IgG (HAF019; R&D systems). Blots were analysed using an Amersham 
Imager 600RGB (GE Healthcare Life Sciences, Chicago, Illinois, USA). 
4.2.5.5 AIM2 and NLRP3 inflammasome activation 
BMMs were electroporated with CT DNA, or infected with MCMV as previously described to 
activate the AIM2 inflammasome (Appendix 2) (Sester et al., 2015a). For NLRP3 inflammasome 
activation, BMMs were primed for 3 h with ultra-pure LPS. Unless otherwise indicated, cells were 
treated with 10 µM nigericin or 5 mM ATP for 1 h or 200 ng/ml alum for 3.5 h at 37°C. For protein 
and ELISA samples cells were primed and treated on 24 (3.5 x 105 cells per well) or 96 (7 x 104 
cells per well) well tissue culture plates respectively. For ASC speck assay and PI staining cells 
were primed on 25 well Sterilin plates (VWR International, Radnor, Pennsylvania, USA) and 
transferred to 1.5 ml tubes before nigericin or ATP treatment. BMMs were infected with Candida 
albicans as previously described (Appendix 2) (Sester et al., 2015a) but with cells seeded at 3 x 105 
cells per well and primed for 4 h with 1 ng/ml ultra-pure LPS.  
4.5.5.6 Measurement of cell viability  
PI was added to samples at a final concentration of 1 µg/ml. Cells were analysed using a BD Accuri 
C6 flow cytometer (BD Biosciences, San Jose, USA) by first gating on a side scatter vs forward 
scatter plot to remove debris but include the dead cells with lowered forward scatter (Fig. 4.2A). 
4.2.5.7 ELISA for secreted IL-1b  
Cell culture supernatants were collected and stored at -80°C. IL-1b levels in the supernatants were 
measured using the Mouse IL-1b/IL1F2 DuoSet ELISA kit (R&D Systems) or BD OptEIA Mouse 
IL-1b ELISA Set (BD Biosciences). 
4.2.5.8 ASC speck assay 
BMMs were primed with LPS and treated with ATP or nigericin as described above. Before ATP 
treatment VX-765 (S2228, Jomar Life Research, Scoresby, Victoria, Australia) was added to the 
cells at a final concentration of 50 µM. After treatment cells were fixed with ethanol, 
immunostained for ASC and analysed for speck formation as previously described using a BD 
Accuri flow cytometer (Chapter 3) (Sester et al., 2015b). This assay involves flow cytometric 
assessment of the redistribution of ASC based on the change in fluorescence peak height:area ratio 
(Fig. 4.4C). 
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4.2.5.9 LDH assay 
Release of lactate dehydrogenase (LDH) into the cell culture medium was assessed as a measure of 
cell viability using the TOX7 In Vitro Toxicology Assay Kit (Sigma-Aldrich) according to the 
manufacturer’s protocol. Percentage cell death is calculated relative to the total LDH released from 
untreated cells by detergent lysis. 
4.2.5.10 Statistical Analysis 
Statistical tests described in the figure legends were conducted using Prism 7.0.  
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4.2.7 Supplementary Information 
 
Supplementary Information Figure 4.1. The trace data that corresponds to the sequences 
reported in Table 4.1. The region of interest was PCR amplified from genomic DNA of NZB, 
NZO and NZW mice from the Kew animal house at The Walter and Eliza Hall Institute (WEHI) 
and The Jackson Laboratory (JAX). PCR products were sequenced by the Australian Genome 
Research Facility (North Melbourne, Australia) using mNLRP3SliceSite R primer 
(5'TGAATAAATGCTGGTGGTG-3'). Sequences were aligned in CLC Main Workbench (Qiagen, 
Hilden, Germany). 
  
NZB - WEHI
NZB-JAX
NZO-WEHI
NZO-JAX
NZW-WEHI
NZW-JAX
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4.3 Extended Results and Discussion 
Our in vitro experiments demonstrated that NZB macrophages have no measurable NLRP3 
inflammasome response (Appendix 2) (Sester et al., 2015a) and that responses in NZB/W F1 cells 
are decreased (section 4.2 Submitted paper).  To further this study we aimed to prove the lack of 
NLRP3 function in NZB in vivo and to investigate the level of NLRP3 deficiency in NZB/W F1 
mice.  
 
4.3.1 Response of NZ mouse strains to intraperitoneal injection of C. albicans  
We have hypothesised that inflammasome deficiencies could alter host interactions with infectious 
and commensal microbes and promote the onset of autoimmunity. Our work has shown that NLRP3 
inflammasome responses to C. albicans are reduced in NZB/W F1 macrophages (4.2 submitted 
paper) and entirely deficient in macrophages from NZB mice (Appendix 2) (Sester et al., 2015a). 
We chose i.p. C. albicans as our first stimulus to test the NLRP3 inflammasome response of NZB, 
NZB/W F1 and NZW mice in vivo. Neutrophil recruitment to the peritoneal cavity and decrease in 
peritoneal macrophages (presumably due to pyroptotic death) has been reported in response to i.p. 
injection of inflammasome stimuli (Chen et al., 2014, Tzeng et al., 2016). In a preliminary 
optimisation experiment, NZW mice were given i.p. injections of C. albicans or mock injections of 
PBS and the peritoneal cavity was flushed at different time points. The percentage of neutrophils 
(Ly-6G positive) and macrophages (F4/80 positive) in the peritoneal lavage fluid were determined 
by flow cytometery. Neutrophil influx in response to i.p. C. albicans was observed after 4 h and 
was maximal by 5.5 h (Figure 4.6A&B).  A clear reduction of peritoneal macrophages was 
observed in the lavage fluid in response to C. albicans at all time points (Figure 4.6C). Peritoneal 
lavage fluid was assayed for IL-1β but levels were below the detectable range (data not shown). 
Based on these results the 4-h time point was chosen for an experiment comparing responses in 
NZB, NZB/W F1 and NZW as there was clear neutrophil influx at this time but it was not yet at a 
maximum.  
Conditions that elicit a sub-maximal response in NZW were desired as it was found in in 
vitro studies that the deficient inflammasome-mediated cell death in NZB/W F1 macrophages could 
be overcome with stronger stimuli or longer incubations. The volume used to wash out the 
peritoneal cavity was halved from 10 ml to 5 ml to improve detection of IL-1β (Figure 4.6F). An 
increase in neutrophils was observed in mice of all genotypes in response to C. albicans compared 
to mock-treated mice (Figure 4.6D). The response was variable between mice of a single genotype 
and overall no difference was observed between NZB, NZB/W F1 and NZW mice. Depletion of 
macrophages was seen in all strains in response to C. albicans injection (Figure 4.6E) and the levels 
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of IL-1β reflected the pattern of neutrophil response with no difference between strains (Figure 
4.6F). The differences in in vitro inflammasome function between the NZB, NZB/W F1 and NZW 
macrophages did not alter their response to i.p. injection with C. albicans. This suggests that the 
measured responses to C. albicans administered i.p. are not solely NLRP3-dependent, and this 
should be checked using Nlrp3-/- mice. An alternative interpretation of our results is that although 
NZB BMMs are almost completely NLRP3-deficient (appendix 2) (Sester et al., 2015a), the point 
mutation does not preclude adequate NLRP3 expression in vivo. This seems unlikely because lack 
of NLRP3 expression was also observed in erythrocyte-depleted bone marrow from NZB mice even 
with LPS priming (Appendix 2) (Sester et al., 2015a). 
Prior work has shown NLRP3 was required for serum IL-1β responses as well as reduced 
fungal burden and protection from disease in response to infection with C. albicans both 
intravenously and via the oral mucosa (Gross et al., 2009, Hise et al., 2009). However, a role for the 
NLRC4 inflammasome in the response to C. albicans has also been described in mice using the 
same technique of infecting via the oral mucosa (Tomalka et al., 2011). Decreased neutrophil influx 
to the site of infection along with increased fungal burden in the kidneys and gastro-intestinal tract 
and decreased expression of pro-inflammatory cytokines in the oral mucosa were observed in Nlrc4-
/- mice after C. albicans infection. Given the concern that C. albicans was too complex a stimulus 
and may be activating pathways other than NLRP3 that elicit IL-1b and neutrophil influx, we 
investigated other options for a purer NLRP3 stimulus.  
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Figure 4.6. No difference in response to i.p. C. albicans injection in NZB, NZB/W F1 and 
NZW mice. (A) Representative flow cytometric plots of Ly-6G:FITC and F4/80:RPE staining of 
cells from the peritoneal lavage fluid of female NZW mice 5.5 h after i.p. injection with 5x106 cells 
of C. albicans in 100 µl sterile PBS or sterile PBS alone (mock). Fixed and stained samples were 
first gated to exclude debris on a SSC-area versus FSC-area plot (scatter gate). Events within the 
scatter gate were then viewed on a FSC-width vs FSC-area plot and gated to exclude doublets 
(singlet gate). These single cell events were then assessed for fluorescence in the FITC and RPE 
channels. (B&C) Ten week old NZW mice were injected intraperitoneally with 5x106 cells of C. 
albicans in 100 µl sterile PBS or sterile PBS alone (mock). Mice were culled and the peritoneal 
cavity was flushed with 10 ml ice-cold PBS at 4, 5.5 or 8 h post injection. The percentages of 
neutrophils (Ly-6G +ve) (B) and macrophages (F4/80 +ve) (C) in the peritoneal lavage fluid were 
assessed by flow cytometry. Each symbol represents an individual mouse. Females are denoted by 
squares and males by circles. (D-F) 8 week old, female NZB, NZB/W F1 and NZW mice were 
injected intraperitoneally with 5x106 cells of C. albicans in 100 µl sterile PBS or sterile PBS alone 
(mock). Mice were culled and the peritoneal cavity was flushed with 5 ml ice-cold PBS at 4 h post 
injection. The total number of neutrophils (Ly-6G +ve) (D) and macrophages (F4/80 +ve) (E) in the 
peritoneal lavage fluid were assessed by flow cytometry and the levels of IL-1β were assessed by 
ELISA (F). Each symbol represents an individual mouse. Different shapes are used for each strain 
and each mouse within a strain has a colour that is kept consistent throughout the three graphs.  
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4.3.2 Response of NZ mouse strains to intraperitoneal injections of LPS and nigericin 
Tzeng et al. reported an increase in neutrophils and decrease in peritoneal macrophages in response 
to nigericin administered i.p. in transgenic C57BL/6 mice expressing ASC-citrine, that was reduced 
in caspase-1 knockout mice (Tzeng et al., 2016). This response to nigericin alone administered by 
i.p. injection could not be replicated in NZW mice (data not shown). This may be due to differences 
between the strains. The neutrophil numbers observed by Tzeng et al. were relatively low and the 
NZW mice may be less sensitive to nigericin i.p. than C57BL/6 mice (Tzeng et al., 2016). The 
published work did not show an ethanol vehicle alone control and the neutrophil influx observed 
may have been due to ethanol alone. In this study the nigericin stock was solubilised in ethanol, 
matching the publication. In our experiments there was a low response to the ethanol control 
injections that was not increased by nigericin. Increasing the dose of nigericin above 3 mg/kg was 
not possible without having to administer more than 3.2% ethanol, which was already shown to 
induce non-specific responses. Instead we chose to try to boost the response by administering a low 
amount of LPS together with the nigericin.  
Nigericin that was solubilised in DMSO was used as this stock could be twice as 
concentrated thus reducing the amount of vehicle administered. Two doses of LPS were trialled 
with and without nigericin, and DMSO mock was used as a vehicle control. Mice were given 3 
mg/kg nigericin and either 3.33 µg/kg or 33.3 µg/kg LPS. This was achieved with an injection of 
400 µl PBS containing a concentration of 0.225 mg/ml (301.2 µM) nigericin and either 0.25 or 2.5 
µg/ml LPS. Neutrophil influx was observed in response to the lower dose of LPS with and without 
nigericin (Figure 4.7A). Surprisingly the response was much lower in mice injected with the higher 
dose of LPS. A moderate increase was also observed in mice treated with the DMSO vehicle 
control. The loss of macrophages and the levels of IL-1β were enhanced in mice that were treated 
with LPS and nigericin together compared to mice that only received LPS, however this appears to 
be influenced by the response to DMSO (Figure 4.7B&C).  
As responses were seen to DMSO alone we returned to using nigericin that was solubilised 
in ethanol for the next trial, administering a lower dose of 1 mg/kg (100 µM), which is still 10x the 
concentration of nigericin used to trigger the NLRP3 inflammasome in vitro. The ethanol mock did 
not induce any of the measured responses above the levels of the PBS alone treated mice. An 
increase in neutrophils and decrease in macrophages was observed in response to the lower LPS 
dose and the responses appeared somewhat increased when nigericin was included (Figure 
4.7D&E). The neutrophil influx was again much less with the higher dose of LPS. Although this 
unexpected result was seen in two experiments with a total of four mice per treatment (Figure 
4.7A&D), further replication would be necessary to confirm this. IL-1β levels were increased in 
response to i.p. LPS and were not changed by LPS dose or the addition of nigericin (Figure 4.7F).  
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Figure 4.7. Optimisation of i.p. LPS and nigericin injections in NZW mice. (A-C) Male NZW 
mice were injected intraperitoneally with LPS alone (3.3 µg/kg or 33 µg/kg in PBS), LPS (3.3 
µg/kg or 33 µg/kg in PBS) combined with 3 mg/kg nigericin (10 mM stock in DMSO diluted in 
PBS), PBS alone or DMSO vehicle control (DMSO mock). All injections were in a final volume of 
400 µl. Mice were culled and the peritoneal cavity was flushed 3 h post injection. The total number 
of neutrophils (Ly-6G +ve) (A) and macrophages (F4/80 +ve) (B) in the peritoneal lavage fluid 
were assessed by flow cytometry and the levels of IL-1β were assessed by ELISA (C). (E-G) 
female NZW mice were injected intraperitoneally with LPS alone (3.3 µg/kg or 33 µg/kg in PBS), 
LPS (3.3 µg/kg or 33 µg/kg in PBS) combined with 1 mg/kg nigericin (5 mM stock in ethanol 
diluted in PBS), PBS alone or ethanol vehicle control (ethanol mock). All injections were 400 µl 
final volume. Mice were culled and the peritoneal cavity was flushed 3 h post injection. The total 
number of neutrophils (Ly-6G +ve) (E) and macrophages (F4/80 +ve) (F) in the peritoneal lavage 
fluid were assessed by flow cytometry and the levels of IL-1β were assessed by ELISA (G). Each 
symbol represents an individual mouse. Different shapes are used for each treatment and each 
mouse has a colour that is kept consistent throughout the three graphs. 
 
The response to nigericin, over any effect of LPS was uncertain in Figure 4.7 due to low 
mouse numbers. Conditions of low LPS with and without nigericin were further examined in NZW, 
NZB/W F1, NZB and Nlrp3-/- mice. This was conducted over two separate experiments due to 
availability of mice. Increase in neutrophil numbers in response to LPS or LPS with nigericin was 
greater in NZW mice compared to NZB/W F1, NZB and Nlrp3-/- (Figure 4.8A). The response from 
the NZB/W F1 mice was low and similar to the NZB and Nlrp3-/- mice, but increased mouse 
numbers were needed to draw conclusions. However, before testing more mice an experiment with 
wild type C57BL/6 and Nlrp3-/- mice was conducted to verify that the response was NLRP3 
dependent. As the previous experiment showed no statistically-significant difference between LPS 
and LPS with nigericin only, LPS treatments and PBS alone controls were used (Figure 4.8B). The 
- 
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experiment did not provide convincing evidence that the increase in neutrophils was NLRP3 
dependent, as there was a modest but variable increase in neutrophils in response to LPS in mice of 
both genotypes. Levels of IL-1β in the corresponding peritoneal lavage fluids were also measured 
in a single ELISA assay (Figure 4.8C). IL-1β levels in control mice (-LPS) varied between 
genotypes and were highest in Nlrp3-/- mice. It should be noted that with the dilution of IL-1β in 
lavage fluid, accurate assessment by ELISA is challenging as levels are very low (approx. 20-300 
pg/ml) and often near the limit of detection. Taken together these results indicated that the current 
experimental setup was not clearly measuring an NLRP3 dependent response.  These experiments 
were performed with mice of mixed age and gender. However, given the gender bias of disease in 
the F1 mice (Perry et al., 2011), it will be important to use age and sex matched mice for final 
comparisons if/when we determine a useful experimental procedure. The experimental design 
should enable it to be clearly apparent if a gender bias exists in the activity of the NLRP3 
inflammasome.” 
 
 
Figure 4.8. Response to low dose i.p. LPS was not clearly NLRP3-dependent. Mice were 
injected intraperitoneally with LPS alone (3.3 µg/kg in PBS), LPS (3.3 µg/kg) combined with 1 
mg/kg nigericin (5 mM stock in ethanol diluted in PBS) or ethanol vehicle control (mock) in a final 
volume of 400 µl and the peritoneal cavity was flushed 3 h after injection. (A) Response of NZW, 
NZB/W F1, NZB and Nlrp3-/- mice (mixed genders). The total number of neutrophils (Ly-6G +ve) 
 
 
88 
in the peritoneal lavage fluid were assessed by flow cytometry. Each symbol represents an 
individual mouse. Results were collected over two separate experiments that are denoted by 
different colours. (B) Response of C57BL/6 and Nlrp3-/- mice. The total number of neutrophils (Ly-
6G +ve) in the peritoneal lavage fluid were assessed by flow cytometry. Each symbol represents an 
individual mouse and different colours denote separate experiments. (C) IL-1β levels in peritoneal 
lavage fluid corresponding to mock and LPS treatments from (A&B) assessed by ELISA. Each 
symbol represents an individual mouse, different strains are denoted by different shapes. 
 
So far we have been unable to measure a clear NLRP3 inflammasome-dependent response 
in vivo. NLRP3 inflammasome-dependent IL-1β production in response to i.p. injections of LPS has 
been reported (Coll et al., 2015). For that experiment a much higher dose of LPS (10 mg/kg) was 
used. Titrating the dose of LPS is one possible way forward. However LPS has been shown to 
activate NLRP3 via caspase-11 and the non-canonical inflammasome (Ruhl and Broz, 2015). 
Expression of caspase-11 and function of the non-canonical inflammasome has not been 
investigated in NZW, NZB/W F1 and NZB mice and continuing to use LPS as a stimulus for in vivo 
experiments would warrant such an investigation in vitro first. If the neutrophil influx seen in NZW 
is NLRP3-dependent, the same was not seen in C57BL/6, suggesting the possible effects of other 
genes. Interestingly LPS is known to cause ATP release from platelets (Zhang et al., 2009), and 
thus the inflammasome response to LPS alone in vivo may involve the P2X7 receptor. NZW has a 
more highly active P2X7R allele than NZB (Elliott et al., 2005). Although we could examine higher 
doses of LPS that will give clearer effects, the outcome may be a mixture of effects of NLRP3 and 
P2X7R genotypes, and not strictly show only the effect of NLRP3 status in the NZB/W F1 mice.  
 C. albicans was administered by i.p. injection as our collaborators have done this 
previously and observed neutrophil influx in C57BL/6 mice (Kaiwen Chen, personal 
communication). Gross et al. administered C. albicans intravenously to C57BL/6 mice and were 
able to measure an IL-1β response in serum that was completely absent in Nlrp3-/- mice (Gross et 
al., 2009). In future experiments we could replicate the technique used by Gross et al. and verify 
their results in C57BL/6 and Nlrp3-/- mice. If we see the same result we could then extend the 
experiment to include NZB, NZB/W F1 and NZW mice. It will be preferable to measure IL-1β as 
an output, as there are fewer genes determining this response than neutrophil influx that could be 
differentially affected by many genes in the various mouse strains, other than those directly 
involved in the NLRP3 inflammasome. This consideration also affected the decision to try and 
investigate NLRP3 function in vivo rather than AIM2, as the only AIM2 stimuli confirmed in vivo 
are infectious agents such as Francisella and MCMV (Rathinam et al., 2010). Whilst we could 
feasibly use MCMV, the response will be affected by many non-inflammasome genes that 
determine the course of infection including genes of the H2 complex that encode MHC I molecules 
and Cmv1 (Ly49H) (Chalmer et al., 1977, Scalzo et al., 1992, Webb et al., 2002). Resistance to 
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MCMV infection in NZW and C57BL/6 mice requires NK cells but this control is mediated by 
Ly49H in C57BL/6 and not NZW (Rodriguez et al., 2004). In contrast to NZW, NZB mice are 
profoundly susceptible to MCMV infection and genetic studies in (NZB x NZW)F1 and F2 
identified susceptibility loci on chromosome 17 outside of the MHC, and on chromosome X 
(Rodriguez et al., 2009).  
4.4 Conclusion 
Our discovery of profound inflammasome deficiencies in NZB mice led us to question the status of 
inflammasome function in NZB/W F1 mice that develop severe symptoms of systemic lupus 
erythematosus. We found that macrophages from NZB/W F1 mice have haploinsufficient 
expression of NLRP3 and demonstrate reduced NLRP3 and AIM2 inflammasome responses, 
particularly at low stimulus strength. Further experiments were undertaken with the aim of 
demonstrating the NZB NLRP3 inflammasome deficiency in vivo and testing the effect of partial 
NLRP3 inflammasome activity in NZB/W F1 mice. A number of different approaches were trialled, 
however, further optimisation of experimental conditions is required to measure canonical NLRP3 
inflammasome-dependent responses in NZW, NZB/W F1 and NZB mice. Investigating the impact 
of reduced NLRP3 expression on the autoimmune phenotype of NZB/W F1 mice will require 
genetic manipulation to restore NLRP3 expression.  To address this we aimed to repair the aberrant 
splicing of Nlrp3 in NZB mice and that is the focus of the next chapter of this thesis.  
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Chapter 5: Correcting the NLRP3 inflammasome deficiency in the NZB strain 
 
5.1 Introduction 
In previous work, we proposed that the NLRP3 inflammasome defect in NZB cells is due to a point 
mutation found in an intron that creates an aberrant splice acceptor site (Appendix 2) (Sester et al., 
2015a). The resulting pseudoexon introduces a premature stop codon producing a less stable 
truncated NLRP3 protein, and an almost complete lack of NLRP3 protein expression.  Chapter 4 
demonstrated that NZB/W F1 macrophages have intermediate NLRP3 inflammasome expression 
and function. Assessment of the contribution of the NLRP3 inflammasome deficiency to 
autoimmune disease in these mouse strains requires genetic manipulation. Prior to embarking on 
genetic modification of the NZB mouse, it was important to establish whether repair of the single 
point mutation would restore NLRP3 expression and function. This was addressed by using 
antisense oligonucleotides (AON) to correct the splicing defect in vitro.  
 AON are short, synthetic, nucleic acid polymers that target pre-mRNA through base-pairing 
and modulate its expression (Southwell et al., 2012). AON are more typically used to knockdown 
genes through RNase H cleavage of the resulting DNA:RNA hybrids and subsequenct degradation 
of the mRNA (Dias and Stein, 2002). However, they can also induce the production of non-
functional mRNA by physically blocking the recognition of exon-intron junctions and regulatory 
sequence elements by splicing machinery, leading to nonsense-mediated decay (Aartsma-Rus et al., 
2009). This second approach lead to the first investigations into antisense-mediated modulation of 
pre-mRNA splicing as a potential disease therapeutic (Dominski and Kole, 1993). AON used to 
modify splicing are modified to improve stability and to confer RNase H resistance (Stein et al., 
1988). AON can be used to block mutations that introduce aberrant donor or acceptor splice sites as 
well as regulating alternative splicing and correcting nonsense mutations by skipping regions of 
pre-mRNA that contain mutations (Du and Gatti, 2011).  
 AON-mediated exon skipping is currently a promising therapeutic approach for Duchenne 
muscular dystrophy where particular mutated exons of the dystrophin gene are skipped to restore a 
correct open reading frame and allowing translation of a partially functioning protein (Koo and 
Wood, 2013). A study by Roescher et al., provided proof-of-concept for the use of exon-skipping 
therapy in autoimmune disease (Roescher et al., 2014). They used exon-skipping to decrease BAFF 
(B-cell-activating factor of the tumor necrosis factor family) expression in a mouse model of 
primary Sjorgen’s syndrome, leading to significantly reduced lymphocyte infiltrates and improved 
salivary flow. Exon-skipping has been applied to the regulation of immune signalling by targeting 
MyD88 and Il-1 receptor accessory protein both in vitro and in vivo (Vickers et al., 2006, Yilmaz-
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Elis et al., 2013). However, one of the main challenges with in vivo experiments is the delivery of 
the AON to the target cell type or organ and AON efficiency in immune cells including 
macrophages is an area open to improvement (Yilmaz-Elis et al., 2013).  
Presented in this chapter is a published paper (Thygesen et al. Immunology & Cell Biology 2016 
94(5):520-4) in which exon skipping AON targeting the pseudoexon were used to restore both 
NLRP3 protein expression and NLRP3 inflammasome activity, demonstrating that this point 
mutation is the sole defect preventing NLRP3 inflammasome function in the NZB strain (Thygesen 
et al., 2016). This supported further work to repair the mutation in NZB mice in vivo using clustered 
regularly interspaced short palindromic repeat (CRISPR)-mediated genetic modification and 
establish the effect on the autoimmune phenotype. Included here, in section 5.3 Extended results 
and discussion, is a description of the work undertaken to plan, produce and verify the necessary 
components to repair NZB Nlrp3 in vivo.    
 
5.2 Published Paper 2 
 
Thygesen SJ, Sester DP, Cridland SO, Wilton SD, Stacey KJ. Correcting the NLRP3 
inflammasome deficiency in macrophages from autoimmune NZB mice with exon skipping 
antisense oligonucleotides. Immunol Cell Biol. 2016;94(5):520-4. 
Contributions to the publication: 
I completed all experimental work presented in this publication as well as preparation of the figures 
and writing the manuscript with editing by Katryn Stacey. Contributions of all authors were: 
Sara Thygesen: Presented experimental work 100%, writing 80%, project design 
David Sester: Preliminary experimental work not presented, project design, supervision 
Simon Cridland: Preliminary/supporting experimental work 
Steve Wilton: Antisense oligonucleotide design and production 
Katryn Stacey: Writing 20%, project concept, project design, supervision  
 
5.2.1 Abstract  
Inflammasomes are molecular complexes activated by infection and cellular stress, leading to 
caspase-1 activation and subsequent IL-1β processing and cell death. The autoimmune NZB mouse 
strain does not express NLRP3, a key inflammasome initiator mediating responses to a wide variety 
of stimuli including endogenous danger signals, environmental irritants and a range of bacterial, 
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fungal and viral pathogens. We have previously identified an intronic point mutation in the Nlrp3 
gene from NZB mice that generates a splice acceptor site. This leads to inclusion of a pseudoexon 
that introduces an early termination codon and is proposed to be the cause of NLRP3 
inflammasome deficiency in NZB cells. Here we have used exon skipping antisense 
oligonucleotides (AON) to prevent aberrant splicing of Nlrp3 in NZB macrophages and shown that 
this restores both NLRP3 protein expression and NLRP3 inflammasome activity. These results 
indicate that the single point mutation leading to aberrant splicing is the sole cause of NLRP3 
inflammasome deficiency in NZB macrophages. The NZB mouse provides a model for addressing a 
splicing defect in macrophages and could be used to further investigate AON design and delivery of 
AONs to macrophages in vivo.  
5.2.2 Introduction 
Inflammasomes are multiprotein complexes that are assembled in response to microbial and 
endogenous danger signals and are responsible for activating caspase-1, leading to both 
prointerleukin (proIL)-1β and proIL-18 processing and pyroptotic cell death (Martinon et al., 2002, 
Ghayur et al., 1997, Thornberry et al., 1992). Inflammasomes can also activate apoptotic cell death 
through caspase-8 activation (Sagulenko et al., 2013). The best-studied inflammasome is initiated 
by oligomerisation of the NLRP3 protein. Many external and host-derived danger signals activate 
the NLRP3 inflammasome, including a range of pathogens, the bacterial ionophore nigericin, host-
derived molecules such as extracellular ATP and environmental irritants including silica and 
asbestos (Bauernfeind and Hornung, 2013, Mariathasan et al., 2006, Dostert et al., 2008). 
Recently we demonstrated that bone marrow derived macrophages (BMMs) from NZB mice 
are deficient in both NLRP3 and AIM2 inflammasome responses (Sester et al., 2015a). The NZB 
strain is a model of autoimmune haemolytic anaemia and systemic lupus erythematosus and 
develops both anti-erythrocyte and anti-nuclear antibodies (Scatizzi et al., 2012, Borchers et al., 
2000). Inflammasome deficiencies could alter the interaction of the host with both microflora and 
pathogens, promoting cytokine release favouring the development of autoimmunity. 
  We proposed that the NLRP3 inflammasome defect in NZB cells is due to a point mutation 
found in an intron that creates a splice acceptor site (Sester et al., 2015a). The resulting pseudoexon 
introduces a premature stop codon producing a less stable truncated NLRP3 protein, and an almost 
complete lack of NLRP3 protein expression.  Here exon skipping antisense oligonucleotides (AON) 
(Aartsma-Rus and van Ommen, 2007) targeting the pseudoexon restored both NLRP3 protein 
expression and NLRP3 inflammasome activity, demonstrating that this is the sole defect preventing 
NLRP3 inflammasome function in the NZB strain. 
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5.2.3 Results 
The 96 base pseudoexon identified by sequencing Nlrp3 cDNA from the NZB strain lies within a 
6.486 kb intron, and results from a G to A mutation shown with an asterisk in Figure 5.1A, (Sester 
et al., 2015a) that generates a splice acceptor site (Long and Deutsch, 1999). A polypyrimidine tract 
upstream is also consistent with a function as a splice acceptor (Coolidge et al., 1997). At the 3' end 
of the pseudoexon the splice donor sequence conforms well with a described consensus sequence 
(Long and Deutsch, 1999). To test whether the incorporation of the pseudoexon in NZB Nlrp3 
mRNA is the sole reason for the profound NLRP3 deficiency, AONs were designed to target the 
pseudoexon (7b) and prevent its inclusion during pre-mRNA splicing (Figure 5.1A). The AONs 
were targeted to the splice acceptor site (AON38), splice donor site (AON40) and an intra-exonic 
region predicted to contain several exonic splice enhancer motifs (AON39) (Fairbrother et al., 2002, 
Yeo et al., 2004). 
Preliminary experiments demonstrated that AON39, but not AON38 or AON40, was able to 
substantially restore NLRP3 protein expression when electroporated into NZB BMMs (data not 
shown). C57BL/6 BMMs were used as a positive control in this study as they have robust NLRP3 
protein expression and inflammasome function (Sester et al., 2015a). Subsequent experiments were 
conducted introducing AON39 or AON40 into both NZB and C57BL/6 BMMs. After 4 h, cells 
were primed with LPS to up-regulate NLRP3 expression. PCR of the region encompassing the 
pseudoexon from cDNA templates showed that in the absence of AON treatment the NZB Nlrp3 
mRNA was predominantly of the longer form that includes the pseudoexon (Nlrp3') (Sester et al., 
2015a) while C57BL/6 samples had the correctly spliced form (Figure 5.1B). NZB cells treated 
with AON40 showed a small amount of correctly spliced mRNA, whilst AON39 restored correct 
splicing to the majority of the Nlrp3 mRNA. Quantitative western blotting showed restoration of 
LPS-induced NLRP3 protein levels in NZB cells treated with AON39 to approximately 65% of the 
level in C57BL/6, while AON40 was largely ineffective (Figure 5.1C). Without LPS priming, a 
small amount of NLRP3 protein was detected in NZB BMMs due to the action of AON39 on the 
smaller amount of nascent Nlrp3 mRNA produced constitutively during this time. 
  
 
 
94 
 
Figure 5.1. Antisense oligonucleotide treatment can restore normal splicing and NLRP3 
expression in NZB cells. (A) Diagram showing the location and sequence of pseudoexon 7b within 
the NZB Nlrp3 gene. The position of the PCR primers used in panel B are shown with arrows. 
Numbers indicate the position of the first and last nucleotide of each exon relative to the first 
nucleotide of NCBI reference sequence NC_000077.6. The sequence of the pseudoexon (bold) and 
some of the flanking intronic region is shown including a pyrimidine-rich intronic sequence 
upstream of the pseudoexon. Annotations show the location of the NZB point mutation (*), the 
splice acceptor (solid underline) and donor (dotted underline) sites, a premature TGA stop codon (. . 
.) and the binding sites of AONs 38-40 (boxed). (B) AON39 restores the normal Nlrp3 mRNA 
splicing within NZB BMMs. BMMs from NZB and C57BL/6 mice were electroporated with 
AON39 or AON40 or with no addition, incubated for 4 h, then primed with 100 ng/ml LPS for 4 h. 
Conventional PCR using primers in exons 6/7 and 9, flanking the pseudoexon 7b, shows the mRNA 
variants with the pseudoexon (Nlrp3') or without the pseudoexon (Nlrp3) in NZB and C57BL/6 
BMMs after AON treatment. (C) AON39 restores NLRP3 protein levels in NZB BMMs. 
Quantitative western blot of NLRP3 protein levels normalised to tubulin expression, from cells 
treated as in panel B, with and without LPS priming. 
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A panel of AONs were designed to microwalk around the annealing site of AON39 in an 
attempt to further enhance exon skipping efficiency, with four overlapping AONs (AON80-83) 
designed with slight target sequence and/or length variations (Figure 5.2A).  These were introduced 
into NZB BMMs and changes in Nlrp3 expression were assessed using real time PCR primers 
designed for either C57BL/6 Nlrp3 mRNA, or the NZB defective Nlrp3' mRNA, previously 
validated on cloned cDNA templates. All four new AONs promoted correct splicing, and AON83 
was most efficient in suppressing the aberrant Nlrp3' transcript and restoring the normal Nlrp3 
transcript (Figure 5.2B).  Concomitantly, AON83 restored NLRP3 protein levels in the NZB cells to 
almost 80% of that in C57BL/6 cells (Figure 5.2C).   
The longevity of the exon skipping effect of the AONs following electroporation was 
investigated. AON83 and AON38 (effective and ineffective treatments respectively) were 
electroporated into NZB and C57BL/6 BMMs. At 0, 4, 24 or 48 h post electroporation, cells were 
primed for 4 h with LPS and then harvested for analysis by quantitative western blot (Figure 5.3). 
Almost complete restoration of NLRP3 expression to C57BL/6 levels was observed in NZB BMMs 
treated with AON83 and immediately primed with LPS, but overall levels of induced NLRP3 
expression in both strains were lower than later time points, probably due to electroporation-
associated stress. Effective NLRP3 restoration was observed in cells left for 4 h before priming. 
Thereafter the effect of the AON declined with time but was still observed 48 h post treatment. 
To test the effect of AON-mediated NLRP3 protein restoration on inflammasome-induced 
pyroptotic cell death, cell viability was measured by MTT cleavage in response to the NLRP3 
activator nigericin. A nigericin dose-dependent reduction in viability was seen in C57BL/6 cells 
(Figure 5.4A). Untreated and AON40-treated NZB cells showed a complete lack of response but 
AON39 treatment restored the cell death response almost to the level of C57BL/6. Subsequently, 
the effect of all AONs on the response to a single, high dose of nigericin was tested. The resulting 
inflammasome function reflected the degree of NLRP3 protein restoration previously observed in 
cells, with AON83-treated cells the most sensitive to nigericin, showing that AON treatment can 
restore NLRP3 inflammasome function in NZB BMMs. 
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Figure 5.2. Refinement of optimal AON targeting sequence.  (A) Diagram showing the position 
of four additional AON relative to AON39. AON80, 81, 82 and 83 all anneal within the 
pseudoexon, targeting nucleotides 21-40, 26-45, 16-40 and 26-50 from the 5' end respectively. A 
predicted exonic splice enhancer motif is shown in white text. (B) Effects of minor sequence 
changes to AON on Nlrp3 splicing, assessed by quantitative PCR. BMMs from NZB or C57BL/6 
mice were electroporated with either no addition (-), a control oligonucleotide (cont), or an AON 
(38-40, 80-83), incubated for 4 h, then primed with 100 ng/ml LPS for 4 h. Quantitative real time 
PCR analysis was performed with primers specific for Nlrp3' (with pseudoexon) and Nlrp3 (correct 
splicing). Data were normalised to NZB without oligonucleotide for Nlrp3' results and C57BL/6 
without oligonucleotide for Nlrp3 results and show the mean and range from two experiments. (C) 
Effects of minor sequence changes to AON on NLRP3 protein expression, assessed by quantitative 
western blotting. NLRP3 protein levels from cells treated as in panel B were assessed relative to 
GAPDH expression. Data shown is the mean and range of two experiments, normalised to the 
C57BL/6 without AON sample.  
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Figure 5.3. Exon skipping AON have diminishing potency during the 48 h post introduction 
into cells. BMMs from NZB and C57BL/6 mice were electroporated with no addition (-), AON38 
or AON83, plated and primed with 100 ng/ml LPS for 4 h, immediately (0h) or after 4, 24 or 48 h 
of incubation. A quantitative western blot is shown for NLRP3 protein levels normalised to 
GAPDH. As samples within each experiment were analysed on two separate blots, 0 h and 4 h 
sample data is shown relative to 4 h C57BL/6 without oligonucleotide and 24 h and 48 h sample 
data is shown relative to 48 h C57BL/6 without oligonucleotide. Quantitative data shown is the 
mean and range of two experiments.  
 
5.2.4 Discussion 
Here we have used splice switching AONs to show that aberrant splicing of the Nlrp3 gene leading 
to inclusion of a pseudoexon is solely responsible for the lack of NLRP3 inflammasome response 
observed in macrophages from NZB mice. This provides proof-of-concept for restoring NLRP3 
inflammasome function in NZB mice and analysing the effect on progression and severity of 
autoimmune disease. In addition, NZB mice could be used as a model to investigate in vivo delivery 
of AONs to macrophages.  
The AONs that targeted within the pseudoexon were effective while those targeting splice 
acceptor and donor sites were not. Although targeting acceptor or donor sites has worked for some 
genes, (Gallego-Villar et al., 2014, Karras et al., 2000) our results fit with a retrospective analysis of 
over 400 AONs designed for the treatment of Duchenne muscular dystrophy, that showed exon-
internal AONs to be the most effective for some exons (Aartsma-Rus et al., 2010). Other work has 
suggested that the proximity of the AON target site to the 5' end of the exon and the binding 
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energetics of the oligonucleotide to the RNA are correlated with effectiveness (Echigoya et al., 
2015). Exonic splice enhancer sites promote splice site recognition and are frequently targeted by 
effective AONs (Aartsma-Rus et al., 2009). Fine-tuning of the optimal AON target sequences 
requires experimental validation; here this was achieved by microwalking with overlapping AONs. 
The five overlapping exon-internal AONs had reproducible differences in their effectiveness 
(Figure 5.2). Such differences could be due to thermodynamic properties, secondary structure of the 
target sequence or the masking of additional exonic splice enhancers. We had previously shown that 
longer AONs (25mers) could confer substantial improvement in exon skipping efficiency, although 
this requires confirmation on a case-by-case basis (Harding et al., 2007). 
 
 
Figure 5.4. Inhibition of aberrant splicing restores NLRP3 inflammasome function in NZB 
BMMs. Relative cell viability was measured by MTT cleavage. (A) NZB and C57BL/6 BMMs 
were electroporated with PBS (-), AON40 or AON39, incubated for 4 h and then primed with 100 
ng/ml LPS for 4 h. NLRP3 inflammasome was triggered by treatment with 0, 1.25, 2.5, 5 or 10 µM 
nigericin for 1 h. Data represent the mean and standard deviation of triplicate nigericin treatments 
of each AON-electroporated sample. Results are relative to the mean of the 0 µM nigericin wells 
for each sample, and are representative of three experiments performed. (B) NZB and C57BL/6 
BMMs were electroporated with PBS (-), control oligonucleotide (cont), or the indicated AON, 
incubated for 4 h and then primed with 100 ng/ml LPS for 4 h. Cells were then treated with or 
without 10 µM nigericin for 1 h. Cell viability is shown relative to the unstimulated cells for each 
oligonucleotide treatment. Data is representative of two experiments and shows the mean and 
standard deviation of triplicate treatments from one experiment.  
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Apart from correction of a splicing defect, exon skipping AONs can be used experimentally 
as an alternative to siRNA to knock down gene expression, or to induce specific splice isoforms 
(Fletcher et al., 2010). A consideration for experimental use is the time course of effectiveness. 
Here we showed that the AONs can work very quickly and hence must get to the nucleus almost 
immediately, where they hybridize with pre-mRNA (Sazani and Kole, 2003). 
Of all disease-causing point mutations, 15% have been predicted to fall within splice sites 
and it has been estimated that a further 25% of confirmed pathogenic nonsense or missense 
mutations alter exonic splice enhancers and silencers and hence lead to abnormal splicing 
(Krawczak et al., 1992, Sterne-Weiler et al., 2011). Targeted exon skipping has potential 
therapeutic uses in knocking down the expression of disease-causing genes or splice variants and in 
the restoration of normal splicing if mutations introduce deleterious pseudoexons (Veltrop and 
Aartsma-Rus, 2014). Exon skipping is currently being tested in clinical trials for the treatment of 
Duchenne muscular dystrophy, where particular mutated exons of the dystrophin gene can be 
targeted to restore a correct open reading frame and protein expression (Koo and Wood, 2013, 
Cirak et al., 2011). Challenges that remain for exon skipping AON therapy are to define the optimal 
nucleic acid modifications required for stability, affinity and safety and also to optimise delivery of 
AONs in vivo. The NZB mouse provides a model for a splicing defect in macrophages and could be 
used to investigate in vivo delivery of AONs to this compartment.  
 
5.2.5 Methods 
5.2.5.1 Materials 
Lipopolysaccharide (LPS) from Salmonella minnesota Re595 (Sigma Aldrich, St Louis, USA) was 
dissolved in Dulbecco′s phosphate-buffered saline (PBS (Life Technologies, Grand Island, 
USA))/0.1% triethylamine at 10 mg/ml. Nigericin (N7143 Sigma-Aldrich) was dissolved in ethanol 
at 5 mM. Recombinant human CSF-1 was a gift from Chiron, Emeryville, CA. Complete RPMI 
1640 is RPMI 1640 with 10% heat inactivated foetal calf serum (FCS), 1x GlutaMAX, 50 U/ml 
penicillin, 50 µg/ml streptomycin and 25 mM HEPES (all Life Technologies). MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (Life Technologies) was prepared as a 5 
mg/ml stock in PBS. 
5.2.5.2 Mice and Cell Culture 
C57BL/6 and NZB mice were housed under specific pathogen-free conditions at the University of 
Queensland and were used under approval from the University of Queensland Animal Ethics 
Committee. Female mouse BMMs were differentiated as previously described (Sester et al., 2006) 
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and used between day 7 and 10 of culture. Cells cultured in this way were approximately 97% 
positive when stained with F4/80 (data not shown), a monoclonal antibody specific for mouse 
macrophages (Austyn and Gordon, 1981). 
5.2.5.3 Treatment of BMMs with exon skipping oligonucleotides  
2'-O-methyl modified AONs with a full phosphorothioate backbone were synthesized on an 
Expedite 8909 synthesizer using the 1 micromole Thiol protocol, cleaved from the support, desalted 
on NAP-10 columns and stored at -20˚C. AONs had the following sequences:  
AON34-5'AAUAGUUUUGGCAUCAAAAUUCU3'; 
AON38-5'AUAUGGAAAUGUAUCUAGAUAAAUG3';  
AON39-5'CUAUGGGUUUUUGUGCUCCAAACUA3';  
AON40-5'CUUACCCAAAAAGUUCUUGACUUAA3',  
AON80-5'GGUUUUUGUGCUCCAAACUA3',  
AON81-5'CUAUGGGUUUUUGUGGUCCA3',  
AON82-5'GGUUUUUGUGCUCCAAACUAUAAGU3',  
AON83-5'GGGUACUAUGGGUUUUUGUGCUCCA3'.  
BMMs were electroporated in 400 µl of complete RPMI-1640, with or without 3.5 µM 
AON at 260 V, 1000 µF using a Bio-Rad Gene Pulser. Cells were immediately washed with 10 ml 
of complete RPMI-1640 without FCS, pelleted (350g, 5 min), resuspended in complete RPMI-1640 
and plated out for analysis. Cells were plated for: RNA extraction at 4 million cells/well in 6-well 
plates, protein at 2.5 x 105 - 5 x 105 cells/well in 24-well plates and nigericin treatment/MTT assay 
at 7 x 104 cells/well in 96 well plates.  Plates were incubated for 4 h and then primed with 100 
ng/ml LPS for 4 h. 
5.2.5.4 Qualitative and Real Time-quantitative PCR of Nlrp3 variants 
RNA was extracted using the RNeasy mini-prep kit (Qiagen, Hilden, Germany). cDNA was 
generated from each sample of RNA using oligo dT priming (Cridland et al., 2012) and amplified 
by conventional PCR using the forward primer 2706 (5'AGAAACTGTGGTTGGTGAG3') and 
reverse primer 3125 (5'TGTGGTTGTGGGTCAGAA3'). The products were visualised after 
electrophoresis on a 2% agarose gel.  Quantitative real time PCR was analysed by the ∆Ct method 
relative to Hprt, as described previously (Cridland et al., 2012). Primers used were: 
 NZBNlrp3-For 5'ATGCCTTGGGAGACTCAGGA3',  
NZBNlrp3-Rev 5'GCTGGTGGTGGGTACTATGG3',  
C57Nlrp3-For 5'CAGAAGCTGGGGTTGGTGAAT3',  
C57Nlrp3-Rev 5'CTGAGTCCTGTGTCTCCAAGG3',  
Hprt-For 5'CAGTCCCAGCGTCGTGATTAG3' and  
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Hprt-Rev 5'AAACACTTTTTCCAAATCCTCGG3'. 
5.2.5.5 Nigericin Treatment and MTT assays 
Cells were treated with nigericin for 1 h. MTT assays of reductase activity indicating cell viability 
(Berridge and Tan, 1993) were performed as previously described except that 5x MTT was added 
directly to 50 µl of medium that was left in the well and was not removed prior to addition of MTT 
solubilisation solution (isopropanol/10% Triton X-100/0.1N HCl). Plates were left overnight for 
maximum solubilisation of MTT formazan product prior to measurement of absorbance at 570 nm.  
5.2.5.6 Quantitative Western Blotting 
Cell monolayers were lysed in 100 µl of 66 mM Tris pH7.4, 2% SDS.  Samples were run on 15-
well mini-PROTEAN TGX gels (Bio-Rad, Hercules, USA) and transferred to immobilon-FL 
membrane (Millipore, Billerica, USA) using a mini-trans blot system (Bio-Rad) with Tris-Glycine 
transfer buffer containing 10% methanol. The membrane was washed for 15 min in Tris-buffered 
saline (TBS) and then blocked for 1 h with Odyssey® Blocking Buffer (LI-COR, Lincoln, USA). 
Primary antibodies were diluted in the Odyssey® Blocking Buffer and incubated overnight at 4°C. 
Primary antibodies used were anti-NLRP3/NALP3 mAB, Cryo-2 (#AG-20B-0014 Adipogen, San 
Diego, USA), anti-a-Tubulin (B-5-12, Sigma Aldrich) and anti-GAPDH (#2275-PC-020, Trevigen, 
Gaithersburg, USA). Membranes were washed with TBS containing 0.05% Tween-20 (TBS-T) and 
then incubated for 2 h, protected from light, at room temperature in secondary antibody diluted in 
the LI-COR buffer/0.1% Tween-20/ 0.01% SDS. Secondary antibodies used were anti-rabbit 
(Dylight) 800 conjugate, anti-rabbit (Dylight) 680 conjugate, anti-Mouse (Dylight) 800 conjugate 
and anti-mouse (Dylight) 680 conjugate (#5151P, #5366P, #5257 and #5470P respectively, Cell 
Signaling Technology, Danvers, USA). Membranes were washed with TBS-T then TBS and 
scanned on the Odyssey (LI-COR) and analysed with Image Studio Lite software (LI-COR).  
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5.3 Extended Results and Discussion 
The work presented in the published paper above shows that the NLRP3 inflammasome deficiency 
in NZB mice can be overcome by correcting the splicing defect caused by the single G to A point 
mutation (Thygesen et al., 2016). Based on this we hypothesised that we could produce NZB mice 
with restored NLRP3 expression and NLRP3 inflammasome function by correcting the splicing 
defect in vivo. By breeding the repaired mice with NZW mice we could also create NZB/W F1 mice 
with a repaired NZB Nlrp3 allele. This would enable us to assess the effect of the NLRP3 
inflammasome deficiency on the autoimmune disease phenotype of both NZB and NZB/W F1 
mice. We aim to repair the Nlrp3 gene in NZB mice using the CRISPR/CRISPR-associated 9 
(Cas9) system. This system originated as a bacterial immune response to foreign genetic material 
and has recently been adapted into a genome-editing tool (Figure 5.5) (Ran et al., 2013b). In the 
CRISPR/Cas9 system a short guide RNA (gRNA) can recruit the Cas9 nuclease to a target genomic 
location, that is followed by a 5'-NGG protospacer- adjacent motif (PAM), where it introduces a 
double stranded break (DSB) in the DNA (Mali et al., 2013, Cong et al., 2013).  The gRNA 
includes a 20-nt guide sequence that directs Cas9 to the genomic target by sequence 
complementarity. The break in the DNA is repaired by error-prone non-homologous end joining 
(NHEJ) producing insertion and deletion (indel) mutations. Alternatively, in the presence of a 
single-stranded DNA repair template or donor plasmid with homology to the sequences flanking the 
DSB, defined sequence modifications can be introduced through homology directed repair (HDR).  
 
 
Figure 5.5. Repair of CRISPR/Cas9-mediated DNA breaks. The Cas9 nuclease is targeted to a 
genomic DNA site by a guide RNA (gRNA) and induces a double stranded break (DSB). The DSB 
can be repaired by one of two ways. Error prone non-homologous end joining (NHEJ) can result in 
Indel mutations. Alternatively, if a repair template is supplied, homology directed repair (HDR) can 
occur and allows precise editing. Adapted from (Ran et al., 2013b). 
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The power of the CRISPR/Cas9 system has led to an exponential increase in the number of 
publications using this technology and information on successful strategies. However, at the time 
this work commenced, the literature was quite small. Consequently the approach taken to repair the 
Nlrp3 defect was modified as the project proceeded. The following sections describe efforts to 
validate in cell culture a number of different approaches to CRISPR-mediated repair of NZB Nlrp3, 
prior to initial injection of mouse embryos. 
5.3.1 CRISPR repair of NZB Nlrp3 - Approach 1 
The initial plan for using CRISPR technology to repair the Nlrp3 mutation in NZB was to inject 
mRNA encoding for Cas9, a gRNA and a long oligonucleotide to act as a repair template into 
fertilised one cell NZB embryos. Ideally, Cas9 would produce a double stranded break in the DNA 
and then by homologous recombination with the repair template the area would be mended and the 
only change would be the A to G repair. This approach has been used previously to produce mice 
with single amino acid substitutions (Inui et al., 2014). The repair template was also designed to 
introduce silent “Cas9 blocking” mutations to the PAM sequence to prevent further cutting after 
HDR has occurred. Precise repair will not always occur, but error-prone repair by NHEJ could also 
abolish the novel splice site, depending on its proximity to the Cas9-mediated cleavage site. The 
location of the target site in the middle of an intron means that imprecise repair is unlikely to 
damage the gene and should result in functional NLRP3.   
Firstly, two independent gRNAs were designed to target the intron region close to the point 
mutation in Nlrp3 (using the design tool at www.CRISPR.MIT.edu made by the Zhang Lab, MIT, 
2013) (Figure 5.6). A long single-stranded oligonucleotide repair template spanning the mutation 
site and carrying the correct sequence, was also designed to facilitate HDR. These two gRNAs were 
chosen as they could also be used together with the Cas9 nickase in order to reduce off target 
effects. The mutated nickase version of Cas9 generates only a single-strand DNA break and can be 
used with a pair of gRNAs complementary to opposite strands of the target site to create a site 
specific DSB (Ran et al., 2013a). This was thought to decrease off target effects as individual nicks 
are repaired by high-fidelity base excision repair (Dianov and Hubscher, 2013). The gRNAs and 
Cas9 mRNA were produced from plasmids by PCR and T7 polymerase-mediated in vitro 
transcription (IVT). The decision was later made to use Cas9 instead of the Cas9 nickase, as the 
nickase was reported as less efficient for HDR (Ran et al., 2013a). We decided that it was most 
important that we first are able to generate a mouse with the aberrant splicing corrected and then 
backcrossing could be conducted to address concerns of off target effects.    
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Figure 5.6. Design of initial CRISPR approach. DNA sequence of the target region of NZB 
Nlrp3 showing the target sites of gRNA A and gRNA B, the point mutation in red and the repair 
oligo (ssODN1) with Cas9 blocking mutations in blue.  
 
5.3.1.1 Cas9 mRNA production 
CRISPR/Cas9 editing in mice can be achieved by microinjection of a plasmid encoding Cas9 and 
the gRNA (Mashiko et al., 2013). However this carries the risk of producing transgenic mice with 
an integrated Cas9 plasmid, and may take longer for DNA cleavage to occur, increasing the chances 
of mosaicism (Kim et al., 2014). We also planned to test our approach in NZB BMMs, and primary 
macrophages are not readily transfectable by plasmids (Stacey et al., 1993). For these reasons we 
chose to produce Cas9 mRNA. Generation of Cas9 mRNA by IVT was followed by poly(A) tailing 
of the RNA and a final clean up step. Problems were encountered during the production of Cas9 
mRNA with the final product appearing partially degraded, when run on an agarose gel, compared 
to a sample taken prior to poly(A) tailing and clean-up (Figure 5.7A). It was eventually found that 
the problem was occurring during clean-up of the mRNA using the MEGAclear Kit from Ambion 
(#AM1908) presumably due to a step in which the sample is heated to 70°C. This was overcome by 
changing to the RNeasy Mini Kit from Qiagen (Figure 5.7B).  To test that Cas9 protein could be 
expressed from this mRNA, HEK293 cells were chemically transfected with our Cas9 mRNA, 
proven Cas9 mRNA (supplied by Jo Bowles, University of Queensland) and the plasmid expressing 
Cas9 (px330) and Cas9 protein expression was compared 24 h later (Figure 5.7C).  Cas9 from 
px330 has an N-terminal FLAG-tag that was used to detect expression by western blot. Cells 
transfected with our Cas9 mRNA did produce Cas9 protein, however it was significantly less than 
that produced by cells transfected with the proven Cas9 mRNA and the plasmid. Further work to 
improve our Cas9 mRNA was not undertaken as it was becoming more readily available from other 
sources. 
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Figure 5.7. Validation of Cas9 mRNA. Samples of Cas9 mRNA produced by IVT before (pre-tail) 
and after (post-tail) poly(A) tailing and clean up using (A) MEGAclear Kit from Ambion and (B) 
RNeasy Mini Kit from Qiagen, run on a 0.8% agarose gel with a 1kb+ DNA marker. (C) Levels of 
FLAG tagged-Cas9 protein expression in HEK293 cells chemically transfected with 1.5 µg of Cas9 
mRNA from our lab or Cas9 mRNA that has been proven in vivo (+ve cont., supplied by Jo 
Bowles, University of Queensland) or 0.5 µg of Cas9 expression plasmid pX330, as assessed by 
western blot using an anti-FLAG antibody.  
 
5.3.1.2 Testing of gRNAs and Cas9  
Next we aimed to test the gRNAs and Cas9 mRNA by transfecting them into NZB BMMs. A 
simple way of measuring restoration of NLRP3 would have been to detect expression by flow 
cytometry. However, attempts to optimise an NLRP3 antibody for this use were unsuccessful. 
Instead we rationalised that if efficient restoration of NLRP3 expression occurred we would be able 
to observe this at the protein level or by measuring cell death in response to nigericin. Alternatively, 
a smaller population of cells with restored NLRP3 function would produce ASC specks upon 
stimulation, and these could be detected by ASC speck assay as described in Chapter 3 of this 
thesis. No cell death or ASC speck formation was observed in response to nigericin in NZB 
macrophages that were first electroporated with Cas9 mRNA and gRNA (data not shown). This was 
suspected to be due to the cells not expressing Cas9. Multiple attempts at electroporation and 
chemical transfection of NZB BMMs with Cas9 mRNA and gRNAs did not yield detectable Cas9 
expression as assessed by western blot (result not shown). Further delay of in vivo experiments in 
order to optimise expression of Cas9 in NZB BMMs was not desirable so different experiments 
using the more readily transfectable B16 mouse melanoma cell line were undertaken.  
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Figure 5.8. gRNA A but not gRNA B can facilitate the introduction of CRISPR/Cas9 
mediated mutations in Nlrp3. The target region of Nlrp3 was amplified by PCR from genomic 
DNA of B16 cells transfected with px330 plasmid expressing Cas9 with gRNA A, gRNA B or no 
gRNA. The amplicons were assessed for mutations: (A) Assessment of mismatched sequences by 
dentaturation, reannealing and cleavage with T7E1. Products were run on a 2% agarose gel. (B) 
DNA sequences of the target region from the no gRNA and gRNA A amplicons. The red star 
indicates the location of the point mutation in NZB Nlrp3 and the yellow shading indicates the 
quality scores.   
 
B16 cells do not have the Nlrp3 mutation found in NZB macrophages, but it was still 
possible to test whether the gRNA sequences chosen would facilitate targeting of the correct 
genomic region. B16 cells were transfected with px330 plasmid expressing Cas9 and one of the 
gRNAs as well as a second plasmid expressing GFP at a 4:1 ratio.  Cells were incubated for 24 h 
and then GFP-positive cells were isolated by fluorescence-activated cell sorting (FACS). It was 
assumed that most of the GFP-positive cells would also be positive for the px330 plasmid. GFP-
positive cells were then incubated for a further four days before their genomic DNA was collected. 
The target Nlrp3 region was then amplified by high fidelity PCR. Cas9 targeting of this region was 
assessed using T7 endonuclease 1 (T7E1), which recognises and cleaves mismatched DNA. The 
PCR products were denatured and re-annealed to form heteroduplexes between wild type DNA and 
CRISPR/Cas9-modified DNA. T7E1 was then used to cleave the heteroduplexes at the site of 
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mismatched DNA and the products were visualised by gel electrophoresis (Figure 5.8A). Cleavage 
of the re-annealed PCR product, indicating mutations caused by Cas9, was observed when gRNA A 
was expressed but not gRNA B. In spite of meeting all design rules some gRNAs do not work, for 
reasons that are still unknown (Ran et al., 2013b).  
The PCR product from cells transfected with px330 expressing gRNA A or no gRNA were 
also sequenced. This showed that the sequences of the PCR products became non-uniform beyond 
the target site for gRNA A suggesting the presence of indel mutations. This target site of gRNA A 
is downstream of the NZB point mutation and the sequence close to the point mutation site showed 
no variation. When designing these guide RNAs we had advice from a laboratory that had 
successfully targeted genes and found large indels of 100-200bp, and so had assumed that deletion 
of the NZB mutation might be possible with a guide RNA at some distance away. Successful 
cleavage and mutation was achieved with gRNA A; however, the sequencing results make it clear 
that the changes introduced were in the vicinity of the guide RNA and are unlikely to affect the 
NZB mutation site without HDR. It has been shown that single base substitution can be made by 
HDR upstream of the DSB as would be required when using gRNA A (Inui et al., 2014). However, 
recent published data suggests that HDR would be inefficient in this case due to the distance 
between the DSB achieved using gRNA A and the desired substitution point (Paquet et al., 2016).  
5.3.2 CRISPR repair of NZB Nlrp3 - Revised approaches 
To improve the likelihood of correcting the NZB NLRP3 deficiency in vivo we designed two new 
CRISPR/Cas9 approaches with the aim of testing each separately in mice. The first approach 
involved still attempting to achieve HDR but selecting the gRNA sequence with DSB closest to the 
NZB mutation site as an inverse relationship has been described between efficiency of base 
substitution by HDR and the distance of the substitution to the DSB point (Paquet et al., 2016).  
gRNA C was chosen and a new single stranded oligonucleotide was designed to be micro-injected 
together with Cas9 (Figure 5.9). The second approach would use gRNA A together with a second 
guide that targets upstream of the NZB mutation in order to remove a ~100 bp section of DNA 
including the aberrant splice acceptor. Two such gRNAs were designed, gRNA E and gRNA F 
(Figure 5.9). The three new gRNAs were cloned into the Cas9-containing plasmid px330 and the 
resulting plasmids were transfected into B16 cells to test targeting. B16 cells were transfected with 
plasmid expressing guide C alone or with two plasmids in combination, one expressing gRNA A 
and the other expressing gRNA E or gRNA F. Transfections also contained GFP-expressing 
plasmids and cells were sorted and genomic DNA extracted as described for initial tests of gRNA A 
and B. It was not necessary to use T7EI to test the efficiency of targeting of gRNA A in 
combination with gRNA E or gRNA F. When the two guides were used together PCR of the region 
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produced two bands, one representing the wt sequence and the other smaller band indicating the 
desired removal of a section of DNA (Figure 5.10A).  Both combinations of guides were able to 
mediate cleavage of the target DNA but the process appeared slightly more efficient with gRNA F 
than gRNA E.  Use of T7EI also showed that Cas9 mediated-mutations had occurred in cells 
transfected with gRNA C (Figure 5.10B).  
 
Figure 5.9. Design of the new CRISPR/Cas9 approaches. DNA sequence of the target region of 
NZB Nlrp3 showing the target sites of gRNA A, gRNA C, gRNA E and gRNA F, the point 
mutation in red and the repair oligo (ssODN2) with Cas9 blocking mutation in blue.  
 
Following successful testing in B16 cells, gRNAs A, C and F were produced by IVT and 
checked by gel electrophoresis. Successful gRNA synthesis products will run according to DNA 
markers at ~100-200 bp on an agarose gel and multiple bands may be seen due to secondary 
structures of the gRNA. The gRNAs appeared intact and not degraded however there were some 
larger bands present particularly for gRNA F, which formed a ladder suggestive of a self 
complementary sequence causing intermolecular interaction (Figure 5.11A). The quality of 
prepared gRNAs was further checked in a cell free assay with Cas9 protein. In this assay a PCR 
product spanning the target region of NZB Nlrp3 was incubated with Cas9 protein and gRNAs in a 
reaction buffer and successful cleavage of the PCR product can be viewed by gel electrophoresis. 
Figure 5.11B shows the relative positions of the PCR primers and gRNA target sites including 
predicted DSB sites for each. The gRNAs alone, gRNA A + gRNA F and controls without Cas9, 
gRNA or both were tested (Figure 5.11C). As expected no cleavage of the PCR product was 
observed unless both Cas9 and a gRNA were present. All gRNAs and combinations of gRNAs 
facilitated cleavage of the PCR product and the profile of the bands was as expected with a single 
gRNA leading to one DSB and two cleavage products while two gRNAs produce two DSBs and 
three cleavage products. We chose to proceed with in vivo trials at this point.  
5'... CAAAATTCAACCCAACACTGTAGTTAGCTATTCAAACTACAAACACTATAGAAGTATTTTTCTTTGACTTGTTTTTCATTTATCTAGATACATTTCCATATGACTTCTAGTTTGGAGCACAAAAACCCATAGTACCCACCACCAGCATTTATTCAGCTACT 3'
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
3'...GTTTTAAGTTGGGTTGTGACATCAATCGATAAGTTTGATGTTTGTGATATCTTCATAAAAAGAAACTGAACAAAAAGTAAATAGATCTATGTAAAGGTATACTGAAGATCAAACCTCGTGTTTTTGGGTATCATGGGTGGTGGTCGTAAATAAGTCGATCA 5'
target of gRNA C
target of gRNA F
target of gRNA A
ACAAACACT AT AGAAGT AT T T T T CT T TGACT TGT T T T T CAT T T AT CTGGAT ACAT T TGCAT ATGACT T CT AGT T TGGAGCACAAAAACCCAT AGT ACCCACCACCAGCAT T T AT T CAGCT5' - - 3' ssODN2
target of gRNA E
5'... CAAAATTCAACCCAACACTGTAGTTAGCTATTCAAACTACAAACACTATAGAAGTATTTTTCTTTGACTTGTTTTTCATTTATCTAGATACATTTCCATATGACTTCTAGTTTGGAGCACAAAAACCCATAGTACCCACCACCAGCATTTATTCAGCTACT 3'
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
3'...GTTTTAAGTTGGGTTGTGACATCAATCGATAAGTTTGATGTTTGTGATATCTTCATAAAAAGAAACTGAACAAAAAGTAAATAGATCTATGTAAAGGTATACTGAAGATCAAACCTCGTGTTTTTGGGTATCATGGGTGGTGGTCGTAAATAAGTCGATCA 5'
target of gRNA C
target of gRNA F
target of gRNA A
ACAAACACT AT AGAAGT AT T T T T CT T TGACT TGT T T T T CAT T T AT CTGGAT ACAT T TGCAT ATGACT T CT AGT T TGGAGCACAAAAACCCAT AGT ACCCACCACCAGCAT T T AT T CAGCT5' - - 3' ssODN2
target of gRNA E
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Figure 5.10. Targeting efficiency of the new gRNAs. (A) Both gRNA E and gRNA F can be used 
together with gRNA A to delete an ~100bp region of Nlrp3 that includes the aberrant splice 
acceptor in NZB. The target region of Nlrp3 was amplified by PCR from genomic DNA of B16 
cells transfected with px330:gRNA A and px330:gRNA E or px330:gRNA F or px330 with no 
gRNA expression. The PCR products were run on a 2% agarose gel.  (B) gRNA C can facilitate the 
introduction of CRISPR/Cas9-mediated mutations in Nlrp3. The target region of Nlrp3 was 
amplified by PCR from genomic DNA of B16 cells transfected with px330:gRNA C or px330 with 
no gRNA expression. Amplicons were assessed for mutations by T7E1 assay with products run on a 
2% agarose gel.  
 
5.3.3 Attempts to produce NZB mice with repaired Nlrp3.  
The initial plan was to microinject single cell NZB embryos with in vitro transcripts of Cas9 mRNA 
and gRNA, however published works have recently described advantages of introducing Cas9 as a 
recombinant protein bound to the gRNA in a ribonucleoprotein particle (RNP). RNP delivery was 
more efficient than Cas9 mRNA at mediating HDR in vivo (Menoret et al., 2015). Microinjection 
of Cas9 mRNA and gRNA into single cell embryos can cause genetic mosaicism due to delays in 
editing (Yang et al., 2013, Ma et al., 2014, Yen et al., 2014), and this may be reduced by using 
RNPs, that can cleave DNA immediately after delivery (Kim et al., 2014). Cas9 protein has also 
been shown to reduce potential off-target editing due to its short life span in cells (Kim et al., 2014, 
Ramakrishna et al., 2014, Sung et al., 2014). With the help of the Transgenic Animal Service of 
Queensland we have made two attempts to produce CRISPR/Cas9-edited NZB mice by injecting 
RNPs of Cas9 and gRNA C accompanied by a repair template or Cas9, gRNA A and gRNA F into 
single cell embryos. NZB mice are difficult to breed and they did not respond well to in vitro 
fertilisation treatments used during the procedure. Relatively few embryos were collected for 
microinjection compared to other mouse strains and neither attempt yielded live pups. 
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Figure 5.11. Testing the in vitro transcripts of gRNA C, gRNA A and gRNA F. (A) The in vitro 
transcripts were visualised on a 2% agarose gel and compared to three gRNAs successfully used in 
vivo for Jo Bowles, University of Queensland (B) DNA sequence of the region surrounding the 
target mutation including the binding sites of the PCR primers and gRNA target sites including 
+ + + + + - - Cas9
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predicted DSB sites for each indicated by vertical red lines. (C) A PCR amplicon produced from 
NZB genomic DNA using the primers in (B) was incubated in vitro with different pairings of Cas9 
and gRNAs and the digestion products were visualised on a 2% agarose gel.  
 
5.3.4 Future directions for in vivo CRISPR/Cas 9 work 
Although NZB mice are poor breeders, earlier cryopreservation of the strain did not strike such 
difficulty obtaining embryos as the recent attempts at CRISPR modification. In case the line had 
suffered unfavourable genetic drift we aimed to rederive from frozen embryo stocks. However, this 
has also struck problems, as in several attempts the embryos have not implanted in CD-1 
pseudopregnant mothers. If implantation of these embryos is so inefficient, it will also be a problem 
following CRISPR modification. However, we observe that the F1 cross between NZB and NZW is 
highly productive with reliable large litters. Consequently, me may more readily obtain a modified 
NZB-derived chromosome within an F1 cross embryo. Pups would have to be backcrossed onto 
NZB for multiple generations to eliminate the NZW genetic contributions. Once pups are born 
following microinjection they will first be screened by restriction digest as the mutation in NZB 
introduces an XbaI site that is abolished by repair. When the region is amplified from genomic 
DNA by PCR and digested with XbaI, the NZB DNA segment carrying the deleterious mutation is 
cleaved (Figure 5.12). Mice showing no cleavage of this product could be mated back to NZB mice, 
and then genotyped for the absence of an NZW-specific single nucleotide polymorphism in the 
vicinity of the CRISPR target site. After backcrossing to NZB, mice will then be bred to 
homozygosity and also bred with NZW mice to create NZB/W F1 mice with repaired NZB Nlrp3 
allele. 
Analysis will then be conducted to determine the effect of repaired NLRP3 on the IFN 
signature and autoimmune phenotype of the mice. To determine the effect of intact NLRP3 on the 
IFN signature and cytokine expression, cDNA will be made from the spleens, and small and large 
intestine of NZB and NZB/W F1 mice with repaired NLRP3.  The expression of Type I IFNs and 
IFN responsive genes such as GBP2, Mx1 and OAS3 will be measured by RT-PCR. Assessing the 
impact of NLRP3 on autoimmunity will involve comparing groups of 20 female NZB and NZB/W 
mice with and without functional NLRP3. The following parameters will be measured from ~4 to 
10-12 months of age: Urinary protein and creatinine, antichromatin antibodies and anti-dsDNA 
antibodies (ELISA) and anti-RBC antibodies. Measuring anti-RBC antibodies has been trialled on 
NZB and elevated levels were clearly detectable in aged NZB mice compared to NZW mice using 
antibody staining and flow cytometry (Figure 5.13A). The remaining analysis will occur after the 
mice are sacrificed and will include kidney histology and weighing the spleens as a measure of 
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splenomegaly. Preliminary work shows that we can readily detect increased spleen weight in older 
NZB mice compared to young NZB mice and NZW mice (Figure 5.13B). 
 
 
Figure 5.12. The G to A mutation in NZB Nlrp3 introduces an Xba I restriction site. DNA 
PCR amplified from the genomic DNA of six NZB mice (1-6) using the primers shown in Figure 
5.11B was digested with Xba I and visualised by gel electrophoresis. Also included were NZW 
DNA used as a control for the “repaired” sequence and a no template control (NTC). 
 
 
Figure 5.13. Anti-erythrocyte antibodies and increased spleen weight can be detected in aged 
NZB mice. 7 month old NZW and 7-16 month old NZB mice were culled and blood and spleens 
were collected. (A) The presence of anti-erythrocyte antibodies was determined by staining red 
blood cells for mouse IgG antibodies with an alexa fluor 488 antibody and the mean fluorescence in 
this channel was measured by flow cytometry. (B) The weight of the spleens in grams. Each symbol 
represents a single mouse with a line designating the mean for each group of mice. 
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5.4 Conclusion 
The work presented in the published paper (Thygesen et al., 2016) describes the use of splice 
switching AONs to show that aberrant splicing of the Nlrp3 gene leading to inclusion of a 
pseudoexon is solely responsible for the lack of NLRP3 inflammasome response observed in 
macrophages from NZB mice and consequently the reduced expression and function in NZB/W F1 
mice. We present the NZB mouse as a model for addressing a splicing defect in macrophages that 
could be used to further investigate AON design and delivery of AONs to macrophages in vivo. The 
results of this study provided proof-of-concept for restoring NLRP3 inflammasome function in 
NZB mice using CRISPR/Cas9 technology and analysing the effect on progression and severity of 
autoimmune disease in NZB and NZB/W F1 mice. To this end we have also described progress 
towards implementing CRISPR/Cas9 in NZB mice with all components produced and verified in 
vitro and in vivo modification in progress.  Prior to introduction of CRISPR, restoring intact NLRP3 
to the NZB mice could have involved generation of a congenic NZB strain with a segment of the 
NZW strain containing the Nlrp3 gene. However, this would carry over substantial amounts of the 
NZW genome surrounding the Nlrp3 gene, and may lead to misinterpretation as has occurred in the 
past with the use of knockout mice that contain 129 strain congenic intervals on C57BL/6 
background (Bygrave et al., 2004). Consequently, CRISPR targeting is far superior as it offers 
precise genome editing. 
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Chapter 6: Measuring inflammasome activation in primary human monocytes 
 
6.1 Introduction 
The assessment of inflammasome function in autoimmune patients is necessary to determine if the 
deficiencies observed in the NZB mouse bear any relationship to human disease etiology. As 
described in Chapter 1, existing studies relating to NLRP3 inflammasome function in human SLE 
monocytes are contradictory and largely restricted to measuring released IL-1β (Portales-Cervantes 
et al., 2010, Portales-Cervantes et al., 2012, Kahlenberg et al., 2013, Liu et al., 2017). Further 
investigation into the activity of the NLRP3 inflammasome in SLE patients could include more 
assays of inflammasome function including cell death and ASC speck formation. AIM2 function in 
SLE patients has not been investigated. We have shown that the autoimmune mouse model NZB is 
deficient in AIM2 inflammasome function due to p202 expression (Yin et al., 2013). There is no 
human orthologue of p202 (Cridland et al., 2012), but AIM2 function could be suppressed by other 
means. Pyrin domain only protein 3 (POP3) has been proposed as an inhibitor of AIM2 signalling 
in human monocytes (Khare et al., 2014). Further investigation into inflammasome function in SLE 
patients is warranted, particularly given use of IL-1β antagonists in preliminary clinical trials for 
SLE (Moosig et al., 2004, Ostendorf et al., 2005), without any clear evidence for a role of this 
cytokine in the pathology. Measuring NLRP3 and AIM2 inflammasome activity in SLE patients 
first requires optimisation of the experimental conditions required to measure inflammasome 
activation in primary human monocytes. 
The majority of studies on AIM2 in human cells, in any context, have used the THP-1 
human monocyte cell line. The AIM2 inflammasome response to dsDNA in THP-1 cells required 
prior differentiation with phorbol 12-myristate 13-acetate (PMA) (Burckstummer et al., 2009) and 
how well this reflects the response of primary human monocytes is unknown.  A small number of 
studies have shown IL-1β release from PBMCs of healthy donors in response to transfection with 
dsDNA (Algaba-Chueca, 2017 and Wang, 2016). One study found a low amount of IL-1β release 
from human monocytes in response to dsDNA and modified vaccinia virus and this was modestly 
increased when POP3 was knocked down (Khare et al., 2014). The reliability of this data is 
uncertain, as we have been unable to confirm that POP3 is actually expressed and is not a 
pseudogene (S. Cridland, unpublished). Lonzano-Ruiz et al., also observed IL-1β release from 
HMDM and ascitic fluid macrophages in response to chemically transfected dsDNA (Lozano-Ruiz 
et al., 2015).  
In general, measurements of inflammasome activation other than IL-1β release are rarely 
investigated in human monocytes. Classical NLRP3 inflammasome activation in primary human 
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monocytes is suggested to result in pyroptotic cell death (Gaidt and Hornung, 2017), but direct 
evidence of this in the literature is limited. LDH release, indicative of cell death, was measured in 
primary human monocytes in response to LPS priming and treatment with ATP or nigericin 
(Ghonime et al., 2014, Gaidt et al., 2016). However, the results were not convincing as in each case 
cell death was barely, or not at all, greater than that induced by ATP or nigericin treatment alone, 
and hence may be inflammasome-independent. Clearer measurement of inflammasome-dependent 
cell death would be required in order to assess differences between patients and controls. A further 
possible measure of inflammasome response is ASC speck formation. Part of the plan for the 
development of the flow cytometric assay in Chapter 3 was for its use in analysis of ASC specks in 
monocytes within total PBMC. However, ASC-speck formation was assessed in ASC-high PBMCs 
because CD14 staining (indicating the monocyte population) was lost from cells during 
inflammasome activation (Figure 3.5). It was thus not possible to determine speck-containing cells 
as a percentage of monocytes. Further experiments were required to determine conditions for 
analysis of ASC specks within isolated monocytes. Thus the purpose of the work described in this 
chapter was to establish the techniques required to measure NLRP3 and AIM2 inflammasome 
activation in human monocytes, to facilitate the future goal of studying inflammasome activity in 
patient cells.  
6.2 Results 
6.2.1 Canonical NLRP3 inflammasome responses in human monocytes 
Release of IL-1β from primary human monocytes was investigated in response to NLRP3 
stimulation. CD14+ monocytes enriched by positive selection from the blood of healthy donors 
readily released IL-1β into the culture medium in response to LPS priming and nigericin treatment 
(Figure 6.1A). As expected this response was inhibited by pre-treatment with MCC950, a small 
molecule inhibitor of NLRP3 (Coll et al., 2015). Preliminary experiments showed cell death at one 
hour in response to LPS priming and nigericin treatment with some increase after two hours (Figure 
6.1B). Further analysis using MCC950 and treatment of unprimed cells with nigericin demonstrated 
that only the cell death occurring within the first hour was NLRP3 inflammasome-dependent, and 
when left longer, nigericin alone caused inflammasome-independent cell death (Figure 6.1C). This 
experiment has been performed once, and needs repeating to confirm this finding. ASC speck 
formation could not be measured using the flow cytometry assay described in chapter 3, in 
positively selected monocytes (data not shown). We hypothesise that this is because the pyroptotic 
cells are fragile and with the selection beads attached are broken apart during centrifugation steps, 
releasing the ASC speck. Because of this complication negative selection was investigated for 
monocyte enrichment.   
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 Negatively selected monocytes also displayed a strong IL-1β response to LPS priming and 
nigericin treatment that was inhibited by MCC950 (Figure 6.2A). Cell death was observed in 
response to LPS priming followed by nigericin or ATP treatment, but not LPS priming alone or 
nigericin or ATP alone for one hour (Figure 6.2B). The same treatment conditions also induced 
ASC speck formation, in cells expressing moderate to high amounts of ASC, which could be 
measured by flow cytometry (Figure 6.2C&D). The ASC expression of the isolated monocytes was 
heterogeneous, with only approximately 70% expressing a level with capacity for forming ASC 
specks. The purity of the negatively selected CD14+ cells was generally greater than 88%.  
Consequently there appears to be variation in ASC expression amongst CD14+ cells. The total ASC 
staining per cell (ASC-area) was higher in cells with specks compared to those without (Figure 
6.2C). This was also noted in Chapter 3, and is most likely due to better retention of ASC within the 
ethanol-fixed cells when it is in a compact speck rather than diffuse in the cytosol. A higher 
percentage of cells became PI positive than were observed with ASC specks. This may be due to 
ASC specks being lost from some cells undergoing pyroptosis. While BMMs maintained speck 
numbers up to one-hour post treatment as shown in Figure 3.9, the percentage of cells with specks 
was not directly compared to cell death and the human monocytes could be more fragile.  
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Figure 6.1. Inflammasome responses observed in positively selected primary human 
monocytes treated with NLRP3 stimuli. (A) IL-1β release measured by ELISA from monocytes 
isolated by positive selection and incubated for 24 h in complete RPMI with CSF-1, prior to LPS 
priming (3 h prior to nigericin, 10 ng/ml) with or without MCC950 (30 min prior to nigericin, 10 
µM) and treatment with or without nigericin (1 h, 10 µM). Bars are drawn to the mean of two (-
MCC950) or one (+MCC950) independent experiments with monocytes from different donors and 
each symbol represents an individual treatment well, with different shapes for different donors. (B) 
Positively selected monocytes were primed with LPS (3 h prior to nigericin, 10 ng/ml) and treated 
with or without nigericin (10 µM) for 1 or 2 h. Samples were then stained with PI and analysed by 
flow cytometry. Bars are drawn to the mean of individual treatments performed over two 
experiments using cells from different donors. Each symbol represents a single treatment, with 
different shapes for different experiments. (C) Positively selected monocytes were primed with LPS 
(3 h prior to nigericin, 10 ng/ml) with or without MCC950 (30 min prior to nigericin, 10 ng/ml), 
followed by treatment with or without nigericin (10 µM) for 1 or 2 h. Samples were then stained 
with PI and analysed by flow cytometry. Data represent the mean and range of duplicate samples 
from one experiment.  
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Figure 6.2. Inflammasome responses observed in negatively selected primary human 
monocytes treated with NLRP3 stimuli.  (A) IL-1β release measured by ELISA from monocytes 
isolated by negative selection after LPS priming (3 h prior to nigericin, 10 ng/ml) with or without 
MCC950 (30 min prior to nigericin, 10 ng/ml) and then treated with or without nigericin (1 h, 10 
µM). Bars are drawn to the mean of three (-MCC950) or two (+MCC950) independent experiments 
with monocytes from different donors. Each symbol represents an individual treatment well with 
different donors indicated by different symbols. (B-D) Monocytes isolated by negative selection 
were LPS primed (3 h prior to nigericin, 100 ng/ml) with or without MCC950 (30 min prior to 
nigericin, 10 µM) and treatment with or without nigericin (10 µM). After 1 h nigericin treatment 
cells were stained with PI and analysed by flow cytometry (B). Data represent the mean and range 
of two independent experiments with cells from two donors. After 30 min nigericin treatment cells 
were fixed and stained for ASC specks and analysed by flow cytometry (C & D). Gating is as per 
Appendix 2, Figure 1, but only cells with moderate to high ASC expression capable of forming 
specks were included in the final quantification of ASC specks positive cells. Data represent the 
mean and range of two independent experiments with cells from two donors.  
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6.2.2 IL-1β release in response to chemically transfected DNA is inhibited by MCC950 
In mouse macrophages chemical transfection of dsDNA enhanced by centrifugation of DNA 
complexes has been shown to elicit an AIM2-dependent IL-1β and cell death response (Stacey et 
al., 2016). In human monocytes an IL-1β response was observed following transfection with CT 
DNA (Figure 6.3A), but unexpectedly the response was largely inhibited by MCC950. MCC950 
has been shown to specifically inhibit the NLRP3 inflammasome and not the AIM2 inflammasome 
in mouse macrophages (Coll et al., 2015). To test that this held true in our hands BMMs were 
chemically transfected with CT DNA with and without MCC950 pre-treatment. MCC950 inhibited 
cell death in response to nigericin but not CT DNA (Figure 6.3B). Coll et al. showed that MCC950 
did not inhibit IL-1β release from mouse BMMs in response to chemically transfected dsDNA (Coll 
et al., 2015). However, a comparison of the effect of MCC950 on the release of IL-1β from human 
monocytes and mouse BMMs in response to chemically transfected CT DNA should be conducted 
in parallel. Further analysis of this phenomenon was conducted using PBMCs rather than purified 
monocytes.  
 Inhibition of IL-1β release in response to chemically transfected CT DNA by MCC950 was 
also observed in PBMCs (Figure 6.3C). The data in Figure 6.3C is from two experiments conducted 
using PBMCs from the same donor. However, the data are representative of two other experiments 
using different donors that could not be combined due to variations in protocol such as different 
transfection reagents (data not shown). The IL-1β release requires priming of the cells before 
transfection to upregulate pro-IL-1β expression and hence IL-1β was not released from unprimed 
PBMCs chemically transfected with CT DNA (Figure 6.3C). After LPS priming cells were washed 
to remove LPS before transfection, in order to prevent inadvertent transfection of LPS and 
activation of the noncanonical inflammasome. To verify that the transfection complex was not 
allowing transfection of any remaining LPS, and amplifying an LPS-dependent NLRP3 response 
through the noncanonical inflammasome, PAM3CSK4 was also used as a priming stimulus. 
PAM3CSK4 is a TLR2 agonist that can prime the inflammasome, but does not elicit a noncanonical 
inflammasome response (Kayagaki et al., 2013). Monocytes primed with Pam3CSK4 responded in 
the same pattern as those primed with LPS (Figure 6.3C).  
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Figure 6.3. The release of IL-1β by negatively-selected primary human monocytes and 
PBMCs in response to chemically transfected CT DNA is inhibited by MCC950. Indicated 
times for LPS and MCC950 are for prior to transfection. LPS is then washed away while MCC950 
is maintained. (A) IL-1β release measured by ELISA from monocytes following LPS priming (3 h, 
10 ng/ml) with or without MCC950 (30 min, 10 µM) and chemical transfection (100 ng/well CT 
DNA, 0.1 µL transfection reagent (TR)) or nigericin treatment for 3 h. TR = lipofectamine 2000. 
Data represents the mean and range of duplicate transfections from one experiment that is 
representative of three experiments. (B) Mouse BMM viability measured by MTT cleavage 
following LPS priming (3 h, 10 ng/ml) with or without MCC950 (30 min, 10 µM) and then 
chemical transfection (100 ng/well CT DNA, 0.1 µL TR) or nigericin treatment for a further 6 h. 
TR = lipofectamine 2000. Data represents the mean and range of triplicate transfections from one 
experiment. (C-E) IL-1β release measured by ELISA from PBMCs following 1 h incubation with 
no priming, 3 ng/ml LPS or 100 ng/ml Pam3CSK4 including 10 µM MCC950 when indicated and 
then chemically transfected (100 ng/well CT DNA, 0.3 µL TR) or treated with nigericin (10 µM). 
TR = X-tremeGENE HP. Culture supernatant was harvested at 3 h after transfection/nigericin 
treatment. C shows the mean and range of two independent experiments using PBMCs from one 
donor, but is representative of two further experiments on cells from different donors. D & E show 
the mean and range of duplicate transfections from a single experiment using PBMCs from a single 
donor. The donor is different for each panel.  
 
The results of Figure 6.3C could indicate that transfected DNA activates NLRP3 in human 
cells. However, an alternative explanation would be that this NLRP3 response is mediated by 
chemical transfection complexes and is not a dsDNA-specific response. As well as CT DNA, single 
stranded poly(dT) and RNA from B16 mouse cells were chemically transfected into PBMCs and 
induced an IL-1β response that was inhibited by MCC950 (Figure 6.3D). Treatment of the cells 
with transfection reagent or nucleic acid alone did not elicit a response. This experiment was 
repeated using PBMCs from a different donor (Figure 6.3E). These PBMCs showed a much higher 
response to LPS priming alone, that may represent alternative inflammasome activation as 
described in monocytes, with involvement of TLR4, TRIF, RIPK1 and caspase-8 signalling 
upstream of NLRP3 activation (Gaidt et al., 2016). However an increased response was still seen 
when transfection complexes were added, and all responses were sensitive to MCC950. These 
results suggest that nucleic acids in complex with a chemical transfection reagent may activate the 
NLRP3 inflammasome in human cells, but the mechanism by which this occurs is still to be 
determined. 
6.2.3 Electroporation of DNA into human monocytes does not elicit a clear inflammasome 
response.  
To further attempt to elicit an AIM2 inflammasome response in monocytes, electroporation was 
trialled instead of chemical transfection for delivering DNA to the cytoplasm. Electroporation 
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seems to deliver DNA directly into the cytosol (Sun et al., 2014). As published (Roberts et al., 
2009, Stacey et al., 2016) and shown here in Chapter 4 (Figure 4.2) electroporation of mouse 
macrophages induces an AIM2 inflammasome response. Optimisation experiments were carried out 
in PBMCs to determine electroporation conditions that would successfully deliver DNA into CD14+ 
cells. When PBMCs were incubated with a Cy3-labelled oligo and electroporated at 320 V most of 
the CD14+ cells become Cy3 positive as measured by flow cytometry (Figure 6.4A). A range of 
voltages between 240 V and 340 V were assessed (data not shown) and voltages lower than 320 V 
were less effective at delivering the oligo into the CD14+ cells. This is a higher voltage than 
required for mouse BMMs, where we routinely use 240 V. The voltage required for cell 
permeabilisation is thought to relate to cell size (Gehl, 2003), due to the need for a threshold 
potential difference across the width of the cell, and the monocytes are smaller than BMMs. When 
monocytes were electroporated with CT DNA at 320 V some increase in cell death after one hour 
was observed above the electroporation alone control and this cell death was not inhibited by 
MCC950 (Figure 6.4B). However, no induction of ASC specks was observed when monocytes 
were electroporated with CT DNA (Figure 6.4C). The monocytes did exhibit a basal level of 
MCC950-inhibited ASC specks that may be attributed to the LPS priming or other NLRP3-
activating stress in culture. Gaidt et al, report a lack of ASC specks in human monocytes in 
response to LPS treatment alone (Gaidt et al., 2016). Experiments comparing primed and unprimed 
cells would be required to confirm whether the basal level of specks observed in this study was due 
to LPS priming. Finally the amount of IL-1β released in response to CT DNA electroporation is 
very low compared to a nigericin treatment control (Figure 6.4D). When viewed on a graph without 
the nigericin-treated samples it can be seen that IL-1β release from monocytes electroporated with 
CT DNA was higher than that of electroporation alone controls (Figure 6.4E). However this was 
largely inhibited by MCC950 and unlikely to be mediated by AIM2. From these results it appears 
that there is no AIM2 inflammasome response in LPS-primed monocytes in response to 
electroporation with CT DNA. The apparent DNA-dependent cell death from Figure 6.4B may be 
through an uncharacterised inflammasome-independent pathway, as is currently under investigation 
within our laboratory in other human cell types (Nazarii Vitak, unpublished).  
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Figure 6.4. Electroporated monocytes do not show a clear AIM2 inflammasome response. 
Times provided for LPS and MCC950 are for treatments prior to electroporation. LPS and MCC950 
was washed away before electroporation and MCC950 was added back into appropriate samples 
following electroporation. (A) PBMCs were untreated or incubated with 20 µg Cy3-labelled 
oligonucleotide for 10 min at room temperature with and without electroporation at 320V and then 
stained for CD14 and analysed for Cy3 and CD14 expression by flow cytometry. (B & C) 
Monocytes were primed with LPS (2 h, 10 ng/ml) with or without MCC950 (30 min, 10 µM) and 
then washed and left untreated, electroporated with or without 20 µg CT DNA or treated with 10 
µM nigericin and incubated for 1 h with MC950 as appropriate. (B) Monocytes were stained with 
PI and analysed by flow cytometry. Bars are drawn to the mean of four electroporations or two 
nigericin treatments performed over two independent experiments/donors and each symbol 
represents an individual electroporation/treatment. (C) Monocytes were fixed and stained for ASC 
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and analysed by flow cytometry. Data represent the mean and range of two 
electroporations/treatments from one experiment. (D) IL-1β release measured by ELISA from 
monocytes that were unprimed or primed with LPS (2 h, 10 ng/ml) with or without MCC950 (30 
min, 10 µM) and then washed and left untreated, electroporated with or without 20 µg CT DNA or 
treated with 10 µM nigericin and incubated for 1 h with MCC950 where appropriate. A line shows 
the mean of four elecroporations/treatments over two experiments that are each represented by an 
individual symbol. (E) Electroporated samples only from D presented in a separate graph.  
 
6.2.4 AIM2 expression in human monocytes and HMDM 
Khare et al., showed a dramatic increase of Aim2 mRNA expression in monocytes primed with 
IFN-β (Khare et al., 2014). Here, AIM2 protein expression was analysed in CD14+ monocytes from 
two donors immediately after isolation from PBMCs and after 4 or 24 h treatment with IFN-β or 
LPS. AIM2 protein was observed in untreated CD14+ cells up to 4 h after isolation, but was barely 
detectable after 24 h (Figure 6.5A). AIM2 protein expression was enhanced by IFN-β, but not LPS 
treatment, suggesting that TLR4-induced IFN-β induction was insignificant. Notably, the AIM2 
expression is significantly lower in the CD14+ cell fraction than in the remaining CD14- cells. This 
is consistent with data from our laboratory showing AIM2 to be much higher in B cells than in 
other cell subsets (J. Cridland, unpublished). Due to the difficulties measuring AIM2 inflammasome 
activation in monocytes it was anticipated that the response may need to be investigated in HMDM. 
AIM2 expression in HMDM was analysed and it was found that without IFN-β or LPS treatment 
AIM2 protein was undetectable (Figure 6.5B). AIM2 expression in HMDM was greatly induced by 
a 24 h treatment with IFN-β and slightly increased by LPS treatment.   
6.2.5 Preliminary experiments in monocytes and HMDM pre-treated with IFN-β.  
Based on the AIM2 protein expression analysis, a 24 h pre-treatment of monocytes with IFN-β was 
performed before electroporation with CT DNA (Figure 6.6A). The results of this experiment did 
not show strong improvement over that of electroporation without IFN-β pre-treatment. There was a 
slight DNA-dependent increase in cell death, but as noted above, we have described AIM2-
independent cell death in human cells with electroporated DNA. There was no induction of 
MCC950-resistant ASC specks by DNA transfection. A small increase in IL-1β release was seen in 
MCC950-treated cells electroporated with DNA compared to the electroporation alone control 
however this was marginal in comparison to IL-1β released from monocytes treated with nigericin. 
In summary, we have not found conditions enabling satisfactory AIM2 responses in monocytes that 
approach the responses seen in mouse BMMs. 
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Figure 6.5. AIM2 protein expression in human monocytes and HMDM is upregulated by IFN-
β treatment. (A) AIM2 expression assessed by western blot in CD14+ and CD14- cell populations 
immediately (0 h) post selection and in CD14+ monocytes after 4 or 24 h untreated or treated with 
1000 U/ml IFN-β or 10 ng/ml LPS. Cells incubated for 24 h were all in the presence of CSF-1. 
Results are shown for cells from two healthy donors. GAPDH expression was measured as a 
loading control. (B) AIM2 expression in HMDM after 4 or 24 h with no treatment, 1000 U/ml IFN-
β or 10 ng/ml LPS assessed by western blot. GAPDH expression was measured as a loading 
control. Results are representative of two donors.  
 
 As AIM2 was highly inducible by IFN-β in HMDM we have commenced investigation of 
responses to electroporated DNA in these cells. HMDM were treated for 24 h with IFN-β and then 
primed for one hour with LPS prior to chemical transfection of CT DNA. A small portion of the cell 
death and IL-1β response was not inhibited by MCC950 and could thus be mediated by the AIM2 
inflammasome (Figure 6.6B). This response was still largely overshadowed by that from cells not 
treated with MCC950 suggesting that the majority of the response of HMDM to chemically 
transfected DNA under these conditions is mediated by NLRP3. Investigation into the response of 
HMDM to electroporated CT DNA is underway, but has been restricted by high background levels 
of cell death following harvesting of cells. These results need to be repeated with monocytes and 
HMDM from more donors, but they suggest that inducing AIM2 expression is not enough and some 
form of licensing of AIM2 may be required.  
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Figure 6.6. Inflammasome-like responses to electroporated DNA in human monocytes or 
HMDM were minimal following IFN-β pre-treatment. Times are provided for pretreatments 
with LPS and MCC950. Following priming, cells were washed to remove LPS prior to transfection. 
MCC950 was readded during transfection as appropriate. (A) Monocytes were pre-treated with 
IFN-β (24 h, 1000 U/ml), primed with LPS (2 h, 10 ng/ml) with or without MCC950 (30 min, 10 
µM), washed and then left untreated, electroporated with or without 20 µg CT DNA or treated with 
10 µM nigericin. Monocytes were incubated at 37°C for 30 min prior to ASC staining and speck 
analysis by flow cytometry or 1 h prior to PI staining or media collection for ELISA to assess IL-1β 
release. Data presented is the mean and range of duplicate electroporations/treatments from one 
experiment. (B) HMDM pre-treated with IFN-β (24 h, 1000 U/ml), primed with LPS (1 h, 10 
ng/ml) with or without MCC950 (30 min, 10 µM) and washed before addition of no treatment, 
treatment with X-tremeGENE HP (TR) and DNA, TR alone or nigericin. After 6 h incubation at 
37°C medium was collected for ELISA to assess IL-1β release and LDH assay to assess cell death. 
Cell death is presented as a percentage compared to wells in which all cells were lysed with 
detergent-containing buffer.  
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6.3 Discussion  
This work investigates techniques for measuring both NLRP3 and AIM2 inflammasome responses 
in human monocytes. Monocyte NLRP3 responses have been measured previously by IL-1β release 
(Gaidt et al., 2016, Liu et al., 2017). In addition, a clear cell death response and ASC speck 
formation was observed here in monocytes isolated by negative selection and primed with LPS and 
triggered with nigericin or ATP. Cell death was best measured at an early time point as nigericin 
alone appeared to cause inflammasome-independent death after two hours. This would explain 
published work, in which cell death after two hours of nigericin treatment was the same in LPS-
primed and unprimed monocytes (Gaidt et al., 2016). Negative selection of monocytes from 
PBMCs was required for ASC specks to be detected. We propose that the microbeads bound to the 
monocytes during positive selection increase the fragility of the cells as they undergo pyroptosis 
leading to the loss of cells displaying ASC specks in spite of fixation. Loss of ASC specks from 
pyroptotic cells due to membrane disintegration has been proposed previously (Gaidt et al., 2016). 
This could potentially be reduced by the use of a caspase-1 inhibitor to prevent cell death as 
described in Chapter 4 for ATP-treated BMMs, if negative selection of monocytes was not an 
option. The techniques described here are ready to be applied to a patient versus control study of 
NLRP3 inflammasome activity. However, given the importance of timing in detecting an 
inflammasome-dependent cell death in response to nigericin, the use of a kinetic plate-based 
fluorescence assay for binding of propidium iodide to nucleic acid in permeable cells (Russo et al., 
2016) would be superior to assaying at one timepoint by flow cytometry. This approach, using 
replicate wells of cells incubated with NLRP3 stimuli with and without MCC950 may provide a 
superior quantitative analysis of loss of membrane integrity. 
 The analysis of AIM2 inflammasome responses in human cells presents a much larger 
challenge. Both chemical transfection of dsDNA and electroporation as performed here induce an 
AIM2 inflammasome-dependent response in mouse macrophages (Stacey, 2016). However, here it 
appears that monocytes and HMDM showed little or no AIM2 response to these same stimuli. 
There was a minimal response of monocytes to electroporated DNA in comparison to the NLRP3 
stimulus nigericin. Presence of DNA in the cytosol following electroporation should be verified and 
this could be achieved by measuring IFN-β release mediated by cGAS recognition of the dsDNA. 
The IL-1β release from human monocytes in response to chemically transfected dsDNA was strong, 
but was almost completely inhibited by MCC950. In mouse macrophages MCC950 blocks neither 
IL-1β release (Coll et al., 2015) nor cell death (Figure 6.3B), in response to chemically transfected 
dsDNA. This suggests that either MCC950 inhibits AIM2 inflammasome responses in human, but 
not mouse cells, or more likely that the NLRP3 inflammasome is involved in the response to 
chemically transfected DNA in these cells. Further to this it was shown that chemical transfection 
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of single stranded DNA or RNA elicits a similar release of IL-1β, indicating that the response may 
be to transfection complexes, rather than specifically to dsDNA. As mouse AIM2 responses are 
specific for dsDNA (Roberts, 2009), this may be further indication of NLRP3 involvement instead 
of AIM2. The transfection reagent may become a much larger complex when nucleic acid is added, 
and get taken into cells in larger amounts than the reagent alone. Lysosomal disruption occurring 
during endocytosis of complexes of transfection reagent with nucleic acid may be activating 
NLRP3. Future experiments could examine whether the same response is elicited by other 
negatively charged polymers such as dextran sulfate. Verifying the role of the NLRP3 
inflammasome would involve knock down of NLRP3. Preliminary attempts were made to knock 
down NLRP3 in monocytes as part of this investigation, but requires further optimisation for the 
successful transfection of siRNAs into monocytes.  
 In line with other published work it was shown that untreated monocytes express detectable 
levels of AIM2 protein (Torii et al., 2017). Here we also showed that AIM2 protein levels in 
monocytes increased with IFN-β treatment. Earlier results in our laboratory showed that AIM2 
mRNA was strongly induced in THP1 monocytic cells at 6 h after DNA electroporation (Samantha 
Hodgson, unpublished). Cytoplasmic DNA may first be recognised by cGAS, subsequently 
inducing a type I IFN response, leading to induction of AIM2. Given that the AIM2 inflammasome 
response elicits rapid, proinflammatory cell death, perhaps it is desirable, that it is only initiated 
when cytosolic DNA persists for a longer time. While the experiment needs to be repeated with 
cells from more donors, pre-treatment with IFN-β was not sufficient to elicit an AIM2 
inflammasome response from monocytes to electroporated CT DNA. It is possible that some further 
licensing of AIM2, perhaps through post-translational modification, may be required before it can 
initiate an inflammasome response. Post-translational modification is a key determining factor in 
the activity of cytoplasmic innate immune sensors, including inflammasome proteins such as 
NLRP3, and dysregulation can result in monogenic autoinflammatory diseases (Baker et al., 2017). 
However, it is unknown if AIM2 is modified at the post-translational level. In this case, unlike 
when studying mouse macrophages, AIM2 inflammasome activation may need to be measured at 
much later time points post electroporation. Alternatively, if transfected DNA is not long-lived in 
the cytoplasm, an approach involving priming the monocytes with DNA by performing two 
electroporations could be explored. The first electroporation would initiate IFN-mediated 
upregulation of AIM2 protein expression as well as initiate the hypothetical licensing of AIM2 to 
then mount an inflammasome response to the second round of DNA electroporation.  
 Another factor to consider in AIM2 stimulation is the specificity of the dsDNA ligand. 
While all tested dsDNA of an appropriate length induced inflammasome responses in mouse 
macrophages (Roberts et al., 2009), poly(dA):poly(dT) (a hybrid of poly deoxyadenylic acid on one 
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strand and poly deoxythymidylic acid on the other strand) was a more potent stimulus than both CT 
DNA and “poly(dA:dT)” that is routinely used by researchers that has alternating deoxyadenlyic 
acid and deoxythymidylic acid on each strand (Adi Idris, unpublished). Human AIM2 may have 
more strict sequence requirements for recognising dsDNA and experiments could be conducted 
using different types of dsDNA including poly(dA):poly(dT).  
 If further attempts to measure AIM2 inflammasome activation in human primary monocytes 
are not successful, the response of HMDM may be further investigated. Here it was shown that 
AIM2 is not detectable following differentiation of CD14+ monocytes to HMDM unless they were 
then treated with IFN or LPS. Even after IFN-β pre-treatment the response of HMDM to chemically 
transfected CT DNA was largely inhibited by MCC950. In contrast, Lozano-Ruiz et al., showed IL-
1β release from LPS-primed HMDM measured 24 h after chemical transfection with poly (dA:dT) 
(Lozano-Ruiz et al., 2015) that was suppressed by A151, an oligonucleotide suggested to function 
as a competitive inhibitor of AIM2 (Kaminski et al., 2013). A151 is a phosphorothioate 
oligonucleotide based on telomeric TTAGGG repeats, first published as a TLR9 inhibitor and 
subsequently shown to act in a sequence-independent manner (Trieu et al., 2006, Gursel et al., 
2003). However, A151 also shows sequence-dependent inhibition of STAT proteins (Shirota et al., 
2004, Shirota et al., 2005). Kaminski et al., showed that A151 pre-treatment inhibited IFN-β 
production, as well as AIM2 responses, to chemical transfection of dsDNA indicating inhibition of 
the cGAS pathway (Kaminski et al., 2013). A151 may be affecting the chemical transfection of 
DNA, rather than specifically inhibiting the DNA receptors. This leaves some room for doubt that 
the IL-1β response seen by Lozano-Ruiz et al. was mediated by AIM2. A151 may be a useful tool 
for further investigations into the MCC950-inhibited response presented here, but further 
assessment of this oligonucleotide as an AIM2 inhibitor should be conducted first by looking at 
inhibition of responses to electroporated DNA. Future experiments with HMDMs could involve 
trying to replicate the response observed by Lozano-Ruiz et al by using poly(dA:dT), but should 
also include MCC950 controls. A role for the AIM2 inflammasome in human cells other than 
monocytes and macrophages also warrants exploration. Our laboratory has shown expression of 
AIM2 to be higher in human B cells than monocytes (J. Cridland, unpublished). This was also 
shown in a recent publication along with data showing release of IL-1β from human B cells in 
response to dsDNA transfection, however whether this is AIM2 dependent was not assessed 
(Svensson et al., 2017).  
In summary, the study of inflammasome activation in human diseases such as SLE requires 
optimisation of the experimental conditions required to measure inflammasome activation in human 
monocytes. Here techniques for measuring NLRP3 inflammsome mediated cell death and ASC 
speck formation human monocytes have been described. Analysis of the AIM2 inflammasome in 
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human cells remains a challenge, as the novel observation was made that IL-1β release from human 
monocytes in response to chemically transfected dsDNA and other transfection complexes was 
inhibited by MCC950, a small molecule inhibitor of the NLRP3 inflammasome. This suggests that 
this response is mediated by the NLRP3 inflammasome and not the AIM2 inflammasome. This 
needs to be considered when measuring IL-1β release from human cells in response to nucleic acids 
and further investigation into the mechanism of this response is required. We are yet to detect a 
clear AIM2 inflammasome response in human cells and it is possible that some uncharacterised 
licencing of AIM2 or a specific DNA sequence may be required. This study provides important 
information for measurement of inflammasome responses in human cells particularly those 
expected to be mediated by AIM2. 
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Chapter 7: Future Directions 
 
This thesis has explored the function of the NLRP3 and AIM2 inflammasomes in autoimmune 
mouse models and made advances towards the genetic manipulation of these strains in order to 
study the relationship between inflammasome activity and disease phenotype. We have gained 
important insight into inflammasome activation in human monocytes and the work presented here 
also provides valuable tools and techniques for measuring inflammasome activation that will 
benefit future studies of inflammasome activity in human cells.  This chapter discusses future 
directions for this work.   
7.1 Future applications for flow cytometric analysis of inflammasome formation 
Chapter 3 describes a novel flow cytometric assay for assessing inflammasome activation based on 
the relocalisation of ASC. This procedure has already proven useful in analysis of protein-protein 
interactions during inflammasome formation and the recruitment of caspase-8 to the ASC speck 
(Vajjhala et al., 2015, Fu et al., 2016). Another group has also used the assay to assess the impact of 
a novel pyrin mutation on ASC speck formation and inflammasome activation in order to better 
understand a pyrin-associated autoinflammatory disease (Moghaddas et al., 2017). The protocol has 
been adapted for use in an investigation of MyD88 clustering induced by MAL (MyD88-adapter-
like) (Ve et al., 2017) highlighting that the assay can be modified to investigate any proteins 
exhibiting a relocalisation from a diffuse state in the cytosol into a more concentrated localisation.  
In Chapter 6, it was shown that ASC speck formation can be measured using this assay in 
isolated human monocytes following NLRP3 inflammasome activation and this will form an 
important part of assessing inflammasome function in human patients. In general, the use of the 
assay in detecting ASC specks that have formed within cells in vivo may be limited; the fragility of 
pyroptotic cells would mean that tissues could not be enzyme digested or extensively processed to 
obtain intact ASC speck-containing cells. In addition, pyroptotic cells may exist for only a short 
time in vivo, and not accumulate to a great extent. Consistent with this, detection of any speck-
containing cells was challenging in a mouse with citrine-tagged ASC (Tzeng et al., 2016). 
Consequently, the major use of this assay is likely to remain in the analysis of cells undergoing 
inflammasome stimuli in vitro. Future work should take advantage of using the assay to assess 
inflammasome formation of cells in a mixed population. This could aid in experiments where 
assessment of inflammasome activity is required in a cell type that forms a small subset of a 
sample, removing the need for isolation and enrichment procedures and maximising the information 
gained per patient sample. The challenge for this application in human blood is choosing 
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appropriate cell markers for analysis of the frequency of responding cells, as CD14 that is GPI 
anchored, was rapidly lost from the cell surface upon inflammasome stimulation.  
Another, as yet untapped, potential application for this ASC speck assay is identifying new 
subsets of inflammasome-competent cells within mixed populations. In the published paper from 
Chapter 3 a subset of cells from the mouse peritoneal cavity, that were negative for the macrophage 
and B cell markers, were found to form ASC specks upon inflammasome stimulation (Figure 3.4) 
(Sester et al., 2015b). The assay may allow rapid identification of cell types that have not yet been 
recognised to be capable of forming inflammasomes, but this will first require the development of a 
panel of cell type markers that are not lost during inflammasome activation or cell fixation.   
7.2 Determining the role of inflammasomes in autoimmune mouse strains 
Macrophages from autoimmune NZB mice are deficient in NLRP3 and AIM2 inflammasome 
responses (Sester et al., 2015a). In Chapter 4, it was shown that NZW mice are competent for these 
inflammasome responses while NZB/W F1 mice, that model SLE with severe GN, have decreased 
inflammasome activity compared to NZW. Genetic modification of the NZB mice to restore 
inflammasome activity, or alternatively, deletion of Nlrp3 from NZW mice, is required to further 
investigate the role of inflammasomes in the progression of autoimmune disease. Repair of the NZB 
Nlrp3 splicing defect alone, using exon-skipping antisense oligonucleotides, was sufficient to 
restore NLRP3 inflammasome activity in NZB macrophages (Chapter 5) (Thygesen et al., 2016). 
This supports our current aim to correct the NZB NLRP3 deficiency in vivo by CRISPR/Cas9-
mediated correction of the point mutation or deletion of the aberrant splice acceptor.  
NLRP3 could conceivably both suppress loss of tolerance and promote tissue damage, 
having contrasting effects at different stages of disease. NLRP3 has been proposed to contribute to 
kidney damage in a range of pathologies (Wang and Yi, 2016), and lack of NLRP3 in NZB mice 
may contribute to their mild GN. As discussed in Chapter 1, we hypothesise that inflammasome 
deficiency predisposes NZB mice to loss of tolerance and thus that restoring NLRP3 inflammasome 
function in NZB mice will decrease autoantibody production. Nlrp3 falls within the NZB Lbw8 
lupus susceptibility locus that has been linked to antichromatin antibody production (Kono et al., 
1994, Morel et al., 1994). However, the locus also includes genes such as IL-4, for which a role has 
been proposed in lupus pathogenesis (Peng et al., 1997). This region of chromosome 11 has also 
been linked to kidney damage in NZM2410 mice (Morel et al., 1999) that develop more rapid GN 
than NZB/W F1 mice (Rudofsky and Lawrence, 1999). The parental origin of this chromosomal 
region in NZM2410 has not been reported (Waters et al., 2001), but as NZM mice are derived by 
backcrossing NZB/W F1 mice with NZW, they may have both alleles of Nlrp3 from NZW and this 
could contribute to accelerated GN. NLRP3 inflammasome activity has been reported in the 
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kidneys of NZM2328 mice that develop severe GN and the kidney disease phenotype was improved 
upon MCC950 treatment (Fu et al., 2017). Thus, it is possible that repairing NLRP3 function in 
NZB mice could promote kidney disease.  
NZB mice develop anti-erythrocyte antibodies resulting in fatal haemolytic anaemia (Helyer 
and Howie, 1963, Izui et al., 1994). NLRP3 is not involved in the generation of anti-erythrocyte 
antibodies seen with transfused red blood cells (Gibb et al., 2016), and there is no indication from 
existing genetic studies that the NZB null allele of Nlrp3 contributes to anaemia (Kikuchi et al., 
2005a, Scatizzi et al., 2012). However, the NLRP3 inflammasome has been shown to play a role in 
the inflammatory response to extracellular heme produced by hemolysis or extensive red blood cell 
damage and Nlrp3-/- mice are protected from hemolysis-induced lethality (Dutra et al., 2014). 
NLRP3 deficiency in NZB mice may be protective against inflammatory responses to damaged red 
blood cells. If restoration of NLRP3 inflammasome function does not reduce anti-erythrocyte 
antibody production, NLRP3 mediated responses to released heme could have a negative impact on 
disease.  
In lieu of successful CRISPR/Cas9-mediated repair of Nlrp3, the effect of intermediate 
NLRP3 expression on the course of disease in NZB/W F1 mice could be investigated by inhibiting 
NLRP3 in vivo with MCC950. Reduced proteinuria and renal lesions were observed in NZM2328 
mice treated with i.p. MCC950 beginning approximately three weeks prior to the presentation of 
severe proteinuria in vehicle-treated mice (Fu et al., 2017). MCC950 administration to NZB/W F1 
mice from birth could additionally be used to assess a role for the NLRP3 inflammasome in the 
onset of autoantibody production. The effect of NLRP3 expression on kidney damage later in 
disease could also be investigated by beginning MCC950 treatment after disease onset.  
As described in section 1.8.2, AIM2 and p202 both fall within the Nba2 lupus-susceptibility 
locus of NZB mice that is associated with loss of tolerance and autoantibody production (Rozzo et 
al., 2001).  This region also contains other candidate genes and an experiment involving the 
analysis of congenic C57BL/6 mice expressing smaller intervals of the Nba2 locus found no effect 
of deleting the region containing both p202 and AIM2 in autoantibody production (Jorgensen et al., 
2010). However, the important modification to test the hypothesis that AIM2 might suppress 
autoimmunity is to delete p202 and allow full function of AIM2, and this has not been done. It 
would be ideal to also restore function of the AIM2 inflammasome in NZB mice via knockout of 
p202 expression by CRISPR/Cas9. As discussed in Chapter 5, implementing CRISPR/Cas9-
mediated genomic modifications is difficult in poorly breeding NZB mice. Restoration of the AIM2 
inflammasome has an added level of complexity compared to correcting the mutation in Nlrp3 
because there is variable copy numbers of the gene encoding p202, Ifi202, in different mouse strains 
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(Cridland et al., 2012) and evidence suggests that there are at least two copies in the NZB genome 
(Jasmyn Cridland, unpublished).  
7.3 Investigating the role of inflammasomes in SLE 
Further investigation into inflammasome function in SLE patients is warranted as current studies 
are limited and contradictory (see Section 1.8.5).  SLE is a complex disease with no complete cure 
or treatment that works for all patients. Since 1959, only one new agent has been approved by the 
FDA for use in SLE (Wallace, 2015). Potential therapeutics have difficulty meeting required 
endpoints in clinical trials because of the heterogeneous nature of the disease, and a number of 
drugs are used off-label to treat SLE without clear demonstration of clinical efficacy (Davis and 
Reimold, 2017). There are currently proposals to improve clinical trials for SLE therapeutics by 
varying study design depending on the proposed role of the treatment, for example disease 
prevention or treatment of organ specific pathology (Wallace, 2015). A much clearer understanding 
of what role, if any, inflammasomes play in SLE disease is required if they are to be considered a 
target of therapeutics for this disease. The IL-1β antagonist, Anakinra was used in preliminary 
clinical trials for SLE, particularly to treat polyarthritis (Moosig et al., 2004, Ostendorf et al., 2005), 
without any clear evidence for a role of this cytokine in the pathology. The first study showed 
transient improvement of arthritis symptoms in two out of three patients (Moosig et al., 2004). 
Beneficial effects on arthritis were also observed in the second study, but two out of four patients 
relapsed within eight months (Ostendorf et al., 2005). These studies, as well as reviews in this field 
(Doria et al., 2012, Shaw et al., 2011) operated on an assumption that inflammasomes exacerbate 
SLE, in advance of the evidence. 
Techniques for measuring NLRP3 inflammasome activation in human monocytes have been 
assessed (Chapter 6) and can be applied to a study comparing the response in SLE patient versus 
control cells. The ability to correlate inflammasome function with disease phenotype and activity 
would be useful if a subpopulation of patients with impaired or enhanced inflammasome function 
becomes apparent and this would require a large SLE patient cohort with documented clinical data. 
Given the evidence for NLRP3 involvement in kidney pathologies (Wang and Yi, 2016), an 
involvement of NLRP3 in SLE GN should be considered. Inflammasomes could contribute to tissue 
damage even without any intrinsic alteration in NLRP3 function that would be detected by 
assessment in monocytes. After initiation of immune complex-mediated inflammation and tissue 
damage, release of DAMPs such as ATP could activate a normally functioning or even suboptimal 
NLRP3 inflammasome leading to an amplifying loop of cell damage. Evidence to support such a 
mechanism would be difficult to obtain in human patients; biopsy material might be needed to 
confirm local release of IL-1β and IL-18 or look for evidence of ASC specks. Mouse models will 
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continue to be informative for determining the effect of any NLRP3 inhibitors. However given the 
exacerbatory effect of Nlrp3 deletion in the B6lpr model (Lech et al., 2014), the role of 
inflammasomes is not likely to be simple. 
Given the established role for cytosolic DNA in SLE cases involving TREX1 deficiency, the 
role of AIM2 remains of interest. p202 expression is high in three lupus prone mouse strains 
including NZB (Chen et al., 2008, Haywood et al., 2006, Ichii et al., 2010) and hence AIM2 
function should be low in these mice. AIM2 expression has been shown to be boosted in human 
SLE (Zhang et al., 2013, Kimkong et al., 2009, Liu et al., 2017). This does not mean that AIM2 is 
part of the pathology, instead it may be functioning to restrain pathology. AIM2 is upregulated in 
response to IFN (DeYoung et al., 1997), which is often elevated in SLE (Baechler et al., 2003) and 
there is evidence that the AIM2 inflammasome can inhibit type I IFN production as discussed in 
section 1.9.3.  To determine whether AIM2 function is normal in human disease we need to identify 
an AIM2 response in human cells. This presents a challenge as we are yet to show an AIM2-
dependent response to cytosolic dsDNA in human cells via techniques known to elicit AIM2 
inflammasome-dependent responses in mouse macrophages. Chemical transfection of dsDNA into 
human monocytes and HMDM induced IL-1β release that was inhibited by MCC950, suggesting a 
potential role for NLRP3 in this response (Chapter 6). The mechanism behind this unusual 
observation warrants further investigation and future directions for this and how to stimulate an 
AIM2-dependent response in human monocytes or HMDM are discussed in Chapter 6.  It may be 
that monocytes and macrophages are not the key cell type for AIM2 inflammasome responses in 
humans. AIM2 expression levels are higher in human B cells than monocytes (Svensson et al., 
2017) and thus determining the function of AIM2 in B cells may be critical for resolving its 
relevance to SLE. As well as secreting pathogenic autoantibodies, B cells are involved in antigen 
presentation and the secretion of pro-inflammatory cytokines such as IL-6 and IFN-γ 
(Lampropoulou et al., 2008, Gray et al., 2007, Lund and Randall, 2010) that can contribute to 
disease as discussed in Chapter 1. IL-10-producing regulatory B cells also play a suppressing role in 
models of autoimmune disease (Wolf et al., 1996, Mizoguchi et al., 2002, Mauri et al., 2003). A 
role for AIM2 in B cells should be investigated. This could begin with looking for conventional 
inflammasome outputs such as IL-1β. IL-1β is released from human B cells in response to dsDNA 
transfection, but whether or not this is AIM2-dependent remains to be established (Svensson et al., 
2017). However, AIM2 may function differently in B cells. AIM2 protects against colorectal cancer 
by controlling the expansion of intestinal stem cells in an inflammasome-independent manner (Man 
et al., 2015), setting a precedent for a non-conventional role of AIM2 in B cells. Once a clear AIM2 
response in human cells is established a comparison could then be made between SLE patients and 
healthy controls.  
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7.4 Conclusion 
An involvement of inflammasome activity in the pathogenicity of autoimmune disease was 
proposed because of the pro-inflammatory nature of inflammasome responses. Published reports are 
conflicting and support a complex role for inflammasomes in autoimmunity. Based on the 
inflammasome deficiencies in NZB mice we proposed that inflammasomes could play conflicting 
roles in suppressing loss of tolerance, but promoting tissue damage. This thesis discusses the need 
for genetic manipulation of naturally occurring autoimmune mouse models that will allow the 
relationship between inflammasome activity and disease phenotype in these mice to be established 
and describes advances made towards this goal. Thorough investigation of inflammasome 
activation in SLE patients is critical for understanding what role this may play in disease. The work 
presented here emphasises differences in the responses of mouse and human cells to inflammasome 
stimuli, provides valuable tools and techniques for measuring inflammasome activation in human 
monocytes and also highlights the need for further investigation into AIM2 activity in human cells. 
Optimisation of the study of inflammasome responses in human cells will enhance future studies of 
inflammasome activity in human disease.  
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ABSTRACT 
Inflammasomes are large protein complexes formed in response to cellular stresses that are 
platforms for recruitment and activation of caspase-1. Central to most inflammasome functions is 
an adapter molecule ASC that links the inflammasome initiator protein to the recruited caspases. 
ASC is normally diffuse within the cell, but within minutes of inflammasome activation relocates to 
a dense speck in the cytosol. The dramatic re-distribution of ASC can be monitored by flow 
cytometry using parameters of fluorescence peak height and width when immune-stained or tagged 
with a fluorescent protein. This can be used to define cells with active inflammasomes within 
populations of primary macrophages and monocytes, allowing quantification of responses and flow-
sorting of responding cells. Protein structural requirements for ASC speck formation and 
recruitment of caspases to ASC specks can be assessed by expressing components in HEK293 cells. 
This provides rapid quantification of responding cell number, and correlation with the expression 
level of inflammasome components within single cells. 
 
 
Keywords: Inflammasome, ASC, flow cytometry, NLRP3, AIM2 
 
INTRODUCTION 
Inflammasomes are protein complexes that form in response to diverse stimuli including a range of 
infections, indications of endogenous stress, and environmental irritants (Latz et al., 2013; Schroder 
and Tschopp, 2010). Inflammasomes recruit and activate caspase 1, which subsequently cleaves the 
precursors of proinflammatory cytokines IL-1b and IL-18 prior to their release, as well as initiating 
a rapid lytic form of cell death termed pyroptosis. Inflammasome formation also leads to caspase 8 
activation, which results in initiation of apoptotic pathways (Sagulenko et al., 2013). Central to the 
function of most characterized inflammasome structures is ASC (apoptosis-associated speck-like 
protein containing a caspase-recruitment domain). ASC is an adapter molecule forming a bridge 
between one of a number of inflammasome-initiating proteins, and the recruited procaspase 1 and 
procaspase 8 (Martinon et al., 2002; Vajjhala et al., 2015). ASC is normally diffuse throughout the 
cell, but upon inflammasome stimulus relocates into a cytosolic “speck”. This appears to be via 
formation of filaments, in a process likened to prion self-association that is complete within minutes 
once oligomerisation is initiated (Cai et al., 2014; Cheng et al., 2010; Lu et al., 2014). This rapid 
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change in ASC localization can be used as a measure of inflammasome assembly at a single cell 
level. The protocols here permit quantitative assessment of ASC specks within cell populations by 
flow cytometry.  
ASC consists of two domains of the death fold superfamily, a pyrin domain (PYD) and caspase 
recruitment domain (CARD) (Masumoto et al., 1999). Inflammasome intiators such as AIM2, 
NLRP3 and pyrin all contain an N-terminal PYD that becomes clustered after the proteins are 
induced to oligomerise by their activating stimuli. ASC is recruited by homotypic PYD-PYD 
interactions, and this nucleates the formation of a filament of ASC (Lu et al., 2014). Inflammasome 
initiator NLRC4 contains a CARD rather than PYD, but also initiates ASC speck formation. This 
appears essential for optimal NLRC4-mediated pro-IL-1b cleavage, but not for the pyroptotic 
response (Broz et al., 2010). The ASC filament is characterized as a triple helix of PYD, with 
CARD located peripherally, and able to recruit procaspase 1 by CARD-CARD interaction. This has 
been shown in vitro to result in formation of further helical filaments of caspase-1 via CARD self-
association (Lu et al., 2014). In contrast procaspase 8 binds through its tandem death effector 
domains (DED) to the end of an ASC PYD filament, which in turn can initiate procaspase 8 
filaments (Vajjhala et al., 2015). 
The relocalisation of ASC from a diffuse state into a single speck permits analysis by flow 
cytometry, either with cells immunostained for native ASC, or expressing ASC fused with a 
fluorescent protein such as enhanced green fluorescent protein (EGFP). As the cell passes the 
interrogation point, a flow cytometer records the pulse of fluorescence emitted from a cell as a time 
of flight profile. Hence, flow cytometers are generally able to measure not only the total emitted 
fluorescence (peak area), but also the height and width of the fluorescence peak. The height and 
width parameters can reveal information regarding the localization of the fluorophore within the 
cell. The diffuse location of ASC in resting cells provides a low broad peak of fluorescence, 
whereas after formation of an ASC speck the peak is high and narrow. This forms the basis of the 
“time of flight inflammasome evaluation” (TOFIE) protocols described here.  
Three protocols are provided for different applications of this technique. The first protocol 
describes immuno-staining of native inflammasomes in murine macrophages and human monocytes 
and can be used to quantify responsive cells from within a mixed cell population. The second 
protocol is for analysis of ASC speck formation with inflammasome components expressed in 
HEK293 cells. This allows investigation of candidate inflammasome initiator proteins and effects of 
truncations or mutations.  The final protocol uses the TOFIE assay to examine the recruitment of 
procaspase 8 to the inflammasome, emphasizing the broader applicability of this technique.   
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BASIC PROTOCOL 1 
ASSESSMENT OF FORMATION OF NATIVE ASC SPECKS IN MONOCYTES AND  
MACROPHAGES 
This protocol describes a flow cytometric assay to assess relocalization of native ASC in 
macrophages due to inflammasome activation. Details are given for ASC speck analysis following 
in vitro stimulation of murine bone marrow-derived macrophages (BMMs) or human peripheral 
blood mononuclear cells (PBMCs). Because cells undergoing inflammasome-dependent pyroptotic 
death are fragile, the procedures aim to minimize handling after inflammasome triggering. For this 
reason cells have been treated with stimuli either in suspension or in plates coated to prevent 
adherence. The procedure given is for NLRP3 priming by LPS followed by a nigericin or ATP 
treatment, which are useful positive control stimuli. The assay can also be used with other NLRP3 
stimuli such as alum, and ligands for other canonical inflammasomes such as transfected dsDNA 
for the AIM2 inflammasome, and infection with Salmonella for activation of the NLRC4 
inflammasome (Sester et al., 2015). 
NOTE: If investigating a new cell type, the capacity for ASC speck formation should be confirmed 
by fluorescence microscopy before use of the flow cytometric protocol described here. 
 
Materials 
BMMs differentiated from bone marrow in the presence of 104 U/ml colony stimulating factor 1 
(CSF1) for 6 to 10 days 
Complete RPMI-1640 (see recipe) unsupplemented and supplemented with 104 
U/ml CSF1 
10 µg/ml LPS (see recipe) 
Dulbecco’s modified PBS (DPBS), without calcium or magnesium (e.g., Thermo Fisher Scientific, 
cat. no. 14190) 
Isolated human PBMCs (or monocytes) 
24-well tissue culture plate coated with poly-HEMA (see Kuroda et al., 2013) 
100 µM nigericin (see recipe) 
150 mM ATP (see recipe) 
100% high-grade ethanol 
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4% (w/v) paraformaldehyde (PFA; see recipe) 
Flow BLOCK (see recipe) 
2.4G2 hybridoma supernatant or anti-mouse CD16/32 (e.g., BD Pharmingen) 
Flow PERM (see recipe) 
Anti-ASC antibody (rabbit anti-ASC [N15]-R; e.g., Santa-Cruz, cat. no. sc-22514-R) 
Flow WASH (see recipe) 
Goat anti-rabbit (H+L) Alexa Fluor 488 (e.g., Thermo Fisher Scientific, cat. no. A11008) 
10-cm square bacteriological plastic plates (e.g., Sterilin) or 10-cm bacterial petri dishes 
Tissue culture incubator, humidified and set at 37°C with 5% CO2 
Centrifuge and microcentrifuge 
Cell counter 
1.5-ml microcentrifuge tubes 
15-ml and 50-ml polypropylene conical centrifuge tubes 
100-µm Nitex nylon mesh (e.g., Genesee Scientific, cat. no. 57-103) or equivalent 
5-ml polypropylene or polystyrene round-bottom tubes as appropriate for flow cytometer 
Flow cytometer with 488-nm laser and appropriate filter configuration 
Software for analysis of flow cytometry 
 
Preparation, priming and inflammasome activation of macrophages or monocytes  
1.   a. For BMMs, plate 5-15 x 106 BMMs in 20 ml of complete RPMI-1640 (supplemented with 
104 U/ml CSF1) in a 10 cm square bacteriological (Sterilin) plate and incubate overnight. 
The following day, prime BMMs by adding 20 µl of 10 µg/ml LPS stock to give a final 
concentration of 10 ng/ml, mix thoroughly and incubate 4 hours at 37°C. Following 
priming, harvest BMMs and centrifuge 5 min at 400 x g, room temperature. Resuspend cells 
in complete RPMI-1640, count and adjust to a concentration of 2 x 106 cells/ml. Aliquot 500 
µl (1 x 106 cells) into 1.5 ml sterile microfuges tubes if fixing with PFA, and 15 ml 
polypropylene tubes if fixing with ethanol. 
 
Note: Harvesting BMMs should be done gently to minimize damage, by the following procedure. 
Transfer the culture medium to a 50 ml polypropylene centrifuge tube, to which all plate washings 
are added. Wash the monolayer of BMMs twice with 5 ml of DPBS. Add a further 10 ml DPBS to 
the cell monolayer, let sit for about 5 minutes at room temperature and then squirt the cells from 
the plate with a 10 ml pipette. Conduct a final wash of the plate with 5 ml of DPBS. When 
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resuspending cells in preparation for inflammasome activation, complete RPMI-1640 medium 
without HI-FCS can also be used. 
 
b. For PBMCs, Count and seed 1 x 106 PBMCs/well in a 24 well plate, which has been coated with 
poly-HEMA (Kuroda et al., 2013) in 450 µl of complete RPMI-1640. Add 50 µl of 100 ng/ml LPS 
per well, mix thoroughly, and incubate 3-4 hours at 37°C.   
 
Poly-HEMA prevents cell adherence and allows easy harvesting without loss of cells. 
 
2.   Add inflammasome stimulus to cells. For nigericin treatment, add 55 µl of 100 µM nigericin 
to the tube/well to give a final concentration of 10 µM. For ATP treatment, add 17 µl of 150 
mM ATP to the tube/well to give a final concentration of 5 mM. Mix thoroughly.  
 
Include mock-treated samples to act as negative controls for assays. Note that these treatments are 
being done on cells in suspension to avoid the need for harvesting cells after stimulus, as this is 
likely to result in loss of ASC specks from fragile cells undergoing pyroptosis. 
 
3.   a. For BMMs, incubate 30 min at 37°C.   
 
Note: If using nigericin stimulation in serum-free complete RPMI-1640, a 15 min incubation 
is adequate for response. Alternatively, if serum-containing RPMI-1640 is used in 
combination with nigericin stimulation, 30-60 min is required to see robust speck formation. 
If using other inflammasome stimuli, such as bacterial infection or alum treatment (Sester et 
al., 2015), incubation time will be longer and should be empirically determined. It is also 
advised that HI-FCS is included when stimuli that require longer incubations are used (eg. 
infections or alum). 
b. For PBMCs, incubate 30 min at 37°C. Following incubation, transfer PBMC samples from 
culture plate wells to tubes for fixation. If using PFA for fixation transfer cells to 1.5 ml microfuge 
tubes.  When using ethanol for fixation transfer to 15 ml polypropylene centrifuge tubes. 
 
 
184 
Fixation and immunostaining of cells 
4.   a. For fixation of cells with ethanol, add 2 ml of 100% high grade ethanol, mix thoroughly 
by inversion and incubate 15 min at room temperature. 
 
b. For fixation with paraformaldehyde (PFA), add 167µl of 4% PFA, mix thoroughly by inversion 
and incubate 5 min on ice.  Add 1 ml of Flow BLOCK. 
 
Both ethanol and PFA fixation allow for analysis of ASC specks. Ethanol fixation generally gives 
superior detection of speck-containing cells. However, if the assay is to be combined with staining 
of cell surface markers, a fixation method compatible with detection of the surface markers that are 
to be analysed will need testing empirically. If cells in full medium with FCS are fixed with ethanol, 
a precipitate of FCS will be observed but this does not seem to affect results.  
 
5.   Centrifuge 5 min at 500 x g, room temperature and discard the supernatant.  
 
6.   a. For BMMs, if ethanol fixation was used resuspend the cells in 250µl of Flow BLOCK 
supplemented with 10% (v/v) of 2.4G2 hybridoma supernatant, and transfer to 1.5 ml 
microfuge tube. 
 
b. For BMMs, if PFA fixation was used resuspend the cells in 250µl of Flow PERM 
supplemented with 10% (v/v) of 2.4G2 hybridoma supernatant.  
To effectively block Fc Receptors, which are expressed at high levels in BMMs, supplement 
Flow BLOCK and Flow PERM at a level of 10% (v/v) with supernatant from 2.4G2 
hybridoma that produces a rat anti-mouse CD16/CD32 monoclonal antibody. The cell line 
can be purchased from ATCC for production of hybridoma supernatant. Alternatively, 
commercially available purified anti-mouse CD16/CD32 antibodies can be used as per 
manufacturer’s instruction.  
Any blocking antibodies should be of a host species other than rabbit as ASC staining in this 
protocol relies on indirect staining methodology utilizing an anti-ASC polyclonal 
preparation produced in rabbits. 
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For all steps, when resuspending cells use a P200 pipettor and pipet cells up and down a 
total of five to ten times to give a single cell suspension.   
c. For PBMCs, if ethanol fixation was used resuspend the cells in 250µl of Flow BLOCK, and 
transfer to 1.5 ml microfuge tube. 
 
d. For PBMCs, if PFA fixation was used resuspend the cells in 250µl of Flow PERM. 
Commercially available anti-human Fc Receptor blocking reagents are available and can 
be included as per manufacturer’s instructions to reduce background binding if necessary. 
N.B. Any blocking antibodies should be of a host species other than rabbit as ASC staining 
in this protocol relies on indirect staining methodology utilizing an anti-ASC polyclonal 
preparation produced in rabbits.   
For all steps when resuspending cells, use a P200 pipettor and pipette cells up and down a total of 
5-10 times to give a single cell suspension.  
 
7.   Incubate 20 min at room temperature.  
 
At this stage samples can be stored at 4°C overnight before proceeding with staining.  
8.   Prepare the primary antibody dilution by aliquoting sufficient Flow BLOCK (for ethanol-
fixed samples) or Flow PERM (for PFA-fixed samples) into a tube to allow 250 µl for each 
sample. Dilute the rabbit anti-ASC antibody 1:750 in this solution, and centrifuge 3 min at 
17,000 × g, room temperature to remove any aggregates. Add 250 µl of this 1:750 rabbit 
anti-ASC (N15)-R to tubes and mix well (final concentration 1:1500). 
 
Include (at least for un-stimulated sample) a secondary only sample (ie no primary 
antibody) as this will confirm effective staining of ASC.  
 
Individual lots of rabbit anti-ASC (N15)-R may vary, and new antibody lots may require 
titration to confirm optimal dilution. 
 
9.   Incubate 30–90 min at room temperature. 
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While 30 minutes has been sufficient, more defined separation of ASC-expressing and non-
expressing populations has been observed after a 60-90 min incubation. This primary antibody 
staining is also effective overnight at 4°C with a final concentration 1/6000.  
 
10.  Add 1ml of Flow WASH, centrifuge 10 min at 600 x g, room temperature in a benchtop 
microfuge, remove supernatant being careful not to disturb pellet.  
 
11.  Resuspend cell pellets in 100 µl Flow BLOCK (for ethanol-fixed samples) or 100 µl Flow 
PERM (for PFA-fixed samples) with a 1:1500 dilution of Alexa Fluor 488 goat anti-rabbit 
IgG. Incubate 45 min at room temperature in the dark.  
 
If desired, include appropriate dilutions of directly fluorescently-labelled cell lineage antibodies at 
this stage, along with the secondary antibody for ASC staining. Any antibodies used should be 
tested for effect of inflammasome stimuli and fixation technique used. 
 
12.  Add 1ml of Flow WASH, centrifuge 10 min at 600 x g, room temperature in a benchtop 
microfuge, remove supernatant being careful not to disturb the pellet. 
 
13.  Resuspend the cells in 200 µl of Flow WASH to achieve a single cell suspension. 
 
Flow cytometry and analysis 
14.  To remove any large clumps of cells, filter samples through 100 µm nylon mesh into 
appropriate tubes for acquisition on flow cytometer. 
 
15.  Acquire and record data for samples on a flow cytometer, with an appropriate laser for 
excitation and filter sets for emission of Alexa Fluor 488 (488 nm blue laser and 530/30 nm 
bandpass filter). For acquisition enable collection of the following parameters: Forward 
Scatter (FSC)-Area, FSC-Width, Side scatter (SSC)-Area, and Area, Height and/or Width 
parameters as available on individual cytometers, for emission of Alexa Fluor 488. 
 
16.  Analyse data by first creating a SSC-Area vs FSC-Area bi-variate plot (dot-plot) and create 
a scatter gate around the main cell population to exclude debris and outlying large events 
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(Fig 1.A or Fig 2.A). Plot scatter gate events using a FSC-Width vs FSC-Area dot-plot and 
create a singlet gate to exclude cell doublets (Fig 1.B or Fig 2.B).  
 
17.  a. For BMMs, plot singlet gate events on an ASC-Height vs ASC-Area dot-plot and create a 
gate to define cells with a high ASC-Height:ASC-Area profile (High H:A) to quantify the 
percentage of cells that have an ASC speck (Fig 1.C).  
 
b. For PBMCs, plot singlet gate events in a univariate (histogram) plot of ASC-Area and apply a 
marker region to define the high ASC-expressing cells (Fig 2.C) that contains the monocyte 
population (Sester et al., 2015). Plot high-ASC expressing cells on an ASC-Height vs ASC-Area 
dot-plot and create a gate to define cells with a high ASC-Height:ASC-Area profile (High H:A) to 
quantify the percentage of cells that have an ASC speck (Fig 2.D).   
 
Discriminating speck-positive cells can be done with either an ASC-Height vs ASC-Area plot or an 
ASC-Width vs ASC-Area plot (see Fig 3). The apparent discrepancy in ASC-Area between speck-
containing and non-containing cells is due to differential retention of ASC during fixation (see 
Anticipated Results). 
 
 
BASIC PROTOCOL 2 
ASSESSMENT OF ASC SPECK FORMATION IN HEK293T CELLS RECONSTITUTED 
WITH FLUORESCENTLY TAGGED INFLAMMASOME COMPONENTS 
HEK293T cells do not express components of the inflammasome, and are therefore useful host cells 
for introduction of expression constructs for native, tagged or mutated proteins, to determine their 
capacity to interact and form inflammasome structures. These cells do not express caspase-1 or 
undergo pyroptotic death, and consequently remain viable for many hours after generation of an 
ASC speck. This technique can be used to (i) investigate candidate inflammasome-initiating 
proteins for their capacity to interact with ASC and induce a speck; (ii) investigate protein-protein 
interactions required in formation of inflammasomes, using transfected mutants. In normal 
macrophages, inflammasome initiators remain in an inactive state until the cell encounters an 
appropriate stimulus that induces their clustering, and subsequent recruitment of ASC.  However, 
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when inflammasome proteins are overexpressed in HEK293T cells this can lead to ASC speck 
formation without application of known inflammasome stimuli. Expression of ASC alone leads to 
formation of an ASC speck when its expression level exceeds a defined threshold (Sester et al., 
2015). The co-expression of initiator proteins such as NLRP3 and AIM2 greatly lowers the 
threshold of ASC expression at which ASC specks form. In the case of AIM2, this could involve 
recognition of cytosolic transfected plasmid, although spontaneous self-association is thought to 
play a role (Morrone et al., 2015). In the case of NLRP3, overexpression itself may lead to 
spontaneous clustering, but it is also possible that cell stress induced by transfection plays a role. 
The probability of oligomerization of the inflammasome components depends on their 
concentrations within the cell. Consequently flow cytometry is an ideal technique for comparing 
speck-initiating potential of proteins, as the level of the relevant proteins can be monitored on a 
single cell basis. In this protocol, HEK293T cells are transiently co-transfected with expression 
constructs for EGFP-tagged ASC and a mCherry-tagged candidate inflammasome initiator. The 
mCherry tag facilitates gating and analysis of cells expressing similar levels of different protein 
constructs, allowing accurate comparison of their speck-initiating potential. The disadvantage of 
this technique is that with transient co-transfection of both tagged expression constructs their levels 
of expression within individual cells tend to correlate. This issue can be resolved by the 
introduction of candidate inflammasome initiators by transient transfection into HEK293T cells 
stably expressing ASC-EGFP, as then the expression level of the two constructs is independent. 
Methods for this assay, which represents the state of the art, are presented in Alternative Protocol 2 
and Support Protocol 2. However, this Basic Protocol is presented first as it requires no preparation 
of stable cell lines, and if properly analysed can be very informative. 
 
Materials 
HEK293T or HEK293 cells 
Complete DMEM with and without antibiotics (see recipe) 
Mammalian expression vectors (prepared in pEF6 plasmid using the EF-1α 
promoter [e.g., Invitrogen]) for: 
mCherry 
Human NLRP3-mCherry or other candidate genes fused to mCherry 
Human ASC-EGFP (ASC with EGFP fused to its C-terminal) 
OptiMEM (e.g., Thermo Fisher Scientific) 
Lipofectamine 2000 (e.g., Thermo Fisher Scientific) 
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Cell dissociation buffer (see recipe) 
Cell counter 
Tissue culture-treated flat-bottom 24-well plate 
Tissue culture incubator, humidified and set at 37°C with 5% CO2 
Centrifuge with plate-spinning capacity 
100-µm Nitex nylon mesh (e.g., Genesee Scientific, cat. no. 57-103) or equivalent 
5-ml polypropylene or polystyrene round-bottom tubes as appropriate for flow cytometer 
Flow cytometer with 488-nm and 561-nm lasers and appropriate filter configurations 
Software for analysis and graphing of flow cytometry data 
HEK293T cells  
 
Transient transfection of HEK293T cells 
1. Culture HEK293T cells in log-phase. Harvest cells by squirting off the plate with a 10 ml pipette 
and count. Plate cells in complete DMEM medium lacking antibiotics at a density of 4 x 105 
cells/ml in 0.5 ml in a 24-well plate, for triplicate transfections. Include wells for single transfection 
controls (ASC-EGFP only, mCherry only) and an un-transfected control. Incubate for a minimum 
of 5 hours before transfecting. 
Results are shown here with HEK293T cells. Optimal plasmid concentrations may differ 
with HEK293 cells.  
2. Prepare DNA-Lipofectamine transfection complexes. 
 
a. Dilute 10 ng pEF6-ASC-EGFP combined with either 100 ng pEF6-mCherry, pEF6-NLRP3-
mCherry, or pEF6 expression vectors for candidate inflammasome initiators fused to mCherry in 50 
µl OptiMEM. 
 
ASC-EGFP is shown here as ASC with EGFP fused to its C-terminal. N-terminal fusions 
are also possible. 
 
b. Dilute 0.3 µl Lipofectamine 2000 in 50 µl OptiMEM. Mix and incubate 5 min at 
room temperature. 
 
c. Combine the diluted DNA and diluted Lipofectamine, mix gently, and incubate 
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20 to 30 min at room temperature. 
 
Volumes are listed here as amounts per well, and should be scaled up to prepare a master mix for 
replicate wells. 
 
Also prepare transfection mixes similarly for single transfection controls, keeping the total amount 
of plasmid constant: ASC-EGFP only (10 ng pEF6-ASC-EGFP with 100 ng 
pEF6-empty vector) and mCherry only (100 ng pEF6-mCherry with 10 ng pEF6). 
 
This procedure can also be performed with native proteins or other epitope tags if antibodies are 
available for detection. In this case, fixation and staining can be done using procedures provided in 
Basic Protocols 1 and 3.  
3. Remove 300 µl of culture medium from each well and add 100 µl of the DNA-Lipofectamine 
complexes per well, mix gently by rocking the plate to distribute DNA-Lipofectamine complexes 
evenly over cell monolayers. Transfect triplicate wells, keeping one well of cells un-transfected as a 
control. 
4. Centrifuge plate(s) 10 min at 1000 x g, room temperature, then incubate for 16 h at 37°C.  
Centrifugation of plates following the addition of DNA-Lipofectamine complexes will improve 
delivery of DNA-Lipofectamine complexes to cells increasing transfection efficiency (Stacey et al., 
2016; Verma et al., 1998). If this centrifugation step is not included, then optimal DNA 
concentrations for transfection are likely to be higher than suggested here and will require testing. 
Cell Harvesting and Flow Cytometry  
5. After overnight incubation, remove medium and add 0.3 ml of chilled Cell Dissociation Buffer to 
each well. Incubate 5 min with plate on ice, and remove cells from wells by gently pipetting up and 
down. Filter samples through 100 µm nylon mesh, to remove any large clumps of cells, into 
appropriate tubes for acquisition on flow cytometer. Store samples on ice until ready to perform 
flow cytometric analysis.  
6. Analyze cells using a flow cytometer with appropriate lasers to excite both EGFP (488 nm laser) 
and mCherry (560 nm laser) fluorescence, and filter setup to isolate the emission of the two 
fluorescent proteins (EGFP – 530/30 nm bandpass filter, mCherry – 620/30 nm bandpass filter) 
with appropriate compensation. Collect the following parameters: Forward Scatter (FSC)-Area, 
FSC-Width, Side Scatter (SSC)-Area, EGFP-Area, EGFP-Width, EGFP-Height, mCherry-Area. 
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Analyse un-transfected and single fluorescent protein transfection controls along with co-
transfections.  
The emission profile of mCherry is such that there should be no requirement for compensation of 
spillover into the EGFP detection channel, however compensation will be required for removing 
EGFP spillover into the mCherry detection channel. 
Note: Area is equivalent to integral, and width is equivalent to TOF on some cytometers. Whether 
analysis using ASC-EGFP-Width or ASC-EGFP-Height vs ASC-EGFP-Area gives the best result 
needs to be determined for individual cytometers, and so both width and height parameters should 
be collected where possible.  
Data Analysis 
7. Analyse data by first creating a SSC-Area vs FSC-Area bivariate plot (dot-plot) and create a 
scatter gate around the main cell population to exclude debris and outlying large events (Fig 3.A). 
Copy scatter gate to all samples. Plot scatter gate events using a FSC-Width vs FSC-Area dot-plot 
and create a singlet gate to exclude cell doublets (Fig 3.B). Copy singlet gate to all samples. 
8. Plot singlet gate events on a mCherry-Area vs ASC-EGFP-Area dot-plot and set quadrants based 
upon the empty vector-transfected cells. Copy quadrants to all samples to define the single 
fluorescent protein-positive events (Q1:Upper Left quadrant and Q3:Lower Right quadrant) and 
double-positive fluorescent protein events (Q2:Upper Right quadrant) (Fig 3.C).  
Apply appropriate compensation to correct for spectral spillover from ASC-EGFP into the mCherry 
detection channel at this stage if not previously applied during acquisition of data.  
9. Plot double-positive fluorescent protein events (Q2/ Upper Right Quadrant) from the sample co-
transfected with ASC-EGFP and mCherry (not tagged to an inflammasome initiator) on a ASC-
EGFP-Width vs ASC-EGFP-Area dot-plot (Fig 3.D).  Create a spontaneous speck-negative gate to 
exclude cells that express ASC-EGFP (ASC-EGFP-Area) at a level where spontaneous specks form 
in cells (the speck-positive cells are those with a low ASC-EGFP-Width:ACS-EGFP-Area profile) 
(Fig 3D.). Copy this gate to all samples.  
Note: The spontaneous speck-negative gate should be defined with the sample in which ASC-EGFP 
and mCherry not tagged to an inflammasome initiator are co-transfected as these cells have no 
inflammasome initiating protein and speck formation in this sample is spontaneous at high levels of 
ASC-EGFP expression. 
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Note: Amounts of plasmids transfected may need to be optimized in individual labs to achieve an 
appropriate level of transfection, so that ASC expression is adequate but spontaneous ASC specks 
are minimised.  
10. Plot events from the spontaneous speck-negative gate with a mCherry-Area vs ASC-EGFP-Area 
dot-plot and create three gates to define subpopulations of low, medium and high expression of 
mCherry/mCherry-tagged inflammasome initiators (Fig 3.E). Copy low-,medium- and high-
mCherry expression gates to all samples. 
Confirm for all samples that reasonable numbers of cells fall within each of these three gates.  
11. To determine the percentage of speck-positive cells in these subpopulations, plot cells from the 
low-,medium- and high-mCherry gates on a ASC-EGFP-Width vs ASC-EGFP-Area dot plot. 
Create a gate defining cells with a low ASC-EGFP-Width:ASC-EGFP-Area profile (Low W:A) 
(Fig 3.F). Copy this Low W:A gate to the three mCherry expression level subpopulations in all 
samples.  
As per step 9, analysis by height:area or width:height may be superior on some cytometers.  
9. Using a suitable graphing program such as GraphPad Prism, plot the percentage of ASC-EGFP 
speck+ cells within the subpopulations with low, medium, and high expression of mCherry and 
NLRP3-mCherry (Fig. 2G). Note that all potential inflammasome initiator proteins included in the 
analysis should be expressed at very similar levels within the subpopulations of low, medium, and 
high expression of mCherry, as assessed by the mean fluorescence intensity (MFI) for mCherry-
Area within each population (Fig. 2G). Similarly, to confirm that potential inflammasome initiator 
proteins included in the analysis are not having selective effects on the level of ASC-EGFP, the 
MFI for ASC-EGFP-Area should be examined for each subpopulation (Fig 2G). 
 
ALTERNATE PROTOCOL 2 
ASSESSMENT OF CANDIDATE INFLAMMASOME INITIATORS BY TRANSIENT 
EXPRESSION IN HEK293T CELLS WITH STABLE EXPRESSION OF ASC-EGFP  
This method is alternative to Basic Protocol 2, and similarly provides a means to identify 
inflammasome-initiating proteins, or investigate their interaction with ASC through targeted 
mutagenesis. Unlike Basic Protocol 2 where transient co-transfection of ASC and inflammasome 
initiator constructs results in correlated levels of expression of the two proteins, this alternative 
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protocol relies on transfection of mCherry-tagged initiator proteins into cells stably expressing a 
more uniform level of ASC-EGFP. Since both the level of the inflammasome initiator and the level 
of ASC affect the probability of speck formation, this method provides superior data to Basic 
Protocol 2, as the levels of expression of the two proteins vary independently within the cell 
population. This makes the analysis more straightforward. However, this does of course require 
stable transfection of HEK293T cells with ASC-EGFP, as described in Support Protocol 2. 
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Materials 
All materials as per Basic Protocol 2 
HEK293T cells stably expressing ASC-EGFP (see Support Protocol 2) 
 
Transient transfection of HEK293T cells expressing ASC-EGFP 
1. Culture HEK293T and HEK293T:ASC-EGFP in log-phase. Harvest cells by squirting off the 
plate with a 10 ml pipette and count. Plate HEK293T:ASC-EGFP cells in complete medium without 
antibiotics at a density of 4 x 105 cells/ml in 0.5 ml in a 24-well plate, for triplicate transfections. 
Include 2 wells of HEK293T for mCherry only and un-transfected controls. Incubate for a 
minimum of 5 hours before transfecting. 
2. Prepare DNA-Lipofectamine transfection complexes. 
 
a. Dilute 100 ng pEF6-mCherry, pEF6-NLRP3-mCherry, or pEF6 expression vectors for candidate 
inflammasome initiators fused to mCherry in 50 µl OptiMEM. 
 
b. Dilute 0.3 µl Lipofectamine 2000 in 50 µl OptiMEM. Mix and incubate 5 min at room 
temperature. 
 
c. Combine the diluted DNA with the diluted Lipofectamine, mix gently, and incubate for 20 to 30 
min at room temperature. 
 
Volumes are listed here as amounts per well and should be scaled up as appropriate to prepare a 
master mix for replicate wells. 
 
Allow for one extra sample of 100 ng pEF6-mCherry to transfect a well of HEK293T cells as a 
single fluorescent protein control. 
 
3. Remove 300 µl of culture medium from each well and add 100 µl of DNA-Lipofectamine 
complexes per well. Transfect triplicate wells of HEK293T:ASC-EGFP.  
Also transfect one well of HEK293T with pEF6-mCherry. Keep one well of HEK293T, and one well 
of HEK293T:ASC-EGFP, as un-transfected controls. 
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4. Centrifuge plates 10 min at 1000 x g, room temperature then incubate for 16 h at 37°C.  
Centrifugation of plates following the addition of DNA-Lipofectamine complexes will improve 
delivery of DNA-Lipofectamine complexes to cells increasing transfection efficiency (Stacey et al., 
2016; Verma et al., 1998). If this centrifugation step is not included, then optimal DNA 
concentrations for transfection are likely to be higher than suggested here and will require testing. 
Cell Harvesting and Flow Cytometry  
5. After overnight incubation,remove medium and add 0.3 ml of chilled Cell Dissociation Buffer to 
each well. Place the plate on ice and gently pipette the cells off the bottom of the well to resuspend. 
Filter samples through 100 µm nylon mesh, to remove any large clumps of cells, into appropriate 
tubes for acquisition on flow cytometer. Store samples on ice until ready to perform flow 
cytometric analysis.  
6. Analyze cells using a flow cytometer with appropriate lasers to excite both EGFP (488 nm laser) 
and mCherry (560 nm laser) fluorescence, and filter setup to isolate the emission of the two 
fluorescent proteins (EGFP – 530/30 nm bandpass filter, mCherry – 620/30 nm bandpass filter) 
with appropriate compensation. Collect the following parameters: Forward Scatter (FSC)-Area, 
FSC-Width, Side Scatter (SSC)-Area, EGFP-Area, EGFP-Width, EGFP-Height, mCherry-Area. 
Analyse un-transfected HEK293-T, pEF6-mCherry-transfected HEK293-T, un-transfected 
HEK293-T:ASC-EGFP, pEF6-mCherry-transfected and pEF6-mCherry-fusion protein transfected 
HEK293-T cells.    
The emission profile of mCherry is such that there should be no requirement for compensation of 
spillover into the EGFP detection channel, however compensation will be required for removing 
EGFP spillover into the mCherry detection channel. 
Note: Area is equivalent to integral, and width is equivalent to TOF on some cytometers. Whether 
analysis using ASC-EGFP-Width or ASC-EGFP-Height vs ASC-EGFP-Area analysis gives the best 
result needs to be determined for individual cytometers, and so both width and height parameters 
should be collected where possible.  
Data Analysis 
7. Analyse data by first creating a SSC-Area vs FSC-Area bivariate plot (dot-plot) and create a 
scatter gate around the main cell population to exclude debris and outlying large events (Fig 3.A). 
Copy scatter gate to all samples. Plot scatter gate events using a FSC-Width vs FSC-Area dot-plot 
and create a singlet gate to exclude cell doublets (Fig 3.B). Copy singlet gate to all samples. 
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8. Plot singlet gate events using a mCherry-Area vs ASC-EGFP-Area dot-plot and set quadrants 
based upon the un-transfected HEK293T control sample. Copy quadrants to all samples to define 
the single fluorescent protein-positive events (Q1:Upper Left quadrant and Q3:Lower Right 
quadrant) and double-positive fluorescent protein events (Q2:Upper Right quadrant) (Fig 4.A). 
Confirm appropriate compensation using pEF6-mCherry-transfected HEK293T and un-transfected 
HEK293T:ASC-EGFP samples. 
Apply appropriate compensation to correct for spectral spillover from ASC-EGFP into the mCherry 
detection channel at this stage if not previously applied during acquisition of data.  
Note that the fluorescence profile of ASC-EGFP will be different, compared to the transiently 
transfected cells shown in Figure 3, as the majority of cells are now expressing a uniform level of 
ASC-EGFP, and there is no correlation between ASC-EGFP and mCherry/mCherry-fusion protein 
expression (compare Fig 3.C and Fig 4.A). 
9. Using the same mCherry-Area vs ASC-EGFP-Area dot-plot, create three gates to define 
subpopulations of low, medium and high expression of mCherry/mCherry-fusion proteins (Fig 
4.A). Copy low-,medium- and high-mCherry expression gates to all samples. 
Confirm for all samples that reasonable numbers of cells fall within each of these three gates.  
10. To determine the percentage of speck-positive cells in these subpopulations, plot cells from the 
low-,medium- and high-mCherry gates on a ASC-EGFP-Width vs ASC-EGFP-Area dot-plot (Fig 
4.B). Create a gate defining cells with a low ASC-EGFP-Width:ASC-EGFP-Area profile (Low 
W:A) (Fig 4.B-C). Copy this Low W:A gate to the three mCherry expression level subpopulations 
from all samples.  
Identification of speck-positive cells may be superior from a plot of height:area or width:height on 
some flow cytometers. 
SUPPORT PROTOCOL 2  
GENERATION OF STABLE HEK293T LINES EXPRESSING ASC-EGFP 
This protocol outlines the generation of a stable HEK293T line expressing ASC-EGFP, as used in 
Alternate Protocol 2.  
Additional Materials (also see Basic Protocol 2) 
 
Blasticidin (or another antibiotic suitable for the expression vector used) 
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Cell freezing medium: 90% (v/v) HI-FCS/10% (v/v) DMSO 
Tissue culture-treated 10-cm plates 
Tissue culture-treated flat-bottom 6-well plates 
Cell freezing containers (e.g., Thermo Fisher Scientific) 
Liquid nitrogen, for long-term storage 
 
Generation of stable HEK293T lines expressing ASC-EGFP 
1. Culture HEK293T cells in log-phase. Harvest cells by squirting off the plate with a 10 ml pipette 
and count. Plate cells in HEK293T complete DMEM without antibiotics at a density of 1 x 105 
cells/ml in 10 ml medium in 10 cm dishes. Incubate for a minimum of 5 hours before transfecting. 
2. Prepare DNA-Lipofectamine transfection complexes for each 10-cm dish. 
 
a. Dilute 10 µg pEF6-ASC-EGFP in 1.5 ml OptiMEM. 
 
b. Dilute 20 μl Lipofectamine 2000 in 1.5 ml OptiMEM, and incubate 5 min at room temperature. 
 
c. Combine the dilutedDNAwith the diluted Lipofectamine, mix gently, and incubate 
20 min at room temperature.  
3. Add 3 ml of the combined transfection mix to the dish, gently swirl dish to evenly distribute 
complexes over cell monolayer and incubate for 24 h.  
4. After 24 h, carefully remove medium and replace with 10 ml of fresh complete DMEM, and 
incubate for a further 24 h. 
5. At 48 h post-transfection, remove medium and replace with 10 ml complete DMEM 
supplemented with 4 µg/ml blasticidin, or other suitable selective antibiotic at a concentration 
optimized for HEK293T cells. 
Note: treat a dish of un-transfected HEK293T with the same concentration of antibiotic in parallel, 
to monitor the selection rate. If the control dish shows no sign of cell death after 48 h, increase the 
concentration of the antibiotic in the control and transfected dishes. 
6. Monitor the selection, replacing medium with selective antibiotic every 2-3 days. Once all the 
un-transfected cells have been eliminated, small colonies of stably transfected cells will appear. 
 
 
198 
Allow them to grow for several days until they are visible with the naked eye, but do not allow the 
colonies to merge.  
7. When the colonies have grown sufficiently, pick individual colonies with a P200 pipettor and 
transfer into separate wells of a 6-well plate. Maintain under selection and keep splitting frequently, 
until the cells stop dying and the clones stabilize. 
Note: As over-expression of ASC-EGFP produces aggregates that are toxic to cells, it may take up 
to 6 weeks under selection for the clones to stabilize at a level of ASC-EGFP expression that is well 
tolerated. The level of spontaneous specks will stabilize at less than 2%. 
8. Refer to Alternate Protocol 2 to perform transient transfection/flow cytometric analysis of clones 
with and without NLRP3-mCherry expression vector to screen for appropriate clones that have a 
low baseline of spontaneous specks and high percentage of speck-positive cells following NLRP3-
mCherry expression. Useful clones will display a baseline level of spontaneous speck-positive cells 
of less than 5% of cells and a substantial increase in speck-positive cells following NLRP3-
mCherry transfection (up to 80% of ASC-EGFP/NLRP3-mCherry double-positive cells being 
speck-positive).  
9. Cryopreserve the selected stable clones by freezing 3 x 106 cells per 1 ml cryovial in 90% HI-
FCS/10% DMSO in a -80˚C freezing container before transferring to liquid nitrogen for long-term 
storage. 
 
BASIC PROTOCOL 3 
ASSESSMENT OF RECRUITMENT OF PROCASPASES TO ASC SPECKS IN 
RECONSTITUTED HEK293 CELLS 
Procaspase 1 and procaspase 8 are recruited to ASC specks formed in HEK293 cells. Although in 
macrophages undergoing inflammasome responses, the native procaspases do not necessarily 
completely move to localize with the ASC speck, under conditions of overexpression of 
components in HEK293 cells, procaspases can become completely speck associated. Consequently 
the TOFIE analysis can be applied not only to ASC, but also to analyse the movement of 
procaspases in HEK293. This can be useful for studies of protein-protein interaction, and 
investigation of structural determinants required for procaspase recruitment. The method described 
is optimized to study the recruitment of procaspase 8 to ASC specks. Conditions are optimized for 
formation of spontaneous ASC specks, without need for an inflammasome initiating protein. In this 
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particular application ASC-EGFP is unable to recruit procaspase 8, presumably due to steric 
hindrance caused by the EGFP tag, and hence here untagged ASC is expressed and stained with 
anti-ASC antibody. Overall this protocol demonstrates that the general principles of TOFIE can be 
extended to other proteins that can exist in either diffuse or localized states within a cell. 
Materials 
HEK293 or HEK293T cells 
Complete DMEM with and without antibiotics (see recipe) 
Plasmids: 
pcDNA3.1 empty vector 
pcDNA3.1 expressing human ASC (pcDNA-ASC) 
pcDNA3.1 expressing catalytically inactive procaspase 8 (C360S) with a 
C-terminal myc tag (pcDNA-Casp8[C360S]-Myc) 
Additive-free DMEM or OptiMEM (e.g., Thermo Fisher Scientific) 
Lipofectamine 2000 (e.g., Thermo Fisher Scientific) 
Dulbecco’s modified PBS (DPBS), without calcium or magnesium (e.g., Thermo 
Fisher Scientific, cat. no. 14190) 
100% ethanol 
Flow BLOCK (see recipe) 
Flow PERM (see recipe) 
Rabbit polyclonal anti-ASC N-15 antibody (e.g., Santa Cruz, cat. no. sc-22514-R) 
Mouse anti-myc 9B11 antibody (e.g., Cell Signaling Technology, cat. no. 2276) 
Flow WASH (see recipe) 
Goat anti-mouse (H+L) Alexa Fluor 647 (e.g., Thermo Fisher Scientific, cat. no.A21236) 
Goat anti-rabbit (H+L) Alexa Fluor 488 (e.g., Thermo Fisher Scientific, cat. no.A11008) 
Tissue culture-treated flat-bottom 12-well plates 
Tissue culture incubator, humidified and set at 37°C with 5% CO2 
Centrifuge with plate-spinning capacity 
15-ml polypropylene conical centrifuge tubes 
1.5-ml microcentrifuge tubes 
100-µm Nitex nylon mesh (e.g., Genesee Scientific, cat. no. 57-103) or equivalent 
5-ml polypropylene or polystyrene round-bottom tubes as appropriate for flow cytometer 
Flow cytometer with 488-nm and 640-nm lasers and appropriate filter configurations 
Software for analysis and graphing of flow cytometry data 
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Transient transfection of HEK cells 
1. Grow HEK293 cells in log phase in complete DMEM medium. Plate 1 ml of HEK293 cells in 
complete DMEM medium without antibiotics at a density of 2 x 105 cells/ml in a 12-well plate and 
incubate overnight at 37°C. 
Results shown here are from HEK293 cells. Optimal plasmid concentrations may differ in 
HEK293T cells.  
2. Prepare DNA-Lipofectamine transfection complexes. 
 
a. Dilute 50 ng pcDNA-ASC, 50 ng pcDNA-Casp8(C360S)-Myc, and 700 ng empty vector 
(pcDNA3.1+) in 100 µl additive-free DMEM. 
 
b. Dilute 2 µl Lipofectamine 2000 in 100 µl additive-free DMEM. Mix gently and incubate 5 min at 
room temperature. 
 
c. Combine the diluted DNA and diluted Lipofectamine. Mix gently and incubate 20 to 30 min at 
room temperature. 
 
Volumes are listed here as amounts per well and should be scaled up to prepare a master mix for 
replicate wells. 
 
Include wells for empty vector (800 ng pcDNA3.1+) and single transfection controls for both ASC 
(50 ng pcDNA-ASC and 750 ng empty vector [pcDNA3.1+]) and Myc-tagged procaspase 8 (50 ng 
pcDNA-Casp8[C360S]-Myc and 750 ng empty vector [pcDNA3.1+]). 
 
Using these conditions with carrier empty plasmid provides an appropriate level of transfection 
and ASC speck numbers.  
 
3. Remove 500 µl of culture medium and then add 200 µl of DNA-Lipofectamine transfection 
complexes per well, mix gently by rocking the plate to distribute DNA-Lipofectamine complexes 
evenly over cell monolayers.  
4. Following addition of DNA-Lipofectamine complexes centrifuge plate(s) 10 min at 1000 x g, 
room temperature and incubate 16 h at 37°C.  
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Note: centrifugation of plates following the addition of DNA-Lipofectamine complexes will improve 
delivery of DNA-Lipofectamine complexes to cells increasing transfection efficiency (Stacey et al., 
2016; Verma et al., 1998). If this centrifugation step is not included, then optimal DNA 
concentrations for transfection are likely to be higher than suggested here and will require testing. 
5. After overnight incubation (16 hr), remove medium from wells and add 250 µl of room 
temperature DPBS to each well. Incubate 5 min at room temperature and remove cells from wells 
by gently pipetting up and down. Transfer cells to a 15 ml tube. 
Cells can be alternatively transferred and processed in 1.5 ml microfuge tubes. However, it should 
be noted that more care is required when removing supernatants from ethanol-fixed cells following 
centrifugation in fixed angle microfuges compared to pellets generated in swing-out centrifuges.  
Fixation and immunostaining of cells 
6. Add 1 ml (4 volumes) of 100% ethanol, and incubate 15 min at room temperature to fix cells. 
Before fixing by addition of ethanol, the cells must have been thoroughly and recently resuspended 
to obtain a single cell suspension.  
7. Pellet cells at 500 x g for 5 min, at room temperature. Aspirate supernatant, resuspend the cell 
pellet in 1 ml of Flow BLOCK and re-centrifuge 5 min at 500 x g, room temperature for.  
8. Thoroughly resuspend the cell pellet in 100 µl of Flow PERM and incubate 15 min at room 
temperature to permeabilise cells and effectively block for further antibody staining. 
9. Prepare primary antibody dilutions. 
 
a. Aliquot sufficient Flow PERM into a 1.5-ml microcentrifuge tube to allow 100 µl for each 
sample. 
 
b. Dilute the anti-ASC antibody 1:750 into the Flow PERM solution and the anti- Myc antibody 
1:500 into the same tube. 
 
c. Centrifuge 3 min at 17,000 × g, room temperature to remove any aggregates. 
 
d. Prepare appropriate volumes of the individual antibodies at the same dilutions for staining the 
single color controls. 
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e. Add 100 µl of the diluted primary antibodies to 100 µl resuspended cells, mix, and incubate 1 hr 
at room temperature. Mix samples every 15 to 30 min by gently flicking the microcentrifuge tube as 
the cells tend to settle. 
 
10. Add 1 ml of Flow WASH to tubes, mix by pipetting, and then centrifuge samples 5 min at 500 x 
g, room temperature.  
11. Prepare the secondary antibody dilutions. 
 
a. Aliquot sufficient Flow PERM into a tube to allow 200 µl for each sample. 
 
b. Dilute the goat anti-mouse Alexa Fluor 647 and goat anti-rabbit Alexa Fluor 488 both at 1:10,000 
into the tube. 
 
c. Centrifuge 3 min at 17,000 × g, room temperature to remove any aggregates. 
 
d. Take the pelleted cells from step 10, aspirate supernatant, and resuspend cell pellets in 200 µl 
diluted secondary antibody solution. 
 
e. Incubate 30 min at room temperature. Mix samples by gentle flicking after 15 min to avoid 
settling of cells. 
 
12. Add 1 ml of Flow WASH, invert to mix and then pellet cells by centrifugation of samples for 5 
min at 500 x g, room temperature. 
13. Resuspend cell pellets in 200 µl of Flow WASH. Filter samples through 100 µm nylon mesh, to 
remove any large clumps of cells, into appropriate tubes for acquisition on flow cytometer.  
Flow Cytometry and Analysis 
14. Acquire and record data for samples on a flow cytometer with appropriate lasers for excitation 
and filter sets for emission of Alexa Fluor 488 (488 nm blue laser and 530/30 nm bandpass filter) 
and Alexa Fluor 647 (640 nm red laser and 675/25 nm bandpass filter). For acquisition enable 
collection of the following parameters: Forward Scatter (FSC)-Area, FSC-Width, Side scatter 
(SSC)-Area, as well as Area, Height and/or Width parameters as available on individual cytometers, 
for emission of both the fluorophores.  
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15. Analyse data by first creating a SSC-Area vs FSC-Area bivariate plot (dot-plot) and create a 
scatter gate around the main cell population to exclude debris and outlying large events (Fig 5.A). 
Plot scatter gate events using a FSC-Width vs FSC-Area dot-plot and create a singlet gate to 
exclude cell doublets (Fig 5.B). Plot singlet gate events on a Procaspase 8-Area vs ASC-Area dot-
plot and set quadrants based upon the empty vector transfected cells. Copy quadrant to other 
transfected samples to define the single positive events (Q1 and Q3) and double positive events Q2 
(Fig 5.C).  
Compensation for spectral overlap is not necessary with the fluorophores selected. 
16. Plot events from the defined quadrant gates for ASC single-positive cells (Q3), procaspase 8 
single-positive cells (Q1) and double-positive cells (Q2) using both ASC-Height vs ASC-Area and 
procaspase 8-Height vs  procaspase 8-Area (Fig 5.D). Within these height vs area plots, create a 
gate to define events with a high ASC Height:Area profile (High H:A) to quantify the percentage of 
cells that are ASC or procaspase 8 speck-positive (Fig 5.D)  
Discriminating speck-positive cells can be done with either an ASC-Height vs ASC-Area plot or an 
ASC-Width vs ASC-Area plot (see Fig 3). The apparent discrepancy in ASC-Area between speck-
containing and non-containing cells is due to differential retention of ASC during fixation (see 
Anticipated Results). 
 
REAGENTS AND SOLUTIONS 
 
Use Milli Q 0.2-µm-filtered water in all recipes and protocol steps. For common stock 
solutions, see APPENDIX 2A. 
 
ATP, 150 mM 
Reconstitute ATP (e.g., Sigma Aldrich, cat. no. A2383-1 G) in water at 150 mM. 
Aliquot in 1.5-ml microcentrifuge tubes in aliquots appropriate for single experiments, 
and store at −80°C. 
 
Use fresh or after no more than one freeze-thaw cycle. 
 
Cell dissociation buffer 
1× DPBS (without calcium or magnesium; e.g., Thermo Fisher Scientific, cat. no. 
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14200) 
1% HI-FCS (heat inactivated fetal calf serum) 
2 mM EDTA 
 
Keep sterile and store at 4°C for up to 12 months 
 
Complete DMEM 
DMEM supplemented with: 
1× GlutaMAX 
50 U/ml penicillin 
50 µg/ml streptomycin 
10% (v/v) HI-FCS 
Store at 4°C for up to 3 months 
 
For complete DMEM without antibiotics, omit penicillin and streptomycin. 
 
Complete RPMI-1640 
RPMI-1640 medium supplemented with: 
1× GlutaMAX 
50 U/ml penicillin 
50 µg/ml streptomycin 
25 mM HEPES 
10% (v/v) HI-FCS 
Store at 4°C for up to 3 months 
 
For complete RPMI-1640 without antibiotics, omit penicillin and streptomycin. 
Flow BLOCK 
1× DPBS (without calcium or magnesium; e.g., Thermo Fisher Scientific, cat. no. 
14200) supplemented with: 
3% (v/v) HI-FCS 
0.1% (w/v) bovine serum albumin (BSA; e.g., Sigma Aldrich, cat. no. A9647) 
0.1% (w/v) sodium azide (e.g., Sigma Aldrich) 
Store at 4°C for up to 18 months 
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Flow BLOCK can be prepared as a 500 ml stock by mixing 50 ml of 10× DPBS with 5 ml 
of 10% (w/v) sodium azide, 5 ml of 10% (w/v) BSA, and 15 ml HI-FCS. Stocks can then be 
made to 500 ml with water. 
 
Flow PERM 
1× DPBS (without calcium or magnesium; e.g., Thermo Fisher Scientific, cat. no. 
14200) supplemented with: 
3% (v/v) HI-FCS 
0.1% (w/v) BSA (e.g., Sigma Aldrich, cat. no. A9647) 
0.1% (w/v) sodium azide 
0.1 % (w/v) saponin (e.g., Sigma Aldrich, cat. no. S4521) 
Store at 4°C for up to 18 months 
 
Flow PERM can be prepared as a 500 ml stock by mixing 50 ml of 10× DPBS with 5 ml 
of 10% (w/v) sodium azide, 5 ml of 10% (w/v) BSA, 15 ml HI-FCS, and 5 ml of 10% (w/v) 
saponin. Stocks can then be made to 500 ml with water. 
 
Flow WASH 
1× DPBS (without calcium or magnesium; e.g., Thermo Fisher Scientific, cat. no. 
14200) supplemented with: 
0.2% (v/v) HI-FCS 
0.1% (w/v) BSA (e.g., Sigma Aldrich, cat. no. A9647) 
0.1% (w/v) sodium azide 
Store at 4°C for up to 18 months 
 
Flow WASH can be prepared as a 500 ml stock by mixing 50 ml of 10× DPBS with 5 ml of 
10% (w/v) sodium azide, 5 ml of 10% (w/v) BSA, and 1 ml HI-FCS. Stocks can then be made 
to 500 ml with water. 
 
LPS, 10 mg/ml 
Prepare a 10 mg/ml stock of Salmonella Minnesota Re595 LPS (e.g., Sigma Aldrich, 
cat. no. L9764) in DPBS with 0.1% (v/v) triethylamine. Sonicate and store at −20°C 
for up to 24 months. 
 
Note that this is not ultrapure LPS, but is adequate for inflammasome priming. 
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LPS, 10 µg/ml 
Prepare a 10 µg/ml stock of Salmonella Minnesota Re595 LPS by diluting 10 mg/ml 
LPS stock (see recipe) 1:1000 in RPMI-1640 with 10% (v/v) HI-FCS. Store at−20°C 
for up to 12 months. 
 
Nigericin, 5 mM 
To 5 mg of nigericin sodium salt (e.g., Sigma Aldrich, cat. no. N7143-5MG) in the 
original bottle, add 1.34 ml of 100% high-grade ethanol, replace lid tightly, and mix 
by inverting until dissolved. Store at 4°C, well-sealed with parafilm for up to 12 
months. 
Nigericin should be stored as a 5mM stock 
Nigericin, 100 µM 
Prepare a fresh 100 µM working stock by diluting the 5 mM nigericin stock (see 
recipe) 1:50 with complete RPMI-1640 and mix thoroughly. 
 
Paraformaldehyde (PFA), 8% 
Add 16 g paraformaldehyde to _160 ml water, and then heat to 50ºC while stirring. 
Once temperature reaches 50ºC, add 1 M NaOH until the paraformaldehyde is just 
dissolved. Make up to 200 ml with water, and adjust pH to between 7.2 and 7.4. 
Filter with 0.22-µm filter, and aliquot in 5-ml tubes. Label and freeze at −20°C for 
up to 24 months. 
 
Prepare solution in a fume hood. 
 
Paraformaldehyde (PFA), 4% 
Defrost 5 ml aliquot of 8% PFA (see recipe), add 3.2 ml water, and 0.8 ml of 
10× DPBS without calcium or magnesium (e.g., Thermo Fisher Scientific, cat. no. 
14200). Mix well and store at 4°C for up to 1 week. 
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COMMENTARY 
Background Information 
This protocol for time of flight inflammasome evaluation (TOFIE) complements other assessments 
of inflammasome function, but provides a superior means of quantifying ASC speck numbers over 
microscopic techniques. In addition it permits sophisticated analysis of reconstitution of 
inflammasome function taking into account levels of expression of components in individual cells. 
Native inflammasome activation is best assessed by a combination of several different methods 
rather than relying on a single measure. ELISA for released IL-1b is frequently used as a measure 
of inflammasome response. This alone cannot confirm inflammasome activation, since the 
antibodies used will generally recognize both pro-IL-1b and mature IL-1b. In addition, other routes 
of cleavage of IL-1b are documented (Netea et al., 2010), and so confirmation by other methods is 
required. Assessment of cleavage of both procaspase 1 and pro-IL-1b by western blot is a more 
definitive confirmation of inflammasome activation. Analysis should be done of both cell pellet and 
proteins released into the medium, since both these proteins are rapidly released upon cleavage. 
Pyroptotic cell death can be monitored as a response to inflammasome stimulus. This is useful, but 
fairly non-specific, since some agents induce cell death through multiple pathways simultaneously. 
Cells with genetic knockouts of inflammasome components can be used to confirm the pathway 
involved in either IL-1b release or cell death.  
The clustering of ASC, unlike many of the other measures discussed above, is uniquely associated 
with inflammasome activation. It provides a direct assessment of an early stage of the response that 
is amenable to analysis by several techniques. The movement of ASC from the soluble portion of 
cell extract into a dense speck can be assessed by centrifugation of cell extracts at 6000 x g 
followed by western blot, and self-association of ASC can be further confirmed using chemical 
cross-linking (Yin et al., 2013). Fluorescence microscopy provides valuable visual evidence for 
speck formation, but is not so readily quantified. The advantages of the described TOFIE assay for 
quantification of ASC speck formation include the objective assessment of large numbers of cells 
and elimination of manual counting. In addition, the flow cytometry format permits detection of 
native ASC speck formation within a minority of cells in a mixed population, and these can be 
defined by co-staining with specific lineage markers. Other parameters, such as cell staining with 
FLICA fluorescent caspase substrates could also be explored in combination with TOFIE. Flow 
sorting of inflammasome-containing cells is a further capacity enabled by this assay (Sester et al., 
2015). 
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The TOFIE assay can be exploited for analysis of inflammasome reconstitution in cells such as 
HEK293 that lack inflammasome components. Simultaneous with assessment of ASC speck 
formation, the relative expression levels of ASC and other inflammasome components can be 
determined within individual cells. This permits a properly controlled analysis of factors promoting 
inflammasome formation, which is not possible by microscopy. TOFIE analysis shows that with 
expression of ASC alone in HEK293 cells, specks are formed above a fairly sharp concentration 
threshold (Sester et al., 2015). Thus the observed total speck numbers depend on transfection 
efficiency and resulting levels of ASC expression. This may differ between experiments, and 
between samples in an individual experiment. By microscopy it is not possible to distinguish 
between ASC specks that are merely the result of high ASC expression in an individual cell, and 
those that may be induced by a stimulus or expression of another protein. Using TOFIE it is 
possible to only study cells expressing ASC at below the threshold for spontaneous speck 
formation, in order to focus on induced specks. Careful selection of an appropriate range of ASC 
expression thus removes the effect of variable transfection efficiency between samples or 
experiments.  
Co-expression, together with ASC, of inflammasome-initiating proteins such as AIM2, NLRP3, and 
NLRC4 promotes speck formation in a manner dependent on the concentration of the initiator. If 
aiming to compare the potency of different inflammasome initiators or effect of site-directed 
mutations, it is necessary to control for the expression level of the initiator. This can be done by 
expressing proteins as fusions with an appropriate fluorescent proteins such as mCherry (Basic 
Protocol 2) or by staining for an epitope tag. Comparisons of the potency of different initiators can 
be made by determining the percentage of cells with ASC specks falling within windows of defined 
initiator expression level (Basic Protocol 2). A more sophisticated analysis can be conducted by 
exporting the single-cell data into the R data analysis software and graphing cumulative percentage 
of speck-positive cells as a function of ASC-GFP expression or as a function of the mCherry-tagged 
inflammasome initiator expression level. This is an alternative to analyzing the subpopulations of 
low, medium, and high Cherry expression that will produce a characteristic curve plot and will 
allow visualization of the threshold of spontaneous and induced speck formation in the presence of 
mCherry and mCherry-tagged inflammasome initiators under consideration. A further application 
of the TOFIE method is to examine recruitment of caspases to the inflammasome speck. Basic 
Protocol 3 utilises a similar method to analyse localization of procaspase 8, since it is also 
quantitatively recruited into the speck when co-expressed in HEK293T cells together with ASC 
(Vajjhala et al., 2015). This permits investigation of structural requirements of both caspase 8 and 
ASC promoting this interaction. The latter protocol emphasizes that this technique can be 
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generalized to proteins exhibiting a change from diffuse to focal localization. Indeed, a similar 
technique has been used to look at aggregation of Huntingtin protein (Ramdzan et al., 2012). In 
summary, this is a versatile assay in which the power of flow cytometry can be harnessed to better 
quantify inflammasome responses on a single cell basis.  
 
Critical Parameters and Troubleshooting  
Instrumentation 
TOFIE assays have been conducted on a wide range of flow cytometers (Table 1). Most cytometers 
now allow pulse width and pulse height determination for fluorescence channels. One cytometer 
lacking fluorescence pulse width reporting is the BD Accuri C6. However, this flow cytometer is 
excellent at discriminating speck-positive cells using fluorescence peak height vs fluorescence peak 
area analysis. Due to the manners in which different flow cytometers/acquisition software programs 
detect, calculate/process and represent fluorescent pulse height area, height and width parameters, 
the resolution of machines for this assay varies. Available machines should be tested for whether it 
is optimal to use fluorescence height or width parameters, or both.  
Cell activation and handling 
Successful staining of native inflammasomes in primary cells is dependent on the timing of 
stimulus exposure and the rapid and effective fixation of cells. Excessively long exposure to 
stimulus or rough handling may compromise assay results due to the inherent fragility of cells 
undergoing pyroptosis. Loss of cell membrane integrity can be initiated within 5-10 minutes of 
inflammasome stimulus (Stacey et al., 2016). Whilst this signals the death of the cell, it does not 
indicate immediate disintegration and loss of identifiable speck-containing cells by flow cytometry. 
However, it does mean that handling of cells has to be gentle. Basic Protocol 1 has been optimized 
for minimal centrifugation and handling. Treatment of cells in suspension with inflammasome 
stimuli followed by fixation allows preservation of ASC specks within cells. If cells are treated with 
inflammasome stimuli whilst adherent to plastic, harvest of cells undergoing pyroptosis may be too 
rough to permit retention of the ASC speck. Short-term treatments can be done in polypropylene 
tubes. However some cells may stick to the tube, and incubation in poly-HEMA coated wells 
provides an alternative for longer incubations and quantitative recovery of cells. Macrophages are 
not dependent on adherence for viability. 
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Table 1. List of flow cytometers on which TOFIE assays have been conducted. 
 TOFIE Assay (Analysis Format) 
Analysers  
Accuri C6  Basic Protocol 1 BMMs and PBMCs (H:A) 
Basic Protocol 3 (H:A) 
Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (H:A) 
BD Accuri C6  Basic Protocol 1 BMMs and PBMCs (H:A) 
Basic Protocol 3 (H:A) 
Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (H:A) 
Beckman Coulter  
Gallios 
Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (H:A and W:A) 
 
Acea Biosciences  
NovoCyte 
Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (H:A) 
BD LSR II Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (W:A) 
BD Canto II Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (W:A) 
Basic Protocol 1 BMMs and PBMCs (W:A) 
Miltenyi Biotec 
MACSQuant 10 
Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (H:A) 
Sorters  
Beckman Coulter  
MoFlo Astrios EQ 
Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (H:A) 
BD Aria I/II Basic Protocol 1 BMMs (H:A) 
Single Colour ASC-EGFP TOFIE (Sester et al., 2015) (W:A) 
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BD Aria Fusion Casp 1-/- iBMM ASC-EGFP cell TOFIE (Sester et al., 2015) (H:A) 
 
 
Application to different sources of primary cells 
TOFIE has been applied to cells taken ex vivo such as PBMC and resident peritoneal cells, and 
stimulated in vitro (Sester et al., 2015). Whilst it is theoretically possible that the frequency of 
inflammasome activation with an in vivo stimulus could also be assessed by TOFIE, this is yet to be 
demonstrated. Pyroptotic cell fragility and in vivo clearance may present obstacles to such analysis, 
although it may be possible to bypass these problems by use of caspase 1-deficient animals. In 
addition, given the necessity for gentle handling noted above, it should not be expected that cells 
undergoing inflammasome activation could be detected following disruption of tissues with 
protease digestion or by mechanical means. In such cases histology is more likely to be successful 
for detection of ASC specks. TOFIE is a robust means of detecting ASC specks in cultured cells, 
but should not be used as the first means to determine that a novel cell population undergoes 
inflammasome activation, or to define novel inflammasome stimuli. In these cases, inflammasome 
activation should first be assessed by western blotting for caspase-1 and pro-IL-1b cleavage. In 
addition, ASC speck formation is only well characterized in macrophages. Although a number of 
other cell types are suggested to release cleaved IL-1b in an inflammasome-dependent manner, in 
general ASC clustering has not been confirmed. In novel cell types, speck formation should be 
confirmed by immunofluorescence staining and microscopy prior to attempting TOFIE.  
Selection of antibodies  
Any antibodies used need to have low background staining. Particularly when following 
fluorescence pulse width as an indication of ASC speck formation, an antibody with a significant 
broad background in the cell will confound speck detection. Background may be reduced by use of 
appropriate blocking agents such as antibodies to Fc receptors, BSA, and sera that are compatible 
with the antibodies being used for detection. 
Inflammasome stimulus strength, multiple ASC specks, and speck size 
Occasionally, high doses of inflammasome-inducing stimuli result in a significant number of 
primary macrophages with multiple ASC specks observed by microscopy. This would presumably 
lessen the sensitivity of both width and height parameters for speck detection, and would decrease 
resolution of populations. Consequently higher doses of stimuli may not always increase detected 
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speck numbers. ASC specks formed in HEK293 cells with overexpression of inflammasome 
components are significantly larger native specks in primary macrophages. However, TOFIE is still 
effective at detecting these, using both width and height parameters (Fig 3,4,5). Even ASC 
mutations that cause a significantly less condensed speck structure when expressed in HEK293 still 
yield specks detectable by Height:Area analysis (Vajjhala et al., 2015). It is anticipated that pulse 
width analysis may be less effective for larger irregular specks. 
Selection of fluorophores and compensation 
If multi-colour analysis is done, selection of compatible fluorophores is very important. The priority 
is to analyse ASC speck formation in a channel not subject to bleed-through from other 
fluorophores. Interfering fluorescence from a second label that is diffusely located in the cell could 
compromise assessment of ASC fluorescent peak width. In Basic Protocol 2 and Alternative 
Protocol 3, ASC is tagged with EGFP and an inflammasome initiator with mCherry. This 
combination is ideal because mCherry fluorescence does not bleed into the optimal channel for 
EGFP detection. Compensation can be applied to account for the bleed through of EGFP into the 
mCherry channel. For antibody-mediated detection as done in Basic Protocols 1 and 3, selection of 
Alexa fluor 488 for ASC detection is optimal, as a range of fluorophores that do not bleed into this 
channel are available. 
  
Sorting ASC speck-containing cells 
An extension of the TOFIE methodology is the sorting of ASC speck-positive cell populations, 
which maybe of particular use in functional screens relating to inflammasome formation. Successful 
sorting of BMMs immunostained as per Basic Protocol 1 has been achieved using ASC-Width vs 
ASC-Height analysis on a BD FACS Aria system (Sester et al., 2015). Cell sorting of ASC speck-
positive cells has also been applied to HEK293 cells reconstituted with ASC-EGFP using ASC-
Width vs ASC-Area analysis on a Beckman Coulter Astrios EQ cell sorter. Finally, sorting of 
speck-positive Casp1-/- immortalized BMM expressing ASC-EGFP (Sester et al., 2015) has been 
conducted using ASC-Height vs ASC-Area analysis on a BD Aria Fusion. In 
summary, successful sorting has been accomplished on both cuvette-based and jet-in-air sorters 
using a number of TOFIE-based cellular assays.  
 
Anticipated Results 
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The Basic Protocol 1 permits analysis of native ASC specks in primary cells by immunostaining for 
ASC. This has been used successfully following in vitro stimulation of murine BMM, murine 
resident peritoneal cells, and human PBMC (Sester et al., 2015). The results shown here are for 
analysis of the Height:Area profile for ASC immonufluorescence on an Accuri C6 flow cytometer 
(Fig. 1 and 2). Cells containing ASC specks can be clearly seen as a population with an increased 
Height:Area ratio profile (Fig 1.C and Fig 2.D). Note that for some other machines, use of the width 
parameter to facilitate Width:Area or Width:Height profile analysis may be superior to Height:Area 
profile analysis. In Fig. 1C, the cells lacking an ASC speck generally have a lower signal for ASC-
Area than the speck-positive cells (high Height:Area profile cells). This is due to loss of some ASC 
from cells that have not formed an ASC speck, during ethanol fixation. The diffuse ASC seems to 
be lost from cells relatively easily, whereas ASC that has formed a speck is comparably well 
retained. The absence of this effect when detecting ASC specks in an unfixed macrophage cell line 
stably expressing ASC-EGFP confirms that this difference in ASC levels between speck-containing 
and untreated cells is due to the fixation/permeabilization process (Sester et al., 2015). 
Consequently, when staining native ASC specks, the generally higher signal for ASC-Area in speck 
containing cells further aids separation of the two populations (Fig. 1C). The loss of diffuse ASC is 
not generally as great with PFA fixation as that observed with ethanol fixation. 
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Figure 1. Analysis of ASC speck formation in murine bone marrow-derived macrophages 
(BMMs) following NLRP3 inflammasome activation as per Basic Protocol 1. (A) The 
predominant population of ethanol fixed cells viewed on a SSC-Area vs FSC-Area dot-plot are 
gated with a scatter plot. (B) Events falling within the scatter plot are then plotted on a FSC-Width 
vs FSC-Area dot-plot allowing gating with a singlet gate to exclude events with a relatively high 
FSC-Width:FSC-Area profile which represent cell doublets. (C) The singlet cell events are then 
plotted on a ASC-Height vs ASC-Area dot-plot, and a gate is created to include cells with a 
relatively high ASC-Height:ASC-Area profile (high H:A) that represent ASC Speck-positive cells. 
High H:A gates allow the quantitation of ASC Speck-positive cells within samples. Displayed are 
C57BL/6 BMMs BMM treated with either LPS-alone, LPS + nigericin or LPS + ATP. Data 
presented here was collected on an Accuri C6 flow cytometer. 
 
The use of a flow cytometry permits analysis of ASC specks within a mixed cell population such as 
PBMCs (Fig. 2). Results here demonstrate induced speck formation in the ASChigh population, 
previously determined to be predominantly CD14+ monocytes (Sester et al., 2015). The use of cell 
lineage markers in combination with the TOFIE speck assay has been demonstrated for resident 
peritoneal cells, where cells competent for ASC speck formation were shown to be predominantly 
F4/80hi macrophages (Sester et al., 2015). For analysis of ASC speck formation in monocytes 
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within a PBMC population, CD14 is not a useful marker, as it is downregulated during the LPS 
priming required for licensing NLRP3 inflammasome responses, and then further diminished upon 
treatments that trigger the inflammasome such as nigericin or ATP. Other markers could be 
explored to define inflammasome-responsive cells within PBMCs. However, as discussed in the 
Troubleshooting section, if multiple fluorophores are used they should be carefully selected as to 
avoid spectral spillover into the channel used for detection of ASC. 
 
 
Figure 2. Analysis of ASC speck formation in human peripheral blood mononuclear cells 
(PBMCs) following NLRP3 inflammasome activation as per Basic Protocol 1. (A) The 
predominant population of ethanol fixed cells viewed on a SSC-Area vs FSC-Area dot-plot are 
gated with a scatter plot. (B) Events falling within the scatter plot are then plotted on a FSC-Width 
vs FSC-Area dot-plot allowing gating with a singlet gate to exclude events with a relatively high 
FSC-Width:FSC-Area profile which represent cell doublets. (C) The singlet cell events are then 
plotted on a ASC-Area histogram and a marker identifying cells with a high level of ASC 
expression is created (ASC High).  This ASC High marker region encompasses monocytes (see 
text) (D) The ASC High events are then plotted on a ASC-Height vs ASC-Area dot-plot, and a gate 
is created to include cells with a relatively high ASC-Height:ASC-Area profile (high H:A) that 
represent ASC Speck-positive cells. High H:A gates allow the quantitation of ASC Speck-positive 
cells within samples. Displayed are human PBMCs treated with either media alone (Untreated), 
nigericin alone, LPS-alone, or LPS + nigericin or LPS + ATP. Data presented here was collected on 
an Accuri C6 flow cytometer. 
 
Basic Protocol 2 and Alternative Protocol 2 present two methods for monitoring formation of 
specks in HEK293T cells reconstituted with inflammasome components. These methods allow 
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confirmation of inflammasome-inducing potential (and presumably also inhibitory potential) of 
expressed proteins. In addition, mutated proteins can be analysed for inflammasome-forming 
potential. The power of these methods is that the expression level of all components, as well as 
ASC-speck formation, can be analysed on a single cell basis. In the Basic Protocol 2, ASC-EGFP is 
co-transfected with candidate inflammasome-initiating proteins that are mCherry tagged. 
Comparison of two proteins as potential inflammasome initiators should only be made using 
windows of mCherry expression that ensure similar levels of protein expression (Fig. 3E). A 
confounding factor in considering the response to increasing doses of an initiator protein such as 
NLRP3-mCherry is the general correlation of its expression with that of ASC-EGFP (Fig 3G). The 
probability of forming an ASC speck is dependent on both the levels of ASC and the levels of the 
initiator NLRP3. However, with consideration of both mCherry expression levels and ASC-EGFP 
expression levels in the populations under analysis, meaningful data can be obtained, that would be 
very difficult to obtain by microscopy (Fig. 3G). The potency of two candidate inflammasome 
initiators should only be compared from the same range of mCherry expression, and the levels of 
ASC-EGFP within the analysed populations should be examined to ensure that this does not 
account for any difference in speck-forming tendency. 
A superior technique for analysis of ASC specks in reconstituted HEK293T cells is provided in 
Alternative Protocol 2, where mCherry-tagged inflammasome initiators are transiently transfected 
into a cell line stably expressing ASC-EGFP. In this case the cells express a relatively uniform level 
of ASC, and have a very low level of constitutive ASC speck formation (Fig. 4). When NLRP3-
mCherry is transfected into these cells, the levels of ASC-EGFP and the mCherry-tagged protein 
are independent. Hence low, medium and high mCherry-expressing cells all have similar level of 
ASC-EGFP expression (Fig. 4A), and analysis of the effect of a dose response of the inflammasome 
initiator on speck formation is straightforward. Both NLRP3 and AIM2 are potent ASC speck 
inducers in this system (Fig. 4B-C). Other candidate initiators can be compared with these, or the 
effects of point mutations on speck induction can be analysed, whilst simultaneously controlling for 
protein expression level. A caveat in searching for novel inflammasome initiators by this method is 
that the initiator must be activated under conditions of transient expression, a situation observed 
with both NLRP3 and AIM2.  
The principles of TOFIE can be extended to other proteins that are recruited to the ASC speck. 
Analysis of procaspase 8 recruitment in Basic Protocol 3 is possible because upon overexpression 
in HEK293, procaspase 8 can become completely ASC speck-associated in individual cells 
(Vajjhala et al., 2015). Figure 5.D shows that similar to ASC, procaspase 8 can be detected in a 
speck structure. When co-expressed with levels of ASC that can form spontaneous specks, 
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procaspase 8 is effectively recruited to the ASC speck, as a procaspase 8 signal can be observed 
with a increased Height:Area profile. Unlike ASC, procaspase 8 expressed alone gives no signal 
consistent with speck formation, and a diffuse localization is confirmed by microscopy (Vajjhala et 
al., 2015). This assay can be used to investigate structural determinants of caspase recruitment by 
ASC. 
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Figure 3. Analysis of ASC speck formation HEK293T cells transiently transfected with ASC-
EGFP and mCherry/mCherry-fusion proteins as per Basic Protocol 2. (A) Healthy cells gated 
with a scatter gate on a SSC-Area vs FSC-Area dot-plot. (B) Plotting scatter gate positive healthy 
 
 
219 
cells on a FSC-Width vs FSC-Area dot-plot allows gating of single cells excluding events with a 
relatively high FSC-Width:FSC-Area profile which represent cell doublets. (C) The healthy, single 
cells from samples that are either un-transfected, transfected with ASC-EGFP alone or mCherry 
alone can be used as controls to define the ASC-EGFP and mCherry/mCherry-fusion protein 
double-positive population in co-transfected samples. (D) Using a sample expressing mCherry (not 
fused to an inflammasome initiator) and ASC-EGFP, determine the threshold of ASC-EGFP 
expression at which formation of spontaneous ASC-EGFP specks occur. Plotting ASC-
EGFP+/mCherry+ double-positive cells on an ASC-EGFP-Width vs ASC-EGFP-Area dot-plot, 
gate as to exclude cells with high levels of ASC-EGFP (ASC-EGFP-Area) in which spontaneous 
specks form (those cells displaying a low ASC-EGFP-Width vs ASC-EGFP-Area). (E) Using the 
cells gated for moderate ASC-EGFP expression, plot mCherry-Area vs ASC-EGFP-Area and gate 
to define subpopulations with low, medium, and high expression of mCherry/mCherry-fusion 
proteins. These gates should be kept the same and applied to all samples to be analysed. (F) 
Analysing the subpopulations based on mCherry-expression defined in panel E, the percentage of 
speck-positive cells can be determined from a plot of ASC-EGFP-Width vs ASC-EGFP-Area, with 
the population displaying low ASC-EGFP-Width:ASC-EGFP-Area profile representing ASC 
speck-positive cells. Examples are shown here for cells transfected with ASC-EGFP and mCherry 
or ASC-EGFP and NLRP3-mCherry. (G) The percentage of speck-positive cells within the defined 
subpopulations with low, medium, and high expression of mCherry or NLRP3-mCherry. Mean 
fluorescence intensity (MFI) for mCherry fluorescence demonstrating equivalent expression of 
constructs within the defined subpopulations with low, medium, and high expression of mCherry or 
NLRP3-mCherry. MFI of ASC-EGFP fluorescence to confirm similar expression of ASC-EGFP 
within the defined subpopulations with low, medium, and high expression of mCherry or NLRP3-
mCherry. Data presented here was collected on a Beckman Coulter Gallios flow cytometer. 
 
Time Considerations 
Assessment of ASC-EGFP specks in HEK293 cells in Basic Protocol 2 requires no 
immunostaining, and thus only takes the time for harvesting of transfected samples and running on 
the flow cytometer (i.e. 2-3 hours depending on sample number). Note that cells are transfected the 
previous day. The immunostaining procedure in Basic Protocols 1 and 3, from cell fixation to 
running on the flow cytometer, requires 4-6 hours, again dependent on sample number. This can be 
difficult or impossible if it follows a day that requires isolation of cells from a primary source, 
lengthy priming with LPS, or any inflammasome stimulus that is not acting in a short time span. 
However, it is possible to stimulate and fix cells on one day, and stain and analyse the following 
day, as noted in Basic Protocol 1. 
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Figure 4. ASC speck formation induced by transfection of mCherry-tagged inflammasome 
initiators into HEK293T cells stably expressing ASC-EGFP as per Alternative Protocol 2. (A) 
Following gating of cells for healthy single cells as per Fig 3.A-B, a plot is prepared for mCherry-
Area vs EGFP-Area, and gates are used to define EGFP and mCherry/mCherry fusion protein 
double-positive cells with low, medium and high levels of mCherry/mCherry fusion protein 
expression. (B-C) Levels of ASC-EGFP specks-positive cells for subpopulations with defined 
levels of mCherry/mCherry fusion protein expression are determined from an EGFP-Width vs 
EGFP-Area dot-plot, as the population with a low ASC-EGFP-Width:ASC-EGFP-Area profile 
(Low W:A). This is shown for cells expressing: high levels of either mCherry or human NLRP3-
mCherry (B), and high levels of human AIM2 HIN domain fused to mCherry or human full length 
AIM2 fused to mCherry (C). Data presented here was collected on a Beckman Coulter Gallios flow 
cytometer. 
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Figure 5. Quantification of procaspase 8 to ASC-EGFP specks. (A) The predominant population 
of ethanol fixed HEK293 cells is gated with a scatter plot. (B) Scatter plot events are then subjected 
to analysis using a FSC-Width vs FSC-Area dot-plot and the predominant population displaying a 
low FSC-Width:FSC-Area profile are gated using a singlet gate to exclude cell doublets. (C) Singlet 
gated events are then analysed on a Procaspase 8-Area vs ASC-Area dot-plot. Cells transfected with 
empty vector (not shown) are used to define quadrants which are copied to all samples including 
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those transfected with ASC alone, Procaspase 8 alone co-transfected with ASC and Procaspase 8. 
Such quadrants facilitate identification of ASC single-positive cells (Q3), procaspase 8 single-
positive cells (Q1) and double-positive cells (Q2). (D) Plotting of samples transfected with and 
gated for ASC alone (Q3), Procaspase 8 alone (Q1) and ASC + procaspase 8 (Q2) on ASC-Height 
vs ASC-Area and Procaspase-8-Height vs Procaspase 8-Area dot-plots allows identification of cells 
with ASC speck-positive and Caspase 8 Speck-positive cells. Data presented here was collected on 
an Accuri C6 flow cytometer. 
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Abstract 
Inflammasomes are protein complexes promoting caspase activation, resulting in processing of IL-
1β and cell death, in response to infection and cellular stresses. Inflammasomes have been 
anticipated to contribute to autoimmunity. The NZB mouse develops anti-erythrocyte antibodies 
and is a model of autoimmune haemolytic anemia. These mice also develop anti-nuclear antibodies 
typical of lupus. Here we have shown that NZB macrophages have deficient inflammasome 
responses to a DNA virus and fungal infection. AIM2 inflammasome responses are compromised in 
NZB by high expression of the AIM2 antagonist protein p202, and consequently NZB cells had low 
IL-1β output in response to both transfected DNA and mouse cytomegalovirus (MCMV) infection. 
Surprisingly, we also found that a second inflammasome system, mediated by the NLRP3 initiating 
protein, was completely lacking in NZB cells. This was due to a point mutation in an intron of the 
nlrp3 gene in NZB mice, which generates a novel splice acceptor site. This leads to incorporation of 
a pseudo-exon with a premature stop codon. The lack of full-length NLRP3 protein results in NZB 
being effectively null for nlrp3, with no production of bioactive IL-1β in response to NLRP3 
stimuli, including infection with Candida albicans. Thus this autoimmune strain harbours two 
inflammasome deficiencies, mediated through quite distinct mechanisms. We hypothesise that the 
inflammasome deficiencies in NZB alter the interaction of the host with both microflora and 
pathogens, promoting prolonged production of cytokines that contribute to development of 
autoantibodies. 
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Introduction 
Inflammasomes are large multiprotein complexes assembled in the cell in response to 
environmental or infectious stress. Canonical inflammasomes act as platforms for the activation of 
caspase-1 and caspase-8 (1, 2). Subsequent to inflammasome activation, caspase-1 cleaves the 
precursors of the inflammatory cytokines IL-1β and IL-18 and also initiates pyroptotic cell death. 
Inflammasome-activated caspase-8 simultaneously initiates apoptotic death (2). Inflammasome 
complex formation depends on the oligomerisation of an initiator protein, either a member of the 
Nod-like receptor family (such as NLRP3 or NLRC4), or absent in melanoma 2 (AIM2), which is a 
member of the PYHIN (pyrin and HIN domain-containing) protein family (3). These clustered 
proteins recruit the adapter molecule ASC (apoptosis-associated speck-like protein containing a 
caspase recruitment domain), and then procaspases. Stimuli initiating NLRP3 inflammasome 
formation include extracellular ATP, the potassium ionophore nigericin from Streptomyces 
hygroscopicus and a wide range of particulates such as monosodium urate crystals, cholesterol 
crystals, β-amyloid and asbestos (1). These are not direct ligands for NLRP3, and their mode of 
action is still debated, but may involve ion flux, lysosomal destabilisation and reactive oxygen 
species. NLRP3 appears to play a role in detection of metabolic disturbance, and there is great 
recent interest in this pathway due to its apparent role in diverse diseases such as atherosclerosis, 
Alzheimer’s disease and type II diabetes (4-6). However NLRP3 is also activated in infection with 
Staphylococcus aureus and Candida albicans (7), and may be involved in gut homeostasis (8, 9). 
NLRC4 mediates responses to cytosolic bacterial flagellin and type III secretion system 
components and is important in combatting a number of bacterial infections including Salmonella 
(7). AIM2 binds to cytosolic DNA and initiates inflammasome responses in response to viruses 
such as MCMV and vaccinia, and the cytosolic bacterium Francisella tularensis (10). In addition, 
there is a non-canonical inflammasome pathway elicited by cytosolic lipopolysaccharide (LPS), 
leading to caspase-11-dependent pyroptosis (11, 12). Recent work showed that mouse caspase-11 
and human caspases-4 and -5 are activated as a result of direct interaction with LPS (12), and are 
thus pattern recognition receptors with effector function. 
 
Inflammasome function has been proposed to contribute to autoimmunity (13, 14). Circulating 
levels of IL-1β were elevated in Sjogren’s syndrome (15), but not in autoimmune haemolytic 
anemia (16). Reported levels of IL-1β in systemic lupus erythematosus (SLE) patient serum range 
from undetected (17, 18), decreased in SLE relative to controls (19, 20), to increased in a small 
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percentage of patients (21). IL-1β levels may be higher in subsets of patients such as those with 
neuro-psychiatric SLE (22) or vascular damage (20). The other cytokine produced by the 
inflammasome, IL-18, is elevated in the serum and glomeruli of SLE patients with lupus nephritis, 
and is associated with localisation of plasmacytoid dendritic cells to glomeruli (23, 24). Since both 
IL-1β and IL-18 can be produced by inflammasome-independent means (25, 26) inflammasome 
involvement in autoimmunity needs confirmation. Human genome-wide association studies have 
suggested the inflammasome initiator NLRP3 may play a role in type I diabetes in a Brazilian 
population (27), and one study showed lowered expression of NLRP3 was associated with Crohn’s 
disease (28), although this has not been replicated (29). Experiments in mice have suggested that 
the NLRP3 inflammasome is activated in kidney during lupus nephritis in two mouse models of 
SLE -  NZBxNZW F1 (first generation cross between New Zealand Black and New Zealand White 
mice) and MRL/Faslpr (Murphy Roths Large with lymphoproliferation lpr mutation of Fas) (30, 31) 
and may contribute to kidney damage. Lupus-like disease can be induced in non-susceptible mice 
by injection of pristane, a mineral oil that induces cell death and elevated IL-1β for at least a month 
after injection (32). Caspase-1 was required for maximal autoantibody production in pristane-
induced lupus (33). Thus inflammasome function promoted disease in this model, but since elevated 
IL-1β is not typical of human lupus the relevance of this to the initiation of the majority of SLE is 
uncertain. In contrast, deletion of NLRP3 or ASC from a mild spontaneous model of SLE (Faslpr 
mutation on C57BL/6 background), causes exacerbated disease (34). Thus the role of 
inflammasomes in lupus-like autoimmunity remains uncertain. 
 
We have investigated inflammasome activity in the NZB mouse. Female NZB mice develop anti-
nuclear antibodies similar to SLE patients, and also anti-erythrocyte antibodies (35). They die 
around 1 year of age, due to hemolytic anemia, and are used as a model for human autoimmune 
hemolytic anemia as well as SLE (36). A more aggressive model of SLE is provided by the first 
generation offspring of the cross between NZB and NZW mice. This is a genetically complex 
model with contributions of multiple loci from both strains (37, 38). Although NZW mice 
themselves do not have overt disease, they contribute a number of loci that exacerbate disease, and 
the NZBxNZW F1 animals die at 10-12 months with severe lupus nephritis (39, 40). In comparison, 
the NZB mice display mild kidney pathology. Our previous work showed that NZB mouse 
macrophages are deficient in cell death mediated by AIM2 inflammasome recognition of cytosolic 
DNA (41, 42). AIM2-dependent cell death was limited by high expression in NZB cells of the 
related PYHIN family member p202 (42), that has been suggested as a lupus-susceptibility factor 
(43). p202 binds directly to AIM2 and prevents downstream ASC oligomerisation. Here we extend 
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this observation to show defects in the AIM2 response to a viral pathogen, and surprisingly, a 
complete lack of NLRP3 inflammasome function in the NZB strain. Thus, in contrast to the concept 
of an important role for the inflammasome in autoimmunity, here we show substantial 
inflammasome deficiencies in cells from NZB mice. This shows that effective inflammasome 
function is not required for loss of tolerance, and suggests that innate immune imbalance could be 
one factor contributing to development of autoantibodies.  
 
Materials and methods 
Materials 
Recombinant human CSF1 was a gift from Chiron. Lipopolysaccharide (LPS) from Salmonella 
minnesota Re595 (Sigma Aldrich) was dissolved in PBS/0.1% triethylamine at 10 mg/ml. Calf 
thymus DNA (CT DNA) (Sigma Aldrich) was further purified as previously described (44).    
 
Mice and Cell Culture 
C57BL/6, asc-/- (45), casp1-/-casp11null (11, 46), nlrp3-/- (47), nlrc4-/- (45) and NZB mice were 
housed in specific pathogen-free facilities at the University of Queensland. Aim2-/- bone marrow 
was obtained from animals gene targeted on a C57BL/6 background and housed at The University 
of Bonn (V. Hornung, unpublished). Mice were used under approval from the University of 
Queensland and University of Bonn Animal Ethics Committees. Bone marrow-derived 
macrophages (BMM) were cultivated from female bone marrow in “complete RPMI-1640” (RPMI-
1640, 25 mM HEPES, 1 X GlutaMAX, 50  U/ml   penicillin and 50  µg/ml streptomycin, 10% heat 
inactivated FCS) (all Life Technologies)) supplemented with 104 U/ml CSF1. BMM were used 
between day 7-11 of culture.   
 
siRNA Gene Knockdown 
Gene knockdown was conducted using Stealth siRNAs (Life Technologies) targeting p202 or TLR9 
as a control, as previously reported (41). BMM (day 6-7) were electroporated with 600 nM siRNA 
duplexes in 400 µL of complete RPMI-1640 at 260 V, 1000 µF using a Gene Puler MX (BioRad) 
and then cultured for a further 3-4 days in complete RPMI-1640 supplemented with 104 U/ml CSF1. 
 
Electroporation with CT DNA 
5 x 105 BMM were electroporated in 400 µL of complete RPMI-1640 with 10 µg CT DNA at 
240V, 1000 µF.  Cells were immediately washed in 10 ml of additive-free RPMI-1640, and then 
resuspended in 350 µl of complete RPMI-1640 lacking heat inactivated FCS, and incubated for a 
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further 35 min at 37oC before cell culture supernatants and cell lysates were processed for 
immunoblot analysis.  
 
Murine Cytomegalovirus (MCMV) BMM Infection Assays 
BMM were plated at 3.5 x 105 cells/well (24-well plate) and cultured overnight in 500 µL of 
antibiotic-free complete RPMI-1640 supplemented with 104 U/ml CSF1. The following day, cells 
were primed for 1 hr with 10 ng/ml LPS after which time medium was replaced with 180 µL of 
serum- and antibiotic-free complete RPMI-1640 supplemented with 10 ng/ml LPS and 0.5x104 
U/ml CSF1. MCMV (K181) (48) was used to infect BMM monolayers at the indicated MOI, and 
following 1 h culture volumes were increased to 350 µL with serum- and antibiotic-free complete 
RPMI-1640 supplemented with 10 ng/ml LPS and 0.5x104 U/ml CSF1. Following a further 6 h of 
incubation at 37oC, cell culture supernatants and cell lysates were processed for immunoblot 
analysis or ELISA. 
 
Candida albicans BMM Infection Assays 
BMM were plated at 3.5 x 105 cells/well (24-well plate) and cultured overnight in 500 µL of 
antibiotic-free complete RPMI-1640 supplemented with 104 U/ml CSF1. The following day, cells 
were primed for 4 h in antibiotic-free complete RPMI-1640 with 10 ng/ml LPS at which time 
medium was replaced with 300 µl of serum- and antibiotic-free complete RPMI-1640 supplemented 
with 10 ng/ml LPS and 0.5x104 U/ml CSF1. Candida albicans strain SC5314 prepared from 
overnight growth at 30ºC on YPD agar was used to infect BMM monolayers at the indicated MOI 
making culture volumes to 350 µl. Following a further 6 h of incubation at 37ºC, cell culture 
supernatants and cell lysates were processed for immunoblot analysis or cell culture supernatants 
were collected and processed for ELISA analysis. 
 
Immunoblot analysis  
Cell supernatants were collected, cell debris was pelleted at 500g for 5 min, and 300 µL of 
supernatant was collected and proteins were precipitated by addition of 4 volumes of 100% acetone 
with centrifugation at 17000g. Cell monolayers were directly lysed in 66 mM Tris pH 7.4, 2% SDS 
and combined with any debris pelleted in the initial 500g centrifugation. Immunoblot analysis for 
caspase processing was conducted using NuPage 4-12% gradient Bis-Tris precast gels (Invitrogen), 
whilst expression level analysis utilized 5-20% gradient mini-PROTEAN® TGX gels (Bio-Rad). 
Proteins where transferred to PVDF (Millipore) using a mini-trans blot system (Bio-Rad) with Tris-
Glycine transfer buffer containing 10-20% methanol. Immunoblot analysis was conducted as 
previously described (42). Primary antibodies used included rabbit polyclonals against caspase-1 
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p10 (M-20, Santa Cruz Biotechnology), ASC (N-15, Santa Cruz), full-length caspase-3 (#9662, Cell 
Signaling Technologies), cleaved caspase-3 (#9661, Cell Signaling Technologies) and AIM2 (made 
to full-length recombinant mouse AIM2, and tested on Aim2-/- extracts), rabbit monoclonal against 
S6 ribosomal protein (5G10, Cell Signaling Technologies), goat polyclonals against mouse IL-1β 
(Cat. # AF-401-NA, R&D Systems) and p202 (S-19, Santa Cruz Biotechnology), mouse 
monoclonals against NLRP3 (Cryo-2, Adipogen), caspase-1 p20 (Casper-1, Adipogen), S6 
ribosomal protein (54D2, Cell Signaling Technologies) and α-Tubulin (B-5-1-2, Sigma Aldrich).  
S6 ribosomal protein and tubulin were used as interchangeable loading controls depending on the 
both the size of previously detected proteins on membranes and the species of primary antibodies 
used to detect them. Secondary antibodies used included anti-rabbit IgG-horse radish peroxidase 
(HRP) antibody (#7074, Cell Signaling Technologies), anti-goat IgG-HRP antibody (#HAF019, 
R&D Systems) anti-mouse IgG-HRP antibody (#7074, Cell Signaling Technologies). Sequential re-
probing of blots was performed after inactivation of HRP with 0.1% NaN3 where possible, followed 
by extensive washing. When not possible, membranes were “stripped” by two 15 min washes with 
agitation at 50oC in 63 mM Tris pH6.7, 2% SDS, 0.8% β-mercaptoethanol, followed by extensive 
washing.  
 
ELISA analysis of IL-1β 
Cell culture supernatants were collected, cell debris was pelleted at 500g for 5 min, and 300 µL of 
supernatant was collected and further cleared by centifugation at 10,000g for 2 min at which time 
supernatants were aliquoted and stored at -80oC for further analysis. IL-1β levels in cell culture 
supernatants were determined using the Mouse IL-1β/IL1F2 DuoSet ELISA kit (R&D Systems 
DY401). 
 
mRNA and miR quantitative RT-PCR analysis    
RNA preparation, cDNA synthesis and quantitative RT-PCR were conducted as outlined previously 
(3). Primers targeting murine genes included nlrp3-For 5’ GCT CCA ACC ATT CTC TGA CC 3’, 
nlrp3-Rev 5’ AAG TAA GGC CGG AAT TCA CC 3’, hprt-For 5’ CAG TCC CAG CGT CGT 
GAT TAG 3’ and hprt-Rev 5’ AAA CAC TTT TTC CAA ATC CTC GG 3’. Primers targeting 
human genes included TATA binding protein (TBP)-For 5’ GCT GGC CCA TAG TGA TCT TT 3’ 
and TBP-Rev 5’ CTT CAC ACG CCA AGA AAC AGT 3’. Preparation of RNA for mIR analysis 
was conducted using a miRNeasy Mini Kit (Qiagen) and miR-223 and RNU6B levels were 
determined as previously described (49).  
 
Analysis of nlrp3 mRNA variants    
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PCR was conducted on cDNA generated form C57BL/6 and NZB BMM using the forward primer 
2706 (5’ AGAAACTGTGGTTGGTGAG 3’) and reverse primer 3125 (5’ 
TGTGGTTGTGGGTCAGAA 3’) that after an initial denaturation of 95oC for 3 min used 35 cycles 
of 94oC/30 sec, 60oC/30 sec, 72oC/60 sec and a final extension of 10 min a 72oC. Products were 
visualised after electrophoresis on a 2% agarose gel. 
 
Construction of NLRP3 & NLRP3’ expression constructs    
Expression of NLRP3 variants was achieved using HEK293 cells and Lipofectamine 2000 
(Invitrogen) for transfection. C57BL/6 N-terminal Flag-tagged coding sequence (CDS) was 
engineered to include the exon 7b sequences, to direct expression of the truncated form of NLRP3 
predominantly present in NZB (NLRP3 ). 
 
Statistical analysis  
Assessment of statistical significance of data generated from ELISA analysis was conducted using a 
one-tailed paired ratio t-test in Prizm 6.0.  
 
Results 
NZB macrophages are deficient in AIM2 inflammasome production of IL-1β  
In previous work we showed NZB macrophages have low AIM2-initiated caspase cleavage and 
resulting cell death. The other output of inflammasome function is proIL-1β cleavage, which 
requires priming of cells with a TLR signal in order to induce proIL-1β. It cannot be assumed that 
under conditions of TLR-mediated priming, NZB cells will maintain deficient AIM2 function, as 
the ratio between AIM2 and its antagonist p202 may change. Consequently, here we examined 
whether NZB cells are deficient in IL-1β production in response to AIM2 inflammasome activation, 
by electroporating LPS-primed NZB and C57BL/6 BMM with calf thymus (CT) DNA. NZB BMM 
showed minimal release of processed caspase-1 and IL-1β, under conditions where the C57BL/6 
BMM response was robust (Fig 1A). Comparison of the expression of components of the AIM2 
inflammasome pathway in NZB and C57BL/6 cells with and without LPS treatment (Fig 1B) 
revealed that AIM2, ASC, and procaspase-1 were expressed identically in the two strains, and 
proIL-1β was similarly induced. The only difference between the strains was in p202 expression, 
which was undetectable in C57BL/6, but readily observed in NZB and induced further by LPS. 
Thus if anything, under the conditions of LPS priming here, the inhibitory role of p202 was 
reinforced. To confirm the role of p202 in limiting AIM2-induced IL-1β cleavage, p202 was 
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knocked down with two independent siRNAs (41, 42), which restored IL-1β processing towards 
levels observed in C57BL/6 cells (Fig 1C and 1D). Cleavage of caspase-1 to p10 and p20 fragments 
was also increased by p202 knockdown, as demonstrated previously in BMM without LPS priming 
(41, 42). We have earlier established that caspase-8 and caspase-3 are activated by the 
inflammasome in parallel with caspase-1 (2), and increased cleavage of caspase-3 further confirms 
inflammasome restoration with p202 knockdown (Fig 1C). Thus, similar to its role in dampening 
the AIM2 inflammasome-mediated processing of caspases and cell death (41, 42), p202 also limits 
AIM2-dependent release of IL-1β from LPS-primed NZB macrophages.  
 
Deficient AIM2 response to MCMV in NZB macrophages 
AIM2 responses are important in combatting cytosolic bacteria such as Francisella tularensis (50), 
and DNA viruses such as mouse cytomegalovirus (MCMV) and vaccinia virus (10). To determine 
whether NZB cells are deficient in responses to MCMV, BMM were primed with LPS to induce 
proIL-1β, and then infected with MCMV. MCMV caused far less cleavage of caspases in NZB than 
C57BL/6 BMM (Fig 2A). Processing and release of IL-1β was also much lower in NZB BMMs 
(Fig 2A and 2B). Interestingly, both strains displayed a lower level of proIL-1β protein in cell 
lysates following infection, which at least for NZB was not explained by IL-1β cleavage and 
release, suggesting that the viral infection either hinders proIL-1β induction by LPS priming or 
promotes its degradation. To confirm the AIM2-dependence of inflammasome activation by 
MCMV, BMM from a number of knockout mouse strains were infected. This showed that MCMV 
detection was dependent upon the dsDNA sensor AIM2 and inflammasome adapter ASC, and not 
upon NLRP3 or NLRC4 (Fig 2C and 2D), as expected (10).  
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FIGURE 1. Low AIM2 inflammasome processing of IL-1β in macrophages.  (A) Immunoblot 
analysis of released and cell-associated proteins from LPS-primed (10 ng/ml, 4 hours) C57BL/6 and 
NZB BMM either untreated, or 30 min after electroporation with or without the indicated amounts 
of DNA. The difference between C57BL/6 and NZB IL-1β cleavage was seen in 4 independent 
experiments. (B) Protein expression levels of AIM2 inflammasome components in un-primed and 
LPS-primed (100 ng/ml 4 hours) C57BL/6 and NZB BMMs as assessed by immunoblot.  Results 
were confirmed with two independent protein preparations. (C) p202 limits AIM2 inflammasome 
processing of IL-1β. Immunoblot analysis of combined released and cell-associated proteins from 
LPS-primed (10 ng/ml, 2.5 hrs) C57BL/6 and NZB BMM collected 35 min after either 
electroporation with no DNA or electroporation with 10 µg DNA. Three days earlier cells had been 
electroporated with either a control siRNA, siRNAs targeting p202, or with no additions. Results 
were replicated in a second experiment. (D) Degree of knockdown of p202 in samples used in panel 
C. 
 
No NLRP3 Inflammasome response to Candida albicans in NZB BMM 
Since the basal elements of inflammasome function (ASC, caspase-1, proIL-1β) were expressed 
similarly in C57BL/6 and NZB (Fig 1B), we thought inflammasomes other than AIM2 were likely 
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to work efficiently in NZB cells. We investigated the activation of the NLRP3 inflammasome as a 
control inflammasome, to demonstrate the specificity of the defect in AIM2 function. NLRP3 was 
activated by treatment of cells with LPS followed by addition of ATP or nigericin. To our surprise, 
no NLRP3 inflammasome activity was evident in NZB cells, whilst caspase and proIL-1β cleavage 
in C57BL/6 cells was robust (Fig 3A). To investigate this further, we infected cells with the 
opportunistic fungal pathogen Candida albicans, which activates the NLRP3 inflammasome (51). 
Exposure of BMMs from C57BL/6 mice to C. albicans resulted in NLRP3-dependent cleavage of 
caspases and IL-1β, with a complete absence of activity in NZB BMM (Fig 3B). Failure of release 
of IL-1β by cells from both NZB and nlrp3-/- mice in response to C. albicans infection was 
confirmed by ELISA (Fig 3C).  
 
FIGURE 2. Low AIM2-dependent response to MCMV in NZB macrophages. (A) Immunoblot 
analysis of released and cell-associated proteins from un-infected or MCMV infected (MOI 8, 7 
hrs) LPS-primed C57BL/6 and NZB BMM. Data is representative of three independent 
experiments.  (B) Quantification of IL-1β levels by ELISA from uninfected or MCMV infected 
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(MOI 8, 7 hrs) LPS-primed C57BL/6 and NZB BMM. Data represents the mean and standard 
deviation (SD) of six independent experiments. ***p<0.001, one-tailed paired ratio t-test. (C) and 
(D) Immunoblot analysis of released and cell-associated proteins from uninfected or MCMV 
infected (MOI 8, 7 hrs) LPS-primed BMM from wildtype (C57BL/6), asc-/-, nlrp3-/-, nlrc4-/- or 
casp1-/-casp11null mice (C), or from wildtype (C57BL/6) and aim2-/- mice (D). Samples in panel D 
were run on one gel, shown with irrelevant lanes removed from the image. 
 
NLRP3 protein is absent from NZB cells 
In investigating the absence of NLRP3 responses, we found a lack of NLRP3 protein in NZB cells, 
whilst C57BL/6 BMM contained readily detected levels of full length protein, that was further 
induced with LPS-priming (Fig 4A). Over-exposure of this blot did reveal a very low level of full-
length NLRP3 protein in NZB, and a smaller species we have termed NLRP3’ (Fig 4A). Evidently 
this low level expression was not sufficient to allow responses, and indeed TLR-mediated induction 
of NLRP3 to a critical level is thought to be essential for its activity (52). Examination of lysates 
prepared from erythrocyte-depleted bone marrow confirmed that the lack of NLRP3 expression in 
the NZB mouse strain was not restricted to in vitro-differentiated BMM (Fig 4B).  Members of the 
PYHIN family to which p202 and AIM2 belong have been implicated in regulation of gene 
expression, so we wished to exclude that p202 expression in NZB BMM was responsible for the 
lack of NLRP3. p202 knockdown did not restore expression of NLRP3 (Fig 4C). We next examined 
nlrp3 mRNA levels. The mRNA was reduced approximately 6-fold in NZB compared to C57BL/6 
(Fig 4D), a ratio maintained following LPS treatment which induced nlrp3 mRNA approximately 9-
fold over the basal level in both strains. Despite levels of nlrp3 mRNA in LPS-primed NZB BMM 
being similar to levels observed in un-primed C57BL/6 BMM (Fig 4D), the protein levels were not 
comparable (Fig 4A). Hence the reduced levels of mRNA did not fully account for the lack of 
NLRP3 protein in NZB BMM. We considered whether micro-RNA miR-223, which has previously 
been shown to be a post-transcriptional regulator of NLRP3 levels (49, 53) could be involved. 
However, miR-223 was not differentially expressed in NZB and C57BL/6 (Fig 4E), suggesting it 
was not contributing to the divergent NLRP3 expression between these two mouse strains. 
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FIGURE 3. Absence of NLRP3 inflammasome function in NZB BMM. (A) Immunoblot analysis 
of released and cell-associated proteins from LPS-primed C57BL/6 and NZB BMM that had been 
untreated, or treated with indicated doses of ATP or nigericin for 30 min. (B) Immunoblot analysis 
of released and cell-associated proteins from LPS-primed C57BL/6, NZB and nlrp3-/- BMM, 
uninfected or infected for 6 hrs with Candida albicans at the indicated MOI. (C) Quantification of 
IL-1β levels by ELISA from LPS-primed C57BL/6, NZB and nlrp3-/- BMM, uninfected or infected 
for 6 hrs with Candida albicans at the indicated MOI. Data represents mean and SD of infections of 
three independent BMM preparations conducted in two independent experiments. 
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FIGURE 4. Low expression of NLRP3 in the NZB mouse strain. (A) Immunoblot analysis of 
NLRP3 protein expression in un-primed and LPS-primed (100 ng/ml, 4 hrs) C57BL/6 and NZB 
BMM. Similar lack of NLRP3 expression in NZB was seen in a further six independent 
experiments. (B) Protein expression levels of NLRP3 in un-primed and LPS-primed (100 ng/ml, 4 
hours) C57BL/6 and NZB erythrocyte-depleted bone marrow.  Results were confirmed with in four 
sets of C57BL/6 and NZB erythrocyte-depleted bone marrow (C) Knockdown of p202 as per Fig 
1C did not restore NLRP3. The result was confirmed in a second independent experiment. (D) 
Quantitative PCR analysis of nlrp3 message levels in un-primed and LPS-primed (10 ng/ml, 4 hr) 
C57BL/6 and NZB BMM (data represent mean and SD of three independent RNA preparations).  
(E) Quantitative PCR for miR-223 levels in un-primed C57BL/6 and NZB BMM (data represent 
mean and range of two independent RNA preparations). 
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A point mutation causes aberrant splicing of the NZB NLRP3 mRNA  
Sequencing of the nlrp3 cDNAs from C57BL/6 and NZB identified that the NZB mRNA contained 
an aberrantly spliced exon, denoted here as 7b, between exons 7 and 8 of the C57BL/6 reference 
sequence (NM_145827.3) (Fig 5A). Exon 7b introduces four new amino acids followed by a stop 
codon. This encodes a protein product of 103 kDa consistent with the smaller NLRP3’ species 
observed in the over-exposed blot (Fig 4A). Apart from this, there were no other differences in the 
NLRP3 amino acid sequence between NZB and C57BL/6. Premature termination codons upstream 
of exon splice boundaries are known to trigger nonsense-mediated decay of transcripts (54), which 
is congruent with the reduced levels of NZB nlrp3 mRNA observed in Figure 4D. To assess the 
prevalence of the variant within the total population of NZB nlrp3 mRNAs, PCR primers were 
designed across the exon 6/7 boundary and within exon 9 of the C57BL/6 mRNA, expected to 
amplify a 420bp product in C57BL/6, and a 516bp product with inclusion of exon 7b in NZB (Fig 
5A). Indeed, whilst a 420bp product was observed in C57BL/6, the majority of product observed 
from NZB mice was the larger 516bp product (Fig 5B). A minor amount of 420bp product observed 
in NZB represents correctly spliced mRNA that gives rise to the small amount of full length NLRP3 
protein (Fig 4A). However, as noted above, the level of the truncated NZB NLRP3’ protein (Fig 
4A) was much lower than expected from a 6-fold lowering of nlrp3 mRNA in NZB (Fig 4D). Also, 
despite the high ratio of abnormal nlrp3 mRNA to normally spliced mRNA in NZB (Fig 5B), there 
were similar levels of the two protein forms (NLRP3 and NLRP3’) within the LPS-primed NZB 
sample (Fig 4A). Consequently we investigated whether the truncated protein is unstable. Normal 
and truncated proteins were transiently expressed in HEK293 cells under control of the same 
promoter. Given that these were encoded by cDNA with no introns, the mRNA encoding the 
truncated NLRP3’ protein was not subject to nonsense-mediated decay (54), and there was similar 
mRNA expression from the two constructs (Fig 5C). Despite this, the truncated NLRP3’ protein 
was present at somewhat lower levels in transfected cells than the normal protein, and this is 
particularly evident comparing transfections with 200 ng of plasmid (Fig 5D). This is consistent 
with reduced stability of the truncated form contributing to its low expression in NZB BMM, in 
addition to the lowered mRNA level. To determine why NZB nlrp3 mRNA was inappropriately 
spliced, we sequenced the genomic DNA at the exon/intron boundaries of exon 7b in NZB. This 
identified a G to A transition in NZB, creating a novel splice acceptor site immediately prior to 
exon 7b (Fig 5E), confirming exon 7b to be a pseudo-exon. In summary, both nonsense-mediated 
decay and an unstable form of NLRP3 result from the introduction of a pseudo-exon in NZB mice 
leading to a state of NLRP3 inflammasome unresponsiveness.    
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FIGURE 5. A point mutation in the NZB genome generates a nlrp3 pseudo-exon. (A) Sequencing 
of the NZB BMM nlrp3 mRNA revealed the introduction of a novel exon denoted here as 7b. The 
shaded region represents the open reading frame and red arrows indicate position of primers used in 
Fig. 5B.  (B) Conventional non-quantitative PCR analysis of mRNA variants expressed in C57BL/6 
and NZB BMM.  (C) mRNAs encoding C57BL/6 NLRP3 or the truncated form present in NZB 
(NLRP3’) were expressed at similar levels in HEK cells following transfection of either cDNA 
expression construct into HEK293 cells for 24 hours.  Data represent the mean and range of relative 
nlrp3 expression gathered from duplicate determinations of nlrp3 and human tbp transcript levels in 
samples presented in Fig 5D. (D) Levels of C57BL/6 NLRP3 protein, or the truncated form present 
in NZB (NLRP3’) after ectopic expression of cDNA in HEK293 cells for 24hrs.  (E) Sequencing of 
C57BL6 and NZB genomic DNA on the 5’ boundary of NZB exon 7b revealed the presence of a 
G/A mutation that introduces a novel splice acceptor site in the NZB strain. 
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Discussion 
This work defined a point mutation in the nlrp3 gene of NZB mice leading to complete lack of 
NLRP3 inflammasome function, and also confirmed the low activity of the AIM2 inflammasome in 
these mice. Although inflammasomes have been proposed to contribute to autoimmunity (13, 14), 
effective AIM2 or NLRP3 activity is clearly not necessary for the autoantibodies and autoimmune 
haemolytic anemia that develop in the NZB mouse. The AIM2 and NLRP3 defects led respectively 
to a low inflammasome response to MCMV, and complete lack of response to C. albicans. This 
may contribute to the published susceptibility of NZB mice to C. albicans and MCMV (55, 56). 
The two inflammasome deficiencies in NZB mice arise from completely unrelated mechanisms. 
Our prior work demonstrated that p202, which is highly expressed in NZB, is an antagonist of 
AIM2 (41, 42). p202 and AIM2 are both members of the PYHIN family with DNA-binding HIN 
domains, but p202 lacks the pyrin domain involved in recruitment of ASC (3). p202 forms a 
tetramer that directly binds two molecules of AIM2, and prevents AIM2 from initiating ASC 
oligomerisation (42). Here we confirmed that p202 is responsible for the low inflammasome 
response to MCMV in NZB cells, but has no role in the NLRP3 inflammasome deficiency. Instead, 
an intronic point mutation in NZB nlrp3 creates a novel splice acceptor site, and subsequent 
incorporation of a pseudo-exon with a premature termination codon. The observed lowered level of 
NZB nlrp3 mRNA is likely due to nonsense-mediated decay, which is elicited by a stop codon 
upstream of an exon-exon boundary, marked by an exon junction complex (54). However, the 
truncated protein also apparently lacks stability, and the normal protein is not expressed at high 
enough level in NZB to provide an NLRP3 response. To our knowledge this is first identification of 
a naturally occurring mutation of NLRP3 resulting in a loss of function, in either mice or humans. 
 
Whether the low inflammasome function actually plays a role in promoting or modifying NZB 
autoimmunity is an open question. Interestingly, recent work on another lupus model demonstrated 
that NLRP3 protected against disease development (34). Contrary to their hypothesis that NLRP3 
would contribute to disease in C57BL/6 mice with a Faslpr mutation, the authors found exacerbated 
pathology upon deletion of the genes for either NLRP3 or ASC. In this model, NLRP3 or ASC 
deficiency increased lymphoproliferation, spleen size and kidney immune infiltrate, and this was 
associated with elevated expression of interferon-induced genes and cytokines such as IL-6 and 
IFN-β. Notably, loss of NLRP3 or ASC alone on the C57BL/6 background was not sufficient to 
induce kidney pathology at 12 months of age, or any autoantibodies by 6 months (34). The 
suppressive role of NLRP3 was not explained by IL-1β or IL-18 production, and instead C57BL/6 
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Faslpr nlrp3-/- dendritic cells were hyporesponsive to TGF-β (34), as previously described in kidney 
epithelial cells (57). The means by which NLRP3 contributes to TGF-  signalling has not been 
established. 
 
The role of NLRP3 in autoimmunity may be dependent on the genetic context, and results from the 
C57BL/6 Faslpr model may not reflect all possible outcomes of inflammasome deficiency. 
Inflammasomes are involved in host defence against a range of pathogens and possibly homeostatic 
interactions with microflora. A consequence of inflammasome deficiency would be the maintained 
viability of cells harbouring intracellular infections, when they would normally undergo pyroptotic 
death (58). Increased cell viability would allow prolonged production of pro-inflammatory 
cytokines and interferon (IFN). We have shown this effect in vitro, where NZB macrophages 
release between 4 and 10-fold more IFN-β in response to cytosolic DNA than C57BL/6, correlating 
with macrophage survival (42). Additionally, deficient inflammasome IL-1β output at sites of 
infection may contribute to ineffective pathogen control. Inflammasome-deficient mice may also 
have an altered interaction with their microflora. Inflammasome components are abundantly 
expressed in the gut, and NLRP6 as well as NLRP3 are suggested to play a role in homeostasis of 
the mucosal environment (9, 59). Alteration in the intestinal microbiome has been observed in 
NLRP3 knockout mice (8), and would be anticipated in NZB mice, which are functionally null for 
nlrp3. Consistent with a role for the microbiota in NZB autoimmunity, germ-free NZB mice had 
delayed and greatly reduced splenomegaly (60), a feature reportedly related to autoantibody-
dependent red cell sequestration in the NZB spleen (36). 
 
Despite having anti-nuclear antibodies typical of SLE, the NZB mice develop only very mild 
glomerulonephritis compared with the NZBxNZW F1 (39, 40). We have examined inflammasome 
status in the NZBxNZW F1 macrophages; p202 levels are high enough to maintain relatively low 
AIM2 function, and NLRP3 protein levels are approximately 50% of NZW. An effective NLRP3 
response occurs if the priming stimulus is strong enough, but with lower levels of priming for 
induction of NLRP3, the inflammasome response is sub-optimal (manuscript in preparation). 
Earlier published work implicated NLRP3 in kidney damage in various scenarios, including lupus 
(30, 31, 61), and from this work it would be reasonable to propose that the lack of NLRP3 in NZB 
protects them from kidney pathology seen in the NZBxNZW F1. The contradictory results of Lech 
et al. (34) suggest that such assumptions on the role of NLRP3 require testing in this model. 
Interestingly, type I IFN, which is commonly chronically elevated in SLE, antagonises NLRP3 
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inflammasome function (62). Thus even where there is no intrinsic inflammasome deficiency, 
disease progression and IFN production may lead to a functional deficiency. 
 
Direct evidence for a role for inflammasome deficiency in NZB mouse disease will require genetic 
manipulation to restore inflammasome function. p202 has been suggested to be a mouse lupus 
susceptibility factor (43, 63), although this remains to be proven. The gene encoding p202, Ifi202, 
has variable copy number in different strains (3), all located within the Nba2 lupus-susceptibility 
locus at 1q22, and p202 is highly expressed in NZB and other lupus-prone mouse strains (43, 63, 
64). The Nba2 congenic strain has this region of chromosome 1 from NZB backcrossed onto 
C57BL/6. Dissection of Nba2 into smaller subregions suggested a major role for other loci such as 
genes for SLAM factors and Fc RIIb, with little or no role for Ifi202 (65). However, it appears that 
the high expression of p202 seen in NZB may not be fully maintained in the Nba2 congenic (43), 
and if there are epistatic effects of other NZB loci on Ifi202 expression, the Nba2 congenic is not a 
suitable system to investigate the role of p202. Regarding the nlrp3 gene, it is notable that this is 
located within the NZB lbw8 lupus susceptibility locus defined in NZBxNZW F2 intercrosses (66). 
Whether nlrp3 contributes to the lbw8 locus remains to be established. 
 
Data on inflammasome function in human SLE is currently limited. One recent paper suggested that 
neutrophil DNA NETs and the antimicrobial peptide LL37 activate the NLRP3 inflammasome, and 
this response is elevated in SLE patient macrophages (67), although the observed difference in IL-
1β production between SLE and healthy control was seen with LPS priming alone. In contrast, two 
reports investigating IL-1β production by monocytes µrom SLE patients showed a subset of SLE 
patients with very limited NLRP3 inflammasome response to extracellular ATP (68, 69).  
 
There is precedent for proposing that appropriate innate immune responses are necessary for 
preventing SLE. One genetically-identified SLE susceptibility factor is neutrophil cytosolic factor 2 
(NCF2- also known as p67phox), a component of NADPH oxidase which generates reactive 
oxygen species essential for microbial killing by neutrophils and macrophages (70). The SLE-
associated variant showed 2-fold decrease in reactive oxygen species production, and it is possible 
that a deficient bacterial killing could predispose to SLE. In this case, genetic and environmental 
factors leading to autoimmunity would not be acting entirely independently. Infections are 
frequently invoked as part of the environmental risk for autoimmune diseases, and genetic defects 
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in innate immune pathways in patients could mean that it is not just an infection per se that triggers 
autoimmunity, but an infection that is inappropriately dealt with. In summary, we find a profound 
deficiency in inflammasome systems in the autoimmune NZB mouse. Establishing the relevance of 
this to disease will require both genetic manipulation of the mouse and further exploration of these 
responses in patients. 
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